(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 February 2005 (24.02.2005)

PCT

(10) International Publication Number
WO 2005/016894 A1

(51) International Patent Classification[7]: C07D 239/48, 405/12, 403/12, 401/12, 401/14, A61K 31/506, 35/00, A61P 37/00, 29/00, C07D 401/14, 405/14

(21) International Application Number: PCT/EP2004/009099

(22) International Filing Date: 13 August 2004 (13.08.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0319227.5 15 August 2003 (15.08.2003) GB
0322370.8 24 September 2003 (24.09.2003) GB

(71) Applicant (*for all designated States except AT, US*): NOVARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant (*for AT only*): NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(71) Applicant (*for all designated States except US*): IRM LLC; Sofia House, 48 Church Street, Hamilton HM XL (BM).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): GARCIA-ECHEVERRIA, Carlos [ES/CH]; Engelgasse 126, CH-4052 Basel (CH). KANAZAWA, Takanori [JP/JP]; 27-8-203, Higashi-arai, Tsukuba-shi, Ibaraki Pref. 305-0033 (JP). KAWAHARA, Eiji [JP/JP]; 4-20, Inarimae, Tsukuba-shi, Ibaraki Pref. 305-0061 (JP). MASUYA, Keiichi [JP/JP]; 1-2-1 Tsukuho, Tsukuba-shi, Ibaraki Pref. 300-3257 (JP). MATSUURA, Naoko [JP/JP]; 2-4-1-507, Amakubo, Tsukuba-shi, Ibaraki Pref. 305-0005 (JP). MIYAKE, Takahiro [JP/JP]; 2-4-1-102,Amakubo, Tsukuba-shi, Ibaraki Pref. 305-0005 (JP). OHMORI, Osamu [JP/JP]; 2-4-6-406, Sengen, Tsukuba-shi, Ibaraki Pref. 305-0047 (JP). UMEMURA, Ichiro [JP/JP]; 2-3-7-406, Ninomiya, Tsukuba-shi, Ibaraki Pref. 305-0051 (JP). STEENSMA, Ruo [CN/US]; 6509 Avenida Manana, La Jolla, CA 92037 (US). CHOPIUK, Greg [CA/US]; 10994 West Ocean Air Drive No.387, San Diego, CA 92130 (US). JIANG, Jiqing [CN/US]; 5225 Fiore Terrace No.D104, San Diego, CA 92122 (US). WAN, Yongqin [CN/US]; 7552 Charmant Drive, No.1622, San Diego, CA 92122 (US). DING, Qiang [CN/US]; 8465 Regents Road No 264, San Diego, CA 92122 (US). ZHANG, Qiong [CN/US]; 8148 Genesee Ave., No.106, San Diego, CA 92122 (US). GRAY, Nathanael, Schiander [US/US]; 5652 Lamas Street, San Diego, CA 92122 (US). KARANEWSKY, Donald [US/US]; 1797 Continental Lane, Escondido, CA 92029 (US).

(74) Agent: GRUBB, Philip; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 2, 4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS



(I)

(57) Abstract: Novel pyrimidine derivatives of formula (I) Wherein R is selected from C_{16-10} aryl, $_{C5-10}$heteroaryl, C_{3-12}cycloalkyl and C_{3-10}heterocycloalkyl; R^0-R^6 as described herein; and their use for the manufacture of a medicament for the treatment or prevention of a disease wich responds to inhibition of FAK and/or ALK and/or ZAP-70 and/or IGF-IR.

WO 2005/016894 A1

2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS.

The present invention relates to the use novel pyrimidine derivatives, the certian novel pyrimidine derivatives, to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.

More particularly the present invention provides in a first aspect, the use of a compound of formula I



(I)

wherein

R is selected from C_{6-10}aryl, C_{5-10}heteroaryl, C_{3-12}cycloalkyl and C_{3-10}heterocycloalkyl;

each of R^0, R^1, R^2,and R^3 independently is hydrogen, C_1-C_8alkyl, C_2-C_8alkenyl, C_2-C_8alkinyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkylC_1-C_8alkyl, C_5-C_{10}arylC_1-C_8alkyl, hydroxyC_1-C_8alkyl, C_1-C_8alkoxyC_1-C_8alkyl, aminoC_1-C_8alkyl, haloC_1-C_8alkyl, unsubstituted or substituted C_5-C_{10}aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1, 2 or 3 hetero atoms selected from N, O and S, hydroxy, C_1-C_8alkoxy, hydroxyC_1-C_8alkoxy, C_1-C_8alkoxyC_1-C_8alkoxy, haloC_1-C_8alkoxy, unsubstituted or substituted C_5-C_{10}arylC_1-C_8alkoxy, unsubstituted or substituted heterocyclyloxy, or unsubstituted or substituted heterocyclylC_1-C_8alkoxy, unsubstitued or substituted amino, C_1-C_8alkylthio, C_1-C_8alkylsulfinyl, C_1-C_8alkylsulfonyl, C_5-C_{10}arylsulfonyl, halogen, carboxy, C_1-C_8alkoxycarbonyl, unsubstitued or substituted carbamoyl, unsubstitued or substituted sulfamoyl, cyano, nitro, $-S(O)_{0-2}NR_{12}R_{13}$, $-S(O)_{0-2}R_{13}$, $-NR_{12}S(O)_{0-2}R_{13}$, $-C(O)NR_{12}R_{13}$, $-C(O)R_{13}$ and $-C(O)OR_{13}$; wherein R_{12} is selected from hydrogen and C_{1-6}alkyl; and R_{13} is selected from hydrogen, C_{1-6}alkyl and C_{3-12}cycloalkyl;

or R^0 and R^1, R^1 and R^2, and/or R^2 and R^3 form, together with the carbon atoms to which they are attached, a 5 or 6 membered carbocyclic or heterocyclic ring comprising 0, 1, 2 or 3 heteroatoms selected from N, O and S;

R^4 is hydrogen or C_1-C_8alkyl;

each of R^5 and R^8 independently is hydrogen, C_1-C_8alkyl, C_1-C_8alkoxyC_1-C_8alkyl, haloC_1-C_8alkyl, C_1-C_8alkoxy, halogen, carboxy, C_1-C_8alkoxycarbonyl, unsubstitued or substituted carbamoyl, cyano, or nitro;

R is unsubstituted or substituted by R_7, R_8, R_9, R_{10}, and R'_{10};

R_7, R_8, R_9, R_{10}, or R'_{10} is a substituent independently selected from hydrogen, C_1-C_8alkyl, C_2-C_8alkenyl, C_2-C_8alkinyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkylC_1-C_8alkyl, C_5-C_{10}arylC_1-C_8alkyl, hydroxyC_1-C_8alkyl, C_1-C_8alkoxyC_1-C_8alkyl, aminoC_1-C_8alkyl, haloC_1-C_8alkyl, unsubstituted or substituted C_5-C_{10}aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1, 2 or 3 hetero atoms selected from N, O and S, hydroxy, C_1-C_8alkoxy, hydroxyC_1-C_8alkoxy, C_1-C_8alkoxyC_1-C_8alkoxy, haloC_1-C_8alkoxy, unsubstituted or substituted aminoC_1-C_8alkoxy, unsubstituted or substituted C_5-C_{10}arylC_1-C_8alkoxy, unsubstituted or substituted heterocyclyloxy, or unsubstituted or substituted heterocyclylC_1-C_8alkyl, unsubstituted or substituted heterocyclylC_1-C_8alkoxy, unsubstitued or substituted amino; C_1-C_8alkylthio, C_1-C_8alkylsulfinyl, C_1-C_8alkylsulfonyl, C_5-C_{10}arylsulfonyl, heterocyclosulfonyl, halogen, carboxy, C_1-C_8alkylcarbonyl, C_1-C_8alkoxycarbonyl, unsubstitued or substituted carbamoyl, unsubstitued or substituted sulfamoyl, cyano, nitro, $-S(O)_{0-2}NR_{12}R_{13}$, $-S(O)_{0-2}R_{12}$, $-C(O)R_{11}$, $-OXR_{11}$, $-NR_{12}XR_{11}$, $-NR_{12}XNR_{12}R_{13}$, $-OXNR_{12}R_{13}$, $-OXOR_{12}$ and $-XR_{11}$;

or two adjacent substituents on R may form together with the carbon atoms to which they are attached, a unsubstitued or substituted 5 or 6 membered carbocyclic or heterocyclic ring comprising 0, 1, 2 or 3 heteroatoms selected from N, O and S;

X is a bond or C_{1-6}alkylene; and

R_{11} is independently selected from C_{6-10}aryl, C_{5-10}heteroaryl, C_{3-12}cycloalkyl and C_{3-10}heterocycloalkyl;

and any aryl, heteroaryl, cycloalkyl or heterocycloalkyl of R_{11} is optionally substituted by 1 to 3 radicals independently selected from C_{1-6}alkyl, C_{3-10}heterocycloalkyl-C_{0-4}alkyl optionally substituted with C_{1-6}alkyl, $-C(O)R_{12}$, $-C(O)NR_{12}R_{13}$, $-XNR_{12}R_{13}$, $-NR_{12}XNR_{12}R_{13}$ and $-NR_{12}C(O)R_{13}$; wherein X is a bond or C_{1-6}alkylene; R_{12} and R_{13} are independently selected from hydrogen and C_{1-6}alkyl;

and salts thereof in the treatment of of a disease associated to tyrosine kinase activity of anaplastic lymphoma kinase (ALK) or for the manufacture of pharmaceutical compositions for use in the treatment of said diseases, as well as use in the treatment of said diseases, to methods of use of such pyrimidine derivatives in the treatment of said diseases, and to pharmaceutical compositions comprising such pyrimidine derivatives for the treatment of said diseases.

The general terms used hereinbefore and hereinafter preferably have within the context of this disclosure the following meanings, unless otherwise indicated:

Where the plural form is used for compounds, salts, and the like, this is taken to mean also a single compound, salt, or the like.

Any asymmetric carbon atoms may be present in the (R)-, (S)- or (R,S)-configuration, preferably in the (R)- or (S)-configuration. The compounds may thus be present as mixtures of isomers or as pure isomers, preferably as enantiomer-pure diastereomers.

The invention relates also to possible tautomers of the compounds of formula I.

C_1-C_8alkyl denotes a an alkyl radical having from 1 up to 8, especially up to 4 carbon atoms, the radicals in question being either linear or branched with single or multiple branching; preferably, C_1-C_8alkyl is butyl, such as n-butyl, sec-butyl, isobutyl, tert-butyl, propyl, such as n-propyl or isopropyl, ethyl or methyl; especially methyl, propyl or tert-butyl.

C_2-C_8alkenyl denotes a an alkenyl radical having from 2 up to 8, especially up to 5 carbon atoms, the radicals in question being either linear or branched with single or multiple branching; preferably, C_2-C_8alkenyl is pentenyl, such as 3-methyl-2-buten-2-yl, butenyl, such as 1- or 2-butenyl or 2-buten-2-yl, propenyl, such as 1-propenyl or allyl, or vinyl.

C_2-C_8alkinyl denotes a an alkinyl radical having from 2 up to 8, especially up to 5 carbon atoms, the radicals in question being either linear or branched; preferably, C_2-C_8alkinyl is propinyl, such as 1-propinyl or propargyl, or acetylenyl.

C_3-C_8cycloalkyl denotes a cycloalkyl radical having from 3 up to 8 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl, preferably cyclopropyl, cyclopentyl or cyclohexyl.

C_1-C_8alkoxy is especially methoxy, ethoxy, isopropyloxy, or tert-butoxy.

HydroxyC$_1$-C$_8$alkyl is especially hydroxymethyl, 2-hydroxyethyl or 2-hydroxy-2-propyl.

HydroxyC$_1$-C$_8$alkoxy is especially 2-hydroxyethoxy or 3-hydroxypropoxy.

C$_1$-C$_8$alkoxyC$_1$-C$_8$alkoxy is especially 2-methoxyethoxy.

C$_1$-C$_8$alkoxyC$_1$-C$_8$alkyl is especially methoxymethyl, 2-methoxyethyl or 2-ethoxyethyl.

Halogen is preferably fluorine, chlorine, bromine, or iodine, especially fluorine, chlorine, or bromine.

HaloC$_1$-C$_8$alkyl is preferably chloroC$_1$-C$_8$alkyl or fluoroC$_1$-C$_8$alkyl, especially trifluoromethyl or pentafluoroethyl.

HaloC$_1$-C$_8$alkoxy is preferably chloroC$_1$-C$_8$alkoxy or fluoroC$_1$-C$_8$alkoxy, especially trifluoromethoxy.

C$_1$-C$_8$alkoxycarbonyl is especially tert-butoxycarbonyl, iso-propoxycarbonyl, methoxycarbonyl or ethoxycarbonyl.

Unsubstitued or substituted carbamoyl is carbamoyl substituted by one or two substituents selected from hydrogen, C$_1$-C$_8$alkyl, C$_2$-C$_8$alkenyl, C$_2$-C$_8$alkinyl, C$_3$-C$_8$cycloalkyl, C$_3$-C$_8$cycloalkylC$_1$-C$_8$alkyl, C$_5$-C$_{10}$arylC$_1$-C$_8$alkyl, hydroxyC$_1$-C$_8$alkyl, C$_1$-C$_8$alkoxyC$_1$-C$_8$alkyl, haloC$_1$-C$_8$alkyl, unsubstitued or substituted C$_5$-C$_{10}$aryl, or aminoC$_1$-C$_8$alkyl, or carbamoyl wherein the substituents and the nitrogen atom of the carbamoyl group represent a 5 or 6 membered heterocyclyl further comprising 0, 1 or 2 hetero atoms selected from N, O and S; and is preferably carbamoyl, methylcarbamoyl, dimethylcarbamoyl, propylcarbamoyl, hydroxyethyl-methyl-carbamoyl, di(hydroxyethyl)carbamoyl, dimethylaminoethylcarbamoyl, or pyrrolidinocarbonyl, piperidinocarbonyl, N-methylpiperazinocarbonyl or morpholinocarbonyl, especially carbamoyl or dimethylcarbamoyl.

Unsubstitued or substituted sulfamoyl is sulfamoyl substituted by one or two substituents selected from hydrogen, C$_1$-C$_8$alkyl, C$_2$-C$_8$alkenyl, C$_2$-C$_8$alkinyl, C$_3$-C$_8$cycloalkyl, C$_3$-C$_8$cycloalkylC$_1$-C$_8$alkyl, C$_5$-C$_{10}$arylC$_1$-C$_8$alkyl, hydroxyC$_1$-C$_8$alkyl, C$_1$-C$_8$alkoxyC$_1$-C$_8$alkyl, haloC$_1$-

C_8alkyl, unsubstitued or substituted C_5-C_{10}aryl, or aminoC_1-C_8alkyl, or sulfamoyl wherein the substituents and the nitrogen atom of the sulfamoyl group represent a 5 or 6 membered heterocyclyl further comprising 0, 1 or 2 hetero atoms selected from N, O and S; and is preferably sulfamoyl, methylsulfamoyl, propylsulfamoyl, cyclopropylmethyl-sulfamoyl, 2,2,2-trifluoroethylsulfamoyl, dimethylaminoethylsulfamoyl, dimethylsulfamoyl, hydroxyethyl-methyl-sulfamoyl, di(hydroxyethyl)sulfamoyl, or pyrrolidinosulfonyl, piperidinosulfonyl, N-methylpiperazinosulfonyl or morpholinosulfonyl, especially sulfamoyl or methylsulfamoyl.

Unsubstitued or substituted amino is amino substituted by one or two substituents selected from hydrogen, C_1-C_8alkyl, C_2-C_8alkenyl, C_2-C_8alkinyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkylC_1-C_8alkyl, C_5-C_{10}arylC_1-C_8alkyl, hydroxyC_1-C_8alkyl, C_1-C_8alkoxyC_1-C_8alkyl, haloC_1-C_8alkyl, unsubstitued or substituted C_5-C_{10}aryl, aminoC_1-C_8alkyl, acyl, e.g. formyl, C_1-C_8alkylcarbonyl, C_5-C_{10}arylcarbonyl, C_1-C_8alkylsulfonyl or C_5-C_{10}arylsulfonyl, and is preferably amino, methylamino, dimethylamino, propylamino, benzylamino, hydroxyethyl-methyl-amino, di(hydroxyethyl)amino, dimethylaminoethylamino, acetylamino, acetyl-methyl-amino, benzoylamino, methylsulfonylamino or phenylsulfonylamino, especially amino or dimethylamino.

AminoC_1-C_8alkyl is especially aminoethyl, methylaminoethyl, dimethylaminoethyl or dimethylaminopropyl.

Unsubstitued or substituted C_5-C_{10}aryl is, for example, phenyl, indenyl, indanyl, naphthyl, or 1,2,3,4-tetrahydronaphthalenyl, optionally substituted by C_1-C_8alkyl, C_1-C_8alkoxyC_1-C_8alkyl, haloC_1-C_8alkyl, hydroxy, C_1-C_8alkoxy, methylenedioxy, amino, substituted amino, halogen, carboxy, C_1-C_8alkoxycarbonyl, carbamoyl, sulfamoyl, cyano or nitro; preferably phenyl, tolyl, trifluoromethylphenyl, methoxyphenyl, dimethoxyphenyl, methylenedioxyphenyl, chlorophenyl or bromophenyl, whereby the substituents may be in ortho, meta or para position, preferably meta or para.

C_5-C_{10}aryloxy is especially phenoxy or methoxyphenoxy, e.g. p-methoxyphenoxy.

C_5-C_{10}arylC_1-C_8alkyl is especially benzyl or 2-phenylethyl.

C_5-C_{10}arylC_1-C_8alkoxy is especially benzyloxy or 2-phenylethoxy.

Unsubstitued or substituted 5 or 6 membered heterocyclyl comprising 1, 2 or 3 hetero atoms selected from N, O and S may be unsaturated, partially unsaturated or saturated, and further condensed to a benzo group or a 5 or 6 membered heterocyclyl group, and may be bound through a hetero or a carbon atom, and is, for example, pyrrolyl, indolyl, pyrrolidinyl, imidazolyl, benzimidazolyl, pyrazolyl, triazolyl, benzotriazolyl, tetrazolyl, pyridyl, quinolinyl, isoquinolinyl, 1,2,3,4-tetrahydroquinolinyl, piperidyl, pyrimidinyl, pyrazinyl, piperazinyl, purinyl, tetrazinyl, oxazolyl, isoxalyl, morpholinyl, thiazolyl, benzothiazolyl, oxadiazolyl, and benzoxadiazolyl. Substituents considered are C_1-C_8alkyl, hydroxyC_1-C_8alkyl, C_1-C_8alkoxyC_1-C_8alkyl, C_1-C_8alkoxyC_1-C_8alkoxy, haloC_1-C_8alkyl, hydroxy, amino, substituted amino, C_1-C_8alkoxy, halogen, carboxy, C_1-C_8alkylcarbonyl, C_1-C_8alkoxycarbonyl, carbamoyl, C_1-C_8alkylcarbamoyl, cyano, oxo, or unsubstitued or substituted 5 or 6 membered heterocyclyl as defined in this paragraph. 5 or 6 membered heterocyclyl preferably comprises 1 or 2 hetero atoms selected from N, O and S, and is especially indolyl, pyrrolidinyl, pyrrolidonyl, imidazolyl, N-methylimidazolyl, benzimidazolyl, S,S-dioxoisothiazolidinyl, piperidyl, 4-acetylaminopiperidyl, 4-methylcarbamoylpiperidyl, 4-piperidinopiperidyl, 4-cyanopiperidyl, piperazinyl, N-methylpiperazinyl, N-(2-hydroxyethyl)piperazinyl, morpholinyl, 1-aza-2,2-dioxo-2-thiacyclohexyl, or sulfolanyl.

In unsubstituted or substituted heterocyclyloxy, heterocyclyl has the meaning as defined above, and is especially N-methyl-4-piperidyloxy. In unsubstituted or substituted heterocyclylC_1-C_8alkoxy, heterocyclyl has the meaning as defined above, and is especially 2-pyrrolidinoethoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 1-methyl-piperidin-3-ylmethoxy, 3-(N-methylpiperazino)propoxy or 2-(1-imidazolyl)ethoxy.

In a 5 or 6 membered carbocyclic or heterocyclic ring comprising 0, 1, 2 or 3 heteroatoms selected from N, O and S, and formed by two adjacent substituents together with the benzene ring, the ring may be further substituted, e.g. by C_1-C_8alkyl, C_1-C_8alkoxy, haloC_1-C_8alkyl, hydroxy, amino, substituted amino, C_1-C_8alkoxy, halogen, carboxy, C_1-C_8alkoxycarbonyl, carbamoyl, cyano, or oxo. The two adjacent substituents forming such a ring are preferably propylene, butylene, 1-aza-2-propylidene, 3-aza-1-propylidene, 1,2-diaza-2-propylidene, 2,3-diaza-1-propylidene, 1-oxapropylene, 1-oxapropylidene, methylenedioxy, difluoromethylene-dioxy, 2-aza-1-oxopropylene, 2-aza-2-methyl-1-oxopropylene, 1-aza-2-oxopropylene, 2-aza-1,1-dioxo-1-thiapropylene or the corresponding butylene derivatives forming a 6 membered ring.

Salts are especially the pharmaceutically acceptable salts of compounds of formula I.

Such salts are formed, for example, as acid addition salts, preferably with organic or inorganic acids, from compounds of formula I with a basic nitrogen atom, especially the pharmaceutically acceptable salts. Suitable inorganic acids are, for example, halogen acids, such as hydrochloric acid, sulfuric acid, or phosphoric acid. Suitable organic acids are, for example, carboxylic, phosphonic, sulfonic or sulfamic acids, for example acetic acid, propionic acid, octanoic acid, decanoic acid, dodecanoic acid, glycolic acid, lactic acid, fumaric acid, succinic acid, adipic acid, pimelic acid, suberic acid, azelaic acid, malic acid, tartaric acid, citric acid, amino acids, such as glutamic acid or aspartic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, cyclohexanecarboxylic acid, adamantanecarboxylic acid, benzoic acid, salicylic acid, 4-aminosalicylic acid, phthalic acid, phenylacetic acid, mandelic acid, cinnamic acid, methane- or ethane-sulfonic acid, 2-hydroxyethanesulfonic acid, ethane-1,2-disulfonic acid, benzenesulfonic acid, 2-naphthalenesulfonic acid, 1,5-naphthalene-disulfonic acid, 2-, 3- or 4-methylbenzenesulfonic acid, methylsulfuric acid, ethylsulfuric acid, dodecylsulfuric acid, N-cyclohexylsulfamic acid, N-methyl-, N-ethyl- or N-propyl-sulfamic acid, or other organic protonic acids, such as ascorbic acid.

For isolation or purification purposes it is also possible to use pharmaceutically unacceptable salts, for example picrates or perchlorates. For therapeutic use, only pharmaceutically acceptable salts or free compounds are employed (where applicable in the form of pharmaceutical preparations), and these are therefore preferred.

In view of the close relationship between the novel compounds in free form and those in the form of their salts, including those salts that can be used as intermediates, for example in the purification or identification of the novel compounds, any reference to the free compounds hereinbefore and hereinafter is to be understood as referring also to the corresponding salts, as appropriate and expedient.

The compounds of formula I have valuable pharmacological properties, as described hereinbefore and herelnafter.

In formula I the following significances are preferred independently, collectively or in any combination or sub-combination. R is C_{6-10}aryl, C_{5-10}heteroaryl, C_{3-12}cycloalkyl or C_{3-10}heterocycloalkyl, preferably R is



wherein R_7, R_8, R_9, R_{10}, or R'_{10} are as defined above;

In each of the following significances A, D or E is C or N but A, D and E may not all be N, preferably A, D or E is C:

(a) each of R^0 or R^2 independently is hydrogen, C_1-C_8alkyl, e.g. methyl, ethyl or isopropyl, hydroxyC_1-C_8alkyl, e.g. hydroxyethyl or hydroxybutyl, haloC_1-C_8alkyl, e.g. trifluoromethyl, unsubstituted or substituted C_5-C_{10}aryl, e.g. phenyl or methoxyphenyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, e.g. morpholino, piperidino, piperazino or N-methylpiperazino, C_1-C_8alkoxy, e.g. methoxy, ethoxy or isopropoxy, haloC_1-C_8alkoxy, e.g. trifluoromethoxy, C_5-C_{10}aryloxy, e.g. phenoxy, unsubstituted or substituted heterocyclyloxy, e.g. 1-methyl-4-piperidyloxy, unsubstituted or substituted heterocyclylC_1-C_8alkoxy, e.g. 2-(1-imidazolyl)ethoxy, 3-morpholinopropoxy or 2-morpholinoethoxy, unsubstituted or substituted amino, e.g. methylamino, dimethylamino or acetylamino, C_1-C_8alkylsulfonyl, e.g. methylsulfonyl, halogen, e.g. fluoro or chloro, unsubstituted or substituted carbamoyl, e.g. cyclohexylcarbamoyl, piperidinocarbonyl, piperazinocarbonyl, N-methylpiperazinocarbonyl or morpholinocarbonyl, unsubstituted or substituted sulfamoyl, e.g. sulfamoyl, methylsulfamoyl or dimethylsulfamoyl; preferably hydrogen, piperazino, N-methylpiperazino or 1-methyl-4-piperidyloxy, $-S(O)_{0-2}NR_{12}R_{13}$, $-S(O)_{0-2}R_{13}$, $-NR_{12}S(O)_{0-2}R_{13}$, $-C(O)NR_{12}R_{13}$, and $-C(O)OR_{13}$ in particular hydrogen;

(b) R^1 is hydrogen, C_1-C_8alkyl, e.g. methyl, ethyl or isopropyl, hydroxyC_1-C_8alkyl, e.g. hydroxyethyl or hydroxybutyl, haloC_1-C_8alkyl, e.g. trifluoromethyl, unsubstituted or substituted C_5-C_{10}aryl, e.g. phenyl or methoxyphenyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, e.g. morpholino, piperidino, piperazino or N-methylpiperazino, C_1-C_8alkoxy, e.g. methoxy, ethoxy or isopropoxy, haloC_1-C_8alkoxy, e.g. trifluoromethoxy, C_5-C_{10}aryloxy, e.g. phenoxy, unsubstituted or substituted heterocyclyloxy, e.g. 1-methyl-4-piperidyloxy, unsubstituted or substituted heterocyclylC_1-C_8alkoxy, e.g. 2-(1-imidazolyl)ethoxy, 3-morpholinopropoxy or 2-morpholinoethoxy, unsubstituted or substituted amino, e.g. methylamino, dimethylamino or acetylamino, C_1-C_8alkylsulfonyl, e.g. methylsulfonyl, halogen, e.g. fluoro or chloro,

unsubstituted or substituted carbamoyl, e.g. cyclohexylcarbamoyl, piperidinocarbonyl, piperazinocarbonyl, N-methylpiperazinocarbonyl or morpholinocarbonyl, unsubstituted or substituted sulfamoyl, e.g. sulfamoyl, methylsulfamoyl or dimethylsulfamoyl; preferably hydrogen, piperazino, N-methylpiperazino, morpholino, 1-methyl-4-piperidinyloxy, 3-morpholinopropoxy or 2-morpholinoethoxy, in particular hydrogen;

(c) R^3 is hydrogen, C_1-C_8alkyl, e.g. methyl or ethyl, hydroxyC_1-C_8alkyl, e.g. hydroxyethyl or hydroxybutyl, haloC_1-C_8alkyl, e.g. trifluoromethyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 heteroatoms selected from N, O and S, e.g. 2-pyrrolidonyl or S,S-dioxoisothiazolidinyl, C_1-C_8alkoxy, e.g. methoxy, substituted amino, e.g. acetylamino, acetyl-methyl-amino, benzoylamino, methylsulfonylamino or phenylsulfonylamino, C_1-C_8alkylsulfonyl, e.g. methylsulfonyl, propyl-sulfonyl, cyclohexyl-sulfonyl, isopropyl-sulfonyl, C_5-C_{10}arylsulfonyl, e.g. phenylsulfonyl, halogen, e.g. fluoro or chloro, carboxy, substituted or unsubstituted carbamoyl, e.g. carbamoyl, methylcarbamoyl, ethyl-amino-carbonyl or dimethylcarbamoyl, unsubstituted or substituted sulfamoyl, e.g. sulfamoyl, methylsulfamoyl, propylsulfamoyl, isopropylsulfamoyl, isobutylsulfamoyl, cyclopropylmethyl-sulfamoyl, 2,2,2-trifluoroethylsulfamoyl, dimethylsulfamoyl or morpholinosulfonyl dimethyl-sulfamoyl, ethyl-sulfamoyl, 1-ethyl-propyl-sulfamoyl, cyclopentyl-sulfamoyl, cyclobutyl-sulfamoyl; preferably sulfamoyl, methylsulfamoyl or propylsulfamoyl;

(d) each pair of adjacent substituents R^0 and R^1, or R^1 and R^2, or R^2 and R^3 are $-CH_2-NH-CO-$, $-CH_2-CH_2-NH-CO-$, $-CH_2-CO-NH-$, $-CH_2-CH_2-CO-NH-$, $-CH_2-NH-SO_2-$, $-CH_2-CH_2-NH-SO_2-$, $-CH_2-SO_2-NH-$, $-CH_2-CH_2-SO_2-NH-$, $-CH_2-CH_2-SO_2-$, $-CH_2-CH_2-CH_2-SO_2-$, $-O-CH_2-O-$, or $-O-CF_2-O-$, and such pairs wherein hydrogen in NH is replaced by C_1-C_8alkyl; preferably the pair of adjacent substituents R^0 and R^1, or R^1 and R^2 being $-O-CH_2-O-$, and the pair of adjacent substituents R^2 and R^3 being $-CH_2-NH-CO-$ or $-CH_2-NH-SO_2-$.

(e) R^4 is hydrogen or C_1-C_8alkyl, e.g. methyl; preferably hydrogen;

(f) R^5 is hydrogen; C_1-C_8alkyl, e.g. methyl or ethyl, halogen, e.g. chloro or bromo, haloC_1-C_8alkyl, e.g. trifluoromethyl, cyano or nitro; preferably hydrogen, methyl, ethyl, chloro, bromo, trifluoromethyl or nitro; in particular chloro or bromo;

(g) R^6 is hydrogen;

(h) each of R^7 and R^9 independently is hydrogen, C_1-C_8alkyl, e.g. methyl, ethyl or isopropyl, hydroxyC_1-C_8alkyl, e.g. hydroxyethyl or hydroxybutyl, C_1-C_8alkylcarbonyl, e.g methyl carbonyl, aminoalkoxy, e.g diethylaminoethoxy, haloC_1-C_8alkyl, e.g. trifluoromethyl,

unsubstituted or substituted C_5-C_{10}aryl, e.g. phenyl or methoxyphenyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, e.g. morpholino, piperidino, piperazino or N-methylpiperazino, C_1-C_8alkoxy, e.g. methoxy, ethoxy or isopropoxy, haloC_1-C_8alkoxy, e.g. trifluoromethoxy, C_5-C_{10}aryloxy, e.g. phenoxy, unsubstituted or substituted heterocyclyloxy, e.g. 1-methyl-4-piperidyloxy, unsubstituted or substituted heterocyclylC_1-C_8alkoxy, e.g. 2-(1-imidazolyl)ethoxy, 3-morpholinopropoxy or 2-morpholinoethoxy, unsubstituted or substituted amino, e.g. methylamino, dimethylamino or acetylamino, C_1-C_8alkylsulfonyl, e.g. methylsulfonyl, heterocyclosulfonyl, e.g piperazinylsulfonyl, heterocyclocarbonyl, e.g. methylpirerazinylcarbonyl, cyano, halogen, e.g. fluoro or chloro, unsubstituted or substituted carbamoyl, e.g. cyclohexylcarbamoyl, piperidinocarbonyl, piperazinocarbonyl, N-methylpiperazinocarbonyl or morpholinocarbonyl, unsubstituted or substituted sulfamoyl, e.g. sulfamoyl, methylsulfamoyl or dimethylsulfamoyl; preferably hydrogen, methyl, isopropyl, trifluoromethyl, phenyl, methoxyphenyl, piperidino, piperazino, N-methylpiperazino, morpholino, methoxy, ethoxy, isopropoxy, phenoxy, 3-morpholinopropoxy, 2-morpholinoethoxy, 2-(1-imidazolyl)ethoxy, dimethylamino, fluoro, morpholinocarbonyl, piperidinocarbonyl, piperazinocarbonyl or cyclohexylcarbamoyl;

(i) R^8 is hydrogen, C_1-C_8alkyl, e.g. methyl, ethyl or isopropyl, hydroxyC_1-C_8alkyl, e.g. hydroxyethyl or hydroxybutyl, haloC_1-C_8alkyl, e.g. trifluoromethyl, C_5-C_{10}aryl, e.g. phenyl or methoxyphenyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, e.g. morpholino, piperidino, piperazino or N-methylpiperazino, heterocyclylalkyl, e.g. methylpiperazinoethyl, heterocyclylcarbonyl, e.g. piperazinocarbonyl, heterocyclyl C_1-C_8alkylamino, e.g. pyridylethyl(methyl)amino, C_1-C_8alkoxy, e.g. methoxy, ethoxy or isopropoxy, haloC_1-C_8alkoxy, e.g. trifluoromethoxy, C_5-C_{10}aryloxy, e.g. phenoxy, unsubstituted or substituted heterocyclyloxy, e.g. 1-methyl-4-piperidyloxy, unsubstituted or substituted heterocyclylC_1-C_8alkoxy, e.g. 2-(1-imidazolyl)ethoxy, 3-morpholinopropoxy or 2-morpholinoethoxy, unsubstituted or substituted amino, e.g. methylamino or dimethylamino, C_1-C_8alkylamino-C_1-C_8alkylamino, e.g. dimethylamino-propylamino, C_1-C_8alkylsulfonyl, e.g. methylsulfonyl, halogen, e.g. fluoro or chloro, unsubstituted or substituted carbamoyl, e.g. cyclohexylcarbamoyl, piperidinocarbonyl, piperazinocarbonyl, N-methylpiperazinocarbonyl or morpholinocarbonyl, unsubstituted or substituted sulfamoyl, e.g. sulfamoyl, methylsulfamoyl or dimethylsulfamoyl, cyano, or nitro; preferably hydrogen, methyl, piperidino, piperazino, N-methylpiperazino, morpholino, methoxy, ethoxy, trifluoromethoxy, phenoxy, 1-methyl-4-

piperidyloxy, 3-morpholinopropoxy, 2-morpholinoethoxy, 3-(N-methylpiperazino)-propoxy, methylamino, fluoro, chloro, sulfamoyl or nitro;

(j) R^{10} is hydrogen, C_1-C_8alkyl, e.g. methyl, ethyl or butyl, hydroxy, cyano, hydroxyC_1-C_8alkyl, e.g. hydroxyethyl or hydroxybutyl, haloC_1-C_8alkyl, e.g. trifluoromethyl, C_1-C_8alkoxy, e.g. methoxy or ethoxy, cycloalkylalkoxy, aryloxy, haloC_1-C_8alkoxy, unsubstituted or substituted heterocyclylC_1-C_8alkoxy, e.g. 2-(1-imidazolyl)ethoxy, unsubstituted or substituted amino, e.g. methylamino or dimethylamino, halogen, e.g. fluoro or chloro; carboxy, carbamoyl, or unsubstituted or substituted sulfamoyl, e.g. sulfamoyl, methylsulfamoyl or dimethylsulfamoyl; preferably methyl, butyl, methoxy, ethoxy, 2-(1-imidazolyl)ethoxy, methylamino, dimethylamino or fluoro; and

(k) each pair of adjacent substituents R^7 and R^8, or R^8 and R^9 or R^9 and R^{10}, are –NH-CH=CH-, -CH=CH-NH-, –NH-N=CH-, –CH=N-NH-, $-CH_2-CH_2-CH_2-$, $-CH_2-CH_2-CH_2-CH_2-$, $-CH_2-CH_2-O-$, $-CH_2C(CH_3)_2O-$, $-CH=C(CH_3)O-$, $-OCH_2CH_2O-$, -(Morpholinopropyl)N-CH=CH-, -CH=CH-O-, $-O-CH_2-O-$, or $-O-CF_2-O-$; preferably the pair of adjacent substituents R^7 and R^8 or R^8 and R^9 being $-O-CH_2-O-$ or the pair of adjacent substituents R^9 and R^{10} being -NH-CH=CH-, -CH=N-NH-, $-CH_2-CH_2-CH_2-$, $-CH_2-CH_2-CH_2-CH_2-$ or $-O-CF_2-O-$.

(l) or R^7, R^8, R^9, R^{10} and R'^{10} are ethoxy, ethyl, propyl, methyl, t-butyl, trifluoromethyl, nitrile, cyclobutyloxy, 2,2,2-trifluoroethoxy, methoxy, isobutyloxy, t-butyloxy, isopropyloxy, methyl-amino-carbonyl, cyclopropyl-methoxy, dimethylamino-propyl-amino, methoxy-ethoxy, $-XR_{11}$, $-C(O)R_{11}$ and $–OXR_{11}$; wherein X is a bond, methylene or ethylene; R_{11} is selected from piperazinyl, piperidinyl, pyrrolidinyl, morpholino, azepanyl and 1,4-dioxa-8-aza-spiro[4.5]dec-8-yl; wherein R_{11} is optionally substituted by 1 to 3 radicals independently selected from methyl, isopropyl, acetyl, acetyl-methyl-amino, 3-dimethylamino-2,2-dimethyl-propylamino, ethyl-methyl-amino-ethoxy, diethyl-amino-ethoxy, amino-carbonyl, ethyl, 2-oxo-pyrrolidin-1-yl, pyrrolidinyl, pyrrolidinyl-methyl, piperidinyl optionally substituted with methyl or ethyl, morpholino, dimethylamino, dimethylamino-propyl-amino, methyl-amino and ethyl-amino.

More preferred are the following meanings, independently, collectively or in any combination or sub-combination:

(a') each of R^0 or R^2 independently is hydrogen, C_1-C_8alkyl, e.g. methyl, ethyl or isopropyl, haloC_1-C_8alkyl, e.g. trifluoromethyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, e.g. morpholino, piperidino, piperazino or N-methylpiperazino, C_1-C_8alkoxy, e.g. methoxy, ethoxy or

isopropoxy, unsubstituted or substituted heterocyclyloxy, e.g. 1-methyl-4-piperidyloxy, unsubstituted or substituted heterocyclylC_1-C_8alkoxy, e.g. 2-(1-imidazolyl)ethoxy, 3-morpholinopropoxy or 2-morpholinoethoxy, unsubstituted or substituted amino, e.g. methylamino, dimethylamino or acetylamino, halogen, e.g. fluoro or chloro; preferably hydrogen, piperazino, N-methylpiperazino or 1-methyl-4-piperidyloxy, in particular hydrogen;

(b') R^1 is hydrogen, C_1-C_8alkyl, e.g. methyl, ethyl or isopropyl, haloC_1-C_8alkyl, e.g. trifluoromethyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, e.g. morpholino, piperidino, piperazino or N-methylpiperazino, C_1-C_8alkoxy, e.g. methoxy, ethoxy or isopropoxy, unsubstituted or substituted heterocyclyloxy, e.g. 1-methyl-4-piperidyloxy, unsubstituted or substituted heterocyclylC_1-C_8alkoxy, e.g. 2-(1-imidazolyl)ethoxy, 3-morpholinopropoxy or 2-morpholinoethoxy, unsubstituted or substituted amino, e.g. methylamino, dimethylamino or acetylamino, halogen, e.g. fluoro or chloro; preferably hydrogen, piperazino, N-methylpiperazino, morpholino, 1-methyl-4-piperidinyloxy, 3-morpholinopropoxy or 2-morpholinoethoxy, in particular hydrogen;

(c') R^3 is hydrogen, C_1-C_8alkyl, e.g. methyl or ethyl, haloC_1-C_8alkyl, e.g. trifluoromethyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 heteroatoms selected from N, O and S, e.g. 2-pyrrolidonyl or S,S-dioxoisothiazolidinyl, C_1-C_8alkoxy, e.g. methoxy, substituted amino, e.g. acetylamino, acetyl-methyl-amino, benzoylamino, methylsulfonylamino or phenylsulfonylamino, C_1-C_8alkylsulfonyl, e.g. methylsulfonyl, C_5-C_{10}arylsulfonyl, e.g. phenylsulfonyl, halogen, e.g. fluoro or chloro, carboxy, substituted or unsubstituted carbamoyl, e.g. carbamoyl, methylcarbamoyl or dimethylcarbamoyl, unsubstituted or substituted sulfamoyl, e.g. sulfamoyl, methylsulfamoyl, propylsulfamoyl, isopropylsulfamoyl, isobutylsulfamoyl, cyclopropylmethyl-sulfamoyl, 2,2,2-trifluoroethylsulfamoyl, dimethylsulfamoyl or morpholinosulfonyl; preferably sulfamoyl, methylsulfamoyl or propylsulfamoyl;

(d') each pair of adjacent substituents R^0 and R^1, or R^1 and R^2, or R^2 and R^3 are -CH_2-NH-CO-, -CH_2-NH-SO_2-, -CH_2-CH_2-SO_2-, -O-CH_2-O-, or -O-CF_2-O-, and such pairs wherein hydrogen in NH is replaced by C_1-C_8alkyl; preferably the pair of adjacent substituents R^0 and R^1, or R^1 and R^2 being -O-CH_2-O-, and the pair of adjacent substituents R^2 and R^3 being -CH_2-NH-CO- or -CH_2-NH-SO_2-.

(e') R^4 is hydrogen;

(f') R^5 is hydrogen, halogen, e.g. chloro or bromo, haloC_1-C_8alkyl, e.g. trifluoromethyl, or nitro; preferably hydrogen, chloro, bromo, trifluoromethyl or nitro; in particular chloro or bromo;

(g') R^6 is hydrogen;

(h') each of R^7 and R^9 independently is hydrogen, C_1-C_8alkyl, e.g. methyl, ethyl or isopropyl, haloC_1-C_8alkyl, e.g. trifluoromethyl, unsubstituted or substituted C_5-C_{10}aryl, e.g. phenyl or methoxyphenyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, e.g. morpholino, piperidino, piperazino or N-methylpiperazino, C_1-C_8alkoxy, e.g. methoxy, ethoxy or isopropoxy, unsubstituted or substituted heterocyclyloxy, e.g. 1-methyl-4-piperidyloxy, unsubstituted or substituted heterocyclylC_1-C_8alkoxy, e.g. 2-(1-imidazolyl)ethoxy, 3-morpholinopropoxy or 2-morpholinoethoxy, unsubstituted or substituted amino, e.g. methylamino, dimethylamino or acetylamino, halogen, e.g. fluoro or chloro, unsubstituted or substituted carbamoyl, e.g. cyclohexylcarbamoyl, piperidinocarbonyl, piperazinocarbonyl, N-methylpiperazinocarbonyl or morpholinocarbonyl, unsubstituted or substituted sulfamoyl, e.g. sulfamoyl, methylsulfamoyl or dimethylsulfamoyl; preferably hydrogen, methyl, isopropyl, trifluoromethyl, phenyl, o-, m- or p-methoxyphenyl, piperidino, piperazino, N-methylpiperazino, morpholino, methoxy, ethoxy, isopropoxy, phenoxy, 3-morpholinopropoxy, 2-morpholinoethoxy, 2-(1-imidazolyl)ethoxy, dimethylamino, fluoro, morpholinocarbonyl, piperidinocarbonyl, piperazinocarbonyl or cyclohexylcarbamoyl;

(i') R^8 is hydrogen, C_1-C_8alkyl, e.g. methyl, ethyl or isopropyl, haloC_1-C_8alkyl, e.g. trifluoromethyl, C_5-C_{10}aryl, e.g. phenyl or methoxyphenyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, e.g. morpholino, piperidino, piperazino or N-methylpiperazino, C_1-C_8alkoxy, e.g. methoxy, ethoxy or isopropoxy, haloC_1-C_8alkoxy, e.g. trifluoromethoxy, C_5-C_{10}aryloxy, e.g. phenoxy, unsubstituted or substituted heterocyclyloxy, e.g. 1-methyl-4-piperidyloxy, unsubstituted or substituted heterocyclylC_1-C_8alkoxy, e.g. 2-(1-imidazolyl)ethoxy, 3-morpholinopropoxy or 2-morpholinoethoxy, unsubstituted or substituted amino, e.g. methylamino or dimethylamino, halogen, e.g. fluoro or chloro, unsubstituted or substituted sulfamoyl, e.g. sulfamoyl, methylsulfamoyl or dimethylsulfamoyl, or nitro; preferably hydrogen, methyl, piperidino, piperazino, N-methylpiperazino, morpholino, methoxy, ethoxy, trifluoromethoxy, phenoxy, 1-methyl-4-piperidyloxy, 3-morpholinopropoxy, 2-morpholinoethoxy, 3-(N-methylpiperazino)-propoxy, methylamino, fluoro, chloro, sulfamoyl or nitro;

(j') R^{10} is C_1-C_8alkyl, e.g. methyl, ethyl or butyl, haloC_1-C_8alkyl, e.g. trifluoromethyl, C_1-C_8alkoxy, e.g. methoxy or ethoxy, unsubstituted or substituted heterocyclylC_1-C_8alkoxy, e.g. 2-(1-

imidazolyl)ethoxy, unsubstituted or substituted amino, e.g. methylamino or dimethylamino, halogen, e.g. fluoro or chloro; preferably methyl, butyl, methoxy, ethoxy, 2-(1-imidazolyl)ethoxy, methylamino, dimethylamino or fluoro; and

(k') each pair of adjacent substituents R^7 and R^8, or R^8 and R^9 or R^9 and R^{10}, are –NH-CH=CH-, -CH=CH-NH-, –NH-N=CH-, –CH=N-NH-, $-CH_2-CH_2-CH_2-$, $-CH_2-CH_2-CH_2-CH_2-$, $-O-CH_2-O-$, or $-O-CF_2-O-$; preferably the pair of adjacent substituents R^7 and R^8 or R^8 and R^9 being $-O-CH_2-O-$ or the pair of adjacent substituents R^9 and R^{10} being -NH-CH=CH-, -CH=N-NH-, $-CH_2-CH_2-CH_2-$, $-CH_2-CH_2-CH_2-CH_2-$ or $-O-CF_2-O-$.

Most preferred as compounds of the formula I are those wherein the substituents have the meaning given in the Examples.

In another embodiment of the invention the invention provides a compound of formula I' with the proviso that this does not include any of the compounds of examples 1 to 52 inclusive.



I'

in which:

n' is selected from 1, 2 and 3;

R'_1 is selected from C_{6-10}aryl, C_{5-10}heteroaryl, C_{3-12}cycloalkyl and C_{3-10}heterocycloalkyl;

wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl of R'_1 is optionally substituted by 1 to 3 radicals independently selected from C_{1-6}alkyl, C_{1-6}alkoxy, alkoxy-substituted-C_{1-6}alkyl, halo-substituted-C_{1-6}alkyl, halo-substituted-C_{1-6}alkoxy, $-C(O)NR'_5R'_8$, $-S(O)_{0-2}NR'_5R'_6$, $-S(O)_{0-2}R'_5$, $-C(O)R'_4$, $-OXR'_4$, $-NR'_5XNR'_5R'$, $-OXNR'_5R'_6$, $-OXOR'_5$ and $-XR'_4$;

wherein X' is a bond or C_{1-6}alkylene; R'_5 is selected from hydrogen and C_{1-6}alkyl; R'_6 is selected from hydrogen, C_{1-6}alkyl and C_{3-12}cycloalkyl-C_{1-4}alkyl; and R'_4 is independently selected from C_{6-10}aryl, C_{5-10}heteroaryl, C_{3-12}cycloalkyl and C_{3-10}heterocycloalkyl;

and any aryl, heteroaryl, cycloalkyl or heterocycloalkyl of R'_4 is optionally substituted by 1 to 3 radicals independently selected from C_{1-6}alkyl, C_{3-10}heterocycloalkyl-C_{0-4}alkyl optionally substituted with C_{1-6}alkyl, $-C(O)NR'_5R'_6$, $-XNR'_5R'_6$, $-NR'_5XNR'_5R'_6$ and $-NR'_5C(O)R'_6$; wherein X is a bond or C_{1-6}alkylene; R'_5 and R'_6 are independently selected from hydrogen and C_{1-6}alkyl;

R'_2 is selected from hydrogen and halo, cyano, C_{1-6}alkyl, halo-substituted-C_{1-6}alkyl;

R'_3 is selected from halo, $-S(O)_{0-2}NR'_5R'_6$, $-S(O)_{0-2}R'_6$, $-NR'_5S(O)_{0-2}R'_6$, $-C(O)NR'_5R'_6$, $-C(O)R'_6$ and $-C(O)OR'_6$; wherein R'_5 is selected from hydrogen and C_{1-6}alkyl; and R'_6 is selected from hydrogen, C_{1-6}alkyl and C_{3-12}cycloalkyl;

and the pharmaceutically acceptable salts, hydrates, solvates, isomers and prodrugs thereof.

Preferably a compound of fomula I' in which:

n' is selected from 1 and 2;

R'_1 is selected from C_{6-10}aryl and C_{5-10}heteroaryl; wherein any aryl or heteroaryl of R_1 is optionally substituted by 1 to 3 radicals independently selected from C_{1-6}alkyl, C_{1-6}alkoxy, $-C(O)NR'_5R'_6$, $-OX'R'_4$, $-C(O)R'_4$, $-NR'_5X'NR'_5R'_6$, $-OX'NR'_5R'_6$, $-OX'OR'_5$ and $-X'R'_4$; wherein X' is a bond or C_{1-6}alkylene; R'_5 is selected from hydrogen and C_{1-6}alkyl; R'_6 is selected from hydrogen, C_{1-6}alkyl and C_{3-12}cycloalkyl-C_{1-4}alkyl; and R'_4 is C_{3-10}heterocycloalkyl optionally substituted by 1 to 3 radicals independently selected from C_{1-6}alkyl, halo-substituted-C_{1-6}alkyl, C_{3-10}heterocycloalkyl-C_{0-4}alkyl optionally substituted with C_{1-6}alkyl, $-C(O)NR'_5R'_6$, $-X'NR'_5R'_6$, $-NR'_5X'NR'_5R'_6$ and $-NR'_5C(O)R'_6$; wherein X' is a bond or C_{1-6}alkylene; R'_5 and R'_6 are independently selected from hydrogen and C_{1-6}alkyl;

R'_2 is selected from hydrogen and halo;

R'_3 is selected from halo, $-S(O)_{0-2}NR'_5R'_6$, $-S(O)_{0-2}R'_6$, $-NR'_5S(O)_{0-2}R'_6$, $-C(O)NR'_5R'_6$ and $-C(O)OR'_6$; wherein R'_5 is selected from hydrogen and C_{1-6}alkyl; and R'_6 is selected from hydrogen, C_{1-6}alkyl and C_{3-12}cycloalkyl.

more prefably a compound of formula I' in which R'_1 is selected from phenyl, pyridinyl, pyrazolyl and pyrimidinyl; wherein any aryl or heteroaryl of R'_1 is optionally substituted by 1 to 3 radicals independently selected from ethoxy, ethyl, propyl, methyl, t-butyl, trifluoromethyl, nitrile,

cyclobutyloxy, 2,2,2-trifluoroethoxy, methoxy, isobutyloxy, t-butyloxy, isopropyloxy, methyl-amino-carbonyl, cyclopropyl-methoxy, dimethylamino-propyl-amino, methoxy-ethoxy, -X'R'$_4$, -C(O)R'$_4$ and –OX'R'$_4$; wherein X' is a bond, methylene or ethylene; R'$_4$ is selected from piperazinyl, piperidinyl, pyrrolidinyl, morpholino, azepanyl and 1,4-dioxa-8-aza-spiro[4.5]dec-8-yl; wherein R'$_4$ is optionally substituted by 1 to 3 radicals independently selected from methyl, isopropyl, acetyl, acetyl-methyl-amino, 3-dimethylamino-2,2-dimethyl-propylamino, ethyl-methyl-amino-ethoxy, diethyl-amino-ethoxy, amino-carbonyl, ethyl, 2-oxo-pyrrolidin-1-yl, pyrrolidinyl, pyrrolidinyl-methyl, piperidinyl optionally substituted with methyl or ethyl, morpholino, dimethylamino, dimethylamino-propyl-amino, methyl-amino and ethyl-amino.

Even more preferably a compound of of formula I' in which R'$_2$ is selected from hydrogen and halo; and R'$_3$ is selected from halo, dimethyl-sulfamoyl, isobutyl-sulfamoyl, methyl-sulfamoyl, ethyl-sulfamoyl, propyl-sulfonyl, ethyl-amino-carbonyl, 1-ethyl-propyl-sulfamoyl, cyclopentyl-sulfamoyl, isopropyl-sulfamoyl, cyclohexyl-sulfonyl, cyclopropyl-methyl-sulfamoyl, cyclobutyl-sulfamoyl, isopropyl-sulfonyl,

Most preferably a compound of example 53

In a yet further embodiment of the invention the present invention also provides a process for the production of a compound of formula I, comprising reacting a compound of formula II



(II)

wherein R^0, R^1, R^2, R^3, R^4, R^5, and R^6 are as defined above, and Y is a leaving group, preferably halogen such as bromide, iodine, or in particular chloride;

with a compound of formula III



(III)

wherein R^7, R^8, R^9 and R^{10} are as defined above;

and, if desired, converting a compound of formula I, wherein the substituents have the meaning as defined above, into another compound of formula I as defined;

and recovering the resulting compound of formula I in free from or as a salt, and, when required, converting the compound of formula I obtained in free form into the desired salt, or an obtained salt into the free form.

The reaction can be carried out in a manner known per se, the reaction conditions being dependent especially on the reactivity of the leaving group Y and the reactivity of the amino group in the aniline of formula III, usually in the presence of a suitable solvent or diluent or of a mixture thereof and, if necessary, in the presence of an acid or a base, with cooling or, preferably, with heating, for example in a temperature range from approximately -30°C to approximately +150°C, especially approximately from 0°C to +100°C, preferably from room temperature (approx. +20 °C) to +80 °C, in an open or closed reaction vessel and/or in the atmosphere of an inert gas, for example nitrogen. Alternatively, the reaction can proceed in the presence of a suitable catalyst (for example, palladium di-benzyl-acetone), in the presence of a base (for example, caesium carbonate) and in the presence of a suitable reaction facilitator (for example, xanthphos).

If one or more other functional groups, for example carboxy, hydroxy or amino, are or need to be protected in a compound of formula II or III, because they should not take part in the reaction, these are such groups as are usually used in the synthesis of peptide compounds, cephalosporins and penicillins, as well as nucleic acid derivatives and sugars.

The protecting groups may already be present in precursors and should protect the functional groups concerned against unwanted secondary reactions, such as substitution reaction or

solvolysis. It is a characteristic of protecting groups that they lend themselves readily, i.e. without undesired secondary reactions, to removal, typically by solvolysis, reduction, photolysis or also by enzyme activity, for example under conditions analogous to physiological conditions, and that they are not present in the end-products. The specialist knows, or can easily establish, which protecting groups are suitable with the reactions mentioned hereinabove.

Salts of a compound of formula I with a salt-forming group may be prepared in a manner known per se. Acid addition salts of compounds of formula I may thus be obtained by treatment with an acid or with a suitable anion exchange reagent.

Salts can usually be converted to compounds in free form, e.g. by treating with suitable basic agents, for example with alkali metal carbonates, alkali metal hydrogencarbonates, or alkali metal hydroxides, typically potassium carbonate or sodium hydroxide.

Stereoisomeric mixtures, e.g. mixtures of diastereomers, can be separated into their corresponding isomers in a manner known per se by means of suitable separation methods. Diastereomeric mixtures for example may be separated into their individual diastereomers by means of fractionated crystallization, chromatography, solvent distribution, and similar procedures. This separation may take place either at the level of a starting compound or in a compound of formula I itself. Enantiomers may be separated through the formation of diastereomeric salts, for example by salt formation with an enantiomer-pure chiral acid, or by means of chromatography, for example by HPLC, using chromatographic substrates with chiral ligands.

It should be emphasized that reactions analogous to the conversions mentioned in this chapter may also take place at the level of appropriate intermediates.

The compounds of formula I, including their salts, are also obtainable in the form of hydrates, or their crystals can include for example the solvent used for crystallization (present as solvates).

The compound of formula II used as starting materials may be obtained by reacting a compound of formula IV



(IV)

with a compound of formula V



(V)

wherein R^1, R^2, R^3, R^4, R^5 and R^6 are as defined above, and Y^1 and Y^2 are identical or different leaving groups as defined above for Y. The reaction conditions are those mentioned above for the reaction of a compound of formula II with a compound of formula III.

The compounds of formula IV and V are known or may be produced in accordance with known procedures.

The compounds of formula I and their pharmaceutically acceptable salts exhibit valuable pharmacological properties when tested in vitro in cell-free kinase assays and in cellular assays, and are therefore useful as pharmaceuticals. In particular, the compounds of the invention are inhibitors of Focal Adhesion Kinase, and are useful as pharmaceuticals to treat conditions caused by a malfunction of signal cascades connected with Focal Adhesion Kinase, in particular tumors as described hereinbelow.

Focal Adhesion Kinase (FAK) is a key enzyme in the integrin-mediated outside-in signal cascade (D. Schlaepfer et al., Prog Biophys Mol Biol 1999, 71, 435-478). Interaction between cells and extracellular matrix (ECM) proteins is transduced as intracellular signals important for growth, survival and migration through cell surface receptors, integrins. FAK plays an essential role in these integrin-mediated outside-in signal cascades. The trigger in the signal transduction cascade is the autophosphorylation of Y397. Phosphorylated Y397 is a SH2 docking site for Src family tyrosine kinases. The bound c-Src kinase phosphorylates other tyrosine residues in FAK. Among them, phsophorylated Y925 becomes a binding site for the SH2 site of Grb2 small adaptor protein. This direct binding of Grb2 to FAK is one of the key steps for the activation of down stream targets such as the Ras-ERK2/MAP kinase cascade.

The inhibition of endogenous FAK signalling results in reduced motility and in some cases induces cell death. On the other hand, enhancing FAK signalling by exogenous expression increases cell motility and transmitting a cell survival signal from ECM. In addition FAK is overexpressed in invasive and metastatic epithelial, mesenchymal, thyroid and prostate cancers. Consequently, an inhibitor of FAK is likely to be a drug for anti-tumor growth and metastasis. The compounds of the invention are thus indicated, for example, to prevent and/or treat a vertebrate and more particularly a mammal, affected by a neoplastic disease, in particular breast tumor, cancer of the bowel (colon and rectum), stomach cancer and cancer of the ovary and prostate, non-small cell lung cancer, small cell lung cancer, cancer of liver, melanoma, bladder tumor and cancer of head and neck.

The relation between FAK inhibition and immuno-system is described e.g. in G.A. van Seventer et al., Eur. J. Immunol. 2001, 31, 1417-1427. Therefore, the compounds of the invention are, for example, useful to prevent and/or treat a vertebrate and more particularly a mammal, affected by immune system disorders, diseases or disorders mediated by T lymphocytes, B lymphocytes, mast cells and/or eosinophils e.g. acute or chronic rejection of organ or tissue allo- or xenografts, atherosclerosis, vascular occlusion due to vascular injury such as angioplasty, restenosis, hypertension, heart failure, chronic obstructive pulmonary disease, CNS disease such as Alzheimer disease or amyotrophic lateral sclerosis, cancer, infectious disease such as AIDS, septic shock or adult respiratory distress syndrome, ischemia/reperfusion injury e.g. myocardial infarction, stroke, gut ischemia, renal failure or hemorrhage shock, or traumatic shock. The agent of the invention are also useful in the treatment and/or prevention of acute or chronic inflammatory diseases or disorders or autoimmune diseases e.g. rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, diabetes (type I and II) and the disorders associated with therewith, respiratory diseases such as asthma or inflammatory liver injury, inflammatory glomerular injury, cutaneous manifestations of immunologically-mediated disorders or illnesses, inflammatory and hyperproliferative skin diseases (such as psoriasis, atopic dermatitis, allergic contact dermatitis, irritant contact dermatitis and further eczematous dermatitises, seborrhoeic dermatitis), inflammatory eye diseases, e.g. Sjoegren's syndrome, keratoconjunctivitis or uveitis, inflammatory bowel disease, Crohn's disease or ulcerative colitis.

Compounds of the invention are active in a FAK assay system as described in the Examples, and show an inhibition IC_{50} in the range of 1 nM to 100 nM. Particularly active are the compounds Example No. 3-12 and No. 3-17 described hereinbelow showing IC_{50} vales in the range of 1 to 5 nM.

Some of the compounds of the invention exhibit also ZAP-70 (zeta chain-associated protein of 70 kD) protein tyrosine kinase inhibiting activity. ZAP-70 protein tyrosine kinase interaction of the agents of the invention may be demonstrated by their ability to prevent phosphorylation of e.g. LAT-11 (linker for activation of T cell) by human ZAP-70 protein tyrosine kinase in aqueous solution, as described in the Examples. The compounds of the invention are thus also indicated for the prevention or treatment of disorders or diseases where ZAP-70 inhibition inhibition play a role.
Compounds of the invention are active in a ZAP-70 assay system as described in the Examples, and show an inhibition IC_{50} in the range of 1 μM to 10 μM, e.g. the compounds Example No. 2 and No. 3-2 described hereinbelow.

Compounds of the present invention are also good inhibitors of the IGF-IR (insulin like growth factor receptor 1) and are therefore useful in the treatment of IGF-1R mediated diseases for example such diseases include proliferative diseases, such as tumours, like for example breast, renal, prostate, colorectal, thyroid, ovarian, pancreas, neuronal, lung, uterine and gastro-intestinal tumours as well as osteosarcomas and melanomas. The efficacy of the compounds of the invention as inhibitors of IGF-IR tyrosine kinase activity can be demonstrated using a cellular "Capture ELISA". In this assay the activity of the compounds of the invention against Insulin-like growth factor I (IGF-I) induced autophosphorylation of the IGF-IR is determined.

The compounds of formula I and their pharmaceutically acceptable salts exhibit valuable pharmacological properties when tested in vitro in cell-free kinase assays and in cellular assays, and are therefore useful as pharmaceuticals. In particular, the compounds of the invention are inhibitors of Anaplastic Lymphoma Kinase (ALK), and are useful as pharmaceuticals to treat conditions caused by a malfunction of signal cascades connected with Anaplastic Lymphoma Kinase, in particular tumors as described hereinbelow.

ALK-mediated signaling could play a role in the development and/or progression of a number of common solid tumors (Pulford, K., et al., J. Cell. Physiol. 2004 Jun;199(3):330-58). The

compounds of the present invention also exhibit powerful inhibition of the tyrosine kinase activity of anaplastic lymphoma kinase (ALK) and its fusion proteins, particularly the fusion protein of NPM-ALK . This protein tyrosine kinase results from a gene fusion of nucleophosmin (NPM) and the anaplastic lymphoma kinase (ALK), rendering the protein tyrosine kinase activity of ALK ligand-independent. NPM-ALK plays a key role in signal transmission in a number of hematopoetic and other human cells leading to hematological and neoplastic diseases, for example in anaplastic large-cell lymphoma (ALCL) and non-Hodgkin's lymphomas (NHL), specifically in ALK+ NHL or Alkomas, in inflammatory myofibroblastic tumors (IMT) and neuroblastomas. (Duyster J et al. 2001 Oncogene 20, 5623-5637). NPM-ALK has been shown to be a potent oncogene in vitro, being able to transform various cell lines and primary hematopoetic cells. Furthermore, NPM-ALK transduced bone marrow cells are able to induce a lymphoma-like disease after transplantation into irradiated recipient mice. Signaling pathways activated by NPM-ALK include ras, PLC and PI3K pathways and, in addition, STAT5 has been shown to be phosphorylated by NPM-ALK. In addition to NPM-ALK, other gene fusions have been identified in human hematological and neoplastic diseases; mainly TPM3-ALK (a fusion of nonmuscle tropomyosin 3 with ALK). Further, the ALK fusion protein CLTC-ALK, is associated with diseases that include classical T cell or null ALCL, ALK^+ DLBCL and inflammatory myofibroblastic tumors. CLTCL-ALK is also thought to play a role in the pathogenesis of large B-cell lymphomas.

Further, the ALK fusion protein CLTC-ALK is associated with diseases that include classical T cell or null ALCL, ALK^+ DLBCL and inflammatory myofibroblastic tumors. CLTCL-ALK is also thought to play a role in the pathogenesis of large B-cell lymphomas.
Aberrant activity of ALK is involved in the development of brain tumors and overexpression of ALK has been reported in neuroblastomas and several cell lines derived from neural tissue. ALK-mediated signaling could play a role in the development and/or progression of a number of common solid tumors (Pulford, K., et al., J. Cell. Physiol. 2004 Jun;199(3):330-58).

The inhibition of ALK tyrosine kinase activity can be demonstrated using known methods, for example using the recombinant kinase domain of the ALK in analogy to the VEGF-R kinase assay described in J. Wood et al. Cancer Res. 60, 2178-2189 (2000). In vitro enzyme assays using GST-ALK protein tyrosine kinase are performed in 96-well plates as

a filter binding assay in 20 mM Tris·HCl, pH = 7.5, 3 mM $MgCl_2$, 10 mM $MnCl_2$, 1 mM DTT, 0.1 µCi/assay (=30 µl) [γ-^{33}P]-ATP, 2 µM ATP, 3 µg/ml poly (Glu, Tyr 4:1) Poly-EY (Sigma P-0275), 1 % DMSO, 25 ng ALK enzyme. Assays are incubated for 10 min at ambient temperature. Reactions are terminated by adding 50 µl of 125 mM EDTA, and the reaction mixture is transferred onto a MAIP Multiscreen plate (Millipore, Bedford, MA, USA), previously wet with methanol, and rehydrated for 5 min with H_2O. Following washing (0.5 % H_3PO_4), plates are counted in a liquid scintillation counter. IC_{50} values are calculated by linear regression analysis of the percentage inhibition. Compared with the control without inhibitor, the compounds of formula I inhibit the enzyme activity by 50 % (IC_{50}), for example in a concentration of from 0.001 to 0.5 µM, especially from 0.01 to 0.1 µM.

The compounds of formula I potently inhibit the growth of human NPM-ALK overexpressing murine BaF3 cells (DSMZ Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany). The expression of NPM-ALK is achieved by transfecting the BaF3 cell line with an expression vector pCIneo™ (Promega Corp., Madison WI, USA) coding for NPM-ALK and subsequent selection of G418 resistant cells. Non-transfected BaF3 cells depend on IL-3 for cell survival. In contrast NPM-ALK expressing BaF3 cells (named BaF3-NPM-ALK hereinafter) can proliferate in the absence of IL-3 because they obtain proliferative signal through NPM-ALK kinase. Putative inhibitors of the NPM-ALK kinase therefore abolish the growth signal and result in antiproliferative activity. The antiproliferative activity of putative inhibitors of the NPM-ALK kinase can however be overcome by addition of IL-3 which provides growth signals through an NPM-ALK independent mechanism. [For an analogous cell system using FLT3 kinase see E Weisberg et al. Cancer Cell; 1, 433-443 (2002)]. The inhibitory activity of the compounds of formula I is determined, briefly, as follows: BaF3-NPM-ALK cells (15,000/microtitre plate well) are transferred to 96-well microtitre plates. The test compounds [dissolved in dimethyl sulfoxide (DMSO)] are added in a series of concentrations (dilution series) in such a manner that the final concentration of DMSO is not greater than 1 % (v/v). After the addition, the plates are incubated for two days during which the control cultures without test compound are able to undergo two cell-division cycles. The growth of the BaF3-NPM-ALK cells is measured by means of Yopro™ staining [T Idziorek et al. J. Immunol. Methods; 185: 249-258 (1995)]: 25 µl of lysis buffer consisting of 20 mM sodium citrate, pH 4.0, 26.8 mM sodium chloride, 0.4 % NP40, 20 mM EDTA and 20 mM is added to each well. Cell lysis is completed within 60 min at room temperature and total amount of Yopro bound to DNA is determined by

measurement using the Cytofluor II 96-well reader (PerSeptive Biosystems) with the following settings: Excitation (nm) 485/20 and Emission (nm) 530/25.
IC_{50} values are determined by a computer-aided system using the formula:

$$IC_{50} = [(ABS_{test} - ABS_{start})/(ABS_{control} - ABS_{start})] \times 100. \text{ (ABS = absorption)}$$

The IC_{50} value in those experiments is given as that concentration of the test compound in question that results in a cell count that is 50 % lower than that obtained using the control without inhibitor. The compounds of formula I exhibit inhibitory activity with an IC_{50} in the range from approximately 0.01 to 1 μM.

The antiproliferative action of the compounds of formula I can also be determined in the human KARPAS-299 lymphoma cell line (DSMZ Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany) [described in WG Dirks et al. Int. J. Cancer 100, 49-56 (2002)] using the same methodology described above for the BaF3-NPM-ALK cell line. The compounds of formula I exhibit inhibitory activity with an IC_{50} in the range from approximately 0.01 to 1 μM.

The action of the compounds of formula I on autophosphorylation of the ALK can be determined in the human KARPAS-299 lymphoma cell line by means of an immunoblot as described in WG Dirks et al. Int. J. Cancer 100, 49-56 (2002). In that test the compounds of formula I exhibit an IC_{50} of approximately from 0.001 to 1 μM.

Among the compounds of formula I, 2-[5-chloro-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-N-methyl-benzamide is an especially potent ALK inhibitor, in that this compound inhibits the growth of the BaF3-NPM-ALK cells with an IC_{50} of 97 nM. Further specifically preferred compounds that inhibit the tyrosine kinase activity of anaplastic lymphoma kinase (ALK) are the compounds described hereinafter in the examples 7A and 7B, as well as 7-2, 7-15, 19-5, 21-1, 26-3 and 28-5, respectively, all of which are having an IC_{50} within the range from <0.5 to 200 nM.

For the above uses in the treatment of neoplastic diseases and immune system disorders the required dosage will of course vary depending on the mode of administration, the particular condition to be treated and the effect desired. In general, satisfactory results are indicated to be

obtained systemically at daily dosages of from about 0.1 to about 100 mg/kg body weight. An indicated daily dosage in the larger mammal, e.g. humans, is in the range from about 0.5 mg to about 2000 mg, conveniently administered, for example, in divided doses up to four times a day or in retard form.

The compounds of the invention may be administered by any conventional route, in particular parenterally, for example in the form of injectable solutions or suspensions, enterally, preferably orally, for example in the form of tablets or capsules, topically, e.g. in the form of lotions, gels, ointments or creams, or in a nasal or a suppository form. Pharmaceutical compositions comprising a compound of the invention in association with at least one pharmaceutical acceptable carrier or diluent may be manufactured in conventional manner by mixing with a pharmaceutically acceptable carrier or diluent. Unit dosage forms for oral administration contain, for example, from about 0.1 mg to about 500 mg of active substance. Topical administration is e.g. to the skin. A further form of topical administration is to the eye.

The pharmaceutical compositions of the present invention are prepared in a manner known per se, for example by means of conventional mixing, granulating, coating, dissolving or lyophilizing processes.

Preference is given to the use of solutions of the active ingredient, and also suspensions or dispersions, especially isotonic aqueous solutions, dispersions or suspensions which, for example in the case of lyophilized compositions comprising the active ingredient alone or together with a carrier, for example mannitol, can be made up before use. The pharmaceutical compositions may be sterilized and/or may comprise excipients, for example preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, salts for regulating osmotic pressure and/or buffers and are prepared in a manner known per se, for example by means of conventional dissolving and lyophilizing processes. The said solutions or suspensions may comprise viscosity-increasing agents, typically sodium carboxymethylcellulose, carboxymethylcellulose, dextran, polyvinylpyrrolidone, or gelatins, or also solubilizers, e.g. Tween 80® (polyoxyethylene(20)sorbitan mono-oleate).

Suspensions in oil comprise as the oil component the vegetable, synthetic, or semi-synthetic oils customary for injection purposes. In respect of such, special mention may be made of liquid fatty acid esters that contain as the acid component a long-chained fatty acid having from 8 to

22, especially from 12 to 22, carbon atoms, for example lauric acid, tridecylic acid, myristic acid, pentadecylic acid, palmitic acid, margaric acid, stearic acid, arachidic acid, behenic acid or corresponding unsaturated acids, for example oleic acid, elaidic acid, erucic acid, brassidic acid or linoleic acid, if desired with the addition of antioxidants, for example vitamin E, β-carotene or 3,5-di-tert-butyl-4-hydroxytoluene. The alcohol component of these fatty acid esters has a maximum of 6 carbon atoms and is a monovalent or polyvalent, for example a mono-, di- or trivalent, alcohol, for example methanol, ethanol, propanol, butanol or pentanol or the isomers thereof, but especially glycol and glycerol. As fatty acid esters, therefore, the following are mentioned: ethyl oleate, isopropyl myristate, isopropyl palmitate, "Labrafil M 2375" (polyoxyethylene glycerol), "Labrafil M 1944 CS" (unsaturated polyglycolized glycerides prepared by alcoholysis of apricot kernel oil and consisting of glycerides and polyethylene glycol ester), "Labrasol" (saturated polyglycolized glycerides prepared by alcoholysis of TCM and consisting of glycerides and polyethylene glycol ester; all available from Gattefossé, France), and/or "Miglyol 812" (triglyceride of saturated fatty acids of chain length C_8 to C_{12} from Hüls AG, Germany), but especially vegetable oils such as cottonseed oil, almond oil, olive oil, castor oil, sesame oil, soybean oil and more especially groundnut oil.

The manufacture of injectable preparations is usually carried out under sterile conditions, as is the filling, for example, into ampoules or vials, and the sealing of the containers.

Pharmaceutical compositions for oral administration can be obtained, for example, by combining the active ingredient with one or more solid carriers, if desired granulating a resulting mixture, and processing the mixture or granules, if desired or necessary, by the inclusion of additional excipients, to form tablets or tablet cores.

Suitable carriers are especially fillers, such as sugars, for example lactose, saccharose, mannitol or sorbitol, cellulose preparations, and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, and also binders, such as starches, for example corn, wheat, rice or potato starch, methylcellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone, and/or, if desired, disintegrators, such as the above-mentioned starches, also carboxymethyl starch, crosslinked polyvinylpyrrolidone, alginic acid or a salt thereof, such as sodium alginate. Additional excipients are especially flow conditioners and lubricants, for example silicic acid, talc, stearic acid or salts thereof, such as magnesium or calcium stearate, and/or polyethylene glycol, or derivatives thereof.

Tablet cores can be provided with suitable, optionally enteric, coatings through the use of, inter alia, concentrated sugar solutions which may comprise gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, or coating solutions in suitable organic solvents or solvent mixtures, or, for the preparation of enteric coatings, solutions of suitable cellulose preparations, such as acetylcellulose phthalate or hydroxypropylmethylcellulose phthalate. Dyes or pigments may be added to the tablets or tablet coatings, for example for identification purposes or to indicate different doses of active ingredient.

Pharmaceutical compositions for oral administration also include hard capsules consisting of gelatin, and also soft, sealed capsules consisting of gelatin and a plasticizer, such as glycerol or sorbitol. The hard capsules may contain the active ingredient in the form of granules, for example in admixture with fillers, such as corn starch, binders, and/or glidants, such as talc or magnesium stearate, and optionally stabilizers. In soft capsules, the active ingredient is preferably dissolved or suspended in suitable liquid excipients, such as fatty oils, paraffin oil or liquid polyethylene glycols or fatty acid esters of ethylene or propylene glycol, to which stabilizers and detergents, for example of the polyoxyethylene sorbitan fatty acid ester type, may also be added.

Pharmaceutical compositions suitable for rectal administration are, for example, suppositories that consist of a combination of the active ingredient and a suppository base. Suitable suppository bases are, for example, natural or synthetic triglycerides, paraffin hydrocarbons, polyethylene glycols or higher alkanols.

For parenteral administration, aqueous solutions of an active ingredient in water-soluble form, for example of a water-soluble salt, or aqueous injection suspensions that contain viscosity-increasing substances, for example sodium carboxymethylcellulose, sorbitol and/or dextran, and, if desired, stabilizers, are especially suitable. The active ingredient, optionally together with excipients, can also be in the form of a lyophilizate and can be made into a solution before parenteral administration by the addition of suitable solvents.

Solutions such as are used, for example, for parenteral administration can also be employed as infusion solutions.

Preferred preservatives are, for example, antioxidants, such as ascorbic acid, or microbicides, such as sorbic acid or benzoic acid.

The compounds of the invention may be administered as the sole active ingredient or together with other drugs useful against neoplastic diseases or useful in immunomodulating regimens. For example, the agents of the invention may be used in accordance with the invention in combination with pharmaceutical compositions effective in various diseases as described above, e.g. with cyclophosphamide, 5-fluorouracil, fludarabine, gemcitabine, cisplatinum, carboplatin, vincristine, vinblastine, etoposide, irinotecan, paclitaxel, docetaxel, rituxan, doxorubicine, gefitinib, or imatinib; or also with cyclosporins, rapamycins, ascomycins or their immunosuppressive analogs, e.g. cyclosporin A, cyclosporin G, FK-506, sirolimus or everolimus, corticosteroids, e.g. prednisone, cyclophosphamide, azathioprene, methotrexate, gold salts, sulfasalazine, antimalarials, brequinar, leflunomide, mizoribine, mycophenolic acid, mycophenolate, mofetil, 15-deoxyspergualine, immuno-suppressive monoclonal antibodies, e.g. monoclonal antibodies to leukocyte receptors, e.g. MHC, CD2, CD3, CD4, CD7, CD25, CD28, CD40, CD45, CD58, CD80, CD86, CD152, CD137, CD154, ICOS, LFA-1, VLA-4 or their ligands, or other immunomodulatory compounds, e.g. CTLA4Ig.

In accordance with the foregoing, the present invention also provides:

(1) A compound of the invention for use as a pharmaceutical;
(2) a compound of the invention for use as a 5-Chloro-N*2*-{2-methoxy-4-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-phenyl}-N*4*-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine, for example for use in any of the particular indications hereinbefore set forth;
(3) a pharmaceutical composition, e.g. for use in any of the indications herein before set forth, comprising a compound of the invention as active ingredient together with one or more pharmaceutically acceptable diluents or carriers;
(4) a method for the treatment of any particular indication set forth hereinbefore in a subject in need thereof which comprises administering an effective amount of a compound of the invention or a pharmaceutical composition comprising same;
(5) the use of a compound of the invention for the manufacture of a medicament for the treatment or prevention of a disease or condition in which FAK and/or ALK and/or ZAP-70 and/or IGF-I activation plays a role or is implicated, preferably ALK;

(6) the method as defined above under (4) comprising co-administration, e.g. concomitantly or in sequence, of a therapeutically effective amount of a compound of the invention and one or more further drug substances, said further drug substance being useful in any of the particular indications set forth hereinbefore;
(7) a combination comprising a therapeutically effective amount of a compound of the invention and one or more further drug substances, said further drug substance being useful in any of the particular indications set forth hereinbefore;
(8) use of a compound of the invention for the manufacture of a medicament for the treatment or prevention of a disease which responds to inhibition of the anaplastic lymphoma kinase;
(9) the use according to (8), wherein the disease to be treated is selected from lymphoma, anaplastic large-cell lymphoma, non-Hodgkin's lymphomas, inflammatory myofibroblastic tumors and neuroblastomas;
(10) the use according to (8) or (9), wherein the compound is 2-[5-chloro-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-N-methyl-benzamide or 5-Chloro-N*2*-{2-methoxy-4-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-phenyl}-N*4*-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine or a pharmaceutically acceptable salt thereof, or any of the the compounds described hereinafter in the examples or a pharmaceutically acceptable salt of any one of these;
(11) a method for the treatment of a disease which responds to inhibition of the anaplastic lymphoma kinase, especially a disease selected from anaplastic large-cell lymphoma, non-Hodgkin's lymphomas, inflammatory myofibroblastic tumors and neuroblastomas, comprising administering an effective amount of a compound of the invention, especially 2-[5-chloro-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-N-methyl-benzamide or 5-Chloro-N*2*-{2-methoxy-4-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-phenyl}-N*4*-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine or a pharmaceutically acceptable salt thereof.

Additionally preferred a compound according to the present invention that is useful as herein before described is a compound specifically mentioned in the examples.
Additional specifically preferred compounds according to the present invention that are useful either as FAK inhibitor, as ALK inhibitor or for inhibition of both and which may be prepared essentially according to the methods described hereinbefore are the following:
2-[5-chloro-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-N-methyl-benzamide,

N^2-(4-[1,4']Bipiperidinyl-1'-yl-2-methoxy-phenyl)-5-chloro-N^4-[2-(propane-1-sulfonyl)-phenyl]-pyrimidine-2,4-diamine,
2-{5-Chloro-2-[2-methoxy-4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-ylamino}-N-isopropyl-benzenesulfonamide,
2-[5-Bromo-2-(2-methoxy-5-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-N-methyl-benzenesulfonamide
2-{2-[5-(1-Acetyl-piperidin-4-yloxy)-2-methoxy-phenylamino]-5-bromo-pyrimidin-4-ylamino}-N-methyl-benzenesulfonamide,
N-[5-Bromo-2-(2,5-dimethoxy-phenylamino)-pyrimidin-4-yl]-N-(4-morpholin-4-yl-phenyl)-methanesulfonamide,
5-Bromo-N-4-(4-fluoro-phenyl)-N*2*-(2-methoxy-4-morpholin-4-yl-phenyl)-pyrimidine-2,4-diamine,
2-[5-Chloro-2-(2-methoxy-4-piperazin-1-yl-phenylamino)-pyrimidin-4-ylamino]-N-methyl-benzenesulfonamide,
2-[5-Bromo-2-(5-fluoro-2-methoxy-phenylamino)-pyrimidin-4-ylamino]-N-methyl-benzenesulfonamide,
2-[5-Chloro-2-(5-fluoro-2-methoxy-phenylamino)-pyrimidin-4-ylamino]-N-isobutyl-benzenesulfonamide, and
2-{5-Chloro-2-[2-methoxy-5-(4-methyl-piperazin-1-ylmethyl)-phenylamino]-pyrimidin-4-ylamino}-N-methyl-benzenesulfonamide,
5-Chloro-N*2*-{2-methoxy-4-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-phenyl}-N*4*-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine.

The invention also provides a compound of formula 2-{5-Chloro-2-[4-(3-methylamino-pyrrolidin-1-yl)-phenylamino]-pyrimidin-4-ylamino}-N-isopropyl-benzenesulfonamide

The invention also provides a compound of formula 5-Chloro-N*2*-{2-methoxy-4-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-phenyl}-N*4*-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine

The following Examples serve to illustrate the invention without limiting the invention in its scope.

Examples

Abbreviations

AcOH = acetic acid, ALK = anaplastic lymphoma kinase, ATP = adenosine 5'-triphosphate, brine = saturated sodium chloride solution, BSA = bovine serum albumin, DIAD = diisopropyl azodicarboxylate, DIPCDI = N,N'-diisopropylcarbodiimid, DMAP = 4-dimethylaminopyridine, DMF = N,N-dimethylformamide, DTT = 1,4-dithio-D,L-threitol, EDTA = ethylene diamine tetraacetic acid, Et = ethyl, EtOAc = ethyl acetate, EtOH = ethanol, Eu-PT66 = LANCE™ europium-W1024-labelled anti-phosphotyrosine antibody (Perkin Elmer), FAK = Focal Adhesion Kinase, FRET = fluorescence resonance energy transfer, HEPES = N-2-hydroxyethyl-piperazine-N'-2-ethanesulfonic acid, HOAt = 1-hydroxy-7-azabenzotriazole, Me = methyl, RT-PCR = reverse transcription polymerase chain reaction, SA-(SL)APC = Streptavidin conjugated to SuperLight™ allophycocyanin (Perkin Elmer), subst. = substituted, TBTU = O-(benzotriazol-1-yl)-N,N,N',N'-tetramethylammonium tetrafluoroborate, THF = tetrahydrofuran.

Example 1: 2-[2-(2,5-Dimethoxy-phenylamino)-5-nitro-pyrimidin-4-ylamino]-N-methyl-benzenesulfonamide



To a solution of 2-(2-chloro-5-nitro-pyrimidin-4-ylamino)-N-methyl-benzenesulfonamide (100 mg, 0.29 mmol) in EtOH (3 mL), 2,5-dimethoxyaniline (49 mg, 0.32 mmol) is added at room temperature. The mixture is heated at 78°C for 5 h. The solvent is evaporated, and the mixture is purified by reverse phase HPLC to give the title product in.

Rf = 0.47 (n-hexane : ethyl acetate = 1:1). ^{1}H-NMR (400 MHz, $CDCl_3$), δ (ppm): 2.36 (d, 3H), 3.57 (s, 3H), 3.73 (s, 3H), 6.72 (d, 1H), 6.99 (d, 1H), 7.17 (s, 1H), 7.35 (t, 1H), 7.4-7.6 (m, 1H), 7.63 (d, 1H), 7.81 (d, 1H), 8.0-8.2 (m, 1H), 9.13 (s, 1H), 9.41 (br.s, 1H), 11.0 (s, 1H).

Preparation of 2-(2-chloro-5-nitro-pyrimidin-4-ylamino)-N-methyl-benzenesulfonamide:

2,4-Dichloro-5-nitro-pyrimidine (1.94 g, 10 mmol) and 2-amino-N-methyl-benzenesulfonamide (1.86 g, 10 mmol) are dissolved in $CHCl_3$ (30 mL). The reaction mixture is heated at 61°C for 2 h. The solvent is evaporated and the residue is washed with ether to give the title product.

Rf = 0.5 (n-hexane : ethyl acetate = 1:1). ^{1}H-NMR (400MHz, $CDCl_3$), δ (ppm): 2.67 (d, 3H), 4.6-4.7 (m, 2H), 7.41 (dd, 1H), 7.7 (dd, 1H), 8.04 (d, 1H), 8.15 (d, 1H), 9.21 (s, 1H), 11.2 (s, 1H).

Example 2: 2-[5-Bromo-2-(2,4-dimethoxy-phenylamino)-pyrimidin-4-ylamino]-N-methyl-benzenesulfonamide



To a solution of 2-(5-bromo-2-chloro-pyrimidin-4-ylamino)-N-methyl-benzenesulfonamide (300 mg, 0.79 mmol), 2,4-dimethoxyaniline (181.5 mg, 1.18 mmol) in ethanol (3 mL), 1 N hydrochloric acid (0.03 mL) is added and stirred under reflux condition for 5 hours. The reaction mixture is cooled to room temperature, poured into water and extracted twice with ethyl acetate. The organic layer is successively washed with water and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue is purified with silica gel column chromatography (n-hexane : ethyl acetate = 5:1 to 1:1) to afford the title compound.
^{1}H-NMR ($CDCl_3$), δ (ppm): 8.95 (s, 1H), 8.44 (d, 1H), 8.20 (s, 1H), 7.98 (dd, 1H), 7.58 (ddd, 1H), 7.22-7.32 (m, 1H), 6.51 (d, 1H), 6.40 (d, 1H), 4.56-4.48 (m, 1H), 3.86 (s, 3H), 3.81 (s, 3H), 2.64 (d, 3H). Rf (n-hexane : ethyl acetate = 1:1): 0.31.

Preparation of 2-(5-bromo-2-chloro-pyrimidin-4-ylamino)-N-methyl-benzenesulfonamide
A solution of 5-bromo-2,4-dichloropyrimidine (684 mg, 3.0 mmol) and 2-amino-N-methyl-benzenesulfonamide (559 mg, 3.0 mmol) in N,N-dimethylformamide (10 mL) containing potassium carbonate (830 mg, 6.0 mmol) is stirred at room temperature for 23 hours. Saturated aqueous ammonium chloride is added and the mixture is poured into water and extracted twice with ethyl acetate. The organic layer is washed with brine, dried over sodium sulfate, and evaporated in vacuo. The residue is purified with silica gel column chromatography (n-hexane - ethyl acetate gradient) to afford the title compound as a slightly yellow solid.
^{1}H-NMR ($CDCl_3$), δ (ppm): 2.67 (d, 3H), 4.79 (q, 1H), 7.26 (s, 1H), 7.29 (ddd, 1H), 7.66 (ddd, 1H), 7.95 (dd, 1H), 8.37 (s, 1H), 8.48 (d, 1H), 9.52 (s, 1H). Rf (n-hexane : ethyl acetate = 10:3): 0.33.

Example 3:

The following 2-[5-bromo-2-(subst. phenylamino)-pyrimidin-4-ylamino]-N-methyl-benzene-sulfonamides are prepared from 2-(5-bromo-2-chloro-pyrimidin-4-ylamino)-N-methyl-benzenesulfonamide and the corresponding aniline following the procedure of Example 2:



ExplNo.	Rx	Rf (solvent) or MS	^{1}H-NMR (400MHz), δ (ppm)
3-1		0.48 (*n*-hexane: AcOEt=1:1)	$CDCl_3$: 2.64(d, 3H), 4.48-4.40(m, 1H), 6.78(d,1H), 6.87(bs, 1H), 6.99(dd, 1H), 6.82(s, 1H),7.54(ddd, 1H), 7.79(d, 1H), 7.97(dd, 1H), 8.28(s, 1H), 8.32(dd, 1H), 9.07(s, 1H)
3-2		0.58 (*n*-hexane: AcOEt=1:1)	$CDCl_3$: 2.25(s, 3H), 2.33(s, 3H), 2.63(d, 3H), 4.53-4.45(m, 1H), 6.61(bs, 1H), 6.99(dd, 1H), 7.04(s, 1H), 7.18(ddd, 1H), 7.43(ddd, 1H), 7.56(d, 1H), 7.92(dd, 1H), 8.19(s, 1H), 8.41(dd, 1H), 9.08(s, 1H)
3-3		0.36 (*n*-hexane: AcOEt=1:1)	$CDCl_3$: 2.23(s, 3H), 2.62(d, 3H), 3.69(s, 3H), 4.53-4.44(m, 1H), 6.62(dd, 1H), 6.69(bs, 1H), 7.10(d, 1H), 7.19(dd, 1H), 7.48(d, 1H), 7.51(dd, 1H), 7.93(dd, 1H), 8.22(s, 1H), 8.44(dd, 1H), 9.09(s1, 1H)
3-4		0.41 (*n*-hexane: AcOEt=1:1)	$CDCl_3$: 2.32(s, 3H), 2.63(d, 3H), 4.45-4.44(m, 1H), 6.85(d, 1H), 6.91(d, 1H), 7.00(bs, 1H), 7.28-7.24(m, 1H), 7.57(dd, 1H), 7.99(dd, 1H), 8.25 (s, 1H), 8.39(d, 1H), 9.00(bs, 1H)

3-5		0.39 (*n*-hexane: AcOEt=1:1)	$CDCl_3$: 2.33(s, 3H), 2.63(d, 3H), 3.87(s, 3H), 4.46-4.44(m, 1H), 6.66(d, 1H), 6.71(s, 1H), 7.48(bs, 1H), 7.63-7.59(m, 1H), 7.97(dd, 1H), 8.05(d, 1H), 8.23 (s, 1H), 8.44(d, 1H), 8.92(bs, 1H)
3-6		0.27 (*n*-hexane: AcOEt=3:1)	$CDCl_3$: 2.63(d, 3H), 3.90(s, 3H), 4.45-4.40(m, 1H), 6.90-6.86(m, 2H), 7.00-6.96(m, 1H), 7.23-7.17 (m, 3H), 7.45(dd, 1H), 7.50-7.60(m, 2H), 7.97(dd, 1H), 8.22(d, 1H), 8.26 (s, 1H), 8.43(d, 1H), 8.94(bs, 1H)
3-7		0.34 (*n*-hexane: AcOEt=3:1)	$CDCl_3$: 2.30(s, 3H), 2.63(d, 3H), 4.44-4.43(m, 1H), 6.68 (bs, 1H), 7.00-6.68(m, 1H), 7.23-7.17(m, 2H), 7.46-7.43(m, 1H), 7.76(d, 1H), 7.93(dd, 1H), 8.22 (s, 1H), 8.40(d, 1H), 9.01(bs, 1H)
3-8		0.12 (*n*-hexane: AcOEt=3:1)	$CDCl_3$: 2.62(d, 3H), 2.81(s, 3H), 4.07-3.98(m, 1H), 4.52-4.45(m, 1H), 6.37(bs, 1H), 6.77-6.73 (m, 2H), 7.12(dd, 1H), 7.24-7.20(m, 1H), 7.30-7.27(m, 1H), 7.35(dd, 1H), 7.88(dd, 1H), 8.18 (s, 1H), 8.41(d, 1H), 9.19(bs, 1H)
3-9		0.28 (*n*-hexane: AcOEt=3:1)	$CDCl_3$: 2.62(d, 3H), 3.94(s, 3H), 4.49-4.43(m, 1H), 6.99-6.90 (m, 3H), 7.18-7.23(m, 1H), 7.31-7.24(m, 3H), 7.63(bs, 1H), 7.93-7.86(m, 1H), 8.28-8.23(m, 1H), 8.28 (s, 1H), 8.45(bs, 1H), 8.89(bs, 1H)
3-10		0.23 (*n*-hexane: AcOEt=3:1)	$CDCl_3$: 0.91(t, 3H), 1.37 (dd, 2H), 1.64-1.55 (m, 2H), 2.64-2.60 (m, 2H), 4.45-4.40 (m, 1H), 6.69 (bs, 1H), 7.23-7.10(m, 1H), 7.46-7.38 (m, 1H), 7.73 (d 1H), 7.92 (d, 1H), 8.21 (s, 1H), 8.38-8.46 (m, 1H), 9.09 (bs, 1H)
3-11		0.12 (*n*-hexane: AcOEt=3:1)	$CDCl_3$: 2.63 (d, 3H), 4.15-4.10 (m, 1H), 6.58 (bs, 1H), 7.31-7.10(m, 4H), 7.53-7.49 (m, 1H), 7.71(d 1H), 7.95 (d, 1H), 8.30-8.23 (m, 1H), 8.26 (s, 1H), 8.45 (d, 1H), 9.03 (bs, 1H)

3-12		0.4 (*n*-hexane: AcOEt=3:1)	$CDCl_3$: 2.09 (dd, 2H), 2.63 (d, 3H), 2.85(t, 2H), 2.96 (t, 2H), 4.46-4.43 (m, 2H), 6.73 (bs, 1H), 6.99 (d, 1H), 7.09 (dd, 1H), 7.25-7.20(m, 1H), 7.52 (dd, 1H), 7.74 (d 1H), 7.92 (dd, 1H), 8.22 (s, 1H), 8.42 (d, 1H), 9.02 (bs, 1H)
3-13		0.33 (AcOEt)	$CDCl_3$: 2.63 (d, 3H), 4.63-4.64 (m, 1H), 7.11(d, 2H), 7.18(dd, 1H), 7.42-7.34(m, 1H), 7.58-7.55(m, 1H), 7.96(d, 1H), 8.07(s, 1H), 8.19-8.10(m, 1H), 8.24(s, 1H), 9.15(s, 1H), 11.6-11.4(m, 1H)
3-14		0.28 (*n*-hexane: AcOEt=3:1)	$CDCl_3$: 2.63(d, 3H), 3.88(s, 3H), 3.89(s, 3H), 4.47-4.41(m, 1H), 6.60(d,1H), 6.92 (dd,1H), 7.64 (dd, 1H),7.66-7.61(m,1H), 7.89(d, 1H), 7.98(dd, 1H), 8.26(s, 1H), 8.43(d, 1H), 8.95(s, 1H)
3-15		0.30 (n-hexane: AcOEt=3:1)	$CDCl_3$: 2.63(d, 3H), 3.66(s, 3H), 3.85(s, 3H), 4.45-4.44(m, 1H), 6.48(dd,1H), 6.79(d,1H), 7.64(dd, 1H), 7.97(dd, 2H), 8.26(s, 1H), 8.44(d, 1H), 8.96(s, 1H)
3-16		0.22 (*n*-hexane: AcOEt=3:1)	$CDCl_3$: 2.17(s, 3H), 2.22(s, 3H), 2.64(s, 3H), 2.63(d, 3H), 4.46-4.44(m, 1H), 6.57(bs, 1H), 7.00(s,1H), 7.17(dd,1H), 7.44-7.40(m,1H), 7.44(s, 1H), 7.93(dd, 1H), 8.19(s, 1H), 8.43(d, 1H), 9.06(s, 1H)
3-17		0.46 (AcOEt)	$CDCl_3$: 2.22(s,3H), 2.63(d, 3H), 3.68(s, 3H), 3.89(s, 3H), 4.52-4.47(m, 1H), 6.51(s,1H), 6.74(s,1H), 7.12(s,1H), 7.16-7.12(m,1H), 7.40(dd, 1H), 7.91(dd, 1H), 8.19(s, 1H), 8.42(d, 1H), 9.12(s, 1H)
3-18		0.35 (*n*-hexane: AcOEt=3:1)	$CDCl_3$: 1.16(d, 6H), 2.25 (s, 3H), 2.62(d, 3H), 2.77(t, 1H), 4.49-4.48(m, 1H), 7.00(s,1H), 7.15(d,1H), 7.41-7.37(m,1H), 7.49(d,2H), 7.54(dd, 1H), 7.92(dd, 1H), 8.21(s, 1H), 8.32(d, 1H), 9.02(s, 1H)

3-19		0.23 (*n*-hexane: AcOEt=1:1)	$CDCl_3$: 2.63(d, 3H), 3.13-3.10 (m, 4H), 3.87(s, 3H), 3.89-3.86(m, 4H), 4.97-4.93(m, 1H), 6.41(dd,1H), 6.52(d,1H), 7.24-7.22(m,1H), 7.32(s,1H), 7.57(dd,1H), 7.96(dd, 1H), 8.01(d, 1H), 8.14(s, 1H), 8.44(d, 1H), 8.98 (s, 1H)
3-20		0.36 (*n*-hexane: AcOEt=1:1)	$CDCl_3$: 2.22(s, 3H), 2.64(d, 3H), 3.00-3.2.97 (m, 4H), 3.76-3.74(m, 4H), 4.54-4.50(m, 1H), 6.64(d,1H), 6.66(dd, 1H), 7.11(d,1H), 7.18(dd,1H), 7.37(d, 1H), 7.46(dd, 1H), 7.93(dd, 1H), 8.22(s, 1H), 8.42(d, 1H), 9.09 (s, 1H)
3-21			
3-22		0.27 (AcOEt)	$CDCl_3$: 2.33(s, 3H), 2.65(d, 3H), 3.60-3.45(m, 8H), 4.53-4.49(m, 1H), 6.74(s, 1H), 7.11(d, 1H), 7.22-7.18(m, 1H), 7.58-7.54(m 1H), 7.94(dd, 1H), 8.00(d, 1H), 8.22(s, 1H), 8.37(d, 1H), 9.13(s, 1H)
3-23		0.38 (AcOEt)	$CDCl_3$: 1.24-1.08(m, 2H), 1.46-1.32(m, 2H),1.76-1.67(m, 2H), 1.98-1.90(m, 2H), 2.33(s, 3H), 2.64(d, 3H), 3.95-3.90(m, 1H), 4.49-4.47(m, 1H), 5.89-5.80(m, 1H), 6.66(s, 1H), 7.15(dd, 1H), 7.48-7.31(m, 2H), 7.91(dd, 1H), 8.12(s, 1H), 8.23(s, 1H), 8.41(d, 1H), 9.18(s, 1H)
3-24		0.11 (AcOEt)	$CDCl_3$: 2.35(s, 3H), 2.71(s, 3H), 3.07-2.73(m, 2H), 3.86-3.31(m, 6H), 6.85(s, 1H), 7.10(d, 1H), 7.24-7.19(m, 1H), 7.52-7.48(m, 1H), 7.66-7.59(m, 2H), 7.93(d, 1H), 8.06(s, 1H), 8.27-8.21(m, 1H), 8.23(s, 1H), 9.11(s, 1H)

3-25		0.5 (*n*-hexane: AcOEt=1:1)	$CDCl_3$: 2.52(d, 3H), 2.62(s, 3H), 4.36-4.32(m, 1H), 6.74(s, 1H), 6.87(d, 2H), 7.00-6.91(m, 2H), 7.00-6.97(m, 2H), 7.38(dd, 2H), 7.86(dd, 1H), 7.98(s, 1H), 8.23(s, 1H), 8.28(d, 1H), 9.04(s, 1H)
3-26		0.45 (*n*-hexane: AcOEt=1:1)	$CDCl_3$: 1.62-1.34(m, 6H), 2.13(s, 3H), 2.56(d, 3H), 3.01-2.87(m, 4H), 4.54-4.38(m, 1H), 6.59(s, 1H), 6.69-6.59(m, 1H), 7.02(d, 1H), 7.10-7.07(m, 1H), 7.37(dd, 1H), 7.84(dd, 1H), 8.15(s, 1H), 8.34(d, 1H), 9.01(s, 1H)
3-27		0.45 (*n*-hexane: AcOEt=1:1)	$CDCl_3$: 2.32(s, 3H), 2.58(d, 3H), 3.75(s, 3H), 4.37-4.44(m, 1H), 6.77-6.73(m, 1H), 6.89-6.82(m 1H), 6.97-6.91(m, 2H), 6.96(d, 1H), 7.20(dd, 1H), 7.25-7.24(m, 1H), 7.33-7.29(m, 1H)
3-28		0.35 (*n*-hexane: AcOEt=1:1)	$CDCl_3$: 2.34(s, 3H), 2.64(d, 3H), 3.81(s, 3H), 4.57-4.50(m, 1H), 6.76(bs, 1H), 6.91-6.84(m, 41H), 7.04(d, 1H), 7.83(dd, 1H), 8.06(d, 1H), 8.19(dd, 1H), 8.23(s, 1H), 9.00(s, 1H)
3-29		0.45 (*n*-hexane: AcOEt=1:1)	$CDCl_3$: 1.50(t, 3H), 2.62 (d, 3H), 4.17(dd, 2H), 4.51-4.44(m, 1H), 6.95-6.89 (m, 2H), 6.94(d, 1H), 7.16 (dd, 1H), 7.31-7.23(m, 5H), 7.67(s, 1H), 7.11(dd, 1H), 7.23(d, 2H), 7.65(s, 1H), 7.88(dd, 1H), 8.28-8.23(m, 1H), 8.28(s, 1H), 8.43(s, 1H), 8.89(s, 1H)
3-30		0.45 (*n*-hexane: AcOEt=1:1)	$CDCl_3$: 1.49(t, 3H), 2.63(d, 3H), 3.85(s, 3H), 4.16(dd, 2H), 4.55-4.48(m, 1H), 6.81(dd, 1H), 6.95-6.91(m, 3H), 7.11(dd, 1H), 7.23(d, 2H), 7.65(s, 1H), 7.90-7.88(m, 1H), 8.28-8.26(m, 1H), 8.27(s, 1H), 8.39(s, 1H), 8.90(s, 1H)
3-31		0.29 (*n*-hexane: AcOEt=1:1)	^{1}H-NMR : ($CDCl_3$) 1.83-1.72 (4H, m), 2.63 (3H, d), 2.66-2.62 (2H, m), 2.80 (2H, t), 4.41-4.44 (1H, m), 6.64 (1H, br.s), 6.92 (1H, d), 7.09 (1H, dd), 7.18 (1H, dd), 7.45 (1H, dd), 7.59 (1H, dd), 7.92 (1H, d), 8.20 (1H, s), 8.42 (1H, d), 9.08 (1H, br.s).

3-32		0.3 (n-hexane: AcOEt=1:1)	DMSO-d_6: 2.43(s, 3H), 2.80-2.82(m, 4H), 3.61-3.64 (m, 4H), 3.75(s,3H), 6.62(dd, 1H), 6.93(d, 1H), 7.46(d, 1H), 7.54(dd, 1H), 7.77(dd, 2H), 8.14(bs, 1H), 8.32(s, 1H), 8.38-8.30(m, 1H), 9.14(bs, 1H)
3-33		0.61 (MeOH: CH2Cl2=1: 1)	DMSO-d_6: 1.59-1.68(m, 2H), 1.88-1.98(m, 2H), 2.13-2.25(m,2H), 2.19(s, 3H), 2.43(s, 3H), 2.60-2.70(m, 2H), 3.75(s, 3H), 4.32-4.40(m, 1H), 6.51(dd, 1H), 6.64(d, 1H), 7.20(dd, 1H), 7.39(d, 1H), 7.75(dd, 1H), 7.70-7.78(s, 1H), 8.22(s, 1H), 8.26(s, 1H), 8.38-8.41(m, 1H), 9.22(s, 1H)
3-34		0.17 (AcOEt)	$CDCl_3$: 2.11(s, 3H), 2.68(d, 3H), 2.76-2.83(m, 2H), 2.89-2.97(m, 2H), 3.47-3.55(m, 2H), 3.58-3.66(m, 2H), 3.86(s, 3H), 4.70-4.78(m, 1H), 6.53(dd, 1H), 6.81(d, 1H), 7.23(dd, 1H), 7.54-7.62(m, 2H), 7.97(dd, 1H), 8.02-8.03(m, 1H), 8.29(s, 1H), 8.40(d, 1H), 8.99(bs, 1H)
3-35		0.22 (AcOEt only)	DMSO-d_6: 2.40-2.48(m, 7H), 2.63(t, 2H), 3.50-3.58(m, 4H), 3.77(s, 3H), 3.91(t, 2H), 6.60(dd, 1H), 6.93(d, 1H), 7.28(dd, 1H), 7.56(d, 1H), 7.60(dd, 1H), 7.75-7.80(m, 1H), 7.80(dd, 1H), 8.10(s, 1H), 8.35(s, 1H), 8.40(d, 1H), 9.21(s, 1H)
3-36		0.4 (n-hexane: AcOEt=1:1)	DMSO-d_6: 2.43(s, 3H), 7.03-7.08(m, 1H), 7.21-7.23(m, 1H), 7.25-7.36(m, 1H), 7.47-7.57(m, 2H), 7.74-7.77(m, 2H), 8.28(s, 1H), 8.35(d, 1H), 9.09(s, 1H), 9.24(s, 1H)
3-37		0.4 (n-hexane: AcOEt=1:1)	$CDCl_3$: 2.64(d, 3H), 4.53-4.54(m, 1H), 6.88-6.93(m, 1H), 7.14-7.28(m, 3H), 7.54-7.58(m, 1H), 7.95-7.98(m, 1H), 8.16-8.21(m, 1H), 8.24(s, 1H), 8.33-8.36(m, 1H), 9.05(s, 1H)
3-38		0.42 (n-hexane: AcOEt=1:1)	$CDCl_3$: 2.64(d, 3H), 4.46-4.47(m, 1H), 6.63-6.68(m, 1H), 7.30-7.32(m, 2H), 7.55(s, 1H), 7.64-7.68(m, 1H), 7.97-7.99(m, 1H), 8.20-8.39(m, 3H), 9.03(s, 1H)

3-39		562, 564 [M+1]+	CDCl3: 2.37(s, 3H), 2.58-2.64(m, 7H), 3.15-3.18(m,4H), 3.87(s, 3H), 4.60-4.65(m,1H), 6.43(dd,1H), 6.44-6.54(m, 1H), 7.22(d, 1H), 7.30(s, 1H), 7.57(dd, 1H), 7.94-7.99(m, 2H), 8.18(s, 1H), 8.45(d, 1H), 8.95(s, 1H)
3-40		572, 574 [M+1]+	DMSO-d6: 1.79-1.88(m,2H), 1.98-2.02(m, 2H), 2.43(s, 3H), 3.02-3.08(m, 3H), 3.28-3.39(m, 2H), 3.76(s, 3H), 6.47(dd, 1H), 6.65(d, 1H), 7.22(dd, 1H), 7.39(d, 1H), 7.45-7.50(m, 1H), 7.74-7.77(m, 2H), 8.18(s, 1H), 8.22(s, 1H), 8.41-8.44(m, 1H), 9.21(bs, 1H)
3-41		565, 567 [M+1]+	DMSO-d6: 2.44(d, 3H), 2.69-2.71(m, 4H), 3.49-3.52(m, 4H), 3.76(s, 3H), 6.45(dd, 1H), 6.62(d, 1H), 7.23(ddd, 1H), 7.38(d, 1H), 7.46-7.50(m, 1H), 7.72-7.77(m, 2H), 8.19(s, 1H), 8.22(s, 1H), 8.42-8.45(m, 1H), 9.22(s, 1H)
3-42		595, 597 [M+1]+	DMSO-d6: 2.44(s, 3H), 3.31(s, 6H), 3.48-3.53(m, 8H), 3.72(s, 3H), 6.24(dd, 1H), 6.37(d, 1H), 7.18-7.21(m, 2H), 7.40-7.55(m, 1H), 7.72-7.76(m, 2H), 8.17-8.19(m, 2H), 8.40-8.50(m, 1H), 9.23(s, 1H)
3-43		590, 592 [M+1]+	DMSO-d6: 1.64-1.71(m, 2H), 1.75-1.82(m, 2H), 2.21-2.28(m,1H), 2.43(d, 3H), 2.62-2.67(m,2H), 3.68-3.74(m, 2H), 3.76(s, 3H), 6.45(dd,1H), 6.63(d, 1H), 6.75-6.81(m, 1H), 7.20(ddd, 1H), 7.25-7.30(m, 1H), 7.35(d, 1H), 7.45-7.52(m, 1H), 7.70-7.77(m, 2H), 8.18(s, 1H), 8.21(s, 1H), 8.40-8.47(m, 1H), 9.22(s, 1H)

3-44		597, 599 [M+1]+	DMSO-d6: 2.44(s, 3H), 3.12-3.17(m, 4H), 3.68-3.85(m, 4H), 3.79(s, 3H), 6.55(dd, 1H), 6.71(d, 1H), 7.19-7.25(m, 1H), 7.43(d, 1H), 7.46-7.53(m, 1H), 7.73-7.78(m, 2H), 8.19-8.22(m, 1H), 8.22(s, 1H), 8.38-8.45(m, 1H), 9.20(bs, 1H)
3-45		600, 602 [M+1]+	DMSO-d6: 1.85-1.95(m, 2H), 2.19(t, 2H), 2.25-2.35(m, 4H), 2.43(s, 3H), 3.52-3.64(m, 4H), 4.19(t, 2H), 6.65(d, 1H), 7.05(dd, 1H), 7.20(d, 1H), 7.23(ddd, 1H), 7.27(d, 1H), 7.40-7.46(m, 1H), 7.42(d, 1H), 7.70-7.75(m, 1H), 7.76(dd, 1H), 8.32(s, 1H), 8.45(d, 1H), 9.22(s, 1H), 9.23(s, 1H)
3-46		590, 592 [M+1]+	DMSO-d6: 2.05(s, 3H), 2.44(s, 3H), 3.08-3.17(m, 4H), 3.55-3.63(m, 4H), 3.77(s, 3H), 6.48(dd,1H), 6.67(d, 1H), 7.23(dd, 1H), 7.41(d, 1H), 7.45-7.52(m, 1H), 7.76(dd, 1H), 7.72-7.78(m, 1H), 8.19(s, 1H), 8.22(s, 1H), 8.40-8.47(m, 1H), 9.22(bs, 1H)
3-47		548, 550 [M+1]+	DMSO-d6: 2.43(s, 3H), 2.82-2.87(m, 4H), 2.99-3.15(m, 4H), 3.76(s, 3H), 6.43(dd,1H), 6.61(d, 1H), 7.22(dd, 1H), 7.36(d, 1H), 7.43-7.51(m, 1H), 7.75(dd, 1H), 8.17(s, 1H), 8.21(s, 1H), 8.38-8.45(m, 1H), 9.12-9.28(m, 1H)
3-48		MS 530, 532	CDCl3: 2.65 (d, 3H), 3.96 (s, 3H), 4.40-4.48 (m, 1H), 6.85-6.88 (m, 2H), 7.22 (d, 1H), 7.25-7.31 (m, 1H), 7.56-7.65 (m, 3H), 7.79 (s, 1H), 8.00 (dd, 1H), 8.29 (s, 1H), 8.39 (dd, 1H), 9.00 (s, 1H).

3-49		Rf (AcOEt: MeOH=9:1) 0.20	$CDCl_3$: 2.18-2.50 (m, 4H), 2.28 (s, 3H), 2.65 (d, 3H), 3.10-3.75 (m, 4H), 3.93 (s, 3H), 4.50-4.61 (m, 1H), 6.89 (d, 1H), 7.06 (dd, 1H), 7.59-7.67 (m, 2H), 7.93-7.97 (m, 1H), 8.26 (s, 1H), 8.37-8.43 (m, 2H), 9.02 (s, 1H).
3-50		Rf 0.4 (Hexane/AcOEt=1/1)	CDCl3: 2.63 (d, 3H), 3.90 (s, 3H), 4.00 (s, 3H), 4.39-4.47 (m, 1H), 6.23 (d, 1H), 7.00 (s, 1H), 7.22-7.25 (m, 1H), 7.57 (dd, 1H), 7.96 (dd, 1H), 8.22 (s, 1H), 8.25 (d, 1H), 8.37 (d, 1H), 8.96 (s, 1H)
3-51		MS 535, 537	CDCl3: 1.17 (t, 3H), 1.71-1.79 (m, 1H), 2.28 (s, 3H), 2.62 (d, 3H), 3.41 (q, 2H), 3.46 (t, 2H), 3.79 (q, 2H), 4.41-4.48 (m, 1H), 6.43 (s, 1H), 6.10-6.18 (m, 2H), 7.15 (dd, 1H), 7.33 (d, 1H), 7.35-7.42 (m, 1H), 7.90 (dd, 1H), 8.16 (s, 1H), 8.45 (d, 1H), 9.07 (s, 1H).
3-52		Rf	CDCl3: 2.66 (d, 3H), 3.91 (s, 3H), 4.41-4.47 (m, 1H), 6.80 (d, 1H), 6.92 (dd, 1H), 7.26-7.35 (m, 1H), 7.54 (s, 1H), 7.76 (dd, 1H), 8.00 (dd, 1H), 8.27-8.32 (m, 2H), 8.38 (dd, 1H), 8.97 (s, 1H).
3-53		MS 491, 493	$CDCl_3$: 2.26 (s, 3H), 2.62 (d, 3H), 2.68 (s, 6H), 4.72 (q, 1H), 6.78 (s, 1H), 6.89 (d, 1H), 7.12 (d, 1H), 7.15 (d, 1H), 7.40-7.47 (m, 2H), 7.91 (dd, 1H), 8.40 (s, 1H), 8.41 (dd, 1H), 9.11 (s, 1H).
3-54		MS 525, 527	$CDCl_3$: 2.04 (s, 3H), 2.65 (d, 3H), 4.42-4.48 (m, 1H), 6.79 (s, 1H), 6.96-7.00 (m, 2H), 7.28-7.34 (m, 4H), 7.87-7.91 (m, 1H), 8.18 (s, 1H), 8.23-8.26 (m, 2H), 8.53 (d, 2H), 9.07 (s, 1H).

3-55		Rf (Hexane: AcOEt=3:1) 0.19	$CDCl_3$: 1.34 (t, 3H), 1.44 (t, 3H), 2.63 (d, 3H), 3.81 (q, 2H), 4.06 (q, 2H), 4.46 (q, 1H), 6.43 (dd, 1H), 6.76 (d, 1H), 7.63-7.69 (m, 2H), 7.94 (d, 1H), 7.98 (dd, 1H), 8.42 (d, 1H), 8.93 (s, 1H).
3-56		MS 570, 572	$CDCl_3$: 2.63 (d, 3H), 3.85 (s, 3H), 3.93 (s, 3H), 4.52 (q, 1H), 6.78-6.83 (m, 2H), 6.93 (d, 2H), 6390-7.02 (m, 1H), 7.11-7.15 (m, 1H), 7.21-7.27 (m, 1H), 7.61 (s, 1H), 7.87-7.92 (m, 1H), 8.26 (s, 1H), 8.20-8.30 (m, 1H), 8.38-8.41 (m, 1H), 8.92 (s, 1H).
3-57		Rf (Hexane:AcOEt=3:1) 0.16	$CDCl_3$: 1.44 (t, 3H), 2.65 (d, 3H),2.79-2.89 (m, 4H), 3.65-3.74 (m, 4H), 4.07 (q, 2H), 4.52 (q, 4H), 6.48 (dd, 1H), 6.80 (d, 1H), 7.20-7.25 (m, 1H), 7.55-7.67 (m, 2H), 7.92-7.98 (m, 2H), 8.29 (s, 1H), 8.43 (d, 1H), 8.95 (s, 1H).
3-58		Rf 0.17 (Hexane/AcOEt=1/1)	$CDCl_3$: 1.46 (t, 3H), 2.63 (d, 3H), 3.08-3.13 (m, 4H), 3.83-3.90 (m, 4H), 4.09 (q, 2H), 4.46 (q, 1H), 6.39 (dd, 1H), 6.51 (d, 1H), 7.21-7.28 (m, 1H), 7.37 (s, 1H), 7.58 (dd, 1H), 7.97 (dd, 1H), 8.03 (d, 1H), 8.21 (s, 1H), 8.46 (d, 1H), 8.94 (s, 1H).
3-59		MS 538, 540	$CDCl_3$: 2.63 (d, 3H), 3.44 (s, 3H), 3.65 (s, 3H), 3.69-3.73 (m, 2H), 4.10-4.15 (m, 2H), 4.40 (q, 1H), 6.45 (dd, 1H), 6.85 (d, 1H), 7.19-7.25 (m, 1H), 7.61 (dd, 1H), 7.88 (s, 1H), 7.93-7.97 (m, 2H), 8.27 (s, 1H), 8.46 (d, 1H), 8.95 (s, 1H).
3-60		Rf (AcOEt) 0.54	$CDCl_3$: 2.63 (d, 3H), 3.67 (s, 3H), 4.18 (t, 2H), 4.38-4.49 (m, 3H), 6.46 (dd, 1H), 6.81 (d, 1H), 7.60-7.69 (m, 2H), 7.92-7.99 (m, 2H), 8.27 (s, 1H), 8.49 (d, 1H), 9.00 (s, 1H).
3-61		Rf (Hexane: AcOEt=2:1) 0.46	$CDCl_3$: 1.44 (t, 3H), 2.63 (d, 3H), 3.64 (s, 3H), 4.07 (q, 2H), 4.47 (q, 1H), 6.45 (dd, 1H), 6.78 (d, 1H), 7.21-7.28 (m, 1H), 7.40-7.48 (m, 2H), 7.93-7.99 (m, 2H), 8.26 (s, 1H), 8.44 (d, 1H), 8.96 (s, 1H).

3-62		Rf (Hexane:AcOEt=3:1) 0.31	$CDCl_3$: 1.36 (d, 6H), 2.63 (d, 3H), 3.63 (s, 3H), 4.41-4.52 (m, 2H), 6.45 (dd, 1H), 6.81 (d, 1H), 7.21-7.26 (m, 1H), 7.59-7.68 (m, 2H), 7.91-7.98 (m, 2H), 8.26 (s, 1H), 8.45 (d, 1H), 8.96 (s, 1H).
3-63		Rf (Hexane: AcOEt=3:1) 0.40	$CDCl_3$: 1.07 (t, 3H), 1.84 (m, 2H), 6.63 (d, 3H), 3.64 (s, 3H), 3.96 (t, 2H), 4.40-4.49 (m, 1H), 6.46 (dd, 1H), 6.79 (d, 1H), 7.20-7.27 (m, 1H), 7.58-7.66 (m, 2H), 7.94-7.97 (m, 2H), 8.26 (s, 1H), 8.45 (d, 1H), 8.97 (s, 1H).
3-64		Rf (Hexane:AcOEt=3:1) 0.19	$CDCl_3$: 2.62 (d, 3H), 6.68 (s, 6H), 3.84 (s, 3H), 4.41-4.48 (m, 1H), 6.36 (dd, 1H), 6.80 (d, 1H), 7.17-7.24 (m, 1H), 7.51-7.62 (m, 2H), 7.83 (s, 1H), 7.95 (dd, 1H), 8.27 (s, 1H), 8.3*9-8.45 (m, 1H), 8.91 (s, 1H).
3-65		Rf (Hexane:AcOEt=1:1) 0.12	$CDCl_3$: 2.66 (d, 3H), 3.97 (s, 3H), 4.47-4.55 (m, 1H), 6.96-7.10 (m, 3H), 7.21-7.24 (m, 1H), 7.66 (s, 1H), 7.93 (dd, 1H), 8.25 (d, 1H), 8.31 (s, 1H), 8.47 (d, 2H), 8.59 (s, 1H), 8.96 (s, 1H).
3-66		MS 541, 543	$CDCl_3$: 2.65 (d, 3H), 3.96 (s, 3H), 4.61-4.71 (m, 1H), 6.89-7.05 (m, 3H), 7.16 (dd, 1H), 7.15-7.23 (m, 1H), 7.60 (d, 1H), 7.65 (s, 1H), 7.89 (d, 1H), 8.21 (d, 1H), 8.28 (d, 1H), 8.51 (br. s, 2H), 8.57 (s, 1H), 8.93 (s, 1H).
3-67		MS 541, 543	$CDCl_3$: 2.65 (d, 3H), 3.96 (s, 3H), 4.51 (q, 1H), 6.90-7.06 (m, 3H), 7.11-7.16 (m, 1H), 7.38 (d, 1H), 7.50-7.61 (m, 2H), 7.62-7.67 (m, 1H), 7.89 (dd, 1H), 8.29 (s, 1H), 8.34 (d, 1H), 8.53 (d, 1H), 8.79 (br.s, 1H), 8.94 (s, 1H).
3-68		LC-MS 590	$CDCl_3$: 1.45-1.59 (m, 2H), 1.70-1.78 (m, 1H), 1.82-1.90 (m, 1H), 2.38-2.50 (m, 1H), 2.43 (s, 3H), 2.62-2.77 (m, 2H), 3.56-3.70 (m, 2H), 3.76 (s, 3H), 6.46 (dd, 1H), 6.63 (d, 1H), 6.82-6.88 (br, 1H), 7.22 (dd, 1H), 7.31-7.40 (m, 2H), 7.43-7.51 (m, 1H), 7.50-7.80 (m, 2H), 8.14-8.20 (br, 1H), 8.21 (s, 1H), 8.39-8.48

			(m, 1H), 9.16-9.26 (br, 1H)
3-69		0.34 (CH2Cl2:MeOH=9:1)	$CDCl_3$: 1.58-1.82 (br, 7H), 1.88-2.03 (br, 3H), 2.44-2.45 (m,5H), 3.42-3.52 (m, 3H), 3.75 (s, 3H), 6.66 (dd, 1H), 6.92 (d, 1H), 7.28 (dd, 1H), 7.44 (br, 1H), 7.51 (dd, 1H), 7.79-7.81 (m, 2H), 8.18 (s, 1H), 8.32 (s, 1H), 8.35-8.37 (m, 1H), 9.17 (s, 1H)
3-70		Ms:607, 609	DMSO-d6: 1.84-1.92(m, 2H), 2.34-2.41(m, 4H), 2.41-2.45(m, 3H), 2.44(t, 2H), 3.58(t, 4H), 3.75(s, 3H), 4.02(t, 2H), 6.48(dd, 1H), 6.63(d, 1H), 7.21(dd, 1H), 7.41(d, 1H), 7.46(dd, 1H), 7.72-7.78(m, 1H), 7.76(dd, 1H), 8.22(s, 1H), 8.25(s, 1H), 8.40(d, 1H), 9.22(s, 1H)
3-71		Ms:591, 593	DMSO-d6: 1.84-1.92(m, 2H), 2.14(s, 3H), 2.35-2.4 (m, 4H), 2.43(t, 2H), 2.44(d, 3H), 3.58(t, 4H), 4.01(t, 2H), 6.77(dd, 1H), 6.82(d, 1H), 7.17(dd, 1H), 7.20(d, 1H), 7.3-7.39(m, 1H, 7.71-7.77(m, 2H), 8.2(s, 1H), 8.35-8.44(m, 1H), 8.71(s, 1H), 9.27(s, 1H)
3-72		Ms:620, 622	DMSO-d6: 1.82−1.9 (m, 2H), 2.13-2.17 (m, 3H), 2.25-2.47(m, 13H), 3.75 (s, 3H), 4.01 (t, 2H), 6.47 (dd, 1H), 6.63(d, 1H), 7.19-7.24 (m, 1H), 7.41 (d, 1H), 7.43-7.5(m, 1H), 7.70-7.79(m, 2H), 8.22(s, 1H), 8.25(brs, 1H), 8.37-8.44(m, 1H), 9.22(s, 1H)
3-73		Ms:607, 609	DMSO-d6: 1.78 (t, 2H), 2.32-2.36 (m, 4H9, 2.35-2.38 (m, 3H), 3.54-3.59 (m, 4H), 3.74 (t, 3H), 3.78 (s, 3H), 6.38-6.42 (m, 1H), 6.85 (d, 1H), 6.86-6.95 (m, 1H), 7.33-7.43(m, 2H), 7.63-7.68 (m, 1H), 7.85-8.15 (m, 3H), 8.64-8.8 (m, 1H).

3-74		Ms:605, 607	DMSO-d6: 1.47-1.67(m, 2H), 1.84-2.01(m, 2H), 2.03 (s, 3H), 2.41-2.46 (m, 3H), 3.23-3.39 (m, 2H), 3.65-3.73 (m, 1H), 3.81(s, 3H), 3.8-3.88 (m, 1H), 4.58-4.65 (m, 1H), 6.55 (dd, 1H), 6.68 (d, 1H), 7.2-7.26(m, 1H), 7.43(d, 1H), 7.42-7.51 (m, 1H), 7.7-7.8(m, 2H), 8.23 (s, 1H), 8.26 (brs, 1H), 8.37-8.44(m, 1H), 9.22(brs, 1H)
3-75		Ms:605, 607	DMSO-d6: 1.38-1.6(m, 2H), 1.74-1.9(m, 2H), 2.0 (s, 3H), 2.42-2.47 (m, 3H), 3.12-3.3 (m, 2H), 3.55-3.65 (m, 1H), 3.7-3.8 (m, 1H), 3.78 (s, 3H), 4.27-4.34 (m, 1H), 6.65 (dd, 1H), 6.94 (d, 1H), 7.24-7.3 (m, 1H), 7.53-7.63(m, 2H), 7.74-7.83 (m, 2H), 8.09 (brs, 1H), 8.35 (s, 1H), 8.38(d, 1H), 9.19(brs, 1H)
3-76		Ms:577, 579	DMSO-d6: 1.51-1.61 (m, 2H), 1.79-1.87 (m, 2H), 2.03-2.11 (m, 2H), 2.14 (s, 3H), 2.42-2.47 (m, 3H), 2.52-2.6 (m, 2H), 3.77 (s, 3H), 4.02-4.09 (m, 1H), 6.6 (dd, 1H), 6.92 (d, 1H), 7.24-7.3 (m, 1H), 7.52-7.6(m, 2H), 7.74-7.82 (m, 2H), 8.08 (brs, 1H), 8.34 (s, 1H), 8.4 (d, 1H), 9.2 (brs, 1H)
3-77		Rf : 0.4 (n-hexane: AcOEt=7:3)	DMSO-d6: 2.41-2.45 (m, 3H), 6.89-6.96 (m, 1H), 6.69(bs, 1H), 7.24-7.33 (m, 2H), 7.51-7.57 (m, 1H), 7.63-7.7 (m, 1H), 7.73-7.78 (m, 1H), 7.79 (dd, 1H), 8.37(s, 1H), 8.41(d, 1H), 9.21 (brs, 1H), 9.24 (brs, 1H)
3-78		Ms:563, 565	DMSO-d6: 1.33-1.43 (m, 2H), 1.79-1.86 (m, 2H), 2.43-2.46 (m, 3H), 2.46-2.53 (m, 2H), 2.87-2.94 (m, 2H), 3.77 (s, 3H), 4.07-4.14 (m, 1H), 6.59 (dd, 1H), 6.91 (d, 1H), 7.23-7.28 (m, 1H), 7.53-7.59 (m, 2H), 7.79 (dd, 1H), 8.03 (brs, 1H), 8.32 (s, 1H), 8.38 (d, 1H), 8.7-9.5 (brs, 1H)

3-79		Ms:563, 565	DMSO-d6: 1.41-1.51 (m, 2H), 1.88-1.95 (m, 2H), 2.41-2.45 (m, 3H), 2.54-2.63 (m, 2H), 2.92-3.0 (m, 2H), 3.75 (s, 3H), 4.35-4.43 (m, 1H), 6.50 (dd, 1H), 6.63 (d, 1H), 7.18-7.23 (m, 1H), 7.40 (d, 1H), 7.42-7.48 (m, 1H), 7.75 (dd, 1H), 8.21 (s, 1H), 8.22-8.25 (m, 1H), 8.37-8.42 (m, 1H), 8.9-9.5 (brs, 1H)
3-80		Ms:482, 484	DMSO-d6: 2.4-2.46 (m, 3H), 3.79 (s, 3H), 6.72 (ddd, 1H), 6.99 (dd, 1H), 7.21-7.26 (m, 1H), 7.47-7.53 (m, 1H), 7.59-7.64 (m, 1H), 7.76 (dd, 1H), 8.25 (s, 1H), 8.29-8.37 (m, 2H), 8.8-9.6 (m, 1H)
3-81		Ms:482, 484	DMSO-d6: 2.41-2.49 (m, 3H), 3.82 (s, 3H), 6.80 (ddd, 1H), 7.01 (dd, 1H), 7.3-7.35 (m, 1H), 7.56-7.63 (m, 1H), 7.7-7.8 (m, 1H), 7.82 (dd, 1H), 7.85 (dd, 1H), 8.16 (s, 1H), 8.35 (dd, 1H), 9.18 (brs, 1H)
3-82		Ms:563, 565	DMSO-d6: 1.73-1.82 (m, 1H), 2.23-2.34 (m, 4H), 2.34-2.42(m, 3H), 2.42-2.46 (m, 3H), 2.59 (dd, 1H), 2.62-2.68 (m, 1H), 2.80 (dd, 1H), 3.75 (s, 1H), 4.85-4.91(m, 1H), 6.42 (dd, 1H), 6.57(d, 1H), 7.19-7.24(m, 1H), 7.41 (d, 1H), 7.43-7.51(m, 1H), 7.68-7.79 (m, 2H), 8.22(s, 1H), 8.23(s, 1H), 8.37-8.43 (m, 1H), 9.21 (brs, 1H).
3-83		MS 544, 546	2.36 (s, 3H), 2.65 (d, 3H), 3.93 (s, 3H), 4.46-4.51 (m, 1H), 6.75-6.80 (m, 2H), 6.97-7.04 (m, 2h), 7.25-7.30 (m, 1H), 7.56-7.66 (m, 2H), 7.98 (dd, 1H), 8.29 (s, 1H), 8.36-8.44 (m, 2H), 9.01 (s, 1H).
3-84		MS 562, 564	CDCl3: 2.32 (s, 3H), 2.39-2.47 (m, 4H), 2.64 (d, 3H), 2.89-2.97 (m, 4H), 3.85 (s, 3H), 4.54-4.52 (m, 1H), 6.52 (dd, 1H), 6.79 (d, 1H), 7.22 (m, 1H), 7.52-7.64 (m, 2H), 7.94-7.99 (m, 2H), 8.28 (s, 1H), 8.42 (d, 1H), 8.93 (s, 1H).

Example 4: 2-[5-Bromo-2-(subst. phenylamino)-pyrimidin-4-ylamino]-N-propyl-benzene-sulfonamides

These compounds are prepared in analogy to Example 2 using 2-(5-bromo-2-chloro-pyrimidin-4-ylamino)-N-propyl-benzenesulfonamide and the corresponding aniline to give compounds No. 4-1 to 4-31 having the substituent Rx as listed under Example 3 for compounds No. 3-1 to 3-31.

Preparation of 2-(5-bromo-2-chloro-pyrimidin-4-ylamino)-N-propyl-benzenesulfonamide

To a solution of 5-bromo-2,4-dichloropyrimidine (90 µL, 0.70 mmol) and 2-amino-N-propyl-benzenesulfonamide (100 mg, 0.47 mmol), sodium hydride (54.2 mg, 0.56 mmol) in DMSO (1.0 mL) is added and the resulting solution is stirred at 80°C for 3.0 h. The mixture is poured into water and extracted with ethyl acetate three times. The organic layer is washed with water and then brine, dried over sodium sulfate, and evaporated in vacuo. The residue is purified with silica gel column chromatography (n-hexane : ethyl acetate = 5 : 1) to afford the title compound as a slightly yellow solid.

^{1}H-NMR (δ, ppm) : 0.89 (t, 3H), 1.41 (q, 2H), 3.56 (t, 2H), 4.92 (br.s, 2H), 6.71 (dd, 1H), 6.77 (dd, 1H), 7.33 (dd, 1H), 7.54 (dd, 1H), 8.79 (s, 1H)

Rf (hexane : ethyl acetate = 1:1): 0.64.

Example 5: 2-[5-Trifluoromethyl-2-(subst. phenylamino)-pyrimidin-4-ylamino]-N-methyl-benzenesulfonamides

These compounds are prepared in analogy to Example 2 using 2-(2-chloro-5-trifluoromethyl-pyrimidin-4-ylamino)-N-methyl-benzenesulfonamide and the corresponding aniline to give compounds No. 5-1 to 5-31 having the substituent Rx as listed under Example 3 for compounds No. 3-1 to 3-31.

Preparation of 2-(2-chloro-5-trifluoromethyl-pyrimidin-4-ylamino)-N-methyl-benzenesulfonamide

To a solution of 2,4-dichloro-5-trifluoromethyl-pyrimidine (386 mg, 1.79 mmol) in acetonitrile (10 mL), 2-amino-N-methyl-benzenesulfonamide (333 mg, 1.79 mmol) and 1,8-diaza[5.4.0]-bicyclo-7-undecene (280 µL, 1.88 mmol) are added successively at ambient temperature. After stirring for 15 h at room temperature, dichloromethane (30 mL) is added to the mixture, and the solution is washed with saturated aqueous sodium hydrogen carbonate and saturated aqueous sodium chloride, dried over magnesium sulfate, and evaporated in vacuo. The resulting solid is purified by flash chromatography.

^{1}H NMR ($CDCl_3$) δ: 3.73(s, 3H), 6.67-6.69(m, 1H), 6.72-6.73(m, 1H), 7.27-7.31(m, 1H), 7.78 (dd, 1H), 8.60(s, 1H). Rf (hexane : ethyl acetate = 1:1): 0.28.

Example 6: 2-[5-Bromo-2-(2,3-[difluoromethylenedioxy]phenylamino)-pyrimidin-4-ylamino]-benzenesulfonamide



This compound is obtained as a side product formed by N-demethylation on reaction of 2-(5-bromo-2-chloropyrimidin-4-ylamino)-N-methyl-benzenesulfonamide with 2,3-(difluoromethylene-dioxy)aniline following the procedure of Example 2. It may also be prepared by reaction of 2-(5-bromo-2-chloropyrimidin-4-ylamino)benzenesulfonamide with 2,3-(difluoromethylenedioxy)-aniline.

Rf (*n*-hexane: ethyl acetate = 1:1): 0.46.

^{1}H-NMR : ($CDCl_3$) 4.83 (bs, 2H), 6.77 (dd, 1H), 6.86 (s, 1H), 6.97 (dd, 1H), 7.31-7.24 (m, 1H), 7.57 (dd, 1H), 7.81 (d, 1H), 8.02 (dd, 1H), 8.28 (d, 1H), 8.29 (s, 1H), 8.88 (s, 1H).

Preparation of 2-(5-bromo-2-chloropyrimidin-4-ylamino)benzenesulfonamide: To a solution of 5-bromo-2,4-dichloropyrimidine (300 mg, 1.32mmol) and 2-amino-benzenesulfonamide (340 mg, 1.97 mmol) in 2-propanol (3 mL), concentrated hydrochloric acid (0.06 mL) is added and the mixture is stirred at 90°C for 4.5 hours. The mixture is poured into aqueous sodium hydrogen carbonate and extracted with ethyl acetate three times. The organic layer is washed with water, dried over sodium sulfate, and evaporated in vacuo. The residue is purified by column chromatography (hexane : ethyl acetate = 2:1) to afford the title compound.

Rf (hexane : ethyl acetate = 1:1): 0.55. ^{1}H-NMR (400MHz, CDCl3) δ : 4.78 (br.s, 2H), 7.22 (dd, 1H), 7.61 (ddd, 1H), 7.95 (dd, 1H), 8.35 (s, 1H), 8.35 (d, 1H), 9.18 (s, 1H).

Example 7A: 2-[5-Chloro-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-N-methyl-benzamide



To a suspension of 2-(2,5-dichloro-pyrimidin-4-yl-amino)-*N*-methyl-benzamide (5.05 g, 17.0 mmol) in 90 mL of 2-methoxyethanol are added 2-methoxy-4-morpholinoaniline dihydrochloride (4.56 g, 16.2 mmol) and 17.0 mL of 1N ethanolic solution of hydrogen chloride (17.0 mmol). After the reaction mixture is stirred at 110°C for 4 hours and cooled to room temperature, the mixture is neutralized with 1N aqueous NaOH solution and extracted with EtOAc (100 mL×3). The organic layer is washed with brine, dried over Na_2SO_4 and concentrated under reduced pressure. The resulting black solid is washed with EtOH (90 mL), then purified with silica gel column chromatography (CH_2Cl_2 to CH_2Cl_2: AcOEt=1:2) to give 2-[5-chloro-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-N-methyl-benzamide as a pale yellow solid. ^{1}H-NMR (400MHz, DMSO-d6, δ): 2.80 (d, 3H, J = 4.52 Hz), 3.10-3.20 (m, 4H), 3.78 (s, 3H), 3.70-3.80 (m, 4H), 6.49 (dd, 1H, J = 8.56, 2.52 Hz), 6.66 (d, 1H, J = 2.52 Hz), 7.08 (dd, 1H, J = 8.04, 8.04 Hz), 7.44 (d, 1H, J = 8.56 Hz), 7.71 (dd, 1H, J = 8.04, 1.48 Hz), 8.10 (s, 1H), 8.13 (s, 1H), 8.59 (d, 1H, J = 8.04 Hz) 8.68-8.75 (m, 1H), 11.59 (S, 1H). MS *m/z* 469, 471 $(M+1)^+$.

The following 2-[5-Chloro-2-(substituted phenylamino)-pyrimidin-4-ylamino]-N-methyl-benzamide are prepared from 2-(2,5-Dichloro-pyrimidin-4-ylamino)-N-methyl-benzamide and the corresponding aniline following the procedure of Example 7A.



Expl No.	Rx	Rf (solvent) or MS	NMR (400MHz) , δ (ppm)

7-1		MS: m/z 550, 552 (M+1)	DMSO-d6: 1.44-1.33 (m, 2H), 1.64-1.45 (m, 6H), 1.73-1.89 (m, 2H), 2.34-2.44 (m, 1H), 2.43-2.55 (m, 4H), 2.65 (t, 2H), 2.80 (d, 3H), 3.75 (s, 3H), 3.72-3.75 (m, 2H), 6.48 (dd, 1H), 6.62 (d, 1H), 7.06 (dd, 1H), 7.32 (dd, 1H), 7.39 (d, 1H), 7.71 (dd, 1H), 8.09(s, 1H), 8.60 (d, 1H), 8.70 (d, 1H), 11.58 (s, 1H)
7-2		0.3 (MeOH: AcOEt =5:95)	$CDCl_3$: 1.70-1.97(m, 4H) ,2.62-2.79(m, 1H), 3.04(d, 3H), 3.02-3.18(m, 2H), 3.23-3.33(m, 2H), 3.88 (s, 3H), 5.39-5.47(m, 1H), 6.15-6.24(m, 1H), 6.55-6.62(m, 2H), 6.74-6.82(m, 1H), 7.09 (dd, 1H),7.23-7.32 (m, 1H), 7.46-7.52(m, 2H), 8.09(s, 1H), 8.15(d, 1H), 8.68(d, 1H) 11.0(bs, 1H)
7-3		MS (ESI) *m/z* 482, 484 $(M+1)^+$	DMSO-d6: 2.24 (s, 3H), 2.45-2.55 (m, 4H), 2.80 (d, 3H, J = 4.52 Hz), 3.12-3.17 (m, 4H), 3.76 (s, 3H), 6.48 (dd, 1H, J = 8.56, 2.52 Hz), 6.63 (d, 1H, J = 2.52 Hz), 7.05-7.10 (m, 1H), 7.27-7.35 (m, 1H), 7.40 (d, 1H, J = 8.56 Hz), 7.69-7.72 (m, 1H), 8.09 (s, 1H), 8.12 (s, 1H), 8.55-8.65 (m, 1H), 8.67-8.75 (m, 1H), 11.59 (s, 1H)
7-4		0.46 (MeOH: CH_2Cl_2=1:4)	DMSO-d6: 2.48-2.55(m, 4H), 2.71(t, 2H), 2.80(d, 3H), 3.58-3.61(m, 4H), 3.76(s, 3H), 4.11(t, 2H), 6.52(dd, 1H), 6.66(d, 1H), 7.06(dd, 1H), 7.32(dd, 1H), 7.46(d, 1H), 7.71(dd, 1H), 8.11(s, 1H), 8.19 (s, 1H), 8.54-8.60(m, 1H), 8.60-8.75(m, 1H), 11.6(s, 1H)
7-5		*m/z* 497, 499 $(M+1)^+$	DMSO-d6: 1.60-1.70 (m, 2H), 1.90-1.98 (m, 2H), 2.13-2.25 (m, 2H), 2.19 (s, 3H), 2.60-2.67 (m, 2H), 2.80 (d, 3H, J = 4.52 Hz), 3.75 (s, 3H), 4.30-4.40 (m, 1H), 6.54 (dd, 1H, J = 8.56, 2.0 Hz), 6.65 (d, 1H, J = 2.0 Hz), 7.04-7.09 (m, 1H), 7.25-7.35 (m, 1H), 7.43 (d, 1H, J = 8.56 Hz), 7.68-7.73 (m, 1H), 8.10 (s, 1H), 8.18 (s, 1H) 8.52-8.59 (m, 1H), 8.68-8.75 (m, 1H), 11.57 (s, 1H)

7-6		0.25 (*n*-hexane: AcOEt=1:2)	$CDCl_3$: 2.95 (m, 4H), 3.03 (d, 3H), 3.75 (m, 4H), 3.86 (s, 3H), 6.21-6.19 (br, 1H), 6.49 (dd, 1H), 6.80 (d, 1H), 7.09-7.05 (m, 1H), 7.50 (dd, 1H), 8.08 (d, 1H), 8.13 (s, 1H), 8.68 (d, 1H), 11.07 (s, 1H)
7-7		MS m/z 510, 512 (M+1)	DMSO-d6: 2.06 (s, 3H), 2.80 (d, 3H), 3.11 (t, 2H), 3.16 (t, 2H), 3.60 (dd, 4H), 3.77 (s, 3H), 6.51 (dd, 1H), 6.68 (d, 1H), 7.08 (dd, 1H), 7.33 (dd, 1H), 7.46 (d, 1H), 7.71 (d, 1H), 8.10(s, 1H), 8.12(s, 1H), 8.59-8.61 (m, 1H), 8.70-8.71(m, 1H), 11.59 (s, 1H)
7-8		0.48 (MeOH: AcOEt =5:95)	$CDCl_3$: 1.46(d, 1H), 1.68-1.82(m, 2H), 2.02-2.09(m, 2H), 2.83-2.96 (m, 2H), 3.03(d, 3H),3.44-3.53(m, 2H), 3.82-3.92(m, 1H),3.87(s, 3H), 6.15-6.23(m, 1H), 6.51 (d, 1H), 6.56(bs, 1H), 7.07(dd, 1H), 7.48(d, 2H), 8.08(s, 1H), 8.08-8.10(m, 1H), 8.69(d, 1H), 11.0(bs, 1H)
7-9		0.4 (*n*-hexane: AcOEt=1:1)	$CDCl_3$: 1.22 (t, 3H), 1.73-1.85 (m, 2H), 2.00-2.09 (m, 2H), 2.81-2.90 (m, 2H), 3.03 (d, 3H), 3.41-3.56 (m, 3H), 3.56 (dd, 2H), 3.58-3.62 (m, 2H), 3.64-3.68 (m, 2H), 3.86 (s, 3H), 6.15-6.24 (m, 1H), 6.50 (dd, 1H), 6.56 (d, 1H), 7.07(dd, 1H), 7.24-7.30 (m, 1H), 7.45-7.52(m, 2H), 8.08(s, 1H), 8.06-8.08 (m, 1H), 8.69 (d, 1H), 11.0 (bs, 1H)
7-10		0.4 (*n*-hexane: AcOEt=1:1)	$CDCl_3$: 1.73-1.85(m, 2H), 2.01-2.10(m, 2H), 2.82-2.90(m, 2H), 3.03(d, 3H), 3.41(s, 3H), 3.45-3.51(m, 2H), 3.56-3.58(m, 2H), 3.65-3.68(m, 2H), 3.86(s, 3H), 6.14-6.22(m, 1H), 6.50 (dd, 1H), 6.56 (d, 1H), 7.07(dd, 1H), 7.23-7.30(m, 1H), 7.44-7.52(m, 2H), 8.08(s, 1H), 8.06-8.08(m, 1H), 8.69(d, 1H), 11.0(bs, 1H)

7-11		0.54 (MeOH: CH_2Cl_2=1:4)	DMSO-d6: 1.78-1.89(m, 1H), 2.13-2.22(m, 1H), 2.22(s, 6H), 2.77-2.87(m, 1H), 2.79(d, 3H), 3.04-3.10(m, 1H), 3.23-3.50(m, 3H), 3.75(s, 3H), 6.11(dd, 1H), 6.22(d, 1H), 7.05(dd1H), 7.21-7.32(m, 1H), 7.26(d, 1H), 7.70(d, 1H), 8.06(s, 1H), 8.08(s, 1H), 8.57-8.66(m, 1H), 8.66-8.73 (m, 1H), 11.6(s, 1H)
7-12		0.27 (MeOH: CH_2Cl_2=1:1)	DMSO-d6: 1.77-1.87(m, 1H), 2.09-2.18(m, 1H), 2.35(s, 3H), 2.79(d, 1H), 3.02-3.07(m, 1H), 3.23-3.50(m, 4H), 3.74(s, 3H), 6.09(dd, 1H), 6.20(d, 1H), 7.04(dd, H), 7.22-7.32(m, 1H), 7.26(d, 1H), 7.70(d, 1H), 8.05(s, 1H), 8.08(s, 1H), 8.57-8.67(m, 1H), 8.67-8.73 (m, 1H), 11.6(s, 1H)
7-13		0.23 (MeOH: AcOEt =5:95)	$CDCl_3$: 1.62-1.74(m, 3H), 1.76-1.85(m, 2H), 2.00-2.09(m, 2H), 2.20-2.31(m, 1H), 2.64-2.69 (m, 2H), 2.79 (d, 3H), 3.56-4.04(m, 2H), 4.04(s, 3H), 6.49(dd, 1H), 6.63(d, 1H), 6.78(bs, 1H), 7.07 (dd, 1H), 7.28-7.38 (m, 1H), 7.39(d, 1H), 7.71(d, 1H), 8.09-8.11(m, 2H), 8.09(s, 1H), 8.60(d, 1H), 8.71(d, 1H),11.6(bs, 1H)
7-14		0.30 (MeOH: CH_2Cl_2=4:1)	DMSO-d6: 1.61-1.46(m, 2H), 1.92-1.82 (m, 2H), 2.14 (s, 3H), 2.41-2.23 (m, 5H, 2.60-2.45 (m, 4H), 2.67 (t, 2H), 2.79 (d, 3H), 3.75 (s, 3H), 3.71-3.75 (m, 2H), 6.48 (dd, 1H), 6.63 (d, 1H), 7.10-7.03 (m, 1H), 7.34-7.27 (m, 1H), 7.43-7.35 (m, 1H), 7.71(dd, 1H), 8.09 (s, 1H), 8.11 (bs, 1H), 8.65-8.56 (m, 1H), 8.75-8.67 (m, 1H), 11.6 (s, 1H)

7-15		MS (ESI) *m/z* 524, 526 $(M+1)^+$	DMSO-d6: 2.19-2.37 (m, 4H), 2.65-2.85 (m, 3H), 2.80 (d, 3H, J = 4.5 Hz), 3.15-3.21 (m, 1H), 3.48-3.59 (m, 2H), 3.61-3.67 (m, 1H), 3.72-3.81 (m, 1H), 3.76 (s, 3H), 6.47 (dd, 1H, J = 8.6, 2.5 Hz), 6.65 (d, 1H, J = 2.5 Hz), 7.04-7.10 (m, 1H), 7.28-7.35 (m, 1H), 7.42 (d, 1H, J = 8.6 Hz), 7.69-7.74 (m, 1H), 8.09 (s, 1H), 8.12 (s, 1H), 8.55-8.63 (m, 1H), 8.68-8.73 (m, 1H), 11.60 (s, 1H)
7-16		MS (ESI) *m/z* 524, 526 $(M+1)^+$	DMSO-d6: 2.19-2.37 (m, 4H), 2.65-2.85 (m, 3H), 2.80 (d, 3H, J = 4.5 Hz), 3.15-3.21 (m, 1H), 3.48-3.59 (m, 2H), 3.61-3.67 (m, 1H), 3.72-3.81 (m, 1H), 3.76 (s, 3H), 6.47 (dd, 1H, J = 8.6, 2.5 Hz), 6.65 (d, 1H, J = 2.5 Hz), 7.04-7.10 (m, 1H), 7.28-7.35 (m, 1H), 7.42 (d, 1H, J = 8.6 Hz), 7.69-7.74 (m, 1H), 8.09 (s, 1H), 8.12 (s, 1H), 8.55-8.63 (m, 1H), 8.68-8.73 (m, 1H), 11.60 (s, 1H)
7-17		MS 510	DMSO-d6: 0.98 (t, 3H), 1.81-1.71 (m, 3H), 1.95-1.84 (m, 3H), 2.68-2.63(m, 1H), 2.80 (d, 3H), 3.12-3.08 (m, 4H), 3.28(d, 2H), 3.76(s,3H), 6.50 (dd, 1H), 6.64 (d, 1H), 6.86(bs, 1H), 7.07(dd, 1H), 7.46-7.19 (m, 3H), 7.71 (d, 1H), 8.09(s, 1H), 8.15-8.10 (m, 1H), 8.66-8.58(m, 1H), 8.77-8.70(m, 1H), 11.6(s, 1H)
7-18		MS 510	DMSO-d6: 0.98 (t, 3H), 1.81-1.71 (m, 3H), 1.95-1.84 (m, 3H), 2.68-2.63(m, 1H), 2.80 (d, 3H), 3.12-3.08 (m, 4H), 3.28(d, 2H), 3.76(s,3H), 6.50 (dd, 1H), 6.64 (d, 1H), 6.86(bs, 1H), 7.07(dd, 1H), 7.46-7.19 (m, 3H), 7.71 (d, 1H), 8.09(s, 1H), 8.15-8.10 (m, 1H), 8.66-8.58(m, 1H), 8.77-8.70(m, 1H), 11.6(s, 1H)

7-19		0.16 (CH2Cl2:MeOH=9:1)	1.40-1.53 (m, 2H), 1.72-1.80 (m, 2H), 2.18 (s, 3H), 2.19-2.44 (m, 5H), 2.80 (d, 3H), 3.46 (m, 2H), 3.74 (s, 3H), 6.65 (dd, 1H), 6.91 (d, 1H), 7.07-7.10 (m, 1H), 7.36-7.40 (m, 1H), 7.45-7.49 (m, 1H), 7.73 (dd, 1H), 8.12 (s, 1H), 8.18 (s, 1H), 8.61 (d, 1H), 8.72-8.77 (m, 1H), 11.68 (s, 1H)
7-20		Ms : 511	1.25-1.37 (m, 2H), 1.62-1.79 (m, 3H), 1.81-1.9 (m, 2H), 2.16 (s, 3H), 2.75-2.85 (m, 5H), 3.76 (s, 3H), 3.8-3.88 (m, 2H), 6.45-6.55 (m, 1H), 6.6-6.67 (m, 1H), 7.02-7.12 (m, 1H), 7.25-7.35 (m, 1H), 7.4-7.5 (m, 1H), 7.67-7.78 (m, 1H), 8.1 (s, 1H), 8.19 (brs, 1H) 8.5-8.62 (m, 1H), 8.66-8.8 (m, 1H), 11.6 (s, 1H)
7-21		Ms : 526	2.17 (s, 3H), 2.29-2.39 (m, 3H), 2.45-2.56 (m, 4H), 2.7 (t, 2H), 3.76 (s, 3H), 4.09 (t, 2H), 6.52 (dd, 1H), 6.66 (d, 1H), 7.06 (dd, 1H), 7.31 (dd, 1H), 7.45 (d, 1H), 7.71 (dd, 1H), 8.1 (s, 1H), 8.19 (s, 1H), 8.5-8.6 (m, 1H), 8.67-8.75 (m, 1H), 11.6 (s, 1H)
7-22		Ms : 482	2.24 (s, 3H), 2.42-2.5 (m, 4H), 2.8 (d, 3H), 2.94-3.0 (m, 4H), 3.74 (s, 3H), 6.65 (dd, 1H), 6.93 (d, 1H), 7.07-7.14 (m, 1H), 7.34-7.4 (m, 1H), 7.45 (d, 1H), 7.73 (dd, 1H), 8.14 (s, 1H), 8.18 (s, 1H), 8.61 (dd, 1H), 8.7-8.77 (m, 1H), 11.7 (s, 1H)
7-23		Ms : 482	1.67-1.76 (m, 1H), 2.0-2.1 (m, 1H), 2.25-2.31 (m, 3H), 2.8 (d, 3H), 2.85-2.91 (m, 1H), 3.04-3.12 (m, 1H), 3.14-3.3 (m, 3H), 3.7 (s, 3H), 6.26 (dd, 1H), 6.91 (d, 1H), 7.01-7.04 (m, 1H), 7.07 (dd, 1H), 7.32 (dd, 1H), 7.72 (d, 1H), 8.14 (s, 1H), 8.17 (s, 1H), 8.63 (d, 1H), 8.7-8.78 (m, 1H), 11.6 (s, 1H)

7-24		Ms : 550	1.35-1.57 (m, 8H), 1.7-1.78 (m, 2H), 2.81 (d, 3H), 3.46-3.52 (m, 2H), 3.74 (s, 3H), 6.65 (dd, 1H), 6.91 (d, 1H), 7.05-7.12 (m, 1H), 7.34-7.42 (m, 1H), 7.46 (d, 1H), 7.73 (dd, 1H), 8.11 (s, 1H), 8.18 (s, 1H), 8.62 (dd, 1H),8.71-8.78 (m, 1H), 11.7 (s, 1H)
7-25		536 [M+1]+	DMSO-d6: 1.48-1.58(m, 2H), 1.65-1.72(m, 4H), 1.90-1.97(m, 2H), 2.07-2.14(m, 1H), 2.49-2.55(m, 4H), 2.70-2.77(m, 2H), 2.79(d, 3H), 3.60-3.65(m, 2H), 3.75(s, 3H), 6.48(dd, 1H), 6.63(d, 1H), 7.03-7.09(m, 1H), 7.28-7.34(m, 1H), 7.39(d, 1H), 7.71(dd, 1H), 8.09(s, 1H), 8.11(s, 1H), 8.55-8.65(m, 1H), 8.69-8.73(m, 1H), 11.59(s, 1H)
7-26		468 [M+1]+	DMSO-d6: 2.80(d, 3H), 2.84-2.89(m, 4H), 3.04-3.08(m, 4H), 3.76(s, 3H), 6.47(dd,1H), 6.62(dd, 1H), 7.04-7.10(m, 1H), 7.28-7.35(m, 1H), 7.40(d, 1H), 7.69-7.73(m, 1H), 8.09(s, 1H), 8.12(s, 1H), 8.55-8.63(m, 1H), 8.68-8.73(m, 1H), 11.59(s, 1H) (an aliphatic NH is hidden)
7-27		393 [M+1]+	DMSO-d6: 2.80(d, 3H), 6.64-6.67(m, 1H), 7.01-7.08(m, 2H), 7.15(d, 1H), 7.24-7.29(m, 2H), 7.44(d, 1H), 7.69-7.73(m, 1H), 8.20(s, 1H), 8.65-8.73(m, 2H), 9.15(s, 1H), 11.06(s, 1H), 11.63(s, 1H)
7-28		407 [M+1]+	DMSO-d6: 2.81(d, 3H), 3.79(s, 3H), 6.67(d, 1H), 7.05-7.10(m, 1H), 7.12(d, 1H), 7.17(d, 1H), 7.23(d, 1H), 7.25-7.30(m, 1H), 7.50(d, 1H), 7.70-7.73(m, 1H), 8.20(s, 1H), 8.67(d, 1H), 8.70-8.75(m, 1H), 9.17(s, 1H), 11.64(s, 1H)

7-29		492 [M+1]+	DMSO-d6: 2.80(d, 3H), 2.91-2.99(m, 4H), 3.65-3.81(m, 2H), 3.82-3.95(m, 2H), 4.12(s, 3H), 6.58(d, 1H), 6.90(d, 1H), 7.05-7.09(m, 1H), 7.14(d, 1H), 7.22-7.28(m, 1H), 7.30(d, 1H), 7.70(dd, 1H), 8.16(s, 1H), 8.63-8.67(m, 1H), 8.68-8.72(m, 1H), 9.06(s, 1H), 11.64(s, 1H)
7-30		MS m/z 510	DMSO-d_6: 2.02 (s, 3H), 2.80 (d, 3H), 2.82-2.92 (m, 2H), 2.92-3.01 (m, 2H), 3.44-3.53 (m, 4H), 3.76 (s, 3H), 6.68 (dd, 1H), 6.95 (d, 1H), 7.09 (dd, 1H), 7.35-7.40 (m, 1H), 7.50 (brs, 1H), 7.73 (d, 1H), 8.15 (s, 1H), 8.19 (s, 1H), 8.59 (d, 1H), 8.69-8.76 (m, 1H), 11.66 (s, 1H).

The following 2-[5-Bromo-2-(substituted phenylamino)-pyrimidin-4-ylamino]-N-ethyl-benzamide are prepared from 2-(5-bromo-2-chloro-pyrimidin-4-ylamino)-N-ethyl-benzamide and the corresponding aniline following the procedure of Example 7A



Expl No.	Rx	Rf (solvent) or MS	NMR
8-1		0.27 (*n*-hexane: AcOEt=1:2)	DMSO-d6: 2.80(d, 3H), 2.88(t, 4H), 3.65 (m, 4H), 3.75 (s, 3H), 6.64 (dd, 1H), 6.94 (d, 1H), 7.11-7.08 (m, 1H), 7.38-7.34 (m, 1H), 7.47-7.46 (m, 1H), 7.70 (dd, 1H), 8.11 (s, 1H), 8.26 (s, 1H), 8.51-8.49 (m, 1H), 8.72-8.71 (m, 1H), 11.41 (s, 1H)

8-2		m/z 513, 515 (M+1)	DMSO-d6: 2.79 (d, 3H, J = 4.04 Hz), 3.10-3.20 (m, 4H), 3.77 (s, 3H), 3.70-3.80 (m, 4H), 6.45-6.55 (m, 1H), 6.63-6.69 (m, 1H), 7.05-7.10 (m, 1H), 7.28-7.34 (m, 1H), 7.40-7.45 (m, 1H), 7.65-7.70 (m, 1H), 8.13 (s, 1H), 8.16 (s, 1H), 8.50-8.56 (m, 1H) 8.65-8.72 (m, 1H), 11.40 (s, 1H)
8-3		0.48 (n-Hexane: AcOEt=4:1)	DMSO-d6: 2.80(d, 3H), 3.83(s, 3H), 4.11(t, 2H), 6.82(ddd, 1H), 7.03(dd, 1H), 7.15(dd, 1H), 7.44(dd, 1H), 7.73(d, 1H), 7.93(dd, 1H), 8.13(s, 1H), 8.33 (s, 1H), 8.50(d, 1H), 8.70-8.77(m, 1H), 11.3(s, 1H).
8-4		MS 446, 448	2.79 (d, 3H), 3.79 (s, 3H), 6.75 (ddd, 1H), 7.0 (dd, 1H), 7.05-7.12 (m, 1H), 7.3-7.36 (m, 1H), 7.62 (dd, 1H), 7.69 (dd, 1H), 8.2 (s, 1H), 8.29 (s, 1H), 8.45 (d, 1H), 8.66-8.73 (m, 1H), 11.4 (brs, 1H).

The following 2-[5-Chloro-2-(substituted phenylamino)-pyrimidin-4-ylamino]-N-ethyl-benzamide are prepared from 2-(2,5-Dichloro-pyrimidin-4-ylamino)-N-ethyl-benzamide and the corresponding aniline following the procedure of Example 7A



Expl No.	Rx	Rf (solvent) or MS	NMR (400MHz) , δ (ppm)
9-1		0.35 (n-hexane: AcOEt=1:2)	$CDCl_3$: 1.27 (t, 3H), 3.10-3.15 (m, 4H), 3.47-3.58 (m, 2H), 3.85-3.93 (m, 4H), 3.89 (s, 3H), 6.08-6.17 (m, 1H), 6.48 (dd, 1H), 6.53 (d, 1H), 7.05-7.11 (m, 1H), 7.42-7.53 (m, 2H), 8.08 (s, 1H), 8.12 (d, 1H), 8.67 (d, 1H), 10.94 (brs, 1H).

9-2		MS (ESI) *m/z* 497, 499 $(M+1)^+$	$CDCl_3$: 1.26 (t, 3H, J = 7.56Hz), 2.37 (s, 3H), 2.57-2.62 (m, 4H), 3.15-3.20 (m, 4H), 3.49 (dq, 2H, J = 7.56, 1.52 Hz), 3.87 (s, 3H), 6.11-6.16 (m, 1H), 6.49 (dd, 1H, J = 8.56, 2.52 Hz), 6.55 (d, 1H, J = 2.52 Hz), 7.05-7.10 (m, 1H), 7.23 (s, 1H), 7.41-7.50 (m, 2H), 8.07 (s, 1H), 8.08 (d, 1H, J = 8.56Hz), 8.65-8.69 (m, 1H), 10.93 (s, 1H)
9-3		*m/z* 564, 566 $(M+1)^+$	DMSO-d6: 1.26 (t, 3H, J = 7.56Hz), 1.40-1.50 (m, 2H), 1.56-1.64 (m, 4H), 1.67-1.82 (m, 2H), 1.88-1.97 (m, 2H), 2.33-2.44 (m, 1H), 2.52-2.57 (m, 4H), 2.63-2.73 (m, 2H), 3.51 (dq, 2H, J = 7.56, 1.52 Hz), 3.62-3.69 (m, 2H), 3.86 (s, 3H), 6.10-6.15 (m, 1H), 6.49 (dd, 1H, J = 8.56, 2.52 Hz), 6.55 (d, 1H, J = 2.52 Hz), 7.05-7.10 (m, 1H), 7.23 (s, 1H), 7.43-7.50 (m, 2H) 8.05-8.11 (m, 1H), 8.07 (s, 1H), 8.65-8.69 (m, 1H), 10.91 (s, 1H)
9-4		0.39 (MeOH: CH_2Cl_2=1:4)	DMSO-d6: 1.19 (t, 3H), 1.52-1.68 (m, 2H), 1.71-1.79 (m, 4H), 1.92-2.05 (m, 2H), 2.12-2.23 (m, 1H), 2.76-2.85 (m, 2H), 3.65-3.73 (m, 2H), 3.82 (s, 3H), 6.54 (dd, 1H), 6.69 (d, 1H), 7.13 (m, 1H), 7.45 (d, 1H), 7.79 (dd, 1H), 8.15 (s, 1H), 8.15-8.18 (m, 1H), 8.60-8.68 (m, 1H), 8.74-8.83 (m, 1H).
9-5		Rf (Hexane: AcOEt = 1:2): 0.30	CDCl3: 1.27 (t, 3H), 3.08-3.14 (m, 4H), 3.52 (q,2H), 3.71-3.90 (m, 7H), 6.05-6.18 (m, 1H), 6.47 (dd, 1H), 6.53 (dd, 1H), 7.08 (dd, 1H), 7.41-7.53 (m, 2H), 8.08 (s, 1H), 8.12 (d, 1H), 8.67 (d, 1H), 10.94 (s, 1H).

9-6		Rf (AcOEt:MeOH= 4:1) 0.050	DMSO: 1.11 (t, 3H), 1.60-1.69 (m, 1H), 1.88-1.96 (m, 2H), 2.19 (s, 3H), 2.55-2.68 (m, 2H), 3.30-3.45 (m, 2H), 3.75 (s, 3H), 4.33-4.43 (m, 1H), 6.54 (dd, 1H), 6.65 (d, 1H), 7.07 (dd, 1H), 7.30 (dd, 1H), 7.43 (d, 1H), 7.71 (dd, 1H), 8.11 (s, 1H), 8.20 (s, 1H), 8.54 (br.d, 1H), 8.75 (dd, 1H), 11.49 (s, 1H).
9-7		0.44 (CH2Cl2:MeOH=8:2)	CDCl3: 1.34 (t, 3H), 1.62-1.68 (m, 2H), 1.93-2.18 (m, 8H), 2.37-2.40 (br, 2H), 2.74-2.86 (br, 3H), 3.20-3.23 (m, 2H), 3.34 (br, 2H), 3.53 (q, 2H), 3.85 (s, 3H), 6.47 (dd, 1H), 6.76 (d, 1H), 7.04-7.08 (m, 1H), 7.30 (dd, 1H), 7.53 (s, 1H), 8.00 (d, 1H), 8.13-8.17 (m, 1H), 8.22 (d, 1H), 8.42-8.53 (br, 1H), 10.91 (s, 1H), 11.59-11.75 (br, 1H)

The following 2-[5-Chloro-2-(substituted phenylamino)-pyrimidin-4-ylamino]-6,N-dimethyl-benzamide are prepared from 2-(2,5-Dichloro-pyrimidin-4-ylamino)-6,N-dimethyl-benzamide and the corresponding aniline following the procedure of Example 7A



Expl No.	Rx	Identification

10-1		NMR (400MHz, DMSO-d6, δ): 1.58-1.68(m, 2H), 1.87-1.96(m, 2H), 2.13-2.22(m, 2H), 2.18(s, 3H), 2.18(s, 3H), 2.29(s, 3H), 2.57-2.65(m, 2H), 2.76(d, 3H), 3.75(s, 3H), 4.29-4.37(m, 1H), 6.45(dd, 1H), 6.61(d, 1H), 6.98(d, 1H), 7.18(dd, 1H), 7.47(d, 1H), 7.89(d, 1H), 8.02(s, 1H), 8.07 (s, 1H), 8.37-8.43(m, 1H), 8.49(s, 1H). Rf: 0.39 (MeOH: CH_2Cl_2=1:4).
10-2		NMR (400MHz, DMSO-d6, δ): 1.35-1.42 (m, 2H), 1.45-1.60 (m, 6H), 1.75-1.85 (m, 2H), 2.29 (s, 3H), 2.30-2.35 (m, 1H), 2.43-2.50 (m, 4H), 2.57-2.66 (m, 2H), 2.76 (d, 3H, J = 5.0Hz), 3.65-3.74 (m, 2H), 3.76 (s, 3H), 6.40 (dd, 1H, J = 9.0, 2.0 Hz), 6.59 (d, 1H, J = 2.0 Hz), 6.98 (d, 1H, J = 7.6 Hz), 7.20 (dd, 1H, J = 7.6, 7.6 Hz), 7.43 (d, 1H, J = 9.0 Hz), 7.91-7.94 (m, 1H), 7.93 (s, 1H), 8.06 (s, 1H), 8.36-8.42 (m, 1H) 8.47 (s, 1H). MS (ESI) *m/z* 564, 566 $(M+1)^+$
10-3		DMSO-d6: 2.29(s, 3H), 2.77(d, 3H), 3.07-3.11(m, 4H), 3.73-3.76(m, 4H), 3.77(s, 3H), 6.41(dd, 1H), 6.63(d, 1H), 7.00 (d, 1H), 7.21(dd, 1H), 7.49(d, 1H), 7.93(d, 1H), 7.96(s, 1H), 8.07(s, 1H), 8.37-8.42(m, 1H), 8.49(s, 1H). MS m/z 483 $[M+1]^+$

The following 2-[5-Chloro-2-(substituted phenylamino)-pyrimidin-4-ylamino]-5-fluoro-N-methyl-benzamide are prepared from 2-(2,5-Dichloro-pyrimidin-4-ylamino)-5-fluoro-N-methyl-benzamide and the corresponding aniline following the procedure of Example 7A



Expl No.	Rx	Identification

11-1		NMR (400MHz, DMSO-d6, δ): 2.79(d, 3H), 3.10-3.15(m, 4H), 3.74-3.78(m, 7H), 6.50(dd, 1H), 6.66(d, 1H), 7.13-7.20 (m, 1H), 7.41(d, 1H), 7.57(dd, 1H), 8.09(s, 1H), 8.14(s, 1H), 8.55-8.65(m, 1H), 8.75-8.82(m, 1H), 11.39(s, 1H). MS (ESI): m/z 487, 489 (M+1).
11-2		NMR (400MHz, DMSO-d6, δ): 1.68-1.33 (m, 8H), 1.93-1.73 (m, 2H), 2.35-2.60 (m, 1H), 2.62-2.74 (m, 2H), 2.67 (t, 2H), 2.74 (d, 3H), 3.25-3.38 (m, 4H), 3.76 (s, 3H), 3.83-3.71 (m, 2H), 6.48 (dd, 1H), 6.49 (dd, 1H), 6.63 (d, 1H), 7.15 (dd, 1H), 7.36 (d, 1H), 7.57 (dd, 1H), 8.09(s, 1H), 8.12(s, 1H), 8.65-8.55 (m, 1H), 8.78(d, 1H), 11.39 (s, 1H) MS (ESI): m/z 568, 570 (M+1)
11-3		DMSO-d6: 2.80(d, 3H), 3.79(s, 3H), 6.64(d,1H), 7.05-7.20(m, 3H), 7.23(d, 1H), 7.42-7.49(d, 1H), 7.57(dd, 1H), 8.20(s, 1H), 8.62-8.69(m, 1H), 8.75-8.82(m, 1H), 9.17(s, 1H), 11.43(s, 1H). MS m/z 425 $[M+1]^+$
11-4		DMSO-d6: 2.06(s, 3H), 2.79(d, 3H), 3.10-3.14(m, 2H), 3.15-3.19(m, 2H), 3.55-3.62(m, 4H), 3.77(s, 3H), 6.52(dd, 1H), 6.69(d, 1H), 7.15-7.23(m, 1H), 7.43(d, 1H), 7.58(dd, 1H), 8.10(s, 1H), 8.14(s, 1H), 8.56-8.65(m, 1H), 8.75-8.81(m, 1H), 11.39(s, 1H). MS m/z 528 $[M+1]^+$

12-1 Preparation of 7-[5-Chloro-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-2-methyl-2,3-dihydro-isoindol-1-one

Synthetic procedure for 7-(2,5-Dichloro-pyrimidin-4-ylamino)-2-methyl-2,3-dihydro-isoindol-1-one

N-Methyl-7-nirto-2,3-dihydroisoindole-1-one. At room temperature, a solution of methyl 2-bromomethyl-6-nitrobenzoate (1.26 g, 4.63 mmol) in THF (13 mL) is treated with 2M soln. of methylamine in THF (14 mL), stirred for 5 h, diluted with EtOAc (100 mL), washed with sat. aqueous solution of $NaHCO_3$ (15 mL) and brine (15 mL), dried ($MgSO_4$), and evaporated. A flash chromatography (30 g of silica gel; CH_2Cl_2/EtOAc 1:1) gives N-Methyl-7-nirto-2,3-dihydroisoindole-1-one (0.561 g, 2.92 mmol) in 63%. Yellow solid. R_f (CH_2Cl_2/EtOAc 1:1) 0.46. ^{1}H-NMR (400 MHz, $CDCl_3$) 3.21 (*s*), 4.44 (*s*), 7.63 – 7.69 (*m*, 2 H), 7.70 – 7.75 (*m*, 1 H).

7-Amino-N-methyl-2,3-dihydroisoindole-1-one. At room temperature, a solution of N-Methyl-7-nirto-2,3-dihydroisoindole-1-one (561.0 mg, 2.92 mmol) in EtOAc (8.4 mL) is treated with $SnCl_2 \cdot 2H_2O$ (2.68 g), stirred at 80°C under reflux for 5 h, and treated with 30 mL of 5N NaOH at 0°C. After the both layers are separated, the aqueous layer is extracted with EtOAc (2 x 8 mL), the combined extracts are washed with brine (5 mL), dried ($MgSO_4$), and evaporated to give 7-Amino-N-methyl-2,3-dihydroisoindole-1-one (455.9 g, 2.81 mmol) in 96%. Yellow solid. R_f (CH_2Cl_2/EtOAc 1:1) 0.53. ^{1}H-NMR (400 MHz, $CDCl_3$) 3.12 (*s*), 4.28 (*s*), 5.20 (br. *s*), 6.56 (*d*, *J* = 8.0), 6.68 (*d*, *J* = 8.0), 7.21 (dd, *J* = 8.0, 8.0).

7-(4-Amino-2,5-dichloropyrimidin-4-yl)amino-N-methyl-2,3-dihydroisoindole-1-one. At 0°C, a solution of 7-Amino-N-methyl-2,3-dihydroisoindole-1-one (232.6 mg, 1.43 mmol) in DMF (2.0 mL) is treated with 60% NaH (89.8 mg), stirred at the same temperature for 1.5 h, treated with a solution of 2,4,5-trichlropyrimidine (0.557 g) in DMF (3.5 mL), stirred for 1 h, and warmed to room temperature. After furthermore stirring for 13 h, the mixture is treated with sat. aqueous NH_4Cl (6 mL), and the resulting brown precipitates are collected by a filtration, followed by washing with H_2O, hexane, and CH_3CN to give 7-(4-Amino-2,5-dichloropyrimidin-4-yl)amino-N-methyl-2,3-dihydroisoindole-1-one (130.2 g, 0.416 mmol) in 26%. Brown solid. R_f (CH_2Cl_2/EtOAc 1:1) 0.50. ^{1}H-NMR (400 MHz, $CDCl_3$): 3.22 (*s*), 4.43 (*s*), 7.15 (*d*, *J* = 8.0), 7.59 (*dd*, *J* = 8.0, 8.0), 8.24 (*s*), 8.71 (*d*, *J* = 8.0), 11.05 (br. *s*).



The following 7-[5-Chloro-2-(substituted phenylamino)-pyrimidin-4-ylamino]-2-methyl-2,3-dihydro-isoindol-1-one are prepared from 7-(2,5-Dichloro-pyrimidin-4-ylamino)-2-methyl-2,3-dihydro-isoindol-1-one and the corresponding aniline following the procedure of Example 7A.

7-[5-Chloro-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-2-methyl-2,3-dihydro-isoindol-1-one



^{1}H-NMR (400MHz, DMSO-d6, δ): 3.07 (s, 3H), 3.13-3.17 (m, 4H), 3.75 (s, 3H), 3.34-3.78 (m, 4H), 4.46 (s, 2H), 6.54 (dd, 1H, J = 8.6, 2.5 Hz), 6.67 (d, 1H, J = 2.5 Hz), 7.15 (d, 1H, J = 7.6 Hz), 7.25-7.34 (m, 1H) 7.36 (d, 1H, J = 8.6 Hz), 8.13 (s, 1H), 8.36 (s, 1H), 8.37-8.50 (m, 1H) 10.57 (s, 1H). MS (ESI) *m/z* 481. 483 $(M+1)^+$

The following7-(5-Chloro-2-(subst.phenylamino)-pyrimidin-4-ylamino)-2-methyl-2,3- dihydro-isoindol-1-ones are prepared from 7-(2,5-Dichloro-pyrimidin-4-ylamino)- 2-methyl-2,3-dihydro-isoindol-1-one and the corresponding aniline following the procedure of Example 2:



Expl No.	Rx	Mass(m/z)	NMR (400MHz) δ (ppm)
12-2		494 $[M+1]^+$	DMSO-d6: 2.24(s, 3H), 2.45-2.50(m,4H), 3.07(s, 3H), 3.15-3.19(m, 4H), 3.74(s, 3H), 4.46(s, 2H), 6.52(dd, 1H), 6.66(d, 1H), 7.15 (d, 1H), 7.25-7.36(m, 2H), 8.12(s, 1H), 8.35(s, 1H), 8.35-8.45(m, 1H), 10.57(s, 1H)
12-3		495 $[M+1]^+$	DMSO-d6: 1.48-1.57(m, 2H), 1.83-1.88(m, 2H), 2.83-2.90(m, 2H), 3.07(s, 3H), 3.51-3.60(m, 2H), 3.61-3.70(m, 2H), 3.73(s, 3H), 4.46(s, 2H), 4.69(d, 1H), 6.52(dd, 1H), 6.64(d, 1H), 7.14 (d, 1H), 7.25-7.35(m, 2H), 8.12(s, 1H), 8.33(s, 1H), 8.35-8.45(m, 1H), 10.57(s, 1H)
12-4		577 $[M+1]^+$	DMSO-d6: 1.48-1.59(m, 2H), 1.83-1.88(m, 2H), 2.14(s, 3H), 2.25-2.39(m, 4H), 2.42-2.60(m, 5H), 2.66-2.73(m, 2H),3.07(s, 3H), 3.73-3.77(m, 2H), 3.74(s, 3H), 4.46(s, 2H), 6.52(dd, 1H), 6.64(d, 1H), 7.14 (d, 1H), 7.25-7.34(m, 2H), 8.12(s, 1H), 8.34(s, 1H), 8.35-8.45(m, 1H), 10.57(s, 1H)
12-5		562 $[M+1]^+$	DMSO-d6: 1.35-1.65(m, 8H), 1.73-1.85(m, 2H), 2.40-2.59(m, 7H), 3.08(s, 3H), 3.52-3.61(m,2H), 3.73(s, 3H), 4.47(s, 2H), 6.72(dd, 1H), 6.94(d, 1H), 7.17(d, 1H), 7.34-7.39(m, 2H), 8.21(s, 1H), 8.37(s, 1H), 8.45-8.53(m, 1H), 10.64(s, 1H)

12-6		MS m/z 536	DMSO-d_6: 2.19-2.42 (m, 4H), 2.65-2.89 (m, 3H), 3.07 (s, 3H), 3.11-3.30 (m, 1H), 3.48-3.61 (m, 2H), 3.62-3.71 (m, 1H), 3.75 (s, 3H), 3.75-3.83 (m, 2H), 4.47 (s, 2H), 6.48-6.52 (m, 1H), 6.66 (d, 1H), 7.15 (d, 1H), 7.26-7.37 (m, 2H), 8.13 (s, 1H), 8.35 (s, 1H), 8.42 (brs, 1H), 10.57 (s, 1H).

The following 7-(5-Chloro-2-(subst.phenylamino) -pyrimidin-4-ylamino)-2-ethyl-2,3-dihydroisoindol-1-ones are prepared from 7-(2,5-Dichloro-pyrimidin-4-ylamino)-2- ethyl-2,3-dihydro-isoindol-1-one and the corresponding aniline following the procedure of Example 2:



Expl No.	Rx	Mass(m/z)	NMR (400MHz) δ (ppm)
13-1		508 $[M+1]^+$	DMSO-d6: 1.19(t, 3H), 2.24(s, 3H), 2.47-2.51(m, 4H), 3.15-3.21(m, 4H), 3.54(q, 2H), 3.74(s, 3H), 4.48(s, 2H), 6.54(dd, 1H), 6.65(d, 1H), 7.15 (d, 1H), 7.26-7.36(m, 2H), 8.12(s, 1H), 8.34(s, 1H), 8.37-8.48(m, 1H), 10.58(s, 1H)

Example 7B: 2-[5-Chloro-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-N-methyl-benzamide (alternative synthesis to Example 7A)

To a suspension of 2-[5-chloro-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-benzoic acid (5.5 g, 12.1 mmol) in 100 mL of THF are added Et_3N (2.06 mL, 14.8 mmol) and isobutyl chloroformate (1.7 mL, 12.8 mmol) at -5°C. After stirring at the same temperature for 30 min, the reaction mixture is further stirred at room temperature for 1 hour and then H_2O is added to the reaction mixture. The resulting precipitate is collected by filtration,

washed with H_2O, and dried under reduced pressure to give an intermediate (4.80 g) (10.96 mmol, 91%) as yellow solid.
NMR (400MHz, DMSO-d6, δ): 3.10-3.20 (m, 4H), 3.70-3.80 (m, 4H), 3.93 (s, 3H), 6.53 (dd, 1H, J = 9.08, 2.0 Hz), 6.70 (d, 1H, J = 2.0 Hz), 7.49-7.54 (m, 1H), 7.67 (d, 1H, J = 8.56 Hz), 7.89 (s, 1H), 7.85-7.95 (m, 1H), 8.23 (d, 1H, J = 9.08 Hz), 8.26 (d, 1H, J = 8.56Hz), 12.60 (s, 1H).

To a 1M solution of methylamine in THF (560 µl, 0.56 mmol) is added 82 mg of the obtained intermediate (0.187 mmol) followed by 1M solution of NaHMDS in THF (560 µl, 0.56 mmol) dropwise. After the reaction mixture is stirred for 10 minutes, 5 mL of H_2O is added and extraction is performed with AcOEt. The organic layer is washed with brine, dried over Na_2SO_4, concentrated under reduced pressure, and purified by silica gel column chromatography (Hexane: AcOEt=1:1 to AcOEt) to give the title compound as a pale yellow solid. Data are given in Example 7A.

By repeating the procedures described above using appropriate starting materials and conditions the following compounds are obtained as identified below.



Expl No.	Ry	Rf (solvent) or MS	NMR (400MHz) , δ (ppm)
14-1		0.10 (n-hexane: AcOEt=1:1)	$CDCl_3$: 3.02-3.19 (m, 10H), 3.83-3.91 (m, 4H), 3.87 (s, 3H), 6.45 (dd, 1H), 6.52 (d. 1H), 7.09-7.14 (m, 1H), 7.29 (m, 1H), 7.31 (dd, 1H), 7.38-7.45 (m, 1H), 8.06 (s, 1H), 8.14 (d, 1H), 8.39 (d, 1H), 8.97 (s, 1H).
14-2		0.36 (n-hexane: AcOEt=1:2)	$CDCl_3$: 1.27 (d, 6H), 3.09-3.16 (m, 4H), 3.81-3.92 (m, 4H), 3.89 (s, 3H), 4.26-4.37 (m, 1H), 5.93-5.98 (m, 1H), 6.48 (dd, 1H), 6.53 (d, 1H), 7.05-7.11 (m, 1H), 7.42-7.49 (m, 2H), 8.08 (s, 1H), 8.12 (d, 1H), 8.65 (d,

			1H), 10.88 (br.s, 1H).
14-3		505 [M+1]+	DMSO-d6: 2.79(d, 3H), 3.09-3.14(m, 4H), 3.74-3.77(m, 4H), 3.75(s, 3H), 6.49(dd, 1H), 6.65(d, 1H), 7.30 (d, 1H), 7.84(dd, 1H), 8.12(s, 1H), 8.40(s, 1H), 8.65-8.79(m, 2H), 11.39(s, 1H)
14-4		466 [M+1]+	DMSO-d6: 2.70-2.75(m, 2H), 3.04-3.09(m, 2H), 3.12-3.18(m, 4H), 3.74-3.80(m, 4H), 3.75(s, 3H), 6.54(dd, 1H), 6.67(d, 1H), 7.14 (d, 1H), 7.34(d, 1H), 7.37-7.44(m, 1H), 8.17(s, 1H), 8.35-8.50(m, 1H), 8.44(s, 1H), 10.59(s, 1H)
14-5		Rf (Hexane : AcOEt=1:2) : 0.31	DMSO: 1.18 (t, 3H), 3.11-3.21 (4, 4H), 3.30-3.60 (m, 2H), 3.71-3.85 (m, 7H), 6.50-6.58 (m, 1H), 6.71 (d, 1H), 7.17-7.26 (m, 1H), 7.46 (d, 1H), 7.64 (dd, 1H), 8.14 (s, 1H), 8.19 (s, 1H), 8.57-8.68 (m, 1H), 8.80-8.87 (m, 1H), 11.36 (s, 1H).
14-6		Rf (Hexane : AcOEt=1:1) : 0.051	DMSO: 1.71-1.92 (m, 2H), 1.92-2.06 (m, 2H), 3.08-3.14 (m, 4H), 3.48-3.57 (m, 2H), 3.63-3.75 (m, 2H), 3.84-3.90 (m, 7H), 6.47 (dd, 1H), 6.53 (d, 1H), 7.09 (ddd, 1H), 7.25-7.29 (m, 1H), 7.38-7.44 (m, 1H), 8.06 (s, 1H), 8.15 (d, 1H), 8.45 (dd, 1H), 9.60 (s, 1H).
14-7			^{1}H-NMR (400MHz, δ ppm, $CDCl_3$): 3.04-3.10 (m, 4H), 3.10-3.16 (m, 4H), 3.63-3.68 (m, 4H), 3.85-3.90 (m, 7H), 6.46 (dd, 1H), 6.53 (d, 1H), 7.20-7.25 (m, 1H), 7.33 (brs, 1H), 7.56-7.62 (m, 1H), 7.85 (dd, 1H), 8.03 (d, 1H), 8.12 (s, 1H), 8.57-8.61 (m, 1H), 9.30 (s, 1H).

The following 2-(5-Chloro-2-(subst. phenylamino)-pyrimidin-4-ylamino)-N-methyl-5- pyrrolidin-1-yl-benzamides are prepared from 2-(5-Chloro-2-methyl-pyrimidin-4- ylamino)-N-methyl-5-pyrrolidin-1-yl-benzamide and the corresponding aniline following the procedure of Example 2:



Expl No.	Rx	Mass(m/z)	NMR (400MHz) δ (ppm)
15-1		551 $[M+1]^+$	DMSO-d6: 1.94-1.99(m, 4H), 2.23(s, 3H), 2.43-2.48(m, 4H), 2.78(d, 3H), 3.11-3.17(m, 4H), 3.22-3.29(m, 4H), 3.76(s, 3H), 6.46(dd, 1H), 6.48-6.53(m, 1H), 6.63(d, 1H), 6.79(d, 1H), 7.44(d, 1H), 7.89(s, 1H), 7.99(s, 1H), 8.24(d, 1H), 8.60(d, 1H), 10.88(s, 1H)
15-2		566 $[M+1]^+$	DMSO-d6: 1.60-1.70(m, 2H), 1.90-2.00(m, 6H), 2.12-2.20(m, 2H), 2.18(s, 3H), 2.60-2.65(m, 2H), 2.78(d, 3H), 3.22-3.28(m, 4H), 3.75(s, 3H), 4.25-4.37(m, 1H), 6.49-6.55(m, 2H), 6.62(d, 1H), 6.80(d, 1H), 7.53(d, 1H), 7.90(s, 1H), 8.00(s, 1H), 8.24(d, 1H), 8.58-8.63(m, 1H), 10.88(s, 1H)

15-3		538 $[M+1]^+$	DMSO-d6: 1.94-1.99(m, 4H), 2.78(d, 3H), 3.09-3.15(m, 4H), 3.22-3.27(m, 4H), 3.73-3.77(m, 4H), 3.76(s, 3H), 6.47(dd, 1H), 6.47-6.53(m, 1H), 6.65(d, 1H), 6.79(d, 1H), 7.47(d, 1H), 7.90(s, 1H), 7.99(s, 1H), 8.24(d, 1H), 8.60(d, 1H), 10.88(s, 1H)

The following 2-[5-Chloro-2-(4-fluoro-2-methoxy-phenylamino)-pyrimidin-4- ylamino]-5-subst.-N-methyl-benzamide are prepared from the corresponding aniline following the procedure of Example 2:



Expl No.	Ry	Mass(m/z)	NMR (400MHz) δ (ppm)
16-1		487 $[M+1]^+$	DMSO-d6: 2.79(d, 3H), 3.11-3.15(m, 4H), 3.74-3.81(m, 4H), 3.81(s, 3H), 6.76(ddd, 1H), 6.95-7.05(m, 2H), 7.21(d, 1H), 7.72(dd, 1H), 8.08(s, 1H), 8.09(s, 1H), 8.33(d, 1H), 8.63-8.73(m, 1H), 11.17(s, 1H)
16-2		500 $[M+1]^+$	DMSO-d6: 2.24(s, 3H), 2.45-2.52(m, 4H),2.79(d, 3H), 3.13-3.18(m, 4H), 3.81(s, 3H), 6.75(ddd, 1H), 6.94-7.02(m, 2H), 7.20(d, 1H), 7.73(dd, 1H), 8.03-8.11(m, 2H), 8.30(d, 1H), 8.60-8.70(m, 1H), 11.14(s, 1H)
16-3		432 $[M+1]^+$	DMSO-d6: 2.79(d, 3H), 3.80-3.81(m, 6H), 6.75(ddd, 1H), 6.90-7.02(m, 2H), 7.27(d, 1H), 7.67(dd, 1H), 8.10(s, 1H), 8.16(s, 1H), 8.39(d, 1H), 8.70-8.76(m, 1H), 11.20(s, 1H)

16-4		568 $[M+1]^+$	DMSO-d6: 1.35-1.62(m, 8H), 1.78-1.85(m, 2H), 2.30-2.40(m, 1H), 2.41-2.52(m, 4H), 2.60-2.70(m, 2H), 2.78(d, 3H), 3.70-3.80(m, 2H), 3.81(s, 3H), 6.75(ddd, 1H), 6.95-7.02(m, 2H), 7.20(d, 1H), 7.72(dd, 1H), 8.05-8.08(m, 2H), 8.28(d, 1H), 8.63-8.69(m, 1H), 11.12(s, 1H)

Example 16B



$CDCl_3$: 3.01-3.10 (m, 4H), 3.63-3.68 (m, 4H), 3.89 (s, 3H), 6.59 (ddd, 1H), 6.66 (dd, 1H), 7.20-7.26 (m, 1H), 7.36 (s, 1H), 7.57-7.63 (m, 1H), 7.84 (dd, 1H), 8.09-8.14 (m, 1H), 8.14 (s, 1H), 8.53 (d, 1H), 9.30 (s, 1H).

Example 16C



$CDCl_3$: 3.56-3.65 (m, 2H), 3.88 (s, 3H), 5.11-5.19 (m, 1H), 6.50-6.56 (m, 1H), 6.61-6.66 (m, 1H), 7.25-7.29 (m, 1H), 7.38 (brs, 1H), 7.58-7.62 (m, 1H), 7.97 (dd, 1H), 8.02-8.10 (m, 1H), 8.15 (s, 1H), 8.41 (dd, 1H), 8.81 (s, 1H).

The following 2-(5-Chloro-2-(subst.phenylamino)-pyrimidin-4-ylamino)-5-fluoro-N-methyl-benzamide are prepared from 2-(2,5-Dichloro-pyrimidin-4-ylamino)-5-fluoro-N-methyl-benzamideand the corresponding aniline following the procedure of Example 2:



Expl No.	Rx	Mass(m/z)	NMR (400MHz) δ (ppm)
18-1		595 $[M+1]^+$	DMSO-d6: 2.06 (s, 3H), 2.78 (d, 3H), 3.05-3.18 (m, 8H), 3.53-3.64 (m, 4H), 3.68-3.77 (m, 4H), 3.77 (s, 3H), 6.51 (dd, 1H), 6.69 (d, 1H), 6.88 (br.d, 1H), 7.20 (d, 1H), 7.43 (d, 1H), 7.99-8.03 (m, 2H), 8.34 (br.d, 1H), 8.63-8.71 (m, 1H), 11.15 (s, 1H).

The following 2-[5-chloro-2-(subst.phenylamino)-pyrimidin-4-ylamino]-N-isopropyl-benzene-sulfonamides are prepared from 2-(5-chloro-2-chloro-pyrimidin-4-ylamino)-N-isopropyl-benzenesulfonamide and the corresponding aniline following the procedure of Example 7A



ExplNo.	Rx	Rf (solvent) Or MS	NMR (400MHz), δ (ppm)

19-1		0.39 (MeOH: CH_2Cl_2=1:4)	DMSO-d6: 0.94(d, 6H), 1.75-1.84(m, 1H), 2.07-2.16(m, 1H), 2.33(s, 3H), 2.98-3.04(m, 1H), 3.22-3.36(m, 5H), 3.42-3.47(m, 1H), 3.74(s, 3H), 6.05(dd, 1H), 6.18(d, 1H), 7.18(dd, 1H), 7.25(d, 1H), 7.35-7.45(m, 1H), 7.77-7.82(m, 1H), 7.70-8.10(m, 1H), 8.09-8.17 (m, 2H), 8.45-8.63(m, 1H), 9.34(s, 1H)
19-2		0.40 (*n*-hexane: AcOEt=1:1)	$CDCl_3$: 1.00(d, 6H), 1.13(t, 3H), 1.83-1.92(m, 1H), 2.23-2.30(m,1H), 2.70-2.78(m, 2H), 3.08-3.13(m, 1H), 3.27-3.54 (m, 5H), 3.85(s, 3H), 4.33(d, 1H), 6.05(d, 1H), 6.13(s, 1H), 7.13(bs, 1H), 7.18-7.22(m, 1H), 7.52-7.56(m, 1H), 7.83-7.86(m, 1H), 7.95-7.98(m, 1H), 8.09(s, 1H), 8.47-8.49(m, 1H), 8.89(s, 1H)
19-3		0.30 (*n*-hexane: AcOEt=1:1)	$CDCl_3$: 0.93 (d, 6H), 1.05-1.09(m, 1H), 1.48-1.99(m, 6H), 2.16(s,3H), 2.61-2.67(m, 1H), 2.80-2.83(m, 1H), 3.75(s, 3H), 3.80-3.89(m, 2H), 6.44-6.47(m, 1H), 6.62-6.63(m, 1H), 7.18-7.22(m, 1H), 7.42-7.46(m, 1H), 7.80-7.89(m, 2H), 8.17(s, 1H), 8.23(s, 1H), 8.42-8.44(m, 1H), 8.89(s, 1H)
19-4		0.69 (MeOH: CH_2Cl_2=1:3)	DMSO-d6 : 0.94(d, 6H), 1.45-1.57(m, 2H), 1.80-1.88(m, 2H), 2.14(s, 3H), 2.25-2.35(m, 4H), 2.45-2.55(m, 4H), 2.62-2.70(m, 2H), 3.28-3.37(m, 1H), 3.68-3.74(m, 2H), 3.75(s, 3H), 6.44(dd, 1H, *J*=8.82, 2.0Hz), 6.61(d, 1H, *J*=2.0Hz), 7.21(dd, 1H), 7.37(d, 1H), 7.45(dd, 1H), 7.81(dd, 1H, *J*=1.82, 1.52Hz), 7.84-7.92(m, 1H), 8.12-8.20(m, 1H), 8.16(s, 1H), 8.43 - 8.51(m, 1H), 9.31(s, 1H)
19-5		0.35 (n-hexane: AcOEt=1:1)	$CDCl_3$: 0.93(d, 6H), 2.23(s, 3H), 2.45-2.48(m, 4H), 3.12-3.15(m,4H), 3.75(s, 3H), 6.42-6.45(m, 1H), 6.63 (s, 1H), 7.19-7.23(m, 1H), 7.38-7.47(m, 2H), 7.80-7.89(m, 2H), 8.16(s, 1H), 8.46-8.48(m, 1H), 9.34(s, 1H)

19-6		0.45 (n-hexane: AcOEt=1:1)	$CDCl_3$: 0.99(d, 6H), 3.40-3.49(m, 1H), 3.88(s, 3H), 4.29-4.31(d, 1H), 6.51-6.56(m, 1H), 6.62-6.65 (m, 1H), 7.24-7.28(m, 1H), 7.37(s, 1H), 7.56-7.60(m, 1H), 7.98-8.15(m, 3H), 8.34-8.37(m, 1H), 8.89(s, 1H)
19-7		0.28 (*n*-hexane: AcOEt=1:1)	DMSO-d6 : 0.93(d, 6H), 1.59-1.67(m, 2H), 1.90-1.93(m, 2H), 2.10-2.24(m, 5H), 2.60-2.67(m, 2H), 3.74(s, 3H), 4.33-4.37(m, 1H), 6.47-6.50(m, 1H), 6.63(d, 1H), 7.18-7.22(m, 1H), 7.41-7.45(m, 2H), 7.79-7.87(m, 2H), 8.16(s, 1H), 8.21(s, 1H), 8.41 - 8.43(m, 1H), 9.29(s, 1H)
19-8		0.25 (*n*-hexane: AcOEt=1:1)	DMSO-d6 : 0.93(d, 6H), 3.09-3.12(m, 4H), 3.74-3.76(m, 7H), 6.43-6.46(m, 1H), 6.64(s, 1H), 7.19-7.23(m, 1H), 7.41-7.48(m, 2H), 7.80(d, 1H), 7.82(d, 1H), 8.17(s, 1H), 8.46-8.48(m, 1H), 9.31(s, 1H)
19-9		0.56 (MeOH: CH_2Cl_2=1:4)	DMSO-d6 : 0.93(d, 6H), 1.89-1.90(m, 1H), 2.30(bs, 6H), 3.13-3.50(m, 6H), 3.74(s, 3H), 6.10(d, 1H), 6.22(s, 1H), 7.16-7.20(m, 1H), 7.25-7.27(m, 1H), 7.40(bs, 1H), 7.79-7.81(m, 1H), 7.86-7.88(m, 1H), 8.12(s, 1H), 8.15(s, 1H), 8.51(s, 1H), 9.34(s, 1H)
19-10		0.45 (MeOH: CH_2Cl_2=1:4)	$CDCl_3$: 0.99(d, 12H), 2.27(s, 2H), 2.31(s, 6H), 2.96(s, 2H), 3.39-3.48(m, 1H), 3.83(s, 3H), 4.30(d, 1H), 6.09-6.12(m, 1H), 6.19(d, 1H), 7.11(s, 1H), 7.19-7.23(m, 1H), 7.51-7.57(m, 1H), 7.76-7.79(m, 1H), 7.95(d, 1H), 8.09(s, 1H), 8.46-8.49(m, 1H), 8.88(s, 1H)
19-11		0.30 (*n*-hexane: AcOEt=1:1)	DMSO-d6 : 0.93(d, 6H), 2.96-2.99(m, 4H), 3.74-3.76(m, 7H), 6.67-6.72(m, 1H), 7.21-7.25(m, 1H), 7.31-7.34(m, 1H), 7.44-7.48(m, 1H), 7.80-7.83(m, 1H), 7.88(d, 1H), 8.21(s, 1H), 8.42(d, 1H), 8.58(s, 1H), 9.30 (s, 1H)

19-12		0.42 (MeOH: CH_2Cl_2=1:4)	DMSO-d6: 0.94(d, 6H), 1.68-1.76(m, 1H), 1.99-2.07(m, 1H), 2.29(s, 3H), 3.05-3.49(m, 6H), 3.75(s, 3H), 6.36-6.40(m, 1H), 7.10-7.37(m, 3H), 7.70-7.80(m, 1H), 8.08-8.39(m, 3H), 9.24(s, 1H)
19-13		0.50 (MeOH: CH_2Cl_2=1:4)	$CDCl_3$: 1.01(d, 6H), 1.94-1.96(m, 1H), 2.01(s, 3H), 2.29-2.37(m, 1H), 3.19-3.58(m, 5H), 3.86(s, 3H), 4.42(d, 1H), 4.59-4.63(m, 1H), 5.70(d, 1H), 6.05-6.08(m, 1H), 6.15-6.16(m, 1H), 7.17-7.24(m, 2H), 7.53-7.57(m, 1H), 7.90(d, 1H), 7.91-7.98(m, 1H), 8.09(s, 1H), 8.47(d, 1H), 8.91(s, 1H)
19-14		0.53 (MeOH: CH_2Cl_2=1:4)	$CDCl_3$: 1.00(d, 6H), 2.04(s, 3H), 2.05-2.29(m, 2H), 2.96(s, 3H), 3.19-3.54(m, 5H), 3.86(s, 3H), 4.57-4.63(m, 1H), 5.39-5.46(m, 1H), 6.07-6.09(m, 1H), 6.16(d, 1H), 7.18-7.26(m, 2H), 7.53-7.57(m, 1H), 7.89-7.98(m, 2H), 8.08(s, 1H), 8.47(d, 1H), 8.94(d, 1H)
19-15		0.56 (MeOH: CH_2Cl_2=1:4)	DMSO-d6 : 0.93(d, 6H), 1.48-1.56(m, 2H), 1.65-1.75(m, 4H), 1.90-1.93(m, 2H), 2.05-2.15(m, 1H), 2.45-2.55(m, 5H), 2.69-2.75(m, 2H), 3.61(d, 2H), 3.74(s, 1H), 6.42-6.51(m, 1H), 6.61(d, 1H), 7.18-7.22(m, 1H), 7.37(d, 1H), 7.43-7.47(m, 1H), 7.80(d, 1H), 7.81-7.89(m, 1H), 8.16(d, 1H), 8.46-8.48(m, 1H), 9.31(s, 1H)
19-16		0.56 (MeOH: CH_2Cl_2=1:4)	DMSO-d6 : 0.92(d, 6H), 1.65-1.75(m, 4H), 1.88-2.00(m, 4H), 2.39-2.43(m, 2H), 2.60-2.65(m, 2H), 3.03-3.07(m, 1H), 3.03-3.40(m, 2H), 3.70(s, 3H), 3.77-3.78(m, 1H), 6.09(d, 1H), 6.23(s, 1H), 7.13-7.17(m, 1H), 7.23-7.25(m, 1H), 7.30-7.42(m, 1H), 7.78(d, 1H), 7.86(d, 1H), 8.10(s, 1H), 8.13(s, 1H), 8.40-8.50(m, 1H), 9.31(s, 1H)

19-17		0.23 (*n*-hexane: AcOEt=1:1)	DMSO-d6 : 0.93(d, 6H), 1.24-1.57(m, 4H), 1.69-1.78(m, 2H), 1.98-2.04(m, 1H), 2.15-2.33(m, 5H), 2.70-2.80(m, 1H), 3.74(s, 3H), 3.91-3.94(m, 1H), 4.05-4.09(m, 1H), 6.46-6.49(m, 1H), 6.63(d, 1H), 7.18-7.22(m, 1H), 7.42-7.46(m, 2H), 7.80(d, 1H), 7.89(d, 1H), 8.17(s, 1H), 8.25(s, 1H), 8.42 -8.44(m, 1H), 9.31(s, 1H)
19-18		0.48 (*n*-hexane: AcOEt=1:1)	DMSO-d6 : 0.93(d, 6H), 1.03(t, 3H), 1.13(t, 3H), 1.42-1.81(m, 4H), 2.57-2.83(m, 4H), 3.17-3.41(m, 4H), 3.65-3.75(m, 1H), 3.80(s, 3H), 4.21(bs, 1H), 6.42-6.47(m, 2H), 6.51(d, 1H), 6.63(d, 1H), 7.18-7.22(m, 1H), 7.38-7.47(m, 2H), 7.80-7.82(m, 1H), 7.89(d, 1H), 8.16(s, 1H), 8.47 -8.49(m, 1H), 9.31(s, 1H)
19-19		0.44 (CH2Cl2:MeOH=9:1)	CDCl3: 1.45-1.62 (m, 2H), 1.72-1.78 (m, 1H), 1.82-1.90 (m, 1H), 2.40-2.46 (m, 1H), 2.61-2.75 (m, 2H), 3.75-3.70 (m, 2H), 3.76 (s, 3H), 6.45 (dd, 1H), 6.62 (d, 1H), 6.85 (s, 1H), 7.19-7.23 (m, 1H), 7.36-7.48 (m, 3H), 7.80-7.82 (m, 1H), 7.85-7.93 (br, 1H), 8.16 (s, 2H), 8.43-8.52 (m, 1H), 9.31 (s, 1H)
19-20		Ms : 547	DMSO-d6 : 0.94 (d, 6H), 1.73-1.82 (m, 1H), 2.23-2.33 (m, 4H), 2.34-2.41 (m, 1H), 2.54-2.62 (m, 1H), 2.62-2.69 (m, 1H), 2.77-2.82 (m, 1H), 3.25-3.35 (m, 1H), 3.74 (s, 3H), 4.85-4.92 (m, 1H), 6.4 (dd, 1H), 6.57 (d, 1H), 7.16-7.24 (m, 1H), 7.38-7.51 (m, 1H), 7.81 (d, 1H), 7.82-7.94 (m, 1H), 8.16 (s, 1H), 8.22 (brs, 1H), 8.38-8.48 (m, 1H), 9.3 (brs, 1H)
19-21		Ms : 579	DMSO-d6 : 0.92 (d, 6H), 1.61-1.71 (m, 2H), 1.86-1.96 (m, 2H), 2.12-2.22 (m, 5H), 2.57-2.64 (m, 2H), 3.2-3.4 (m, 1H), 3.77 (s, 3H), 4.27-4.35(m, 1H), 6.86 (dd, 1H), 7.19-7.27 (m, 1H), 7.39-7.46 (m, 1H), 7.81 (dd, 1H), 7.84-7.92 (m, 1H), 8.21 (s, 1H), 8.36-8.42 (m, 1H), 8.62 (s, 1H), 9.28 (s, 1H)

19-22		Ms : 549	DMSO-d6 : 0.90 (s, 6H), 0.94 (d, 6H), 2.9 (d, 2H), 3.24 (d, 2H), 3.25-3.35(m, 1H), 3.27-3.36 (m, 1H), 3.68 (s, 3H), 4.58 (t, 1H), 5.3 (t, 1H), 6.16 (dd, 1H), 6.39 (d, 1H), 7.13 (d, 1H), 7.15-7.21 (m, 1H), 7.35-7.45 (m, 1H), 7.8 (dd, 1H), 7.83-7.92 (m, 1H), 8.09 (s, 1H), 8.11 (s, 1H), 8.45-8.57 (m, 1H), 9.33 (s, 1H)
19-23		Rf : 0.51 (n-hexane : AcOEt=1:1)	DMSO-d6 : 0.94 (d, 6H), 1.22 (s, 6H), 3.25-3.35 (m, 1H), 3.36 (d, 2H), 3.68 (s, 3H), 4.73-4.79 (brs, 1H), 4.81 (t, 1H), 6.29 (dd, 1H), 6.44 (d, 1H), 7.14-7.22 (m, 2H), 7.38-7.46 (m, 1H), 7.8 (dd, 1H), 7.85-7.9 (m, 1H), 8.1 (s, 1H), 8.13 (s, 1H), 8.45-8.55 (m, 1H), 9.32 (s, 1H)
19-24		Ms : 577	DMSO-d6 : 0.93 (d, 6H), 0.96 (s, 6H), 2.22 (s, 6H), 3.25-3.35 (m, 1H), 3.7 (s, 3H), 3.75 (s, 3H), 6.46 (dd, 1H), 6.62 (d, 1H), 7.16-7.23 (m, 1H), 7.38-7.47 (m, 1H), 7.81 (dd, 1H), 7.85-7.9 (m, 1H), 8.17 (s, 1H), 8.23 (s, 1H), 8.38-8.48 (m, 1H), 9.31 (s, 1H)
19-25		Ms : 521	DMSO-d6 : 0.94 (d, 6H), 3.12 (t, 4H), 3.25-3.35 (m, 1H), 3.75 (t, 4H), 6.73 (dd, 1H), 6.85 (dd, 1H), 7.16-7.24 (m, 1H), 7.25-7.32 (m, 1H), 7.38-7.47 (m, 1H), 7.8 (dd, 1H), 7.88 (d, 1H), 8.18 (s, 1H), 8.42-8.52 (m, 1H), 8.86 (s, 1H), 9.36 (s, 1H)
19-26		Ms : 565	DMSO-d6 : 0.93 (d, 6H), 2.4-2.56 (m, 4H), 2.69 (t, 2H), 3.25-3.38 (m, 1H), 3.59 (t, 4H), 4.11 (t, 1H), 6.75 (dd, 1H), 6.93 (dd, 1H), 7.16-7.23 (m, 1H), 7.3-7.4 (m, 1H), 7.4-7.38 (m, 1H), 7.8 (dd, 1H), 7.88 (d, 1H), 8.19 (s, 1H), 8.36-8.5 (m, 1H), 8.92 (s, 1H), 9.34 (s, 1H)

19-27		Ms : 614	DMSO-d6 : 0.93 (d, 6H), 1.3-1.62 (m, 8H), 1.75-1.85 (m, sH), 2.26-2.4 (m, 1H), 2.4-2.58 (m, 4H), 3.28-3.38 (m, 1H), 3.68-3.78 (m, 5H), 6.42 (dd, 1H), 6.64 (d, 1H), 7.18-7.24 (m, 1H), 7.42-7.5 (m, 2H), 7.77 (d, 1H), 7.82 (dd, 1H), 8.13 (s, 1H), 8.17 (s, 1H), 8.4-8.5 (m, 1H), 9.36 (s, 1H)
19-28		Rf : 0.5 (MeOH: CH2Cl2=3: 7)	DMSO-d6 : 0.93 (d, 6H), 1.6-1.7 (m, 2H), 1.88-1.98 (m, 2H), 2.17-2.35 (m, 5H), 2.6-2.73 (m, 2H), 3.25-3.4 (m, 1H), 4.34-4.44 (m, 1H), 6.75 (dd, 1H), 6.93 (dd, 1H), 7.16-7.23 (m, 1H), 7.29-7.36 (m, 1H), 7.37-7.47 (m, 1H), 7.8 (dd, 1H), 7.89 (d, 1H), 8.19 (s, 1H), 8.36-8.46 (m, 1H), 8.92 (s, 1H), 9.31 (s, 1H)
19-29		Ms : 577	DMSO-d6 : 0.93 (d, 6H), 2.45-2.55 (m, 4H), 2.7 (t, 2H), 3.25-3.35 (m, 1H), 3.59 (t, 3H), 3.76 (s, 3H), 4.1 (t, 1H), 6.48 (dd, 1H), 6.65 (d, 1H), 7.18-7.24 (m, 1H), 7.4-7.5 (m, 2H), 7.82 (dd, 1H), 7.88 (d, 1H), 8.17 (s, 1H), 8.24 (s, 1H), 8.4-8.48 (m, 1H), 9.31 (s, 1H)
19-30		Ms : 590	DMSO-d6 : 0.93 (d, 6H), 2.15 (s, 3H), 2.2-2.4 (m, 4H), 2.4-2.6 (m, 4H), 2.69 (t, 2H), 3.25-3.35 (m, 1H), 3.75 (s, 3H), 4.08 (t, 2H), 6.47 (dd, 1H), 6.64 (d, 1H), 7.18-7.24 (m, 1H), 7.41-7.49 (m, 2H), 7.81 (dd, 1H), 7.86-7.91 (m, 1H), 8.17 (s, 1H), 8.24 (s, 1H), 8.39-8.46 (m, 1H), 9.31 (s, 1H)

19-31		Ms : 588	DMSO-d6 : 0.94 (d, 6H), 2.19-2.36 (m, 4H), 2.66-2.85 (m, 3H), 3.15-3.21 (m, 1H), 3.73-3.8 (m, 5H), 6.43 (dd, 1H), 6.63 (d, 1H), 7.18-7.25 (m, 1H), 7.4 (d, 1H), 7.43-7.5 (m, 1H), 7.81 (dd, 1H), 7.89 (d, 1H), 8.16 (s, 1H), 8.17 (s, 1H), 8.42-8.52 (m, 1H), 9.32 (s, 1H)
19-32		Ms : 560	CDCl3 : 1.01(s, 6H), 1.45-1.56 (m, 2H), 2.03-2.11 (m, 2H), 2.11-2.2 (m, 2H), 2.31 (s, 3H), 2.78-2.87 (m, 2H), 3.22-3.31 (m, 1H), 3.39-3.5 (m, 1H), 3.82 (s, 3H), 4.5-4.6 (m, 1H), 6.13 (dd, 1H), 6.21 (d, 1H), 7.16 (s, 1H), 7.18-7.24 (m, 1H), 7.5-7.57 (m, 1H), 7.82 (d, 1H), 7.97 (dd, 1H), 8.16 (s, 1H), 8.08 (s, 1H), 8.46 (d, 1H), 8.92 (s, 1H)

The following 2-[5-chloro-2-(subst.phenylamino)-pyrimidin-4-ylamino]-N-methyl-benzene-sulfonamides are prepared from 2-(5-chloro-2-chloro-pyrimidin-4-ylamino)-N-methyl-benzenesulfonamide and the corresponding aniline following the procedure of Example A



ExplNo.	Rx	Rf (solvent) or MS	NMR (400MHz), δ (ppm)
20-1		0.50 (AcOEt)	$CDCl_3$: 2.63(d, 3H), 3.14(t, 4H), 3.87-3.90(m,7H), 4.64(m,1H), 6.45(dd, 1H), 6.55(d, 1H), 7.23-7.26(m, 1H), 7.51-7.55(m, 1H), 7.91(d, 1H), 7.95(dd, 1H), 8.06(s, 1H), 8.47(d, 1H), 9.26(s, 1H)

20-2		m/z 546, 548 (M+1)	DMSO-d6: 2.06 (s, 3H), 2.43 (s, 3H), 3.10 (m, 2H), 3.16 (m, 2H), 3.59-3.62 (m, 4H), 3.77 (s, 3H), 6.49 (dd, 1H), 6.68 (d, 1H), 7.21-7.25 (m, 1H), 7.42 (d, 1H), 7.49 (dd, 1H), 7.75-7.77 (m, 1H), 7.78(s, 1H), 8.16(s, 1H), 8.21 (s, 1H), 8.50(d, 1H), 9.35 (s, 1H)
20-3		0.27 (*n*-hexane: AcOEt=3:1)	$CDCl_3$: 2.65(d, 3H), 4.45-4.49(m, 1H), 6.99-7.04(m, 1H), 7.17-7.28(m, 4H), 7.56-7.60(m, 1H), 7.96-7.98(m, 1H), 8.18(s, 1H), 8.31-8.34(m, 1H), 8.41-8.44(m, 1H), 9.14(s, 1H)
20-4		0.27 (*n*-hexane: AcOEt=3:1)	$CDCl_3$: 2.65(d, 3H), 4.54-4.58(m, 1H), 6.53(dd, 1H), 6.98-7.02(m, 1H), 7.11-7.15(m, 2H), 7.24-7.28(m, 1H), 7.35(bs, 1H), 7.57-7.61(m, 1H), 7.95-7.98(m, 1H), 8.16(s, 1H), 8.29-8.32(m, 1H), 8.42-8.46(m, 1H), 9.14(s, 1H)
20-5		0.46 (MeOH: CH_2Cl_2=1:4)	$CDCl_3$: 1.95-2.00(m, 5H), 2.29-2.37(m, 1H), 2.62(d, 3H), 3.20-3.78(m, 4H), 3.86(s, 3H), 4.60-4.64(m, 2H), 5.68-5.69(m, 1H), 6.09-6.16(m, 2H), 7.15(bs, 1H), 7.19-7.23(m, 1H), 7.54-7.58(m, 1H), 7.88-7.95(m, 2H), 8.06(s, 1H), 8.55-8.57(m, 1H), 9.08(s, 1H)
20-6		518 [M+1]+	DMSO-d6: 2.23(s, 3H), 2.43(s, 3H), 2.45-2.50(m, 4H), 3.12-3.17(m, 4H), 3.76(s, 3H), 6.45(dd,1H), 6.63(d, 1H), 7.22(dd, 1H), 7.37(d, 1H), 7.45-7.50(m, 1H), 7.74-7.78(m, 1H), 7.76(d, 1H), 8.15(s, 1H), 8.19(s, 1H), 8.46-8.53(m, 1H), 9.35(bs, 1H)
20-7		504 [M+1]+	DMSO-d6: 2.43(s, 3H), 2.80-2.89(m, 4H), 2.99-3.07(m, 4H), 3.76(s, 3H), 6.44(dd,1H), 6.61(d, 1H), 7.18-7.24(m, 1H), 7.37(d, 1H), 7.44-7.50(m, 1H), 7.76(dd, 1H), 8.15(s, 1H), 8.18(s, 1H), 8.45-8.55(m, 1H), 9.20-9.45(m, 1H)

20-8		586 [M+1]+	DMSO-d6: 1.35-1.43(m, 2H), 1.45-1.61(m, 6H), 1.75-1.85(m,2H), 2.30-2.40(m, 1H), 2.43(d, 3H), 2.42-2.55(m, 4H), 2.60-2.70(m, 2H), 3.68-3.77(m, 2H), 3.75(s, 3H), 6.45(dd, 1H), 6.62(d, 1H), 7.21(dd, 1H), 7.36(d, 1H), 7.43-7.51(m, 1H), 7.73-7.81(m, 1H), 7.75(dd, 1H), 8.15(s, 1H), 8.17(s, 1H), 8.45-8.52(m, 1H), 9.34(bs, 1H)
20-9		569 [M+1]+	DMSO-d6: 1.85-1.95(m, 2H), 2.15(s, 3H), 2.18(t, 2H), 2.22-2.40(m, 8H), 2.43(s, 3H), 4.17(t, 2H), 6.65(d, 1H), 7.06(dd, 1H), 7.20(d, 1H), 7.22(ddd, 1H), 7.25(d, 1H), 7.39-7.47(m, 2H), 7.72-7.82(m, 1H), 7.77(dd, 1H), 8.26(s, 1H), 8.52(d, 1H), 9.22(s, 1H), 9.36(s, 1H)
20-10		556 [M+1]+	DMSO-d6: 1.85-1.95(m, 2H), 2.19(t, 2H), 2.25-2.35(m, 4H), 2.43(s, 3H), 3.55-3.60(m, 4H), 4.19(t, 2H), 6.66(d, 1H), 7.06(dd, 1H), 7.17-7.24(m, 1H), 7.21(d, 1H), 7.27(d, 1H), 7.39-7.45(m, 1H), 7.44(d, 1H), 7.70-7.80(m, 1H), 7.76(dd, 1H), 8.26(s, 1H), 8.52(d, 1H), 9.21(s, 1H), 9.36(s, 1H)
20-11		Rf (Hexane : AcOEt=1:1) 0.29	DMSO-d6: 2.64 (d, 3H), 2.87-2.96 (m, 4H), 3.65-3.74 (m, 4H), 3.86 (s, 3H), 4.41-4.51 (m, 1H), 6.50 (dd, 1H), 6.81 (d, 1H), 7.55-7.64 (m, 2H), 7.96 (d, 1H), 8.01 (s, 1H), 8.19 (s, 1H), 8.49 (d, 1H), 9.07 (s, 1H).
20-12		MS 535	DMSO-d6: 2.64 (d, 3H), 3.05 (bs, 4H), 3.59 (bs, 3H), 3.87(bs, 3H), 3.89 (bs, 4H), 4.52-4.48 (m, 1H), 6.57(bs, 1H), 7.25-7.20(m, 1H), 7.44-7.32 (m, 1H), 7.63-7.52 (m, 1H), 7.94(bs, 1H), 8.06 (d, 1H), 8.25(s, 1H), 8.48(d, 1H), 9.06(bs, 1H)

20-13		MS 548	DMSO-d6: 2.17 (bs, 3H), 2.63 (d, 3H), 2.68 (bs, 4H), 3.10(bs, 4H), 3.57 (s, 3H), 4.54-4.46 (m, 1H), 6.59(bs, 1H), 7.27-7.18(m, 1H), 7.37 (bs, 1H), 7.62-7.55 (m, 1H), 7.94(bs, 1H), 7.95 (d, 1H), 8.16(s, 1H), 8.48(d, 1H), 9.04(bs, 1H)
20-14		MS 546	DMSO-d6: 1.06 (t, 3H), 1.86 (dd, 2H), 2.37 (s, 3H), 2.62-2.59 (m, 4H), 2.64(d, 3H), 4.00-3.97 (m, 4H), 4.62-4.54 (m, 1H), 6.44 (dd, 1H), 6.54(d, 1H), 7.27-7.22(m, 1H), 7.34(bs, 1H), 7.58-7.54(m, 1H), 7.95(dd, 1H), 8.02(d, 1H), 8.11(s, 1H), 8.53(d, 1H), 9.07(bs, 1H)
20-15		LC-MS 545	DMSO-d6: 1.46-1.62 (m, 2H), 1.72-1.79 (m, 1H), 1.82-1.90 (m, 1H), 2.38-2.46 (m, 1H), 2.43 (s, 3H), 2.62-2.76 (m, 2H), 3.59-3.69 (m, 2H), 3.43 (s, 3H), 6.47 (dd, 1H), 6.63 (d, 1H), 6.82-6.89 (br, 1H), 7.21 (dd, 1H), 7.32-7.41 (m, 2H), 7.44-7.52 (m, 1H), 7.71-7.82 (m, 2H), 8.15 (s, 1H), 8.15-8.20 (br, 1H), 8.44-8.53 (m, 1H), 9.28-9.38 (m, 1H)
20-16		0.24 (CH2Cl2:MeOH=8:2)	DMSO-d6: 1.47-1.55 (m, 2H), 1.80-1.91 (m, 2H), 2.16 (s, 3H), 2.25-2.41 (m, 5H), 2.42-2.48 (m, 3H), 2.61-2.73 (m, 2H), 3.68-3.79 (m, 5H), 6.45 (dd, 1H), 6.62 (d, 1H), 7.21 (dd, 1H), 7.34 (d, 1H), 7.45-7.49 (m, 1H), 7.73-7.80 (m, 2H), 8.15 (s, 1H), 8.20 (s, 1H), 8.45-8.54 (m, 1H), 9.34 (s, 1H)
20-17		LC-MS 518	DMSO-d6: 1.76-1.84 (m, 1H), 2.08-2.16 (m, 1H), 2.33 (s, 3H), 2.42 (s, 3H), 3.00-3.03 (m, 1H), 3.23-3.27 (m, 3H), 3.42-3.46 (m, 1H), 3.74 (s, 3H), 6.06 (dd, 1H), 6.18- 6.20 (m, 1H), 7.17-7.23 (m, 1H), 7.38-7.48 (br, 1H), 7.72-7.77 (m, 1H), 8.12 (s, 1H), 8.17-8.21 (br, 1H), 8.46-8.58 (br, 1H), 9.30-9.40 (br, 1H)

20-18		LC-MS 601	DMSO-d6: 1.36-1.49 (m, 2H), 1.69-1.76 (m, 2H), 2.13 (s, 3H), 2.15-2.23 (m, 1H), 2.24-2.36 (br, 4H), 2.39-2.48 (m, 5H), 2.43 (s, 3H), 3.27-3.40 (m, 2H), 3.74 (s, 3H), 6.62 (dd, 1H), 6.90 (d, 1H), 7.22-7.26 (m, 1H), 7.41-7.46 (m, 1H), 7.49-7.53 (m, 1H), 7.55-7.86 (br, 1H), 7.77 (dd, 1H), 8.16 (s, 1H), 8.25 (s, 1H), 8.42 (d, 1H), 9.28 (s, 1H)
20-19		LC-MS 519	DMSO-d6: 1.37-1.46 (m, 2H), 1.69-1.75 (m, 2H), 2.43 (s, 3H), 2.53-2.61 (m, 2H), 3.18-3.26 (m, 2H), 3.40-3.74 (m, 2H), 4.62 (d, 1H), 6.62 (dd, 1H), 6.90 (d, 1H), 7.22-7.26 (m, 1H), 7.42-7.46 (br, 1H), 7.48-7.55 (m, 1H), 7.77-7.80 (m, 2H), 8.13-8.18 (br, 1H), 8.25 (s, 1H), 8.40-8.45 (m, 1H), 9.25-9.30 (m, 1H)
20-20		LC-MS 532	DMSO-d6: 1.66-1.76 (m, 1H), 2.00-2.07 (m, 1H), 2.14 (s, 6H), 2.43 (s, 3H), 2.68-2.76 (m, 1H), 2.87-2.91 (m, 1H), 2.99-3.10 (m, 2H), 3.24-3.28 (m, 1H), 3.71 (s, 3H), 6.25 (dd, 1H), 6.90 (d, 1H), 7.00-7.03 (m, 1H), 7.21-7.24 (m, 1H), 7.40-7.45 (m, 1H), 7.78-7.83 (m, 2H), 8.19 (s, 1H), 8.24 (s, 1H), 8.46 (d, 1H), 9.27-9.36 (br, 1H)
20-21		Ms : 549	DMSO-d6: 2.37-2.47 (m, 4H), 2.48-2.53 (m, 3H), 2.64 (t, 2H), 3.57 (t, 3H), 3.77 (s, 3H), 3.92 (t, 2H), 6.61(dd, 1H), 6.93 (d, 1H), 7.28 (dd, 1H), 7.56-7.63 (m, 2H), 7.75-7.85 (m, 2H), 7.74-7.84 (m, 2H), 8.14 (s, 1H), 8.29 (s, 1H) 8.46 (d, 1H), 9.33(s, 1H)
20-22		Ms:562	DMSO-d6: 2.20 (s, 3H), 2.3-2.5 (m, 11H), 2.64 (t, 2H), 3.77 (s, 3H), 3.91 (t, 2H), 6.61(dd, 1H), 6.94 (d, 1H), 7.25-7.31(m, 1H), 7.57 (d, 1H), 7.58-7.64 (m, 1H), 7.74-7.84 (m, 2H), 8.12 (brs, 1H), 8.28 (s, 1H) 8.46 (d, 1H), 9.33(brs, 1H)

20-23		Ms:438	DMSO-d6: 2.42-2.45 (m, 3H), 3.83 (s, 2H), 6.8 (ddd, 1H), 7.02 (dd, 1H), 7.3-7.36 (m, 1H), 7.58-7.64 (m, 1H), 7.74-7.8 (m, 1H), 7.82 (dd, 1H), 7.85 (dd, 1H), 8.18 (brs, 1H), 8.31 (s, 1H), 8.41 (d, 1H), 9.3 (brs, 1H)
20-24		Ms:438	DMSO-d6: 2.41-2.45 (m, 3H), 3.79 (s, 2H), 6.74 (ddd, 1H), 7.0 (dd, 1H), 7.22-7.28 (m, 1H), 7.49-7.55 (m, 1H), 7.6 (dd, 1H), 7.75-7.8 (m, 2H), 8.21 (s, 1H), 8.37 (brs, 1H), 8.39-8.45 (m, 1H), 9.34 (brs, 1H)
20-25		Ms:547	DMSO-d6: 1.24-1.38 (m, 2H), 1.64-1.8 (m, 3H), 1.83-1.92 (m, 2H), 2.16 (s, 3H), 2.41-2.45(m, 3H), 2.76-2.83 (m, 2H), 3.75 (s, 3H), 3.84 (d, 2H), 6.48 (dd, 1H), 6.64 (d, 1H), 7.2-7.25 (m, 1H), 7.41 (d, 1H), 7.43-7.5 (m, 1H), 7.74-7.8 (m, 2H), 8.16 (s, 1H), 8.26 (brs, 1H) 8.44-8.5 (m, 1H), 9.34 (brs, 1H)
20-26		Ms:547	DMSO-d6: 1.18-1.3 (m, 2H), 1.56-1.7 (m, 3H), 1.8-1.88 (m, 2H), 2.15 (s, 3H), 2.41-2.45(m, 3H), 2.73-2.8 (m, 2H), 3.75 (s, 3H), 3.65 (d, 2H), 3.77 (s, 3H), 6.57 (dd, 1H), 6.93 (d, 1H), 7.25 (dd, 1H), 7.51-7.6 (m, 2H), 7.7-7.9 (m, 2H), 8.09 (brs, 1H), 8.28 (s, 1H), 8.45 (d, 1H), 9.31 (brs, 1H)
20-27		Ms:533	DMSO-d6: 1.62-1.72 (m, 2H), 1.9-1.99 (m, 2H), 2.3-2.35 (m, 5H), 2.41-2.45(m, 3H), 2.64-2.74 (m, 2H), 3.75 (s, 3H), 4.35-4.43 (m, 1H), 6.52 (dd, 1H), 6.65 (d, 1H), 7.19-7.25 (m, 1H), 7.41 (d, 1H), 7.43-7.49 (m, 1H), 7.74-7.8 (m, 2H), 8.16 (s, 1H), 8.27 (brs, 1H), 8.42-8.5 (m, 1H), 9.34 (brs, 1H)
20-28		Ms:547	DMSO-d6: 0.96-1.2 (m, 2H), 1.75-1.9 (m, 1H), 2.2-2.3 (m, 1H), 2.35-2.45 (m, 1H), 2.41-2.45(m, 2H), 2.43(d, 3H), 2.6-3.0 (m, 3H), 3.76 (s, 3H), 4.85-5.0 (m, 1H), 6.43-6.49 (m, 1H), 6.57-6.64 (m, 1H), 7.18-7.25 (m, 1H), 7.39-7.52 (m, 2H), 7.73-7.83 (m, 2H), 8.17 (s, 1H), 8.27 (brs, 1H), 8.44-8.51 (m, 1H), 9.35 (brs, 1H)

20-29		Ms:519	DMSO-d6: 1.74-1.83 (m, 1H), 2.23-2.31 (m, 1H), 2.28 (s, 3H), 2.35-2.4 (m, 1H), 2.41-2.45(m, 3H), 2.58-2.63 (m, 1H), 2.63-2.7 (m, 1H), 2.78-2.83 (m, 1H), 3.75 (s, 3H), 4.86-4.92 (m, 1H), 6.43 (dd, 1H), 6.58 (d, 1H), 7.19-7.25 (m, 1H), 7.41 (d, 1H), 7.44-7.51 (m, 1H), 7.73-7.83 (m, 2H), 8.16 (s, 1H), 8.26 (brs, 1H), 8.43-8.52 (m, 1H), 9.34 (brs, 1H)
20-30		Ms : 533	DMSO-d6: 1.04 (t, 3H), 1.74-1.82 (m, 1H), 2.23-2.33 (m, 1H), 2.47-2.5(m, 6H), 2.62-2.72 (m, 2H), 2.8-2.87 (m, 1H), 3.75 (s, 3H), 4.86-4.92 (m, 1H), 6.44 (dd, 1H), 6.59 (d, 1H), 7.19-7.25 (m, 1H), 7.41 (d, 1H), 7.44-7.51 (m, 1H), 7.73-7.8 (m, 2H), 8.16 (s, 1H), 8.26 (brs, 1H), 8.44-8.51 (m, 1H), 9.34 (brs, 1H)
20-31		Ms : 518	DMSO-d6: 2.23(s, 3H), 2.38-2.47 (m, 7H), 2.87-2.93 (m, 4H), 3.75 (s, 3H), 6.63 (dd, 1H), 6.93 (d, 1H), 7.22-7.28 (m, 1H), 7.42 (d, 1H), 7.48-7.54 (m, 1H), 7.76-7.84 (m, 1H), 8.2 (s, 1H), 8.25(s, 1H), 8.43 (dd, 1H) 9.29 (s, 1H)
20-32		Ms : 586	DMSO-d6: 1.35-1.55 (m, 8H), 1.66-1.75 (m, 2H), 2.23(s, 3H), 2.41-2.45 (m, 3H), 3.74 (s, 3H), 6.63 (dd, 1H), 6.91 (d, 1H), 7.21-7.28 (m, 1H), 7.44 (d, 1H), 7.48-7.54 (m, 1H), 7.76-7.87 (m, 1H), 8.16 (s, 1H), 8.25 (s, 1H), 8.43 (dd, 1H) 9.29 (s, 1H)
20-33		Ms : 518	DMSO-d6: 1.62-1.71 (m, 1H), 1.95-2.04 (m, 1H), 2.23-2.27 (m, 3H), 2.39-2.43 (m, 3H), 2.93-3.1 (m, 2H), 3.13-3.26 (m, 2H), 3.71 (s, 3H), 6.19 (dd, 1H), 6.88 (d, 1H), 7.07-7.13 (m, 1H), 7.13-7.2 (m, 1H), 7.4-7.48 (m, 1H), 7.75 (dd, 1H), 8.06 (brs, 1H), 8.18 (s, 1H), 8.4 (d, 1H)
20-34		Ms : 546	DMSO-d6: 2.02 (m, 1H), 2.42-2.46 (m, 3H), 2.71-2.91 (m, 4H), 3.44-3.51 (m, 4H), 3.76 (s, 3H), 6.66 (dd, 1H), 6.94 (d, 1H), 7.21-7.27 (m, 1H), 7.75-7.85 (m, 2H), 8.19 (s, 1H), 8.26 (s, 1H), 8.41 (d, 1H), 9.28 (brs, 1H).

20-35		MS (ESI) 464 (M+H)	HPLC Retention time (min) 2.68

The following 2-[5-chloro-2-(subst.phenylamino)-pyrimidin-4-ylamino]-N-*sec*-butyl-benzene-sulfonamides are prepared from 2-(5-chloro-2-chloro-pyrimidin-4-ylamino)-N-*sec*-butyl-benzenesulfonamide and the corresponding aniline following the procedure of Example 7A



ExplNo.	Rx	Rf (solvent) or MS	NMR (400MHz) , δ (ppm)
21-1		0.35 (*n*-hexane: AcOEt=1:1)	$CDCl_3$: 0.62(t, 3H), 0.88(d, 3H), 1.22-1.29(m, 2H), 2.23(s,3H), 2.45-2.47(m, 4H), 3.05-3.14(m, 5H), 3.75 (s, 3H), 6.40-6.43(m, 1H), 6.62(s, 1H), 7.18-7.22(m, 1H), 7.39-7.47(m, 2H), 7.80-7.82(m, 1H), 8.15-8.16(m, 2H), 8.44-8.46(m, 1H), 9.32(s, 1H)
21-2		0.30 (*n*-hexane: AcOEt=3:1)	DMSO-d6 : 0.62(t, 3H), 0.87(d, 3H), 1.17-1.26(m, 2H), 3.03-3.10(m, 1H), 3.79(s, 3H), 6.66-6.71(m, 1H), 6.96-7.00(m, 1H), 7.21-7.25(m, 1H), 7.47-7.51(m, 1H), 7.60-7.64(m, 1H), 7.79-7.83(m, 2H), 8.21(s, 1H), 8.31(s, 1H), 8.35-8.37(m, 1H), 9.29(s, 1H)

21-3		0.30 (*n*-hexane: AcOEt=1:1)	DMSO-d6 : 0.61(t, 3H), 0.87(d, 3H), 1.21-1.29(m, 2H), 1.58-1.67(m, 2H), 1.86-1.93(m, 2H), 2.14-2.20(m, 5H), 2.59-2.67(m, 2H), 3.06-3.08(m, 1H), 3.74(s, 3H), 4.32-4.36(m, 1H), 6.46-6.48(m, 1H), 6.63(d, 1H), 7.17-7.21(m, 1H), 7.40-7.50(m, 2H), 7.79-7.81(m, 2H), 8.16(s, 1H), 8.21(bs, 1H), 8.35-8.42(m, 1H), 9.29(s, 1H)
21-4		0.30 (*n*-hexane: AcOEt=1:1)	DMSO-d6 : 0.61(t, 3H), 0.87(d, 3H), 1.22-1.29(m, 2H), 2.43-2.47(m, 2H), 2.61-2.63(m, 1H), 2.68-2.70(m, 2H), 3.04-3.11(m, 1H), 3.56-3.60(m, 5H), 3.75(s, 3H), 3.93-3.96(m, 1H), 4.08-4.11(m, 2H), 6.45-6.47(m, 1H), 6.64(d, 1H), 7.18-7.22(m, 1H), 7.43-7.46(m, 2H), 7.80-7.82(m, 2H), 8.17(s, 1H), 8.21(s, 1H), 8.42-8.44(m, 1H), 9.31(s, 1H)

The following 2-[5-chloro-2-(subst.phenylamino)-pyrimidin-4-ylamino]-N-*iso*-butyl-benzene-sulfonamides are prepared from 2-(5-chloro-2-chloro-pyrimidin-4-ylamino)-N-*sec*-butyl-benzenesulfonamide and the corresponding aniline following the procedure of Example 7A



ExplNo.	Rx	Rf (solvent) or MS	NMR (400MHz) , δ (ppm)
22-1		0.30 (*n*-hexane: AcOEt=3:1)	DMSO-d6 : 0.69(d, 6H), 1.52-1.59(m, 1H), 2.57-2.58(m, 2H), 3.82(s, 3H), 6.75-6.80(m, 1H), 6.99-7.02(m, 1H), 7.29-7.33(m, 1H), 7.56-7.60(m, 1H), 7.82-7.93(m, 3H), 8.14(bs, 1H), 8.31(s, 1H), 8.33(s, 1H), 9.23(s, 1H)

22-2		0.30 (*n*-hexane: AcOEt=3:1)	$CDCl_3$: 0.74(d, 6H), 1.57-1.64(m, 1H), 2.72-2.76(m,2H), 3.88(s, 3H), 4.55-4.56(m, 1H), 6.52-6.57 (m, 1H), 6.62-6.65(m, 1H), 7.24-7.28(m, 2H), 7.36(bs, 1H), 7.56-7.60(m, 1H), 7.95-8.08(m, 1H), 8.10-8.14(m, 2H), 8.36-8.39(m, 1H), 8.98(bs, 1H)
22-3		0.54 (AcOEt)	DMSO-d6 : 0.73(d, 6H), 1.55-1.62(m, 1H), 2.56-2.59(m, 2H), 3.10-3.12(m, 4H), 3.74-3.76(m, 7H), 6.43-6.46(m, 1H), 6.65(d, 1H), 7.20-7.24(m, 1H), 7.40-7.48(m, 2H), 7.76-7.78(m, 1H), 7.90-7.95(m, 1H), 8.16(s, 1H), 8.17(s, 1H), 8.43-8.45(m, 1H), 9.32(s, 1H)

The following 2-[5-chloro-2-(subst.phenylamino)-pyrimidin-4-ylamino]-N-(1-ethyl-propyl)-benzenesulfonamides are prepared from 2-(5-chloro-2-chloro-pyrimidin-4-ylamino)-N-(1-ethyl-propyl)-benzenesulfonamide and the corresponding aniline following the procedure of Example 7A



ExplNo.	Rx	Rf (solvent) or MS	NMR (400MHz) , δ (ppm)
23-1		0.46 (MeOH: CH_2Cl_2=3:7)	DMSO-d6: 0.58(t, 6H), 1.14-1.34(m, 4H), 1.58-1.68(m, 2H), 1.87-1.96(m, 2H), 2.12-2.22(m, 2H), 2.18(s, 3H), 2.57-2.65(m, 2H), 2.86-2.96(m, 1H), 3.75(s, 3H), 4.30-4.39(m, 1H), 6.46(dd, 1H), 6.63(d, 1H), 7.19(dd, 1H), 7.39-7.48(m, 2H), 7.75-7.84(m, 2H), 8.18(s, 1H), 8.20 (s, 1H), 8.39(m, 1H), 9.33(bs, 1H)

23-2		0.35 (*n*-hexane: AcOEt=1:1)	$CDCl_3$: 0.59(t, 6H), 1.14-1.34(m, 4H), 2.23(s,3H), 2.45-2.47(m, 4H), 2.90-2.95(m, 1H), 3.11-3.14(m, 4H), 3.76 (s, 3H), 6.39-6.42(m, 1H), 6.62(s, 1H), 7.18-7.22(m, 1H), 7.41-7.46(m, 2H), 7.76-7.82(m, 2H), 8.12(s, 1H), 8.16(s, 1H), 8.43-8.44(m, 1H), 9.35(s, 1H)
23-3		0.41 (MeOH: CH_2Cl_2=1:4)	DMSO-d6: 0.59(t, 6H), 1.16-1.35(m, 4H), 1.75-1.89(m, 1H), 2.08-2.15(m, 1H), 2.32(s, 3H), 2.90-3.02(m, 2H), 3.21-3.45(m, 4H), 3.73(s, 3H), 6.02(dd, 1H), 6.18(d, 1H), 7.16(dd, 1H), 7.27(d, 1H), 7.35-7.45(m, 1H), 7.77-7.82(m, 2H), 8.10 (s, 1H) 8.12 (s, 1H), 8.45-8.55(m, 1H), 9.38(s, 1H)
23-4		0.41 (MeOH: CH_2Cl_2=1:4)	DMSO-d6: 0.60(t, 6H), 1.04(t, 3H), 1.17-1.35(m, 4H), 1.76-1.83(m, 1H), 2.10-2.15(m, 1H), 2.56-2.64(m, 2H), 2.91-3.01(m, 2H), 3.21-3.47(m, 4H), 3.74(s, 3H), 6.02(dd, 1H), 6.18(d, 1H), 7.14-7.17(m, 1H), 7.28(d, 1H), 7.35-7.45(m, 1H), 7.77-7.82(m, 2H), 8.11 (s, 1H) 8.12 (s, 1H), 8.45-8.55(m, 1H), 9.38(s, 1H)
23-5		0.25 (*n*-hexane: AcOEt=1:1)	DMSO-d6 : 0.58(t, 6H), 1.06-2.16(m, 11H), 2.16(s, 3H), 2.62-2.67(m, 1H), 2.81-2.94(m, 2H), 3.75(s, 3H), 3.80-3.89(m, 2H), 6.41-6.44(m, 1H), 6.62(d, 1H), 7.17-7.21(m, 1H), 7.42-7.47(m, 2H), 7.77-7.82(m, 2H), 8.18(s, 1H), 8.19(s, 1H), 8.35 -8.42(m, 1H), 9.35(s, 1H)
23-6		Ms : 561	DMSO-d6 : 0.59 (t, 6H), 1.14-1.38 (m, 4H), 2.87-2.98 (m, 1H), 3.1 (t, 4H), 3.72-3.79 (m, 7H), 6.42 (dd, 1H), 6.64 (d, 1H), 7.18-7.24 (m, 1H), 7.42-7.5 (m, 2H), 7.77 (d, 1H), 7.81 (dd, 1H), 8.13 (s, 1H), 8.17 (s, 1H), 8.4-8.5 (m, 1H), 9.36 (s, 1H)

23-7		Ms : 575	DMSO-d6 : 0.58 (t, 6H), 1.13-1.37 (m, 4H), 1.72-1.82 (m, 1H), 2.21-2.31 (m, 4H), 2.32-2.4 (m, 1H), 2.54-2.61 (m, 1H), 2.62-2.68 (m, 1H), 2.75-2.82 (m, 1H), 2.87-2.97 (m, 1H), 3.75 (s, 3H), 4.84-4.91 (m, 1H), 6.37 (dd, 1H), 6.56 (d, 1H), 7.14-7.24 (m, 1H), 7.38-7.52 (m, 2H), 7.72-7.86 (m, 1H), 8.12-8.25 (m, 2H), 8.34-8.45 (m, 1H), 9.33 (brs, 1H)
23-8		Ms : 605	DMSO-d6 : 0.58 (t, 6H), 1.14-1.36 (m, 4H), 2.43-2.53 (m, 4H), 2.69 (t, 2H), 2.89-2.95 (m, 1H), 3.59 (t, 4H), 3.76 (s, 3H), 4.09 (t, 1H), 6.45 (dd, 1H), 6.64 (d, 1H), 7.17-7.23 (m, 1H), 7.41-7.52 (m, 2H), 7.78 (d, 1H), 7.81 (dd, 1H), 8.18 (s, 1H), 8.19 (s, 1H), 8.36-8.46 (m, 1H), 9.35 (s, 1H)
23-9		Ms : 618	DMSO-d6 : 0.58 (t, 6H), 1.14-1.37 (m, 4H), 2.15 (s, 1H), 2.25-2.4 (m, 4H), 2.45-2.55 (m, 4H), 2.68 (t, 2H), 2.88-2.97 (m, 1H), 3.76 (s, 3H), 4.07 (t, 1H), 6.44 (dd, 1H), 6.64 (d, 1H), 7.15-7.23 (m, 1H), 7.41-7.51 (m, 2H), 7.7-7.84 (m, 2H), 8.12-8.22 (m, 1H), 8.34-8.44 (m, 1H), 9.34 (s, 1H)

The following 2-[5-chloro-2-(subst.phenylamino)-pyrimidin-4-ylamino]-N-*iso*-butyl-benzene-sulfonamides are prepared from 2-(5-chloro-2-chloro-pyrimidin-4-ylamino)-N-cyclobutyl-benzenesulfonamide and the corresponding aniline following the procedure of Example 7A



ExplNo.	Rx	Rf (solvent) or MS	NMR (400MHz) , δ (ppm)

24-1		0.35 (*n*-hexane: AcOEt=1:1)	DMSO-d6 : 1.37-1.48(m, 2H), 1.69-1.91(m, 4H), 3.09-3.12(m, 4H), 3.63-3.74(m, 1H), 3.76(s, 3H), 6.43-6.45(m, 1H), 6.63(d, 1H), 7.18-7.22(m, 1H), 7.41-7.47(m, 2H), 7.76-7.78(m, 1H), 8.17-8.24(m, 3H), 8.46(d, 1H), 9.33(s, 1H)
24-2		0.46 (MeOH: CH_2Cl_2=3:7)	DMSO-d6: 1.37-1.93(m, 10H), 2.18(s, 3H), 2.59-2.62(m, 1H), 3.60-3.74(m, 1H), 3.77(s, 3H), 4.32-4.36(m, 1H), 6.46-6.49(m, 1H), 6.62(d, 1H), 7.16-7.20(m, 1H), 7.41-7.44(m, 2H), 7.75-7.77(m, 1H), 8.16(s, 1H), 8.22 (bs, 1H), 8.40-8.42(m, 1H), 9.30(bs, 1H)
24-3		0.46 (MeOH: CH_2Cl_2=1:4)	$CDCl_3$: 1.45-1.75(m, 5H), 1.94-2.06(m, 6H), 2.29-2.37(m, 1H), 3.21-3.56(m, 4H), 3.72-3.81(m, 1H), 3.86(s, 3H), 4.55-4.65(m, 1H), 4.90(d, 1H), 5.72(d, 1H), 6.07(bs, 1H), 6.15(bs, 1H), 7.18-7.22(m, 2H), 7.52-7.56(m, 1H), 7.89-7.94(m, 2H), 8.08(s, 1H), 8.50(d, 1H), 9.00(s, 1H)



Expl No.	Rx	Ms	NMR (400MHz), δ (ppm)
25-1		Ms : 559	DMSO-d6 : 1.2-1.38 (m, 4H), 1.4-1.65 (m, 4H), 3.11 (t, 4H), 3.42-3.5 (m, 1H), 3.7-3.8 (m, 7H), 6.44 (dd, 1H), 6.64 (d, 1H), 7.18-7.26 (m, 1H), 7.38-7.5 (m, 2H), 7.81 (d, 1H), 7.88-7.96 (m, 1H), 8.16 (s, 1H), 8.17 (s, 1H), 8.4-8.5 (m, 1H), 9.34 (s, 1H)

25-2		Ms : 587	DMSO-d6 : 1.2-1.38 (m, 4H), 1.42-1.6 (m, 6H), 1.88-1.98 (m, 2H), 2.1-2.25 (m, 5H), 2.55-2.65 (m, 2H), 3.4-3.5 (m, 1H), 3.74 (s, 3H), 4.3-4.4 (m, 1H), 6.48 (dd, 1H), 6.63 (d, 1H), 7.18-7.24 (m, 1H), 7.38-7.47 (m, 1H), 7.77-7.82 (m, 1H), 7.88-7.96 (m, 1H), 8.17 (s, 1H), 8.22 (s, 1H), 8.36-8.46 (m, 1H), 9.31 (s, 1H)

The following 5-Chloro-N^2-(substituted phenyl)-N^4-[2-(propane-1-sulfonyl)-phenyl]-pyrimidine-2,4-diamine are prepared from (2,5-Dichloro-pyrimidin-4-yl)-[2-(propane-1-sulfonyl)-phenyl]-amine and the corresponding aniline following the procedure of Example 7A



ExpIN o.	Rx	Rf (solvent) , MS or Mp	NMR (400MHz) , δ (ppm)
26-1		0.58 (AcOEt)	$CDCl_3$: 0.97(t,3H), 1.72-1.82(m, 2H), 3.08-3.14(m, 6H), 3.87-3.89(m, 7H), 6.46(dd, 1H), 6.53(d,1H), 7.24-7.28(m,1H), 7.30(s, 1H), 7.60-7.64(m, 1H), 7.94(dd, 1H), 8.05(d, 1H), 8.15(s, 1H), 8.59(d, 1H), 9.40(s, 1H)
26-2		0.57 (MeOH: AcOEt=1:4)	$CDCl_3$: 0.98(t, 3H), 1.85-1.68(m, 2H), 2.15(s, 3H), 3.16-3.07(m, 6H), 3.67-3.62(m, 2H), 3.81-3.78(m, 2H), 3.89(s, 3H), 6.47(d, 1H), 6.55(d, 1H), 7.36-7.33(m, 1H), 7.62 (dd, 1H), 7.95(dd, 1H), 8.08(d, 1H), 8.15(s, 1H),8.58(d, 1H), 9.41(s, 1H)

26-3		0.13 (MeOH: AcOEt=1:4)	$CDCl_3$: 0.97(t, 3H), 1.43-1.52(m, 2H), 1.52-1.67 (m, 4H), 1.69-1.72(m, 4H), 1.90-1.98(m, 2H), 2.34-2.46(m, 1H), 2.51-2.59(m, 4H), 2.64-2.74(m, 2H), 3.11(dd, 2H), 3.64-3.73(m, 2H), 3.87(s, 3H), 6.47(dd, 1H), 6.56 (d, 1H), 7.24-7.33(m, 1H), 7.62(dd, 1H), 7.94(dd, 1H), 8.00(d, 1H), 8.14(s, 1H), 8.59(d, 1H), 9.39(bs, 1H).
26-4		0.22 (AcOEt)	$CDCl_3$: 0.97(t, 3H), 1.45(d, 1H), 1.68-1.82(m, 4H), 2.0-2.1(m, 2H), 2.91(ddd, 2H),3.10(ddd, 2H), 3.46-3.51 (m, 2H), 3.84-3.92(m, 1H), 3.88 (s, 1H), 6.48(dd, 1H), 6.57(d, 1H), 7.23-7.32 (m, 1H), 7.62(dd, 1H), 7.94(dd,1H), 8.02 (dd, 1H), 8.14(s, 1H), 8.59(d, 1H), 9.39(bs, 1H)
26-5		0.1 (AcOEt)	$CDCl_3$: 0.97(t, 3H) ,1.71-1.82(m, 2H), 1.86-1.98(m, 2H), 2.01-2.08(m, 2H), 2.25-2.37(m, 1H), 2.75 (ddd, 2H), 3.10(ddd, 2H), 3.63-3.66(m, 2H), 3.88(s, 3H), 5.25-5.40(m, 1H), 5.40-5.58 (m, 1H), 6.48(dd, 1H), 6.57(d, 1H), 7.22-7.34 (m, 1H), 7.62(ddd, 1H), 7.93 (d, 1H), 7.94 (dd, 1H), 8.02 (d, 1H), 8.14(s, 1H), 8.59(d, 1H), 9.40(m, 1H)
26-6		MS 587	$CDCl_3$: 0.97 (t, 3H), 1.77 (ddd, 2H), 2.00-1.85 (m, 4H), 2.27-2.18(m, 1H), 2.72(ddd, 2H) 3.12-3.08 (m, 2H), 3.69-3.61(m, 2H), 3.58-3.46(m, 1H), 3.64 (t, 2H), 3.80(t, 2H), 3.88(s,3H), 5.56-5.46 (m, 1H), 6.47(dd, 1H), 6.55(d, 1H), 7.32-7.23 (m, 1H), 7.30(bs, 1H), 7.64-7.60(m, 1H), 7.94(dd, 1H), 8.02(d, 1H), 8.14(s, 1H), 8.59(d, 1H), 9.40(s, 1H)
26-7		MS 587	$CDCl_3$: 0.98 (t, 3H), 1.46(bs, 6H) 1.82-1.73 (m, 2H), 2.17(s, 3H), 3.58-3.46(m, 1H), 2.95-2.84 (m, 2H), 3.12-3.08 (m, 2H), 3.90(s,3H), 6.48(dd, 1H), 6.52(d, 1H), 7.30-7.22 (m, 1H), 7.31(bs, 1H), 7.66-7.60(m, 1H), 7.95(dd, 1H), 8.06(d, 1H), 8.15(s, 1H), 8.59(d, 1H), 9.43(s, 1H)

26-8		MS 573	$CDCl_3$: 0.97 (t, 3H), 1.19(t, 3H), 1.77 (ddd, 2H), 2.41(m, 2H), 3.18-3.09(m, 6H), 3.68-3.64 (m, 2H), 3.85-3.78 (m, 2H), 3.89(s,3H), 6.47(dd, 1H), 6.55(d, 1H), 7.29-7.25 (m, 1H), 7.34(bs, 1H), 7.64-7.60(m, 1H), 7.95(dd, 1H), 8.07(d, 1H), 8.15(s, 1H), 8.58(d, 1H), 9.41(s, 1H)
26-9		MS 587	$CDCl_3$: 0.97 (t, 3H), 1.17(d, 3H) 1.76 (ddd, 2H), 2.88-2.81(m, 2H), 3.18-3.05(m, 6H), 3.74-3.67 (m, 2H), 3.86-3.78 (m, 2H), 3.89(s,3H), 6.47(dd, 1H), 6.55(d, 1H), 7.29-7.20(m, 1H), 7.34(bs, 1H), 7.64-7.60(m, 1H), 7.95(dd, 1H), 8.07(d, 1H), 8.15(s, 1H), 8.58(d, 1H), 9.41(s, 1H)
26-10		MS 517	$CDCl_3$: 0.97 (t, 3H), 1.76 (ddd, 2H), 2.86(d, 3H), 3.14-3.08(m, 2H), 3.13(t, 4H), 3.55 (t, 4H), 3.89(s,3H), 4.48-4.39 (m, 1H), 6.46(dd, 1H), 6.55(d, 1H), 7.29-7.21(m, 1H), 7.34(bs, 1H), 7.64-7.60(m, 1H), 7.95(dd, 1H), 8.06(d, 1H), 8.15(s, 1H), 8.58(d, 1H), 9.41(s, 1H)
26-11		MS 587	$CDCl_3$: 0.98 (t, 3H), 1.51 (s, 6H), 1.82-1.72 (m, 1H), 2.13 (s, 3H), 3.12-3.08 (m, 2H), 3.26(s, 2H), 3.44 (t, 2H), 3.74(t, 2H), 3.88(s,3H), 5.56-5.46 (m, 1H), 6.45(dd, 1H), 6.51(d, 1H), 7.00(bs, 1H), 7.62-7.58 (m, 1H), 7.64-7.60(m, 1H), 7.93(d, 1H), 7.96(dd, 1H), 8.13(s, 1H), 8.62(d, 1H), 9.42(s, 1H)

26-12		MS 559	$CDCl_3$: 0.98 (t, 3H), 1.81-1.71 (m, 3H), 1.95-1.84 (m, 3H), 2.68-2.63(m, 1H), 3.12-3.08 (m, 4H), 3.28(d, 2H), 3.89(s,3H), 5.45-5.38 (m, 1H), 6.53(dd, 1H), 6.59(d, 1H), 6.71-6.62 (m, 1H), 7.28-7.21 (m, 1H), 7.35(bs, 1H), 7.65-7.61(m, 1H), 7.95(dd, 1H), 8.08(d, 1H), 8.15(s, 1H), 8.58(d, 1H), 9.41(s, 1H)
26-13		MS 559	$CDCl_3$: 0.98 (t, 3H), 1.81-1.71 (m, 3H), 1.95-1.84 (m, 3H), 2.68-2.63(m, 1H), 3.12-3.08 (m, 4H), 3.28(d, 2H), 3.89(s,3H), 5.45-5.38 (m, 1H), 6.53(dd, 1H), 6.59(d, 1H), 6.71-6.62 (m, 1H), 7.28-7.21 (m, 1H), 7.35(bs, 1H), 7.65-7.61(m, 1H), 7.95(dd, 1H), 8.08(d, 1H), 8.15(s, 1H), 8.58(d, 1H), 9.41(s, 1H)
26-14		MS 559	$CDCl_3$: 0.98 (t, 3H), 1.85-1.74 (m, 3H), 2.00-1.86 (m, 3H), 2.70-2.51(m, 1H), 3.13-3.08 (m, 4H), 3.29-3.27 (m, 2H), 3.89(s,3H), 5.46-5.37 (m, 1H), 6.53(dd, 1H), 6.59(d, 1H), 6.69-6.56 (m, 1H), 7.29-7.19 (m, 1H), 7.34(bs, 1H), 7.65-7.61(m, 1H), 7.95(dd, 1H), 8.08(d, 1H), 8.15(s, 1H), 8.58(d, 1H), 9.41(s, 1H)
26-15		MS 559	$CDCl_3$: 0.99(t, 3H), 1.79-1.72 (m, 2H), 2.92 (t, 2H), 2.98(t, 2H), 3.16-3.12 (m, 2H), 3.53(t, 2H), 3.67(t, 2H), 3.87(s,3H), 6.54(dd, 1H), 6.82 (d, 1H), 7.29-7.19 (m, 1H), 7.56(bs, 1H), 7.67-7.62(m, 1H), 7.96(dd, 1H), 8.07(d, 1H), 8.21(s, 1H), 8.59(dd, 1H), 9.46(s, 1H)
26-16		MS 561	$CDCl_3$: 0.98 (t, 3H), 1.81-1.72 (m, 2H), 2.49 (t, 4H), 2.66 (t, 2H), 3.12-3.08(m, 2H), 3.18 (t, 2H), 3.74(t, 4H), 3.86(s,3H), 6.53(dd, 1H), 6.20(dd, 1H), 6.26 (d, 1H), 7.13(bs, 1H), 7.25-7.21 (m, 1H), 7.62-7.57(m, 1H), 7.87(dd, 1H), 7.93(dd, 1H), 8.12(s, 1H), 8.62(d, 1H), 9.40(s, 1H)

26-17		MS 518	$CDCl_3$: 0.98 (t, 3H), 1.78-1.73 (m, 2H), 2.49 (t, 4H), 2.66 (t, 2H), 2.94-2.92 (m, 4H), 3.15-3.11(m, 2H), 3.76-3.73(m, 4H), 3.88(s,3H), 6.52(dd, 1H), 6.82(d, 1H), 7.28-7.24 (m, 1H), 7.57(bs, 1H), 7.25-7.21 (m, 1H), 7.68-7.63(m, 1H), 7.95(dd, 1H), 8.02(d, 1H), 8.20(s, 1H), 8.56(d, 1H), 9.41(s, 1H)
26-18		MS 559	$CDCl_3$: 0.97 (t, 3H), 1.81-1.72 (m, 2H), 2.08-2.00 (m, 2H), 2.49 (t, 4H), 2.66 (t, 2H), 2.40 (t, 2H), 3.59 (t, 2H), 3.69(t, 2H), 3.87(s,3H), 6.41 (dd, 1H), 6.51(d, 1H), 7.29-7.25 (m, 2H), 7.65-7.60(m, 1H), 7.95(dd, 1H), 8.05(d, 1H), 8.15(s, 1H), 8.56(d, 1H), 9.41(s, 1H)
26-19		MS 587	$CDCl_3$: 0.98 (t, 3H), 1.82-1.73 (m, 2H), 2.14 (s, 3H), 3.12-3.08 (m, 2H), 3.55-3.45(m, 2H), 3.66-3.56 (m, 4H), 3.79-3.68 (m, 2H), 3.95(s,3H), 6.95(dd, 1H), 7.03 (d, 1H), 7.32-7.28(m, 1H), 7.69-7.64 (m, 1H), 7.71(s, 1H), 7.97(dd, 1H), 8.22 (s, 1H), 8.39(d, 1H), 8.52(d, 1H), 9.46(s, 1H)
26-20		MS 546	$CDCl_3$: 0.97 (t, 3H), 1.82-1.73 (m, 2H), 3.12-3.08 (m, 2H), 3.80-3.58(m, 8H), 3.94(s,3H), 6.94(dd, 1H), 7.02 (d, 1H), 7.32-7.28(m, 1H), 7.69-7.64 (m, 1H), 7.32-7.28(m, 1H), 7.97(dd, 1H), 8.21 (s, 1H), 8.34(d, 1H), 8.52(d, 1H), 9.45(s, 1H)
26-21		MS 615	$CDCl_3$: 0.97 (t, 3H), 1.82-1.72 (m, 2H), 2.71 (t, 3H), 3.05 (s, 2H), 3.10 (m, 2H), 3.18 (t, 4H), 3.88(s,3H), 4.17-4.08 (m, 1H), 6.47 (dd, 1H), 6.54 (d, 1H), 6.99-6.89(m, 1H), 7.28-7.24 (m, 1H), 7.31(bs, 1H), 7.65-7.60 (m, 1H), 7.32-7.28(m, 1H), 7.95(dd, 1H), 8.05 (d, 1H), 8.15(s, 1H), 8.59(d, 1H), 9.41(s, 1H)

26-22		MS 530	$CDCl_3$: 0.98 (t, 3H), 1.80-1.74 (m, 2H), 3.12-3.08 (m, 2H), 3.45-3.42 (m, 2H), 3.55-3.53 (m, 2H), 3.87 (s, 2H), 3.89(s,3H), 5.98-5.89 (m, 1H), 6.44 (dd, 1H), 6.50(d, 1H), 7.35-7.19 (m, 2H), 7.62-7.58(m, 1H), 7.95(dd, 1H), 8.09 (d, 1H), 8.15(s, 1H), 8.57(d, 1H), 9.43(s, 1H)
26-23		MS 558	$CDCl_3$: 0.97 (t, 3H), 1.10 (s, 3H), 1.12 (s, 3H), 1.80-1.74(m, 2H), 2.80-2.63 (m, 5H), 3.12-3.08 (m, 2H), 3.19-3.17 (m, 4H), 3.87(s,3H), 6.48 (dd, 1H), 6.56(d, 1H), 7.30-7.23 (m, 2H), 7.62-7.58(m, 1H), 7.94(dd, 1H), 8.00 (d, 1H), 8.14(s, 1H), 8.59(d, 1H), 9.40(s, 1H)
26-24		MS 544	$CDCl_3$: 0.98 (t, 3H), 1.81-1.72 (m, 2H), 2.03-1.91 (m, 1H), 2.28-2.19 (m, 1H), 2.33 (s, 6H), 2.92-2.84 (m, 1H), 3.12-3.08 (m, 2H), 3.17(t, 1H), 3.35(ddd, 1H), 3.51-3.42 (m, 2H), 3.87 (s, 3H), 6.11 (dd, 1H), 6.14 (d,1H), 7.09 (s, 1H), 7.26-7.20(m, 1H), 7.60-7.56 (m, 1H), 7.85(d, 1H), 7.92(dd, 1H), 8.11(s, 1H), 8.38(d, 1H), 9.41(s, 1H)
26-25		MS 530	$CDCl_3$: 0.98 (t, 3H), 1.82-1.71 (m, 2H), 1.96-1.86 (m, 1H), 2.33-2.20 (m, 1H), 2.51 (s, 1H), 3.17-3.08 (m, 3H), 3.35-3.30 (m, 1H), 3.54-3.30 (m, 3H), 3.87 (s, 3H), 6.12 (dd, 1H), 6.16 (d,1H), 7.09 (s, 1H), 7.32-7.21(m, 1H), 7.58 (dd, 1H), 7.85(d, 1H), 7.92(dd, 1H), 8.11(s, 1H), 8.64(d, 1H), 9.40(s, 1H)
26-26		MS 546	$CDCl_3$: 0.98 (t, 3H), 1.83-1.71 (m, 2H), 1.98-1.81 (m, 2H), 2.16-2.02(m, 2H), 2.53-2.28 (m, 5H), 2.87-2.72 (m, 2H), 3.12-3.08 (m, 2H), 3.88 (s, 3H), 4.32 (bs, 3H), 6.44 (dd, 1H), 6.53(d, 1H), 7.32-7.25 (m, 2H), 7.63-7.59 (m, 2H), 7.94(dd, 1H), 8.04 (d, 1H), 8.15(s, 1H), 8.57(d, 1H), 9.42(s, 1H)

26-27		MS 545	$CDCl_3$: 0.97 (t, 3H), 1.38-1.30 (m, 1H), 1.49-1.40 (m, 2H), 1.70-1.62 (m, 1H), 1.83-1.72 (m, 2H), 1.89 (d, 2H), 2.74-2.10 (m, 2H), 3.12-3.08 (m, 2H), 3.57 (d, 2H), 3.63 (d, 2H), 3.90 (s,3H), 6.50 (d, 1H), 6.58 (s, 1H), 7.34-7.24 (m, 2H), 7.64-7.60(m, 1H), 7.94(dd, 1H), 8.02 (d, 1H), 8.14(s, 1H), 8.60(dd, 1H), 9.40(s, 1H)
26-28		MS 517	$CDCl_3$: 0.97 (t, 3H), 1.88-1.65 (m, 3H), 2.05-1.97 (m, 2H), 2.21-2.08 (m, 1H), 2.67-2.55 (m, 4H), 2.78-2.71(m, 2H), 3.12-3.08 (m, 2H), 3.61 (d, 2H), 3.87 (s,3H), 6.47 (dd, 1H), 6.56 (d, 1H), 7.28-7.23 (m, 2H), 7.64-7.60(m, 1H), 7.94(dd, 1H), 7.99 (d, 1H), 8.13(s, 1H), 8.60(dd, 1H), 9.39(s, 1H)
26-29		MS 585	$CDCl_3$: 0.97 (t, 3H), 1.89-1.65 (m, 8H), 2.03 (d, 2H), 2.20-2.10 (m, 1H), 2.68-2.58 (m, 4H), 2.78-2.72 (m, 2H), 3.12-3.08 (m, 2H), 3.61(d, 2H), 3.87(s,3H), 6.47 (dd, 1H), 6.56(d, 1H), 7.30-7.23 (m, 2H), 7.64-7.60(m, 1H), 7.94(dd, 1H), 7.99 (dd, 1H), 8.13(s, 1H), 8.60(dd, 1H), 9.39 (s, 1H)
26-30		MS 451, 453	0.97 (t, 3H), 1.71-1.82 (m, 2H), 3.06-3.14 (m, 2H), 3.89 (s, 1H), 6.60 (ddd, 1H), 6.66 (dd, 1H), 7.25-7.30 (m, 1H), 7.35 (br.s, 1H), 7.63 (dd, 1H), 7.95 (dd, 1H), 8.09-8.18 (m, 1H), 8.17 (s, 1H), 8.52 (dd, 1H), 9.42 (s, 1H).
26-31		MS 647, 649	0.98 (t, 3H), 1.71-1.83 (m, 2H), 2.18 (s, 3H), 2.47-2.64 (m, 4H), 2.72-2.84 (m, 2H), 3.08-3.15 (m, 2H), 3.42-3.54 (m, 2H), 3.58-3.69 (m, 2H), 3.84 (s, 3H), 3.94-4.03 (m, 2H), 6.45-6.51 (m, 1H), 6.78 (d, 1H), 7.22-7.27 (m, 1H), 7.60 (s, 1H), 7.67-7.74 (m, 1H), 7.93-7.97 (m, 1H), 7.73 (d, 1H), 8.02 (s, 1H), 8.54 (d, 1H), 9.33 (s, 1H).

26-32		m.p. 139,4	400MHz, CDCl3, δ (ppm): 0.98 (t; 3H), 1.55-1.90 (m; 6H), 2.38 (s; 3H), 2.45-2.80 (m; 6H), 3.13 (m; 2H), 3.47 (m; 2H), 3.84 (s; 3H), 6.54 (dd; 1H), 6.79 (d; 1H), 7.23 (dd; 1H); 7.51 (s; 1H), 7.64 (dd: 1H), 7.92 (d; 1H), 8.00 (s; 1H), 8.19 (s; 1H), 8.57 (d; 1H), 9.41 (s; 1H).
26-33		m.p. 163,4	400MHz, CDCl3, δ (ppm): 0.98 (t; 3H), 1.50-1.90 (m; 6H), 2.24 (bs; 1H), 2.45-2.65 (m; 6H), 3.12 (m; 2H), 3.45 (m; 2H), 3.77 (m; 4H9, 3.85 (s; 3H), 6.55 (dd; 1H); 6.79 (d; 1H), 7.24 (dd; 1H). 7.52 (s; 1H), 7.64 (dd; 1H), 7.93 (d; 1H), 8.01 (s; 1H), 8.20 (s; 1H9, 9.42 (s; 1H).
26-34		m.p. 232,9	400MHz, CDCl3, δ (ppm): 1.00 (s; 3H), 1.78 (m; 2H), 2.83 (s; 3H), 3.03 (m; 2H), 3.12 (m; 2H), 3.38-3.60 (m; 8H), 3.88 (s; 3H), 6.56 (m; 1H), 6.82 (d; 1H), 7.29 (m; 1H), 7.60 (s; 1H), 7.64 (m; 1H), 7.95 (d; 1H), 8.12 (s; 1H), 8.20 (s; 1H), 8.59 (d; 1H), 9.50 (s; 1H).
26-35		m.p. 197,3	400MHz, CDCl3, δ (ppm): 0.99 (t; 3H), 1.43 (m; 1H), 1.63 (m; 2H), 1.77 (m; 2H), 1.90 (m; 2H), 2.70 (m; 2H), 3.13 (m; 2H), 3.28 (m; 2H), 3.75 (s; 1H), 3.84 (s; 3H), 6.55 (m; 1H), 6.80 (d; 1H), 7.24 (m; 1H), 7.53 (s; 1H), 7.64 (s; 1H), 7.93 (d; 1H), 8.02 (s; 1H), 8.20 (s; 1H), 8.58 (d; 1H), 9.41 (s; 1H).
26-36		m.p. 147,6	400MHz, CDCl3, δ (ppm): 1.00 (t; 3H), 1.78 (m; 2H), 3.12 (m; 2H), 3.56 (m; 1H), 3.87 (s; 3H), 6.53 (dd; 1H), 6.80 (d; 1H), 7.30 (dd; 1H), 7.52 (s; 1H), 7.64 (m; 1H), 7.95 (dd; 1H), 8.08 (s; 1H), 8.20 (s; 1H), 8.60 (d; 1H), 9.48 (s; 1H).
26-37		m.p. 143.2	500MHz, CDCl3, δ (ppm): 0.96 (t; 3H), 1.70 (m; 2H), 2.11 (m; 1H), 2.39 (m; 1H), 2.75 (s; 3H), 3.02 (m; 1H), 3.22 (m; 2H), 3.43 (d; 2H), 3.82 (s; 3H), 3.86 (m; 1H), 6.40 (dd; 1H), 6.94 (d; 1H), 7.34 (ddd; 1H), 7.47 (s; 1H), 7.63 (ddd; 1H), 7.93 (dd; 1H), 8.18 (s; 1H), 8.51

			(d; 1H).
26-38		m.p. 133.5	400MHz, CDCl3, δ (ppm): 1.00 (t; 3H), 1.70-1.95 (m; 6H), 2.63 (s; 1H), 2,92 (s; 1H), 3.00-3.25 (m; 5H), 3.89 (s; 3H), 5.42 (s; 1H), 6.70 (s; 1H), 6.83 (m; 2H), 7.25 (m; 1H), 7.55 (s; 1H), 7.63 (m; 1H9, 8.95 (m; 1H), 8.15 (s; 1H), 8.23 (s; 1H), 8.54 (d; 1H), 9.45 (s; 1H).
26-39		m.p. 188.8	400MHz, CDCl3, δ (ppm): 0.99 (t; 3H), 1.70-1.90 (m; 3H), 2.08 (m; 1H), 2.28 (s; 6H9, 2.83 (s; 1H), 3.00-3.23 (m; 4H9, 3.37 (m; 1H), 3.83 (s; 3H), 6.19 (dd; 1H), 6.83 (d; 1H), 7.23 (dd; 1H), 7.50 (s; 1H), 7.59 (m; 2H), 7.93 (d; 1H), 8.19 (s; 1H), 8.60 (d; 1H), 9.42 (s; 1H).

The following 5-Chloro-N^2-(substituted phenyl)-N^4-[2-ethanesulfonyl-phenyl]-pyrimidine-2,4-diamine are prepared from (2,5-Dichloro-pyrimidin-4-yl)-[2-ethanesulfonyl-phenyl]-amine and the corresponding aniline following the procedure of Example 7A



Expl No.	Rx	Rf (solvent) or MS	NMR (400MHz), δ (ppm) or Retention time min. (HPLC)
27-1		0.53 (AcOEt)	$CDCl_3$: 1.28(t,3H), 3.12-3.19(m, 6H), 3.87-3.89(m, 7H), 6.45(dd, 1H), 6.53(d,1H), 7.24-7.28(m,1H), 7.31(s, 1H), 7.60-7.64(m, 1H), 7.95(dd, 1H), 8.04(d, 1H), 8.14(s, 1H), 8.58(d, 1H), 9.39(s, 1H)

27-2		585 (M+H)	2.38
27-3		486 (M+H)	3.07
27-4		587 (M+H)	2.29
27-5		545 (M+H)	2.59
27-6		545 (M+H)	2.45

27-7		531 (M+H)	2.25
27-8		545 (M+H)	2.45
27-9		600 (M+H)	2.17

HPLC condition
Column: YMC CombiScreen ODS-A (5um, 12nm), 50 x 4.6 mm I.D.
Flow rate: 2.0 ml/min
Eluent: A) TFA/water (0.1/100), B) TFA/acetonitrile (0.1/100)
Gradient: 5-100%B (0-5min)
Detection: UV at 215nm

The following 5-Chloro-N^2-(substituted phenyl)-N^4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine are prepared from (2,5-Dichloro-pyrimidin-4-yl)-[2-(propane-2-sulfonyl)-phenyl]-amine and the corresponding aniline following the procedure of Example 7A



ExpIN o.	Rx	Rf (solvent) or MS	NMR (400MHz) , δ (ppm) or Retention time min. (HPLC)
28-1		0.2 (AcOEt)	$CDCl_3$: 1.31 (d, 6H), 1.85-1.73 (m, 1H), 1.86-1.98 (m, 3H), 2.62-2.70 (m, 1H), 3.11-3.13 (m, 2H), 3.21-8.28 (m, 1H), 3.28 (m, 2H), 3.88 8s, 3H), 5.41 (brs, 1H), 6.53 (d, 1H), 6.59 (d, 1H), 6.64 (brs, 1H), 7.28-7.34 (m, 1H), 7.34 (s, 1H), 7.60-7.67 (m, 1H), 7.91 (dd, 1H), 8.08 (d, 1H), 8.13 (s, 1H), 8.60 (d, 1H), 9.55 (s, 1H).
28-2		MS m/z 561, 563 (M+1).	$CDCl_3$: 1.31(d, 6H), 2.64 (t, 2H), 2.68-2.77 (m, 4H), 3.19(t, 4H), 3.17-3.28(m, 1H), 3.68(t, 2H), 3.88(s, 3H), 6.48(dd, 1H), 6.55 (d, 1H), 7.23-7.32(m, 1H), 7.62(ddd, 1H), 7.91(dd, 1H), 8.04(dd, 1H), 8.12(s, 1H), 8.60(d, 1H), 9.54(bs, 1H)
28-3		0.55 (AcOEt)	$CDCl_3$: 1.31(d, 6H), 3.12-3.14(m, 4H), 3.21-3.27(m, 1H), 3.87-3.89(m, 7H), 6.46(dd, 1H), 6.53(d,1H), 7.23-7.27(m, 1H), 7.30(s, 1H), 7.59-7.64(m, 1H), 7.91(dd, 1H), 8.05(d, 1H), 8.14(s, 1H), 8.60(d, 1H), 9.55(s, 1H)
28-4		0.37 (AcOEt)	$CDCl_3$: 1.32(d, 6H), 3.21-3.27(m, 1H), 4.00(s, 1H), 7.11(dd, 1H), 7.26-7.27(m, 1H), 7.29-7.33(m, 1H), 7.64(s, 1H), 7.66-7.71(m, 1H), 7.95(dd, 1H), 8.10(s, 1H), 8.21(s, 1H), 8.46(d, 1H), 8.50(s, 1H), 8.54(d, 1H), 9.59(s, 1H)

28-5		0.03 (AcOEt)	$CDCl_3$: 1.31(d, 6H), 1.67-1.77(m, 2H), 1.95-2.05 (m, 2H), 2.39-2.48 (m, 1H), 2.48-2.61(m, 2H), 2.63-2.78(m, 8H), 3.24 (sept, 1H), 3.71-3.63 (m, 2H), 3.87(s, 3H), 6.47(dd, 1H), 6.55 (d, 1H), 7.21-7.28(m, 1H), 7.61(ddd, 1H), 7.91(dd, 1H), 8.00(dd, 1H), 8.12(s, 1H), 8.60(d, 1H), 9.53(bs, 1H)
28-6		502 (M+H)	2.84
28-7		478 (M+H)	4.53
28-8		MS 599	$CDCl_3$: 1.31(d, 6H),1.51-1.42(m, 2H), 1.67-1.53(m, 4H), 1.81-1.68(m, 2H), 1.96-1.89(m, 2H), 2.47-2.36(m, 1H), 2.57-2.54(m, 4H), 2.69(dd, 2H)3.24(sept, 1H), 3.67(d,1H), 3.87(s , 1H), 6.48 (dd, 1H), 6.56 (d, 1H), 7.31-7.21(m, 1H), 7.63-7.59 (m, 1H), 8.00(d, 1H), 8.12(s, 1H), 8.60(d, 1H), 9.55(s, 1H)
28-9		MS 585	$CDCl_3$: 1.26 (t, 3H), 1.31(d, 6H),1.74-1.68(m, 2H), 1.85-1.76(m, 4H), 2.08-1.98(m, 2H), 2.19-2.10(m, 2H), 2.67-2.58(m, 4H), 2.79-2.72(m, 2H), 3.24(sept, 1H) 3.61(d, 2H), 3.87(s,3H), 6.48(dd, 1H), 6.56 (d, 1H), 7.29-7.22 (m, 1H), 7.62(dd, 1H), 7.90(dd, 1H), 7.99(d, 1H), 8.12(s, 1H), 8.60(d, 1H), 9.53(s, 1H)

28-10		MS 559	$CDCl_3$: 1.31(d, 6H),1.59-1.37(m, 2H), 1.81-1.69(m, 1H), 1.87(d, 2H), 2.73-2.67(m, 2H), 3.28-3.21(m, 1H), 3.37(s, 3H),3.61(d, 1H),3.87(s, 3H),6.49(dd, 1H),6.57(s, 1H), 7.31-7.21(m, 1H),7.64-7.60 (m, 1H), 7.91(dd, 1H), 8.00(d, 1H), 8.60(d, 1H) 9.53(s, 1H)
28-11		MS 558	$CDCl_3$: 1.31(d, 6H), 2.15(s, 3H), 3.12(ddd, 4H), 3.24(sept, 1H), 3.64 (t, 2H), 3.80(t, 2H), 3.89(s, 3H),6.47(dd, 1H),6.55(d, 1H),7.29-7.24(m, 1H),7.33(bs, 1H), 7.62(m, 1H),7.92(dd, 1H), 8.08(d, 1H), 8.14(s, 1H), 8.60(d, 1H) 9.55(s, 1H)
28-12		MS 544	$CDCl_3$: 1.16, (t, 3H), 1.31(d, 6H), 2.56-2.44(b, 2H), 2.71-2.60 (m, 4H), 3.28-3.17(m, 5H), 3.88(s, 3H), 6.48(dd, 1H),6.58(d, 1H),7.30-7.22(m, 1H), 7.63-7.58(m, 1H),7.90(dd, 1H), 8.01(d, 1H), 8.12(s, 1H), 8.60(d, 1H) 9.54(s, 1H)
28-13		MS 601	$CDCl_3$: 1.31(d, 6H, J=6.55),1.75-1.63(m, 2H),2.00-1.91(m, 2H),2.37-2.27(m, 1H),2.60 (t, 4H, J=4.79), 2.74-2.59(m, 2H), 3.24(sept, 1H), 3.66 (d, 2H, J=12.1), 3.75(t, 4H, J=4.53), 3.88(s, 3H), 6.48(dd, 1H, J=2.52, 8.56),6.56(d, 1H, J=2.52),7.33-7.22(m, 1H), 7.64-7.59 (m, 1H),7.91(dd, 1H, J=8.05, 1.51), 8.01(d, 1H, J=8.56), 8.12(s, 1H), 8.61(d, 1H, J=7.55) 9.54(s, 1H)

28-14		MS 559	$CDCl_3$: 1.11 (d, 6H, J=6.55), 1.31(d, 6H, J=7.05), 2.82-2.68(m, 5H), 3.20-3.17(m, 4H), 3.28-3.17(m, 1H), 3.87(s, 3H), 6.48(dd, 1H, J=2.52, 8.56),6.56(d, 1H, J=2.52),7.33-7.24(m, 1H), 7.62-7.58(m, 1H),7.90(dd, 1H, J=), 8.01(d, 1H, J=8.56), 8.12(s, 1H), 8.60(d, 1H, J=8.56) 9.54(s, 1H)
28-15		MS 559	$CDCl_3$: 1.31 (d, 6H, J=7.05), 1.97-1.85(m, 2H), 2.17-1.98(m, 2H), 2.35-2.25(m, 1H), 2.75(m, 2H), 3.24(sept, 1H), 3.65(d, 2H), 3.88(s, 3H), 5.30 (bs, 1H), 5.48(bs, 1H), 6.48(dd, 1H, J=2.51, 8.56), 6.56(d, 1H, J=2.52), 7.33-7.21(m, 1H), 7.62 (m, 1H), 7.91(dd, 1H, J=1.51, 8.06), 8.03(dd, 1H, J=3.02, 8.56), 8.13(s, 1H), 8.60(d, 1H, J=8.57), 9.54(s, 1H)
28-16		MS 532	$CDCl_3$: 1.31 (d, 6H, J=7.06), 1.46-1.43(m, 1H), 1.79-1.68(m, 2H), 2.08-1.99(m, 2H),2.99-2.88(m, 2H), 3.24(sept, 1H), 3.51-3.45(m, 2H), 3.91-3.80(m, 1H), 3.88(s, 3H), 6.49(dd, 1H, J=2.52, 8.56),6.57(d, 1H, J=2.52),7.34-7.23(m, 1H), 7.64-7.60(m, 1H),7.91(dd, 1H, J=1.51, 8.06), 8.02(dd, 1H, J=3.02, 9.06), 8.13(s, 1H), 8.60(d, 1H, J=8.06) 9.53 (s, 1H)
28-17		MS 532	$CDCl_3$: 1.31 (d, 6H, J=6.96), 2.18-2.12(m, 2H), 3.24(sept, 1H),3.37-3.32(m, 2H), 3.39(s, 3H), 3.43(d, 1H, J=8.56), 3.51(dd, 1H, J=5.04, 10.6), 3.87(s, 3H), 4.17—4.09 (m,1H) 6.13 (dd, 1H, J=2.51, 8.56),6.16(d, 1H, J=2.52),7.09(bs, 1H),7.31-7.21(m, 1H), 7.60-7.56 (m, 1H),7.85(d, 1H, J=8.56), 7.89(dd, 1H, J=1.51, 8.06), 8.10(s, 1H), 8.65(d, 1H, J=9.06) 9.54 (s, 1H)

28-18		MS 546	$CDCl_3$: 1.31 (d, 6H, J=7.05), 1.82-1.70(m, 2H), 2.08-1.99(m, 2H),2.96-2.87(m, 2H), 3.24(sept, 1H), 3.41-3.33(m, 1H), 3.40(s, 3H),3.51-3.42(m, 2H), 3.87(s, 3H), 6.49(dd, 1H, J=2.52, 9.07),6.57(d, 1H, J=2.52),7.32-7.22(m, 1H), 7.64-7.60 (m, 1H),7.91(dd, 1H,), 8.00(dd, 1H, J=3.02, 9.06), 8.12(s, 1H), 8.60(d, 1H, J=8.56) 9.53 (s, 1H)
28-19		0.33 (AcOEt)	$CDCl_3$: 1.31 (d, 6H, J=7.05), 1.82-1.70(m, 2H), 2.08-1.99(m, 2H),2.96-2.87(m, 2H), 3.24(sept, 1H), 3.41-3.33(m, 1H), 3.40(s, 3H),3.51-3.42(m, 2H), 3.87(s, 3H), 6.49(dd, 1H, J=2.52, 9.07),6.57(d, 1H, J=2.52),7.32-7.22(m, 1H), 7.62(m, 1H),7.91(dd, 1H,), 8.00(dd, 1H, J=3.02, 9.06), 8.12(s, 1H), 8.60(d, 1H, J=8.56) 9.53 (s, 1H)
28-20		MS 544	$CDCl_3$: 1.31 (d, 6H), 1.66-1.53(m, 2H), 2.10-2.01(m, 2H),2.51 (s, 3H), 2.70-2.13(m, 1H),2.83-2.74(m, 2H), 3.24(Sept, 1H), 3.63-3.55(m, 2H), 3.87(s, 3H), 4.34-4.25(m, 1H), 6.48(dd, 1H),6.56(d, 1H),7.34-7.24(m, 1H), 7.64-7.60(m, 1H),7.90(dd, 1H), 8.00(d, 1H), 8.12(s, 1H), 8.60(dd, 1H), 9.53(s, 1H)
28-21		MS 531	$CDCl_3$: 1.30 (s, 3H),1.32 (s, 3H), 2.33-2.22(m, 1H), 2.54(s, 3H), 3.37-3.20(m, 3H),3.57-3.44(m, 3H), 3.86(s, 3H), 6.12(dd, 1H),6.16(d, 1H),7.14-7.08(m, 1H), 7.30-7.20(m, 1H),7.65-7.58(m, 1H), 7.93-7.87(m, 1H,), 8.10(s, 1H), 8.64(d, 1H) 9.54 (s, 1H)

28-22		MS 545	$CDCl_3$: 1.30 (s, 3H), 1.32 (s, 3H), 2.03-1.89(m, 1H),2.30-2.18(m, 1H), 2.34(s, 6H),2.96-2.83(m, 1H), 3.29-3.16(m, 2H), 3.40-3.34(m, 1H),3.53-3.43(m, 2H), 3.87(s, 3H), 6.11(dd, 1H,) 6.13(dd, 1H),7.08(bs, 1H),7.31-7.21(m, 1H), 7.60-7.56(m, 1H),7.85(d, 1H), 7.89(dd, 1H), 8.10(s, 1H), 8.66(d, 1H) 9.54(s, 1H)
28-23		MS 545	$CDCl_3$: 1.31 (s, 3H), 1.32 (s, 3H),3.05(s, 3H), 3.24(sept, 1H), 3.50-3.43(m, 4H),3.85(s, 2H), 3.89(s, 3H), 6.11(dd, 1H,) 6.43(dd, 1H),6.50(d, 1H),7.31-7.28(m, 1H), 7.64-7.60(m, 1H),7.92(dd, 1H), 8.09(d, 1H), 8.13(s, 1H), 8.58(d, 1H) 9.55(s, 1H)
28-24		0.05 (AcOEt/MeOH=4/1)	$CDCl_3$: 1.30 (s, 3H), 1.32 (s, 3H), 1.92-1.83(m, 1H),2.17-1.95(m, 1H), 2.43-2.27(m, 2H),2.79-2.71(m, 4H), 3.15-2.97(m, 4H), 3.23-3.16(m, 4H),3.24(sept, 1H), 3.87(s, 3H), 6.11(dd, 1H,) 6.47(dd, 1H),6.55(d, 1H),7.33-7.23(m, 1H), 7.63-7.59(m, 1H),7.95(dd, 1H), 8.01(dd, 1H), 8.12(s, 1H), 8.60(d, 1H) 9.54(s, 1H)
28-25		MS 600	$CDCl_3$: 1.30 (s, 3H), 1.32 (s, 3H), 1.80-1.70(m, 2H),2.01-1.93(m, 2H), 2.49-2.28(m, 12H),2.76-2.62(m, 4H), 3.04-2.96(m, 4H), 3.16-3.05(m, 2H),3.24(sept, 1H), 3.72-3.63(m, 2H), 3.87(s, 3H),6.48(dd, 1H),6.55(d, 1H),7.31-7.23(m, 1H), 7.66-7.589(m, 1H),7.91(dd, 1H), 8.01(d, 1H), 8.12(s, 1H), 8.60(d, 1H) 9.53(s, 1H)

28-26		MS 573	$CDCl_3$: 1.30 (s, 3H), 1.32 (s, 3H), 2.59-2.43 (m, 4H),2.78-2.73(m, 1H), 3.00-2.86(m, 2H),3.38-3.20(m, 3H), 3.54-2.45(m, 1H), 3.73(dd, 1H),3.84-3.77(m, 1H), 3.94-3.87(m, 1H), 3.88(s, 3H),6.46(dd, 1H),6.53(d, 1H),7.32-7.23(m, 1H), 7.31 (bs, 1H), 7.63-7.52(m, 1H),7.91(dd, 1H), 8.04(d, 1H), 8.13(s, 1H), 8.60(d, 1H) 9.54(s, 1H)
28-27		MS 559	$CDCl_3$: 1.30(s, 3H), 1.32 (s, 3H), 1.82-1.73 (m, 1H), 1.97-1.84(m, 3H), 2.73-2.51 (m, 1H), 3.12(t, 2H), 3.31-3.20 (m, 3H), 3.90(s,3H), 5.46-5.37(m, 1H), 6.53(dd, 1H), 6.59(d, 1H), 6.68-6.62 (m, 1H), 7.28-7.21 (m, 1H), 7.33(bs, 1H), 7.65-7.61(m, 1H), 7.92(dd, 1H), 8.08(d, 1H), 8.14(s, 1H), 8.60(d, 1H), 9.55(s, 1H)
28-28		MS 559	$CDCl_3$: 1.30(s, 3H), 1.32 (s, 3H), 1.82-1.73 (m, 1H), 1.97-1.84(m, 3H), 2.73-2.51 (m, 1H), 3.12(t, 2H), 3.31-3.20 (m, 3H), 3.90(s,3H), 5.46-5.37(m, 1H), 6.53(dd, 1H), 6.59(d, 1H), 6.68-6.62 (m, 1H), 7.28-7.21 (m, 1H), 7.33(bs, 1H), 7.65-7.61(m, 1H), 7.92(dd, 1H), 8.08(d, 1H), 8.14(s, 1H), 8.60(d, 1H), 9.55(s, 1H)
28-29		MS 413	$CDCl_3$: 1.31 (s, 3H), 1.33(s, 3H),2.92(t, 4H), 3.28(sept, 1H) 3.73(t, 4H), 3.87(s,3H), 6.51(dd, 1H), 6.82(d, 1H), 7.32-7.23 (m, 1H), 7.57(bs, 1H), 7.70-7.64(m, 1H), 7.92(dd, 1H), 8.01(bs, 1H), 8.12(s, 1H), 8.60(d, 1H), 9.53(s, 1H)
28-30		MS 493	$CDCl_3$: 1.30 (s, 3H), 1.33(s, 3H), 3.25(sept, 1H) 3.60 (bs,3H), 3.89(s, 3H), 6.59(s, 1H), 7.27-7.18 (m, 1H),7.61(dd, 1H), 7.83(bs, 1H), 7.90(dd, 1H), 8.15 (s , 1H), 8.55(d, 1H), 9.55(s, 1H)

28-31		MS 445	$CDCl_3$: 1.31(d, 6H),1.59-1.37(m, 2H), 1.81-1.69(m, 1H), 1.87(d, 2H), 2.73-2.67(m, 2H), 3.28-3.21(m, 1H), 3.37(s, 3H),3.61(d, 1H),3.87(s, 3H),6.49(dd, 1H),7.025(bs, 1H), 7.28-7.23(m, 1H),7.64-7.59(m, 1H), 7.93-7.89(m, 2H), 8.15(s, 1H), 8.57(dd, 1H) 9.56(s, 1H)



Expl No.	Rx	HPLC Retention time (min)	Mass (ESI) m/z
29-1		3.30	546 (M+H)
29-2		2.82	627 (M+H)
29-3		3.07	587 (M+H)



Expl No.	Rx	HPLC Retention time (min)	Mass (ESI) m/z
30-1		2.82	516 (M+H)
30-2		2.65	557 (M+H)
30-3		2.50	557 (M+H)
30-4		3.10	498 (M+H)

30-5		2.30	543 (M+H)
30-6		2.52	557 (M+H)
30-7		2.23	612 (M+H)



Expl No.	Rx	HPLC Retention time (min)	Mass (ESI) m/z
31-1		3.15	423 (M+H)

31-2		2.62	490 (M+H)



Expl No.	Rx	MS	NMR (400MHz) in $CDCl_3$, δ (ppm)
32-1		585.3	1.03 (s, 3H), 1.04(s, 3H),2.15(s, 3H), 2.32(sept, 1H) 3.00(d, 2H) 3.10(t, 2H), 3.13(t, 2H), 3.64(t, 2H),3.79(t, 2H), 3.89(s,3H), 6.45(dd, 1H), 6.55(d, 1H), 7.34-7.26 (m, 1H), 7.52(bs, 1H), 7.64-7.60(m, 1H), 7.97(dd, 1H), 8.07(d, 1H), 8.15(s, 1H), 8.54(d, 1H), 9.32(s, 1H)
32-2		532 (M+H)	3.17



Expl No.	Rx	MS	NMR (400MHz) in $CDCl_3$, δ (ppm)
33-1		585.3	1.66-1.52 (m, 2H), 1.92-1.73 (m, 4H), 2.12-2.03 (m, 2H), 2.15(s, 3H), 3.00(d, 2H) 3.11(t, 2H), 3.14(t, 2H), 3.58-3.46(m, 1H), 3.64 (t, 2H),3.80(t, 2H), 3.89(s,3H), 6.48(dd, 1H), 6.55(d, 1H), 7.30-7.24 (m, 1H), 7.52(bs, 1H), 7.63-7.58(m, 1H), 7.94(dd, 1H), 8.08(d, 1H), 8.14(s, 1H), 8.60(d, 1H), 9.54(s, 1H)
33-2		544 (M+H)	3.15



Expl No.	Rx	HPLC Retention time (min)	Mass (ESI) m/z
34-1		3.15	532 (M+H)

34-2		3.34	558 (M+H)
34-3		3.35	546 (M+H)
34-4		3.32	546 (M+H)
34-5		3.09	566 (M+H)
34-6		2.87	552 (M+H)

Ex No		MS	NMR (400MHz), $CDCl_3$, δ ppm
34-7		MS 435, 436	1.05 (t, 3H), 1.69-1.78 (m, 2H), 2.86-2.95 (m, 1H), 3.16-3.25 (m, 1H), 6.57-6.68 (m, 2H), 7.17 (dd, 1H), 7.35-7.39 (m, 1H), 7.50 (dd, 1H), 8.13 (s, 1H), 8.16-8.21 (m, 1H), 8.48 (d, 1H), 10.14 (s, 1H)
34-8		MS 549, 551	0.94 (t, 3H), 1.69-1.80 (m, 2H), 2.38 (s, 3H), 2.55-2.64 (m, 4H), 3.02-3.08 (m, 2H), 3.22-3.29 (m, 4H), 3.88 (s, 3H), 6.55 (ddd, 1H), 6.60-6.66 (m, 1H), 7.13-7.18 (m, 1H), 7.34 (br.s, 1H), 7.44 (d, 1H), 8.10 (s, 1H), 8.10-8.23 (m, 2H), 8.88 (s, 1H).



35-1		567 [M+1]+	DMSO-d6: 2.24 (s, 3H), 2.45-2.50 (m, 4H), 2.78 (d, 3H), 3.10-3.17 (m, 8H), 3.74-3.79 (m, 7H), 6.49 (dd, 1H), 6.66 (d, 1H), 6.85-6.89 (m, 1H), 7.18 (d, 1H), 7.40 (d, 1H), 7.98-8.02 (m, 2H), 8.29 (br.d, 1H), 8.60-8.66 (m, 1H), 11.17 (s, 1H).
35-2		505 $[M+1]^+$	DMSO-d6: 2.24(s, 3H), 2.46-2.50(m, 4H), 2.79(d, 3H), 3.13-3.17(m, 4H), 3.78(s, 3H), 6.69(d, 1H), 6.87(dd, 1H), 7.07-7.17(m, 2H), 7.19-7.23(m, 2H), 7.54(d, 1H), 8.13(s, 1H), 8.45(s, 1H), 8.65-8.75(m, 1H), 9.04(s, 1H), 11.19(s, 1H)

Example 36 (Intermediates for Left anilines)

36-1 Preparation of 2-amino-*N*-methyl-benzamide



To a suspension of 16.3 g (100 mmol) of isatoic anhydride in 100mL of H_2O is added portionwise 100mL of 2N methylamine - tetrahydrofuran solution (200 mmol) at room temperature. The reaction mixture is stirred for 1 hour and then extracted with AcOEt. The organic layer is washed with H_2O and brine, dried over Na_2SO_4, and concentrated under

reduced pressure to give 13.79 g of desired product, 2-amino-*N*-methyl-benzamide (92 mmol, 92%) as colorless solid.

NMR (400MHz, CDCl3, δ): 2.97 (d, 3H, J = 4.52 Hz), 5.49 (bs, 1H), 6.07 (bs, 1H), 6.64 (ddd, 1H, J = 8.04, 7.56, 1.0 Hz), 6.68 (dd, 1H, J = 8.32, 1.0 Hz), 7.20 (ddd, 1H, J = 8.32, 7.56, 1.52 Hz), 7.29 (dd, 1H, J = 8.04, 1.52 Hz).

36-2

2-(2,5-Dichloro-pyrimidin-4-ylamino)-*N*-methyl-benzamide



To a solution of 15.0 g (99.8 mmol) of 2-amino-*N*-methyl-benzamide in DMF (300mL) are added 2, 4, 5-trichloropyrimidine (23.8 g, 130 mmol) and potassium carbonate (17.9 g, 130 mmol). The reaction mixture is stirred at 75°C for 5 hours, cooled to room temperature, and then poured into H_2O (600mL). The resulting precipitate is collected by a filtration followed by washing with 50% aqueous CH_3CN (200mL) and dried under reduced pressure (40°C, 10 hours) to give desired 2-(2,5-dichloro-pyrimidin-4-yl-amino)-*N*-methyl-benzamide as ivory solid (26.4 g, 88.9 mmol, 89%).

NMR (400MHz, DMSO-d6, δ): 2.81 (d, 3H, J = 4.52 Hz), 7.22 (dd, 1H, J = 8.56, 8.04 Hz), 7.60 (ddd, 1H, J = 8.56, 8.56, 1.0 Hz), 7.81 (dd, 1H, J = 8.04, 1.0 Hz), 8.48 (s, 1H), 8.52 (d, 1H, J = 8.56 Hz) 8.80-8.90 (m, 1H), 12.18 (s, 1H).

According the manner described above, the following compounds are prepared.

36-3

2-(5-Bromo-2-chloro-pyrimidin-4-ylamino)-N-methyl-benzamide



NMR (400MHz, DMSO-d_6, δ): 2.81(d, 3H), 7.23(ddd, 1H, *J*=7.54, 7.54, 1.0Hz), 7.59(ddd, 1H, *J*=7.93, 8.06, 1.52Hz),7.79(dd, 1H, *J*=7.8, 1.52Hz), 8.47(dd, 1H *J*=8.06, 1.0Hz), 8.55(s, 1H), 8.81-8.87(m, 1H), 12.0(brs, 1H). Rf: 0.46 (n-Hexane: AcOEt=7:3).

36-4

2-(2,5-Dichloro-pyrimidin-4-ylamino)-N-ethyl-benzamide



NMR (400MHz, $CDCl_3$, δ): 1.28 (t, d=7.04, 3H), 3.48-3.57 (m, 2H), 6.22 (br. s, 1H), 7.11-7.17 (m, 1H), 7.51 (dd, J=1.0, 8.04, 1H), 7.53-7.61 (m, 1H), 8.22 (s, 1H), 8.69-8.74 (m, 1H), 11.66 (br. s, 1H). Rf : 0.60 (Hexane :AcOEt=1 :1).

36-5

Preparation of 2-(5-bromo-2-chloro-pyrimidin-4-ylamino)-N-methyl-benzenesulfonamide



A suspension of 5-bromo-2,4-dichloropyrimidine (684 mg, 3.0 mmol) and 2-amino-N-methyl-benzenesulfonamide (559 mg, 3.0 mmol) in N,N-dimethylformamide (10 mL) containing potassium carbonate (830 mg, 6.0 mmol) is stirred at room temperature for 23 hours. Saturated aqueous ammonium chloride is added and the mixture is poured into water and extracted twice with ethyl acetate. The organic layer is washed with brine, dried over sodium sulfate, and evaporated in vacuo. The residue is purified by silica gel column chromatography (n-hexane - ethyl acetate gradient) to afford the title compound as a slightly yellow solid.

^{1}H-NMR ($CDCl_3$), δ (ppm): 2.67 (d, 3H), 4.79 (q, 1H), 7.26 (s, 1H), 7.29 (ddd, 1H), 7.66 (ddd, 1H), 7.95 (dd, 1H), 8.37 (s, 1H), 8.48 (d, 1H), 9.52 (s, 1H). Rf (n-hexane : ethyl acetate = 10:3): 0.33.

According to the manner described above, the following compound is prepared.

36-6

2-(2,5-Dichloro-pyrimidin-4-ylamino)-N-methyl-benzenesulfonamide



^{1}H-NMR (400MHz, $CDCl_3$, δ);2.67(d, 3H),4.97-5.04(m, 1H), 7.29(ddd, 1H, *J*=7.54, 7.54, 1.0Hz), 7.66(ddd, 1H, *J*=7.93, 8.08, 1.48Hz),7.94(dd, 1H, *J*=8.04, 1.52Hz), 8.24(s, 1H), 8.51(dd, 1H *J*=8.06, 1.0Hz), 9.64(brs, 1H). Rf: 0.45 (n-Hexane: AcOEt=4:1).

36-7

2-(2,5-Dichloro-pyrimidin-4-ylamino)-N-isopropyl-benzenesulfonamide



To a solution of 2-amino-N-isopropyl-benzenesulfonamide (16.1g, 75.1mmol) in DMI (150mL) is added sodium hydride (6.6g, 165.3mmol) portionwise at 0°C. After the mixture is stirred at room temperature for one hour, 2, 4, 5-trichloropyrimidine (20.7g, 112.7mmol) is added at 0°C. After further stirring at room temperature for 5 hrs, water is added and the mixture is extracted with AcOEt three times. Organic layer is washed with brine, dried over sodium sulfate and evaporated under reduced pressure. The residue is purified by silica gel column chromatography (Hexane to Hexane:AcOEt=4:1) to afford the title compound as pale brown solid (10.2g, 38%).

^{1}H-NMR (400MHz, $CDCl_3$, δ);1.06(d, 6H), 3.43-3.53(m, 1H), 4.38(d,1H), 7.29(dd, 1H), 7.66(dd, 1H), 7.98(d, 1H), 8.29(s, 1H), 8.51(d, 1H), 9.51(brs, 1H). Rf: 0.45 (n-Hexane:AcOEt=4:1)

The following compounds are prepared in the same manner described above.



Expl No.	Rz	Rf (solvent) or MS	NMR (400MHz) , δ (ppm)
36-8		0.45 (n-Hexane: AcOEt=4:1)	DMSO-d_6; 0.63(t, 6H), 0.86(d, 3H), 1.21-1.31(m, 2H), 3.02-3.12(m, 1H), 7.37(dd,1H), 7.71(dd, 1H), 7.85(d, 1H), 7.89(d, 1H), 8.20(d, 1H), 8.56(s, 1H), 9.51(brs, 1H)
36-9		0.46 (n-Hexane: AcOEt=7:3)	$CDCl_3$; 0.70(t, 6H),1.23-1.45(m, 4H), 3.03-3.13(m, 1H), 4.27(d,1H), 7.27(dd, 1H), 7.65(dd, 1H), 7.98(d, 1H), 8.29(s, 1H), 8.52(d, 1H), 9.59(brs, 1H)

36-10

Preparation of 2-(2-chloro-5-nitro-pyrimidin-4-ylamino)-N-methyl-benzenesulfonamide:



2,4-Dichloro-5-nitro-pyrimidine (1.94 g, 10 mmol) and 2-amino-N-methyl-benzenesulfonamide (1.86 g, 10 mmol) are dissolved in $CHCl_3$ (30 mL). The reaction mixture is heated at 61°C for 2 h. The solvent is evaporated and the residue is washed with ether to give the title product.
Rf = 0.5 (n-hexane : ethyl acetate = 1:1). ^{1}H-NMR (400MHz, $CDCl_3$), δ (ppm): 2.67 (d, 3H), 4.6-4.7 (m, 2H), 7.41 (t, 1H), 7.7 (t, 1H), 8.04 (d, 1H), 8.15 (d, 1H), 9.21 (s, 1H), 11.2 (s, 1H).

36-11

Preparation of (2,5-Dichloro-pyrimidin-4-yl)-[2-(propane-1-sulfonyl)-phenyl]-amine



To a solution of 2-(Propane-1-sulfonyl)-phenylamine (3.69g, 18.5 mmol) of N,N-dimethylformamide (40mL), sodium hydride (1.48g, 37 mmol) is added portionwise at 0°C. After stirring, 2,4,5-trichloropyrimidine (2.1mL, 18.5 mmol) is added. The mixture is stirred at 0°C for 30 minutes and is further stirred at room temperature for 7hrs. After adding saturated aqueous ammonium chloride, the mixture is poured into water and extracted twice with ethyl acetate. The organic layer is washed with brine, dried over sodium sulfate, and evaporated in vacuo. The residue is purified by silica gel column chromatography (n-hexane - ethyl acetate gradient) to afford the title compound as colorless solids.

^{1}H-NMR ($CDCl_3$), δ (ppm): 0.99 (t, 3H), 1.77 (d, 2H), 3.07-3.11 (m, 2H), 7.26 (s, 1H), 7.32 (ddd, 1H), 7.73 (ddd, 1H), 7.95 (dd, 1H), 8.31 (s, 1H), 8.61 (dd, 1H), 9.94 (bs, 1H). Rf (n-hexane : ethyl acetate = 3:1): 0.63

According to the manner described above, the following compounds are prepared.



ExpIN o.	Rx	Identification
36-12		^{1}H-NMR ($CDCl_3$), δ (ppm): 1.35(d, 6H), 3.18-3.24(m, 1H), 7.30-7.34(m, 1H), 7.70-7.75(m, 1H), 7.92(dd, 1H), 8.30(s, 1H), 8.63(d, 1H), 10.06(s, 1H). Rf 0.70: (AcOEt)
36-13		NMR (400MHz) in $CDCl_3$, δ (ppm): 1.29(t, 3H), 3.15(q, 1H), 7.31-7.35(m, 1H), 7.71-7.75(m, 1H), 7.96(dd,

		1H), 8.31(s, 1H), 8.60(d, 1H), 9.92(s, 1H). Rf: 0.67 (AcOEt).
36-14		1.01-1.06(m, 2H), 1.32-1.37(m, 2H), 2.49-2.55(m,1H), 7.29-7.33(m, 1H), 7.69-7.73(m, 1H), 7.91(dd, 1H), 8.31(s, 1H), 8.58(d, 1H), 9.90(s, 1H). Rf 0.69 (AcOEt)
36-15		0.99(t, 6H), 1.72-1.90(m, 4H), 2.76-2.82(m, 1H), 7.26-7.34(m, 1H), 7.69-7.74(m, 1H), 7.92(dd, 1H), 8.30(s, 1H), 8.62(d, 1H), 10.02(s, 1H). Rf: 0.73 (AcOEt)

Example 36-16

Synthesis of substituted amines which are commercially not available:

Preparation of 3-amino-4'-methoxy-4-methylbiphenyl

To a solution of 4-methoxyphenyl-boronic acid (500 mg, 3.29 mmol) in toluene (5.2 mL) and ethanol (1.3 mL), potassium carbonate (910 mg, 6.58 mmol), tetrakis(triphenylphosphine)-palladium (228.1 mg, 0.099 mmol) and 4-bromo-1-methyl-2-nitrobenzene (711 mg, 3.29 mmol) are added and stirred at 100°C for 7 hours. The mixture is poured into water and extracted with ethyl acetate two times. The organic layer is washed with water and then brine, dried over magnesium sulfate, and evaporated in vacuo. The residue is purified with silica gel column chromatography (n-hexane : ethyl acetate = 5 : 1) to afford the 4'-methoxy-4-methyl-3-nitro-biphenyl as a yellow solid.

^{1}H-NMR (δ, ppm) : 2.62 (s, 3H), 3.86 (s, 3H), 7.02-6.98 (m, 2H), 7.37 (d, 1H), 7.54 (dd, 2H), 7.68 (dd, 1H), 8.18 (d, 1H). Rf (hexane : ethyl acetate = 3:1): 0.40.

A suspension of 4'-methoxy-4-methyl-3-nitrobiphenyl (630 mg, 2.95 mmol) and 10% palladium on charcoal (63 mg, 0.059 mmol) in methanol (6 mL) is stirred under hydrogen atmosphere for 12 hours. Palladium catalyst is removed by filtration and the resulting solution is evaporated in vacuo to afford the title compound.

^{1}H-NMR (δ, ppm) : 2.20 (s, 3H), 3.84 (s, 3H), 6.87 (d, 1H), 6.89 (dd, 1H), 6.95 (d, 2H), 7.09 (d, 1H), 7.48 (d, 2H). Rf (n-hexane : ethyl acetate = 1:1): 0.50.

Preparation of 4-(3-amino-4-methylbenzoyl)-piperazine-1-carboxylic acid tert-butyl ester

To a solution of 4-methyl-3-nitro-benzoic acid (300 mg, 2.76 mmol), N-butoxycarbonyl-piperazine (340 mg, 1.83 mmol) in DMF (3.0 mL), triethylamine (300 μL, 3.59 mmol), TBTU (800 mg, 2.49 mmol) and HOAt (270.5 mg,1.99 mmol) are added and stirred at room temperature for 24 hours. The mixture is poured into water and extracted twice with ethyl acetate. The organic layer is washed with water and then brine, dried over magnesium sulfate, and evaporated in vacuo. The residue is purified with silica gel column chromatography (n-hexane : ethyl acetate = 5 : 1) to afford 4-(4-methyl-3-nitrobenzoyl)-piperazine-1-carboxylic acid tert-butyl ester as a colorless solid.

^{1}H-NMR (δ, ppm) : 1.47 (s, 9H), 2.64 (s, 3H), 3.28-3.88 (m, 8H), 7.42 (d, 1H), 7.56 (dd, 1H), 8.03 (d, 1H). Rf (hexane : ethyl acetate = 10:1): 0.13.

The title compound is obtained by reduction with hydrogen over 10% palladium on charcoal in methanol solution.

Preparation of 4-(3-amino-4-methylphenyl)-morpholine

To a solution of 4-bromo-1-methyl-2-nitrobenzene (225 mg, 1.04 mmol), morpholine (125 μL, 1.25 mmol), and cesium carbonate (474.4 mg, 1.46 mmol) in toluene, palladium diacetate (31.2 mg, 0.139 mmol) and 2-(di-t-butylphosphino)biphenyl (125 mg, 0.403 mmol) are added and stirred at 100°C for 5 hours. After cooling, the mixture is filtered to remove insoluble material. The filtrate is poured into water and extracted with ethyl acetate twice. The organic layer is washed with water and then brine, dried over magnesium sulfate, and evaporated in vacuo. The residue is purified with silica gel column chromatography (n-hexane : ethyl acetate = 5 : 1) to afford 4-(4-methyl-3-nitrophenyl)-morpholine as a yellow solid.

^{1}H-NMR (δ, ppm) : 2.50 (s, 3H), 3.17-3.19 (m, 4H), 3.86-3.88(m, 4H), 7.04 (dd, 1H), 7.21 (d, 1H), 7.47 (d, 1H). Rf (hexane : ethyl acetate = 5:1): 0.20.

The title compound is obtained by reduction with hydrogen over 10% palladium on charcoal in methanol solution.

Example 37: Synthesis of substituted amines which are commercially not available:

37-1

Preparation of 1-(3-Methoxy-4-nitro-phenyl)-piperdin-4-ol



To a suspension of piperidin-4-ol (2.79g, 28 mmol) and potassium carbonate (3.88 g, 28 mmol) in N,N-dimethylformamide (40 mL), 4-Fluoro-2-methoxy-1-nitro-benzene (4.0g, 23 mmol) is added and stirred at room temperature for 24 hours. The mixture is poured into water and the precipitate is collected by a filtration. The resulting solid is dried in vacuo at 50°C to afford 1-(3-methoxy-4-nitro-phenyl)-piperidin-4-ol (5.23g) as yellow solids in 89% yield.
^{1}H-NMR (400MHz, $CDCl_3$, δ, ppm) :1.54(d, 1H), 1.62-1.71(m, 2H), 1.98-2.04(m, 2H), 3.22(ddd, 4H), 3.73-3.80(m, 2H), 3.95(s, 3H), 3.98-4.02(m, 1H), 6.33(d, 1H), 6.43(dd, 1H), 8.00(d, 1H).

By repeating the procedures described above using appropriate starting materials and conditions the following compounds are obtained.

Ex-No	Rx	Identification
37-2		^{1}H-NMR (400MHz, $CDCl_3$, δ, ppm) :1.53-1.72(m, 2H), 1.80-1.83(m, 4H), 1.99-2.04(m, 2H), 2.24-2.31(m, 1H), 2.54-2.67(m, 4H), 3.03(dt, 2H), 3.84-3.89 (m, 2H), 3.95(s, 3H), 6.31(d, 1H), 6.42(dd, 1H), 8.01(d, 1H). Rf 0.54 (AcOEt)
37-3		^{1}H-NMR (400MHz, $CDCl_3$, δ, ppm) : 1.81-1.91(m, 2H), 1.99-2.04(m, 2H), 2.38-2.48(m, 1H), 3.03(ddd, 2H), 3.91-3.96(m, 2H), 3.95(s, 3H), 5.22-5.41(m, 1H), 5.40-5.53(m, 1H), 6.36(d, 1H), 6.43(dd, 1H), 8.00(d, 1H). Rf 0.15 (AcOEt)

37-4	 Ethyl-[1-(3-methoxy-4-nitro-phenyl)-pyrrolidin-3-yl]-amine	^{1}H-NMR (400MHz, $CDCl_3$, δ, ppm) : 1.15(t, 3H),1.88-1.96(m, 1H), 2.22-2.30(m,1H), 2.68-2.77(m, 2H),3.15-3.18(m, 1H), 3.38-3.44(m, 1H), 3.52-3.62(m, 2H), 3.93(s, 3H), 5.92(d, 1H), 6.07-6.10(m, 1H), 8.00-8.02(m, 1H). Rf 0.65 (*n*-hexane: AcOEt=1:1).
37-5	 1-(3-Methoxy-4-nitro-phenyl)-4-methyl-piperazine	^{1}H-NMR (400MHz, $CDCl_3$, δ, ppm) : 2.36(s, 3H), 2.52-2.57(m, 4H), 3.40-3.43(m, 4H), 3.95(s, 3H), 6.32(d, 1H, *J*=2.52Hz), 6.43(dd, 1H, *J*=9.56, 2.52Hz), 7.99(d, 1H, *J*=9.08Hz). Rf 0.60 (MeOH : CH_2Cl_2=4:1).
37-6	 3-(3-Methoxy-4-nitro-phenoxymethyl)-1-methyl-piperidine	^{1}H-NMR (400MHz, $CDCl_3$, δ, ppm) : 1.10-1.19(m, 1H), 1.59-2.18(m, 6H), 2.28(s,3H), 2.71-2.74(m, 1H), 2.88-2.91(m, 1H), 3.86-3.95 (m, 5H), 6.47-6.52(m, 2H), 7.97-8.00(m, 1H). Rf 0.65 (*n*-hexane: AcOEt=1:1)
37-7		^{1}H-NMR (400MHz, $CDCl_3$, δ, ppm) : 4.08(s,3H), 7.30(dd,1H), 7.58(d, 1H), 8.05(d, 1H), 8.15(s, 1H), 8.67(s, 1H). Rf: 0.42 (AcOEt)

37-8		^{1}H-NMR (400MHz, $CDCl_3$, δ, ppm): 1.40 – 1.50 (m, 2H), 1.55 – 1.69 (m, 6H), 1.90 – 1.96 (m, 2H), 2.45 – 2.53 (m, 5H), 2.90 – 2.99 (m, 2H), 3.90 – 4.00 (m, 2H), 3.94 (s, 3H), 6.30 (d, 1H, J =, 2.5 Hz), 6.41 (dd, 1H, J = 9.0, 2.5 Hz), 7.99 (d, 1H, J = 9.0 Hz)
37-9		^{1}H-NMR (400MHz, DMSO-d6, δ, ppm) : 1.95-1.82(m, 2H), 2.15-2.06 (m, 1H), 2.30 (s, 3H), 3.17 (dd, 1H), 3.32-3.23 (m, 1H), 3.56-3.34 (m, 3H), 3.96 (s, 1H), 6.09 (d, 1H), 6.21 (dd, 1H), 7.91 (d, 1H)
37-10		^{1}H-NMR (400MHz, $CDCl_3$, δ, ppm): 2.30 - 2.48 (m, 3H), 2.59 - 2.66 (m, 1H), 2.70 - 2.76 (m, 1H), 2.85 - 2.92 (m, 1H), 3.09 - 3.17 (m, 1H), 3.30 - 3.34 (m, 1H), 3.52 - 3.58 (m, 1H), 3.68 - 3.84 (m, 3H), 3.87 - 3.91 (m, 1H), 3.96 (s, 3H), 6.32 (d, 1H, J = 2.5 Hz), 6.42 (dd, 1H, J = 9.6, 2.5 Hz), 8.00 (d, 1H, J = 9.6 Hz)
37-11		^{1}H-NMR (400MHz, DMSO-d6, $CDCl_3$, δ, ppm) : 1.90-1.79(m, 1H), 2.25-2.15 (m, 1H), 2.21 (s, 3H), 2.87-2.77 (m, 1H), 3.16 (dd, 1H), 3.42-3.32 (m, 1H), 3.59-3.52 (m, 1H), 3.67-3.61 (m, 1H), 3.91 (s, 3H), 6.13 (d, 1H), 6.24 (dd, 1H)), 7.91 (dd, 1H)

37-12		^{1}H-NMR (400MHz, $CDCl_3$): 1.43-1.00(m, 2H),1.95-1.81 (m, 2H),2.94-2.17(m, 2H),2.96(s, 3H),3.27 (d, 2H), 3.35(s, 3H),3.97-3.90 (m, 2H), 3.95(s, 3H), 6.30(d, 1H), 6.42(dd, 1H) 8.00(d, 1H). Rf: 0.25 (AcOEt)
37-13		^{1}H-NMR (400MHz, $CDCl_3$): 1.14(t, 3H),2.48(dd, 2H), 2.59(t, 4H),3.42 (t, 4H), 3.95(s,3H), 6.32(d, 1H), 6.43(dd, 1H) 8.01(d, 1H). Rf 0.15 (AcOEt)
37-14		^{1}H-NMR (400MHz, $CDCl_3$): 1.02-0.89 (m, 2H), 2.01-1.94 (m, 2H), 2.52-2.38 (m, 1H), 2.65-2.53 (m, 4H),3.04-2.94(m, 2H), 3.79-3.69(m, 4H),3.97-3.88 (m, 2H), 3.95(s,3H), 6.32(d, 1H), 6.42(dd, 1H) 8.00(d, 1H). . Rf 0.10 (AcOEt)
37-15		^{1}H-NMR (400MHz, $CDCl_3$): 1.08 (s, 3H),1.09(s, 3H), 2.66(t, 4H),2.74 (sept, 1H), 3.41 (t, 4H), 3.95(s,3H), 6.32(d, 1H), 6.42(dd, 1H) 8.00(d, 1H). Rf 0.15 (AcOEt)

37-16		^{1}H-NMR (400MHz, $CDCl_3$): 1.91-1.81 (m, 2H), 2.06-1.97(m, 2H),2.48-2.40(m, 1H), 3.07-2.98(m, 2H),3.97-3.93(m, 2H), 3.93(s,3H), 5.37-5.30(m, 1H),5.55-5.43 (m, 1H), 6.33(d, 1H), 6.43(dd, 1H) 8.00(d, 1H). Rf 0.10 (AcOEt)
37-17		^{1}H-NMR (400MHz, $CDCl_3$): 2.18-2.07 (m, 1H), 2.30-2.22 (m, 1H), 3.38(s, 3H), 3.56-3.44(m, 4H),3.95 (s, 3H), 4.13 (ddd,1H), 5.96(d, 1H), 6.12(dd, 1H) 8.03(d, 1H). Rf 0.30 (AcOEt)
37-18		^{1}H-NMR (400MHz, $CDCl_3$): 1.46(s, 9H),1.81-1.68(m, 4H), 2.73(bs, 3H),3.07-2.97(m, 2H), 3.95(s,3H), 4.03-3.94 (m, 2H), 6.32(d, 1H), 6.43(dd, 1H) 8.00(d, 1H). Rf 0.55 (Hexane:AcOEt)
37-19		^{1}H-NMR (400MHz, $CDCl_3$): 3.60-3.57(m, 2H),3.68-3.65(m, 2H), 3.97(s, 3H),4.07(s, 2H), 6.17(bs, 1H), 6.26(d, 1H), 6.39(dd, 1H) 8.04(d, 1H). Rf 0.85 (AcOEt)

37-20		^{1}H-NMR (400MHz, $CDCl_3$): 3.08(s, 3H), 3.54(dd, 2H),3.67(dd, 2H), 3.96 (s, 3H), 4.05(s, 2H), 6.25(d, 1H), 6.38(dd, 1H) 8.03(d, 1H) . Rf 0.30 (AcOEt)
37-21		^{1}H-NMR (400MHz, $CDCl_3$): 1.73-1.55 (m, 2H), 1.99-1.91 (m, 2H), 2.09(s, 3H),2.61-2.49 (m, 5H), 3.47(t, 2H),3.63(t, 2H), 3.99-3.89 (m, 3H), 3.95 (s, 3H), 6.32(d, 1H), 6.42(dd, 1H) 8.01(d, 1H) . Rf 0.10 (AcOEt:MeOH=4:1)
37-22		^{1}H-NMR (400MHz, $CDCl_3$): 3.90(s, 3H), 3.98(s, 3H), 3.98 〈s, 3H), 6.56(s, 1H), 7.59(s, 1H) . Rf 0.605 (AcOEt)
37-23		^{1}H-NMR (400MHz, $CDCl_3$): 3.25-3.22 (m, 4H), 3.90-3.87 (m, 4H), 3.95(s, 3H), 6.48(s, 1H), 7.57(s, 1H) . Rf 0.060 (Hexane:AcOEt=5:1)

37-24		^{1}H-NMR (400MHz, $CDCl_3$): 2.37 (s, 3H), 2.61 (bs, 4H),3.27 (bs, 4H), 3.88 (s, 3H), 3.95(s, 3H), 6.48(s, 1H), 7.56(s, 1H) . Rf 0.10 (AcOEt:MeOH=5:1)
37-25		^{1}H-NMR (400MHz, $CDCl_3$): 1.09(t, 3H), 1.89(dd, 2H), 2.36(s, 3H), 2.55(t, 4H), 3.39(t, 4H), 4.03(t, 2H), 6.32(d, 1H), 6.42(dd, 1H), 7.98(d, 1H) . Rf 0.12 (AcOEt:MeOH=9:1)
37-26		^{1}H-NMR (400MHz, $CDCl_3$): 1.36(s, 3H), 1.38 (s, 3H), 2.10 (s, 2H), 2.17(s, 3H), 3.27-2.96 (m, 2H), 3.71 (d, 2H), 3.96 (s, 3H), 6.33(d, 1H), 6.43(dd, 1H), 8.02(d, 1H) . Rf 0.10 (AcOEt)
37-27		^{1}H-NMR (400MHz, $CDCl_3$): 1.16(s, 3H), 1.18 (s, 3H), 2.50(dd, 2H), 3.02-2.47 (m, 2H), 3.69 (dd, 2H), 3.96 (s, 3H), 6.31(d, 1H), 6.43(dd, 1H), 8.00(d, 1H) . Rf 0.070(AcOEt)
37-28		^{1}H-NMR (400MHz, $CDCl_3$): 1.16(d, 3H), 2.57(dd, 1H), 3.00-2.89 (m, 4H), 3.18-3.11 (m, 1H), 3.75-3.68 (m, 2H),3.96 (s, 3H), 6.31(d, 1H), 6.43(dd, 1H), 8.01(d, 1H) . Rf 0.070 (AcOEt)

37-29		^{1}H-NMR (400MHz, $CDCl_3$): 1.18(t, 3H), 2.40(dd, 2H), 3.47-3.38(m, 4H), 3.71-3.63(m, 2H), 3.85-3.79(m, 2H), 3.96(s, 3H), 6.32(d, 1H), 6.42(dd, 1H), 8.01(d, 1H) . Rf 0.20 (AcOEt)
37-30		^{1}H-NMR (400MHz, $CDCl_3$): 1.16(s, 3H), 1.18(s, 3H), 2.82(sept, 1H), 3.50-3.37(m, 4H), 3.77-3.65(m, 2H), 3.86-3.78(m, 2H), 3.96(s, 3H), 6.33(d, 1H), 6.43(dd, 1H), 8.01(d, 1H) . Rf 0.48 (AcOEt)
37-31		^{1}H-NMR (400MHz, $CDCl_3$): 2.86(d, 3H), 3.48-3.45(m, 4H), 3.61-3.58(m, 4H), 3.96(s, 3H), 4.48-4.37 (m, 1H), 6.29(d, 1H), 6.40(dd, 1H), 8.01(d, 1H) . Rf 0.20 (AcOEt)
37-32		^{1}H-NMR (400MHz, $CDCl_3$): 1.72-1.60(m, 2H), 2.06-1.97(m, 2H), 3.25-3.17 (d, 3H), 3.78-3.70(m, 2H), 3.95(s, 3H), 4.04-3.99(m, 1H), 6.33(d, 1H), 6.43(dd, 1H), 8.00(d, 1H) . Rf 0.20 (AcOEt)

37-33		^{1}H-NMR (400MHz, $CDCl_3$): 1.53 (s, 6H), 2.14(s, 3H), 3.50(s, 2H), 3.61-3.58(m, 2H), 3.97-3.81(m, 2H), 3.97 (s, 3H), 6.10 (d, 1H), 6.26(dd, 1H), 8.05(d, 1H) . Rf 0.030 (AcOEt)
37-34		^{1}H-NMR (400MHz, $CDCl_3$): 2.54-2.23 (m, 4H), 2.67 (t, 2H), 3.29-3.23(m, 2H), 3.74(t, 4H), 3.94(s, 3H), 6.07(d, 1H), 6.16 (dd, 1H), 8.00(d, 1H) . Rf 0.15 (AcOEt)
37-35		^{1}H-NMR (400MHz, $CDCl_3$): 2.10-2.02 (m, 2H), 2.41(t, 2H), 3.56(dd, 2H), 3.71(t, 2H), 3.95(s, 3H), 4.19(t, 2H), 6.49(dd, 1H), 6.55(d, 1H), 7.99(d, 1H) . Rf 0.10 (AcOEt)
37-36		^{1}H-NMR (400MHz, $CDCl_3$): 2.14(s, 3H), 3.87-3.34(m, 8H), 3.99 (s, 3H), 7.01(dd, 1H), 7.16(d, 1H), 7.88(d, 1H) . Rf 0.25 (AcOEt)

37-37		^{1}H-NMR (400MHz, $CDCl_3$): 3.49-3.37(m, 2H), 3.88-3.55(m, 6H), 3.99 (s, 3H), 7.00(dd, 1H), 7.16(d, 1H), 7.87(d, 1H) . Rf 0.50 (AcOEt)
37-38		^{1}H-NMR (400MHz, $CDCl_3$): 1.17 (s, 3H), 1.19(s, 3H), 2.69 (t, 4H), 3.06(s, 2H), 3.42 (t, 4H), 3.96(s, 3H),4.13(sept, 1H), 6.34 (d, 1H), 6.44(dd, 1H), 6.90-6.79(m, 1H), 8.00(d 1H) . Rf 0.20 (AcOEt)
37-39		^{1}H-NMR (400MHz, $CDCl_3$): 1.44-1.34 (m, 2H),1.84-1.77 (m, 1H), 1.94-1.85 (m, 2H), 3.04-2.94 (m, 2H), 3.55 (t, 2H), 3.96-3.57(m, 2H), 3.95(s, 3H), 6.31(d, 1H), 6.42(dd, 1H), 8.00(d, 1H) . Rf 0.30 (AcOEt)
37-40		^{1}H-NMR (400MHz, $CDCl_3$): 1.44-1.34 (m, 2H),1.84-1.77 (m, 1H), 1.94-1.85 (m, 2H), 3.04-2.94 (m, 2H), 3.55 (t, 2H), 3.96-3.57(m, 2H), 3.95(s, 3H), 6.31(d, 1H), 6.42(dd, 1H), 8.04(d, 1H) . Rf 0.45 (AcOEt)

37-41		^{1}H-NMR (400MHz, $CDCl_3$) : 4.05 (s, 3H), 7.07 (d, 1H), 7.08 (d, 1H), 7.27-7.26 (m, 1H), 7.33 (t, 1H), 7.92 (s, 1H), 8.04 (d, 1H). Rf: 0.20 (AcOEt)
37-42		^{1}H-NMR (400MHz, $CDCl_3$) :2.34 (s, 3H), 2.55-2.37 (m, 4H), 3.86-3.38 (m, 4H), 4.00 (s, 3H), 7.13 (d, 1H). 7.66 (dd, 1H).7.93 (d, 1H). Rf: 0.30 (AcOEt:MeOH=4:1)
37-43		^{1}H-NMR (400MHz, $CDCl_3$) : 2.43 (s, 3H), 2.74 (s, 6H), 7.91 (dd, 1H), 7.23 (d, 1H), 7.24 (d, 1H), 7.46 (dd, 1H). Rf: 0.70 (Hexane:AcOEt=5:1)
37-44		^{1}H-NMR (400MHz, $CDCl_3$) :2.15 (s, 3H), 3.80-3.48 (m, 2H), 6.87 (dd, 1H), 6.92(dd, 1H), 7.09 (d, 1H), 7.40 (dd, 2H), 8.54 (dd, 2H).
37-45		^{1}H-NMR (400MHz, $CDCl_3$) :3.86 (s, 3H), 4.00 (s, 3H), 6.78 (d, 1H), 6.99 (dd, 2H), 7.14(d, 1H), 7.48 (dd, 2H), 7.71 (dd, 1H), 8.03 (d, 1H). Rf: 0.30 (Hexane:AcOEt=3:1)

37-46		^{1}H-NMR (400MHz, $CDCl_3$) :1.44 (t, 3H), 3.10 (t, 4H), 3.86 (t, 4H), 4.13 (q, 2H), 7.01(dd, 1H), 7.08 (dd, 1H), 7.35 (d, 1H). Rf: 0.25 (Hexane:AcOEt=3:1)
37-47		^{1}H-NMR (400MHz, $CDCl_3$) :1.26 (t, 3H), 3.32 (t, 4H), 3.85 (t, 4H), 4.15 (q, 2H), 6.34(d, 1H), 6.42 (dd, 1H), 7.98 (d, 1H). Rf: 0.45 (Hexane:AcOEt=5:1)
37-48		^{1}H-NMR (400MHz, $CDCl_3$) :3.45 (s, 3H), 3.77 (dd, 2H), 3.81 (s, 3H), 4.06 (t, 2H), 7.08-7.08(m, 2H), 7.37 (t, 1H). Rf: 0.45 (Hexane:AcOEt=3:1)
37-49		^{1}H-NMR (400MHz, $CDCl_3$) :2.44 (t, 1H), 3.83 (s, 3H), 3.96 (ddd, 2H), 4.20 (t, 2H), 7.06 (d, 1H), 7.12(dd, 1H), 7.40 (d, 1H). Rf: 0.10 (Hexane:AcOEt=3:1)
37-50		^{1}H-NMR (400MHz, $CDCl_3$) :1.45 (t, 3H), 3.81 (s, 3H), 4.13 (q, 2H), 7.01(d, 1H), 7.08 (dd, 1H), 7.36 (d, 1H). Rf: 0.20 (Hexane:AcOEt=3:1)
37-51		^{1}H-NMR (400MHz, $CDCl_3$) :1.35 (s, 3H), 1.36(s, 3H), 3.81(s, 3H), 4.52 (sept, 1H), 7.08-7.01 (m, 2H), 7.31 (d, 1H). Rf: 0.30 (Hexane:AcOEt=3:1)

37-52		^{1}H-NMR (400MHz, $CDCl_3$) :1.05 (t, 3H), 1.83 (ddd, 2H), 3.81(s, 3H), 4.01(t, 2H), 7.01 (d, 1H), 7.08 (dd, 1H), 7.36 (d, 1H). Rf: 0.35 (Hexane:AcOEt=3:1)
37-53		^{1}H-NMR (400MHz, $CDCl_3$) :3.86 (s, 6H), 3.79 (s, 3H), 6.91 (dd, 1H), 7.00 (d, 1H), 7.18 (d, 1H). Rf: 0.5 (Hexane:AcOEt=9:1)
37-54		^{1}H-NMR (400MHz, $CDCl_3$) :4.04(s, 3H), 7.22 (d, 1H), 7.48(dd, 2H), 7.83 (dd, 1H), 8.16 (d, 1H), 8.69 (dd, 2H). Rf: 0.12 (Hexane:AcOEt=1:1)
37-55		^{1}H-NMR (400MHz, $CDCl_3$) :4.02 (s, 3H), 7.22 (d, 1H), 7.39 (ddd, 1H), 7.77(dd, 1H), 7.85(ddd, 1H), 8.08 (d, 1H), 8.63(dd, 1H), 8.83 (d, 1H). Rf: 0.55 (Hexane:AcOEt=2:1)
37-56		^{1}H-NMR (400MHz, $CDCl_3$) :4.03 (s, 3H), 7.19 (d, 1H), 7.28-7.24 (m, 1H), 7.72(dd, 1H), 7.80-7.76(m, 1H), 8.25 (dd, 1H), 8.52 (d, 1H), 8.69 (ddd, 1H). Rf: 0.55 (Hexane:AcOEt=2:1)

37-57		mp 90.7 °C; ^{1}H-NMR (400MHz, $CDCl_3$) δ (ppm): 1.68 (m; 2H), 2.00 (m; 2H), 2.36 (s; 1H), 2.62 (bs; 4H), 2.72 (m; 2H), 3.62 (m; 2H), 3.78 (bs; 4H), 3.90 (s; 3H), 6.99 (d; 1H); 7.13 (dd; 1H), 7.26 (s; 1H); 7.40 (s; 1H).

38

Preparation of 1-[4-(4-Methoxy-3-nitro-phenyl)-piperazin-1-yl]-ethanone



To a solution of 5-bromo-1-methoxy-2-nitrobenzene (300 mg, 1.29 mmol) in dioxane, 1-acetyl piperazine (400mg, 3.12 mmol), cesium carbonate (1.0g, 3.07 mmol), palladium diacetate (29.0 mg, 0.129 mmol) and 2-(di-t-butylphosphino)biphenyl (77 mg, 0.258 mmol) are added and stirred at 100°C for 8 hours. After cooling, the mixture is filtered to remove insoluble material. The filtrate is poured into water and extracted with ethyl acetate twice. The organic layer is washed with water and then brine, dried over magnesium sulfate, and evaporated in vacuo. The residue is purified by silica gel column chromatography (n-hexane : ethyl acetate gradient) to afford 1-[4-(4-Methoxy- 3-nitro-phenyl)-piperazin-1-yl]-ethanone (319mg, 44%) as yellow solids. ^{1}H-NMR (400MHz, $CDCl_3$, δ, ppm) : 2.14 (s, 3H), 3.63 (ddd, 4H), 3.63 (t, 2H), 3.78 (t, 2H), 3.92 (s, 3H), 7.03 (d, 1H), 7.12 (d, 1H), 7.41 (d, 1H). Rf (ethyl acetate): 0.18

39

Preparation of 1-(3-Methoxy-4-nitro-phenyl)-piperidin-4-one



To a solution of 4-piperidone hydrochloride monohydrate (10.0 g, 0.065mol) in DMF (80 mL) are added 4-Fluoro-2-methoxy-1-nitro-benzene (10.0 g, 0.058 mol) and potassium carbonate

(20.2 g), and the mixture is stirred at 70°C for 20 h. After a filtration, the filtrate is poured into H_2O (*ca.* 300 mL), and the resulting precipitates are collected by a filtration followed by washing with H_2O for several times to give title compound (8.98 g) in 61% yield. Orange solid. ^{1}H-NMR (400 MHz, $CDCl_3$, δ): 2.65-2.62 (4H, *m*), 3.81-3.78 (4H, *m*), 3.98 (3H, *s*), 6.34 (1H, *d*), 6.45 (1H, *dd*), 8.05 (1H, *d*).

40

Preparation of 1-[1-(3-Methoxy-4-nitro-phenyl)-piperidin-4-yl]-4-methyl-piperazine



To a solution of 1-(3-Methoxy-4-nitro-phenyl)-piperidin-4-one (4.96g, 0.020mol) in dichloroethane (50 ml) is added N-methylpiperazine (2.7ml, 0.024 mol) at 0 °C and the mixture is stirred at room temperature. After 4 h, sodium triacetoxy-borohydride (5.04g, 0.024mol) is added and the mixture is further stirred at room temperature for 24 h. After addition of 1N sodium hydroxide at 0 °C, the mixture is poured into water and extracted three times with dichloromethane. The organic layer is combined and extracted three times with 1N hydrochloride. The water layer is basified with 2N sodium hydroxide and extracted three times with dichloromethane. The organic layer is washed with brine, dried over sodium sulfate, and evaporated in vacuo to give the title compound as yellow solids (6.04g) in 91% yield.

^{1}H-NMR (400 MHz, $CDCl_3$, δ): 1.70-1.57 (2H, *m*), 2.03-1.93 (2H, *m*), 2.29 (3H, *s*), 2.55-2.38 (5H, *m*), 2.70-2.56 (4H, m), 2.97 (2H, *ddd*), 3.97-3.92 (2H, *m*), 3.95 (3H, *s*), 6.31 (1H, *d*,), 6.42 (1H, *dd*), 8.00 (1H, *d*).

41

Preparation of 4'-Methoxy-4-methyl-3-nitro-biphenyl



To a solution of 4-methoxyphenyl-boronic acid (500 mg, 3.29 mmol) in toluene (5.2 mL) and ethanol (1.3 mL), potassium carbonate (910 mg, 6.58 mmol), tetrakis(triphenylphosphine)-palladium (228.1 mg, 0.099 mmol) and 4-bromo-1-methyl- 2-nitrobenzene (711 mg, 3.29 mmol) are added and stirred at 100°C for 7 hours. The mixture is poured into water and extracted with ethyl acetate two times. The organic layer is washed with water and then brine, dried over magnesium sulfate, and evaporated in vacuo. The residue is purified with silica gel column chromatography (n-hexane : ethyl acetate = 5 : 1) to afford the 4'-methoxy-4-methyl-3-nitro-biphenyl (630mg, 79%) as a yellow solid.

^{1}H-NMR (400MHz, $CDCl_3$, δ, ppm) : 2.62 (s, 3H), 3.86 (s, 3H), 7.02-6.98 (m,2H), 7.37 (d, 1H), 7.54 (dd, 2H), 7.68 (dd, 1H), 8.18 (d, 1H). Rf (hexane : ethyl acetate = 3:1): 0.40.

42

Preparation of 4-(2-Ethoxy-ethoxy)-1-(3-methoxy-4-nitro-phenyl)-piperidine



To a solution of 1-(3-Methoxy-4-nitro-phenyl)-piperidin-4-ol (300mg, 1.2 mmol) in N,N-dimethylformamide (3.0 mL), sodium hydride (1.52g, 3.8 mmol) is added. After stirring, 2-bromoethyl methyl ether (150µl, 1.6 mmol) is added and the mixture is further stirred at 70°C for 15 hours. After addition of saturated aqueous ammonium chloride, the mixture is poured into water and extracted twice with ethyl acetate. The organic layer is washed with brine, dried over sodium sulfate, and evaporated in vacuo. The residue is purified by silica gel column chromatography (n-hexane - ethyl acetate gradient) to afford 4-(2-Methoxy-ethoxy)-1-(3-methoxy-4-nitro-phenyl)-piperidine (111mg, 29%) as a yellow oil.

^{1}H-NMR (400MHz, $CDCl_3$, δ, ppm) : 1.52(t, 3H), 1.95-2.00(m, 2H), 1.70-1.79(m, 2H), 3.23(ddd, 2H), 3.58-3.64(m, 2H), 3.65-3.68(m, 2H), 3.64-3.72(m, 2H), 3.95(s, 3H), 6.31(d, 1H), 6.42(dd, 1H), 8.00(d, 1H). Rf 0.53 (*n*-hexane: AcOEt=1:1).

According the procedure described above using appropriate alkyl halides, the following compounds are prepared.

Ex-No.	Rx	Identification

42-1		^{1}H-NMR (400MHz, $CDCl_3$, δ, ppm) : 2.04-2.21(m, 1H), 2.63(t, 2H), 2.68(t, 2H), 3.42(t, 4H), 3.87(t, 4H), 3.96(s, 3H), 6.33(d, 1H), 6.44(dd, 1H), 8.02(d, 1H). Rf 0.09 (AcOEt).
42-2		^{1}H-NMR (400MHz, $CDCl_3$, δ, ppm) : 1.71-1.79(m, 2H), 1.95-2.02(m, 2H), 3.22(ddd, 2H), 3.40(s, 3H), 3.55-3.57(m, 2H), 3.59-3.73(m, 3H), 3.65-3.67(m, 2H), 3.95(s, 3H), 6.31(d, 1H), 6.42(dd, 1H), 8.00(d, 1H). Rf 0.35 (*n*-hexane: AcOEt=1:1)

Example : 43

2-Methoxy-4-(1-methyl-piperidin-4-yloxy)-phenylamine 4-(3-Methoxy-4-nitro-phenoxy)-1-methyl-piperidine



To a solution of 4-Fluoro-2-methoxy-1-nitro-benzene (10.3g, 60 mmol) in toluene (50 mL) and 25% KOH aq.(50mL), 4-hydroxy-1-methylpiperidine (13.8g, 120 mmol) and tetra-n-butyl ammonium bromide (3.87g, 12mmol) are added at room temperature. The mixture is heated at 60°C for 1 day. The reaction mixture is cooled to room temperature, poured into ice water and extracted twice with ethyl acetate. The organic layer is successively washed with dil.HCl and brine, dried over sodium sulfate, and evaporated in vacuo to afford the crude compound in quantitative yield (13.4g).

Rf = 0.22 (methanol : dichloromethane = 1:4). ^{1}H-NMR (400 MHz, $CDCl_3$, δ, ppm): 1.84-1.92(m, 2H), 2.0-2.1(m, 2H), 2.3-2.4 (m, 2H), 2.33 (s, 3H), 2.65-2.75(m, 2H), 3.94(s, 3H), 4.39-4.46(m, 1H), 6.49 (dd, 1H), 6.99 (d, 1H), 6.54 (d, 1H), 7.99 (d, 1H).

Example : 44

2-Methoxy-4-(2-morpholin-4-yl-ethoxy)-phenylamine

3-Methoxy-4-nitro-phenol



To a solution of 3-Fluoro-4-nitro-phenol (15.7g, 100 mmol) in THF (300 mL) , 30% KOMe in Methanol(49mL, 210mmol) is added at 0°C. The mixture is heated to gentle reflux for 18 hours.

4-[2-(3-Methoxy-4-nitro-phenoxy)-ethyl]-morpholine



To a solution of 3-Methoxy-4-nitro-phenol (1.69g, 10 mmol) in DMF (25 mL) , 4-(2-Chloroethyl)morpholine hydrochloride(2.05g, 11mmol), K2CO3(1.52g, 11mmol), KI(332mg, 2mmol) are added at room temperature. The mixture is heated to gentle reflux for 4 hours. The reaction mixture is cooled to room temperature and quenched with water. The resulting mixture is extracted twice with ethyl acetate and then the organic layer is successively washed with water and brine, dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude compound in 90% yield (2.55g).

Rf = 0.11 (AcOEt only). ^{1}H-NMR (400 MHz, $CDCl_3$), δ (ppm): 2.56-2.61(m, 4H), 2.83(t, The reaction mixture is cooled to room temperature and quenched slowly with 1NHCl aq at 0°C. The resulting mixture is extracted twice with ethyl acetate and then the organic layer is successively washed with brine, dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude compound in 94% yield(15.9g).

Rf = 0.22 (methanol : dichloromethane = 1:4). ^{1}H-NMR (400 MHz, $CDCl_3$), δ (ppm): 3.95(s, 3H), 5.49(s, 1H), 6.44 (dd, 1H, J=8.8, 2.52Hz), 6.54 (d, 1H, J=2.52Hz), 7.96 (d, 1H J=8.6Hz).

3.72-3.76(m, 4H), 3.94(s, 3H), 4.18(t, 2H), 6.51 (dd, 1H, *J*=9.08, 2.52Hz), 6.56 (d, 1H, *J*=2.48Hz), 8.00 (d, 1H *J*=9.08Hz).

2H),

Example : 45
2-Methoxy-4-(2-morpholin-4-yl-ethoxy)-phenylamine
Acetic acid 4-methoxy-3-nitro-phenyl ester



To a solution of 4-Methoxyphenol (12.4g, 100 mmol) in AcOH (50 mL), Ac_2O (50mL) is added at room temperature. The mixture is heated to gentle reflux for 1.5 hour. The reaction mixture is cooled to room temperature and c.HNO_3 (d=1.38, 10mL) is added slowly at 0 °C. The mixture is heated to 55°C for 1.5h. The reaction mixture is cooled to room temperature and quenched with water at 0oC. The resulting solid is filtered on Buchner funnel to afford the crude compound in 76% yield (16.0g).

Rf = 0.59 (AcOEt : n-Hexane = 3:7). ^{1}H-NMR (400 MHz, $CDCl_3$), δ (ppm): 2.31(s, 3H), 3.96(s, 3H), 7.08 (d, 1H, *J*=9.04Hz), 7.31 (dd, 1H, *J*=9.04, 3.04Hz), 7.96 (d, 1H *J*=3.04 Hz).

4-Methoxy-3-nitro-phenol

To a solution of Acetic acid 4-methoxy-3-nitro-phenyl ester (1.06g, 5 mmol) in EtOH (20 mL), 1N NaOH aq (5.5mL) is added at 0°C. The mixture is stirred at room temperature for 2 hours. The reaction mixture is quenched with AcOH and extracted twice with ethyl acetate. The organic layer is successively washed with water and brine, dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude compound in quantitative yield (840mg).

Rf = 0.59 (AcOEt : n-Hexane = 3:7). ^{1}H-NMR (400 MHz, $CDCl_3$), δ (ppm): 3.91(s, 3H), 6.99 (d, 1H, *J*=9.04Hz), 7.17 (dd, 1H, *J*=9.04, 3.00Hz), 7.38 (d, 1H *J*=3.04 Hz).

4-[2-(4-Methoxy-3-nitro-phenoxy)-ethyl]-morpholine



To a solution of 4-Methoxy-3-nitro-phenol (1.01g, 6 mmol) in DMF (15 mL) , 4-(2-Chloroethyl)morpholine hydrochloride (1.34g, 7.2mmol), K2CO3 (2.49g, 18mmol), KI(2.99g, 18mmol) are added at room temperature. The mixture is heated to 80°C for 4 hours. The reaction mixture is cooled to room temperature and quenched with saturated NH4Cl solution in water. The resulting mixture is extracted twice with ethyl acetate and then the organic layer is successively washed with water and brine, dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude compound in quantitative yield (1.70g). Rf = 0.14 (AcOEt only). ^{1}H-NMR (400MHz, DMSO, δ, ppm) : 2.36-2.51 (m, 4H), 2.67 (t, J=5.5, 2H), 3.52-3.60 (m, 4H), 3.86 (s, 3H), 4.11 (t, J=6.0, 2H), 7.25-7.29 (m, 2H), 7.46-7.49 (m, 1H).

Preparation of 2-Methoxy-4-(1-methyl-piperidin-4-yloxy)-phenylamine:



To a solution of 4-(3-Methoxy-4-nitro-phenoxy)-1-methyl-piperidine (3.0g, 11.3 mmol) in ethanol (50 mL), 5% palladium on carbon(300mg) is added under a nitrogen atmosphere. The reaction vessel is fitted with a balloon adapter and charged with hydrogen and evacuated three times until the reaction is under a hydrogen atmosphere. The reaction is allowed to stir overnight. The reaction mixture is filtered through a pad of Celite and washed with methanol. The filtrate is concentrated in vacuo to afford 2-Methoxy-4-(1-methyl-piperidin-4-yloxy)-phenylamine in quantitative yield (2.7g).

Rf = 0.41 (methanol : dichloromethane = 1:1). ^{1}H-NMR (400 MHz, $CDCl_3$), δ (ppm): 1.75-1.86(m, 2H), 1.92-2.05(m, 2H), 2.2-2.32 (m, 2H), 2.30 (s, 3H), 3.4-3.7(brs, 2H), 3.82(s, 3H), 4.1-4.2(m, 1H), 6.37(dd, 1H), 6.46 (d, 1H), 6.61 (d, 1H).

By repeating the procedures described above using appropriate starting materials and conditions the following compounds are obtained.

Ex-No.	Rx	Identification
46-1		^{1}H-NMR (400MHz, $CDCl_3$, δ, ppm) : 3.92(s,3H), 3.97(br,2H), 6.75(d,1H), 7.00(dd, 1H), 7.12(d, 1H), 8.06(s, 1H), 8.41(s, 1H). Rf 0.32 (AcOEt)
46-2	 [1-(4-Amino-3-methoxy-phenyl)-pyrrolidin-3-yl]-ethyl-amine	^{1}H-NMR (400MHz, $CDCl_3$, δ, ppm) : 1.13(t, 3H), 1.77-1.86(m, 1H), 2.19-2.27(m,1H), 2.67-2.75(m, 2H), 3.01-3.06(m, 1H), 3.20-3.26(m, 1H), 3.33-3.38(m, 1H), 3.42-3.49(m, 2H), 3.84(s, 3H), 6.04-6.07(m, 1H), 6.14-6.15(m, 1H), 6.64-6.66(m, 1H). Rf 0.2 (AcOEt only)
46-3	 2-Methoxy-4-(4-methyl-piperazin-1-yl)-phenylamine	^{1}H-NMR (400MHz, $CDCl_3$, δ, ppm) : 2.44(s, 3H), 2.70-2.73(m, 4H), 3.13-3.17(m, 4H), 3.48(brs, 2H), 3.84(s, 3H), 6.41(dd, 1H, J=8.5, 2.52Hz), 6.51(d, 1H, J=2.52Hz), 6.64(d, 1H, J=8.5Hz). Rf 0.2 (AcOEt only).
46-4	 2-Methoxy-4-(1-methyl-piperidin-3-ylmethoxy)-phenylamine	^{1}H-NMR (400MHz, $CDCl_3$, δ, ppm) : 1.01-1.12(m, 1H), 1.57-2.13(m, 6H), 2.26(s,3H), 2.74-2.77(m, 1H), 2.93-2.96(m, 1H), 3.47 (bs, 2H), 3.70-3.80(m, 2H), 3.82(s, 3H), 6.31-6.34(m, 1H), 6.44-6.45(m, 1H), 6.60-6.62(m, 1H). Rf 0.2 (AcOEt only)

46-5		^{1}H-NMR (400 MHz, $CDCl_3$) 1.80-1.67 (2H, *m*), 1.99-1.90 (2H, *m*), 2.42-2.27 (1H, *m*), 2.56-2.43 (4H, *m*), 2.68-2.58 (2H, *m*), 2.76-2.58 (4H, *m*), 3.57-3.48 (2H, *m*), 3.83 (3H. *s*), 6.41 (1H, *dd*), 6.52 (1H, *d*), 6.63 (1H, *d*). R_f (hexane/acetone 1:1) 0.44.
46-6		^{1}H-NMR (400MHz, $CDCl_3$, δ, ppm) : 1.83-1.95 (m, 2H), 1.97-2.08 (m, 2H), 2.20-2.31 (m, 1H), 2.60-2.72 (m, 2H), 3.46-3.53 (m, 2H), 3.84 (s, 3H), 5.42-5.60 (m, 1H), 6.43 (dd, 1H), 6.53 (d, 1H), 6.64 (d, 1H).
46-7		^{1}H-NMR (400MHz, $CDCl_3$, δ, ppm) : 2.13 (s, 3H), 3.01-3.05 (m, 4H), 3.59 (t, 2H), 3.75 (t, 2H), 3.81 (s, 3H), 6.30 (dd, 1H), 6.39 (bs, 1H), 6.71 (d, 1H).
46-8		^{1}H-NMR (400MHz, $CDCl_3$, δ, ppm) : 1.84-1.97 (m, 2H), 1.98-2.07 (m, 2H), 2.20-2.32 (m, 1H), 2.61-2.72 (m, 2H), 3.47-3.55 (m, 2H), 3.95 (s, 3H), 5.20-5.38 (m, 1H), 5.40-5.56 (m, 2H), 6.43 (d, 1H), 6.53 (bs, 1H), 6.64 (d, 1H).
46-9		^{1}H-NMR (400MHz, $CDCl_3$, δ, ppm) : 2.59-2.67 (m, 2H), 2.77-2.68 (m, 4H), 3.08-3.15 (m, 4H), 3.49-3.56 (m, 1H), 3.67-3.77 (m, 2H), 3.98 (s, 3H), 6.41-6.43 (m, 1H), 6.52 (bs, 1H), 6.65 (d, 1H).

46-10		^{1}H-NMR (400MHz, $CDCl_3$, δ, ppm) : 1.72-1.96 (m, 2H), 1.98-2.10 (m, 2H), 2.63 (s, 3H), 2.73-2.84 (m, 2H), 3.40 (s, 3H), 3.34-3.42 (m, 2H), 3.44-3.49 (m, 1H), 3.55-3.57 (m, 2H), 3.64-3.66 (m, 2H), 3.83 (s, 3H), 6.41-6.43 (m, 1H), 6.53 (bs, 1H), 6.63 (d, 1H).
46-11		^{1}H-NMR (400MHz, $CDCl_3$, δ, ppm) : 1.22(t, 3H), 1.72-1.84 (m, 2H), 2.00-2.10 (m, 2H), 2.72-2.82 (m, 2H), 3.33-3.38 (m, 2H), 3.43-3.49 (m, 1H), 3.55 (q, 2H), 3.58-3.61 (m, 2H), 3.64-3.66 (m, 2H), 3.83 (s, 3H), 6.41-6.43 (m, 1H), 6.53 (bs, 1H), 6.63 (d, 1H).
46-12		^{1}H-NMR (400MHz, $CDCl_3$, δ, ppm) : 2.20 (s, 3H), 3.84 (s, 3H), 6.87 (d, 1H), 6.89 (dd, 1H), 6.95 (d, 2H), 7.09 (d, 1H), 7.48 (d, 2H). Rf (n-hexane : ethyl acetate = 1:1): 0.50.
46-13		^{1}H- NMR (400MHz, $CDCl_3$, δ, ppm): 1.49 – 1.59 (m, 3H), 1.70 – 1.95 (m, 6H), 2.00 – 2.20 (m, 2H), 2.60 – 2.90 (m, 7H), 3.50 – 3.60 (m, 3H), 3.83 (s, 3H), 3.85 - 3.91 (m, 1H), 6.41 (dd, 1H, J = 8.0, 2.5 Hz), 6.50 (d, 1H, J = 2.5 Hz), 6.63 (d, 1H, J = 8.0 Hz)

46-14		^{1}H-NMR (400MHz, DMSO-d6, δ, ppm) : 1.87-1.79(m, 1H), 2.22 (ddd, 1H), 2.48 (s, 3H), 3.05 (dd, 1H), 3.28-3.21 (m, 1H), 3.40-3.32 (m, 2H), 3.45 (dd, 1H), 3.84 (s, 3H), 6.06 (dd, 1H), 6.15 (d, 1H)), 6.66 (d, 1H)
46-15		^{1}H-NMR (400MHz, $CDCl_3$, δ, ppm): 2.35 - 2.73 (m, 4H), 2.68 - 2.75 (m, 1H), 2.82 - 2.93 (m, 2H), 3.14 – 3.19 (m, 1H), 3.29 - 3.40 (m, 2H), 3.50 - 3.60 (bs, 2H), 3.69 - 3.78 (m, 2H), 3.84 (s, 3H), 3.85 - 3.91 (m, 1H), 6.40 (dd, 1H, J = 8.0, 2.5 Hz), 6.50 (d, 1H, J = 2.5 Hz), 6.64 (d, 1H, J = 8.0 Hz)
46-16		^{1}H-NMR (400MHz, DMSO-d6, δ, ppm) : 1.95-1.85(m, 1H), 2.22-2.14 (m, 1H), 2.31 (s, 3H), 2.89-2.79 (m, 1H), 3.10 (t, 1H), 3.39-3.25 (m, 3H), 3.42 (t, 1H), 3.85 (s, 3H), 6.05 (dd, 1H), 6.14 (d, 1H), 6.67 (d, 1H)
46-17		^{1}H-NMR (400MHz, $CDCl_3$, δ, ppm) : 1.68-1.81 (m, 2H), 1.97-2.09 (m, 2H), 2.74-2.87 (m, 2H), 3.31-3.41 (m, 2H), 3.77-3.88 (m, 1H), 3.84 (s, 3H), 6.40-6.48 (m, 1H), 6.65 (bs, 1H), 6.64 (d, 1H).
46-18		^{1}H-NMR (400 MHz, $CDCl_3$), δ (ppm): 2.55-2.61(m, 4H), 2.80(t, 2H), 3.72-3.77(m, 4H), 3.81(s, 3H), 4.05(t, 2H), 6.24 (dd, 1H, *J*=8.56, 2.52Hz), 6.34 (d, 1H, *J*=2.52Hz), 6.68 (d, 1H *J*=8.56Hz). Rf = 0.31 (methanol : dichloromethane = 1:9).

46-19		^{1}H-NMR (400 MHz, $CDCl_3$), δ (ppm): 2.55-2.61(m, 4H), 2.78(t, 2H), 3.72-3.77(m, 4H), 3.82(s, 3H), 4.05(t, 2H), 6.35 (dd, 1H, *J*=8.56, 2.52Hz), 6.47 (d, 1H, *J*=2.52Hz), 6.63 (d, 1H *J*=8.56Hz). Rf = 0.61 (methanol : dichloromethane = 1:4).
46-20		^{1}H-NMR (DMSO), δ (ppm): 3.84 (s, 3H), 6.95-7.00 (m, 1H), 7.08-7.12 (m, 2H).
46-21		^{1}H-NMR (400MHz, $CDCl_3$): 1.47-1.34(m, 2H), 1.75-1.63 (m, 1H), 1.86-1.79(m, 2H), 2.64-2.58 (m, 2H), 3.28(d, 2H),3.61(d, 3H),3.87(s, 3H), 3.36(s, 1H),3.49-3.45 (m, 2H), 3.84(s,3H), 6.43(dd, 1H), 6.53(d, 1H) 6.64(d, 1H)
46-22		^{1}H-NMR (400MHz, $CDCl_3$): 1.13(t, 3H),2.49(dd, 2H), 2.68-2.59 (m, 4H),3.10 (t, 4H), 3.84(s,3H), 6.43(dd, 1H), 6.53(d, 1H) 6.65(d, 1H)
46-23		^{1}H-NMR (400MHz, $CDCl_3$): 1.78-1.68 (m, 2H), 1.99-1.89 (m, 2H), 2.36-2.20(m, 1H),2.67-2.50(m, 6H), 3.56-3.48(m, 2H),3.79-3.69(m, 4H), 3.84(s,3H), 6.42(dd, 1H), 6.52(d, 1H) 6.64(d, 1H)

46-24		^{1}H-NMR (400MHz, $CDCl_3$): 1.08 (s, 3H),1.10 (s, 3H), 2.69(t, 4H),2.72-2.68 (m, 1H), 3.08 (t, 4H), 3.83(s,3H), 6.42(dd, 1H), 6.53(d, 1H) 6.64(d, 1H)
46-25		^{1}H-NMR (400MHz, $CDCl_3$): 1.96-1.84 (m, 2H), 2.07-1.99 (m, 2H), 2.32-2.28(m, 1H), 2.70-2.60(m, 2H), 3.54-3.47(m, 2H), 3.84(s, 3H), 5.35-5.24(m,1H), 5.50-5.45 (m, 1H), 6.42(dd, 1H), 6.52(d, 1H) 6.64(d, 1H)
46-26		^{1}H-NMR (400MHz, $CDCl_3$): 2.18-2.03 (m, 2H), 3.28-3.19 (m, 2H), 3.39-3.31(m, 1H), 3.36(s, 3H), 3.49-3.42 (m, 1H), 3.85 (s,3H), 6.07(dd, 1H), 6.16(d, 1H), 6.66(d, 1H)
46-27		^{1}H-NMR (400MHz, $CDCl_3$): 1.48(s, 9H), 1.88-1.71 (m, 2H), 1.97-1.82 (m, 2H), 2.78 (s, 3H), 2.84-2.64(m, 2H), 3.55-3.48(m, 2H), 3.95(s,3H), 3.84 (s, 3H), 6.43(d, 1H), 6.52(bs, 1H), 6.64(d, 1H)
46-28		^{1}H-NMR (400MHz, $CDCl_3$): 3.02(s, 3H), 3.33(dd, 2H), 3.44(t, 2H), 3.74 (s, 2H), 3.83(s, 3H), 6.38(dd, 1H), 6.47(d 1H), 6.66(d, 1H)

46-29		^{1}H-NMR (400MHz, $CDCl_3$): 1.78-1.38 (m, 2H), 1.96-1.89 (m, 2H), 2.30(s, 3H),2.39-2.31(m, 1H), 2.55-2.42(m, 4H),2.71-2.56(m, 6H), 3.35-3.49 (m,2H), 3.83 (s, 3H), 6.41(dd, 1H), 6.52(d, 1H) 6.63(d, 1H)
46-30		^{1}H-NMR (400MHz, $CDCl_3$): 3.80(s, 3H), 3.82(s, 3H), 3.82 (s, 3H), 6.40(s, 1H), 6.54(s, 1H)
46-31		^{1}H-NMR (400MHz, $CDCl_3$): 3.20(t, 2H), 4.57(t, 2H), 6.55(dd, 1H), 6.70-6.65(m, 1H), 6.68 (d, 1H). Rf 040 (AcOEt)
46-32		^{1}H-NMR (400MHz, $CDCl_3$): 2.98 (t, 4H), 3.62 (bs, 2H), 3.79 (s, 3H), 3.81 (s, 3H), 3.87(t, 4H), 6.36(s, 1H), 6.53(s, 1H)
46-33		^{1}H-NMR (400MHz, $CDCl_3$): 2.37 (s, 3H), 2.61 (t, 4H), 3.27 (t, 4H), 3.88 (s, 3H), 3.95(s, 3H), 6.48(s, 1H), 7.56(s, 1H)

46-34		^{1}H-NMR (400MHz, $CDCl_3$): 1.05(t, 3H), 1.83 (ddd, 2H), 2.35(s, 3H), 2.58(t, 4H), 3.07(t, 4H), 3.94(t, 2H), 6.41(dd, 1H), 6.51(d, 1H), 6.65(d, 1H)
46-35		^{1}H-NMR (400MHz, $CDCl_3$): 1.28(s, 3H), 1.30 (s, 3H), 2.04 (s, 2H), 2.17(s, 3H), 2.84-2.72 (m, 2H), 3.20 (d, 2H), 3.86 (s, 3H), 6.41(d, 1H), 6.46(dd, 1H), 6.66(d, 1H),
46-36		^{1}H-NMR (400MHz, $CDCl_3$): 1.18(t, 3H), 2.39(dd, 2H), 3.07-2.98(m, 4H), 3.61(t, 2H), 3.78(t, 2H), 3.88(s, 3H), 6.41(dd, 1H), 6.51(d, 1H), 6.65(d, 1H)
46-37		^{1}H-NMR (400MHz, $CDCl_3$): 1.15(s, 3H), 1.16(s, 3H), 2.83(sept, 1H), 3.07-2.98(m, 4H), 3.73-3.64(m, 2H), 3.83-3.76(m, 2H), 3.84(s, 3H), 6.41(dd, 1H), 6.51(d, 1H), 6.65(d, 1H)

46-38		^{1}H-NMR (400MHz, $CDCl_3$): 2.84(d, 3H), 3.02(t, 4H), 3.51(t, 4H), 3.84(s, 3H), 4.48-4.38(m, 1H), 6.41(dd, 1H), 6.51(d, 1H), 6.65(d, 1H)
46-39		^{1}H-NMR (400MHz, $CDCl_3$): 1.99-1.81 (m, 2H), 2.23-2.12(m, 2H), 2.69-2.58(m, 2H), 2.84 (d, 3H), 3.54-3.45(m, 2H), 3.84(s, 3H), 5.55-5.45(m, 1H), 6.42(dd, 1H), 6.52(d, 1H), 6.64(d, 1H)
46-40		^{1}H-NMR (400MHz, $CDCl_3$): 1.53 (s, 6H), 2.11(s, 3H), 3.05(s, 2H), 3.28(t, 2H), 3.64(t, 2H), 3.86 (s, 3H), 6.26 (dd, 1H), 6.33(d, 1H), 6.67(d, 1H)
46-41		^{1}H-NMR (400MHz, $CDCl_3$): 2.55-2.41 (m, 4H), 2.63 (t, 2H), 3.13(t, 2H), 3.77-3.68(m, 4H), 3.83(s, 3H), 6.15(dd, 1H), 6.25 (d, 1H), 6.62(d, 1H)

46-42		^{1}H-NMR (400MHz, $CDCl_3$): 2.05-2.00 (m, 2H), 2.39(t, 2H), 3.57(t, 2H), 3.64 (t, 2H), 3.83(s, 3H), 4.04(t, 2H), 6.32 (dd, 1H), 6.44(d, 1H), 6.63(d, 1H)
46-43		^{1}H-NMR (400MHz, $CDCl_3$): 2.13 (s, 3H), 3.53-3.46 (m, 2H), 3.65-3.55(m, 4H), 3.71-3.66(m, 2H), 3.88 (s, 3H), 6.67(d, 1H), 6.87(dd, 1H), 6.95(d, 1H)
46-44		^{1}H-NMR (400MHz, $CDCl_3$): 3.73-3.61(m,8H), 3.87(s, 3H), 6.65(d, 1H), 6.86(dd, 1H), 6.95(d, 1H)
46-46		^{1}H-NMR (400MHz, $CDCl_3$): 1.17 (s, 3H), 1.19(s, 3H), 2.69(t, 4H), 3.04 (s, 2H), 3.08(t, 4H),4.15-4.07(m, 1H), 6.41 (dd, 1H), 6.51(d, 1H), 6.65(d, 1H), 7.01-6.94(m 1H)

46-47		^{1}H-NMR (400MHz, $CDCl_3$): 3.35-3.28 (m, 2H), 3.53-3.46(m, 2H), , 3.76 (s, 2H), 3.84(s, 3H), 5.92-5.83 (m, 1H), 6.40(dd, 1H), 6.48(d, 1H), 6.67 (d,1H)
46-48		^{1}H-NMR (400MHz, $CDCl_3$): 2.09-2.00 (m, 2H), 2.25-2.15 (m, 2H), 3.29-3.20 (m, 2H), 3.51-3.40(m, 4H), 3.85(s, 3H), 4.62-4.55(m, 1H), 6.08(d, 1H), 6.18(d, 1H), 6.67(d, 1H)
46-49		^{1}H-NMR (400MHz, $CDCl_3$): 1.52-1.40 (m, 2H), 1.90-1.84 (m, 2H), 2.68-2.59 (m, 2H), 3.51-3.45(m, 2H), 3.84(s, 3H), 6.44(dd, 1H), 6.54(d, 1H), 6.64(d, 1H)
46-50		^{1}H-NMR (400MHz, $CDCl_3$) : 2.14 (s, 3H), 2.66 (s, 6H), 6.44 (d, 1H), 6.54 (d, 1H), 6.98 (t, 1H).
46-51		^{1}H-NMR (400MHz, $CDCl_3$) :2.63 (s, 3H), 7.49-7.45 (m, 1H), 7.74-7.62 (m, 2H), 7.76 (dd, 1H), 8.24(d, 1H), 8.77-8.64 (m, 2H).
46-52		^{1}H-NMR (400MHz, $CDCl_3$) :3.84 (s, 3H), 3.88 (s, 3H), 6.78(d, 1H), 6.83 (d, 1H), 7.00-6.89 (m, 3H), 7.45 (d, 1H).

46-53		^{1}H-NMR (400MHz, $CDCl_3$) :1.40 (t, 3H), 3.03 (t, 4H), 3.84 (t, 4H), 4.00 (q, 2H), 6.27 (dd, 1H), 6.38 (d, 1H), 6.71 (dd, 1H),
46-54		^{1}H-NMR (400MHz, $CDCl_3$) :1.26 (t, 3H), 3.02 (t, 4H), 3.85 (t, 4H), 4.05 (q, 2H), 6.40(dd, 1H), 6.49 (d, 1H), 6.66 (d, 1H),
46-55		^{1}H-NMR (400MHz, $CDCl_3$) :3.44 (s, 3H), 3.73 (s, 3H), 3.74-3.68 (m, 2H), 3.95-3.85 (m, 2H), 4.10-4.05 (m, 2H), 6.21 (dd, 1H), 6.32(d, 1H), 6.75 (d, 1H).
46-56		^{1}H-NMR (400MHz, $CDCl_3$) :2.35-2.26 (m, 1H), 3.74 (s, 3H), 3.93-3.86 (m, 2H), 4.09-4.07 (m, 2H), 6.25 (dd, 1H), 6.34(d, 1H), 6.76 (d, 1H).
46-57		^{1}H-NMR (400MHz, $CDCl_3$) :1.40 (t, 3H), 3.71 (s, 3H), 4.00 (q, 2H), 6.22(dd, 1H), 6.33 (d, 1H), 6.69 (d, 1H).
46-58		^{1}H-NMR (400MHz, $CDCl_3$) :1.32(d, 6H), 3.73(s, 3H), 3.85-3.71 (m, 2H), 4.37 (sept, 1H), 6.22 (dd, 1H), 6.32 (d, 1H), 6.72 (d, 1H).

46-59		^{1}H-NMR (400MHz, $CDCl_3$) :1.04 (t, 3H), 1.80 (ddd, 2H), 3.72 (s, 3H), 3.85-3.75 (m, 2H), 3.90 (t, 2H), 6.22 (dd, 1H), 6.33 (d, 1H), 6.69 (d, 1H).
46-60		^{1}H-NMR (400MHz, $CDCl_3$) :2.94 (s, 6H), 3.89 (s, 3H), 6.16 (dd, 1H), 6.25 (d, 1H), 6.72 (d, 1H).
46-61		^{1}H-NMR (400MHz, $CDCl_3$) :3.91(s, 3H), 6.87 (d, 1H), 7.02 (dd, 1H), 7.05 (d, 1H), 7.44 (dd, 2H), 8.59 (dd, 2H).
46-62		^{1}H-NMR (400MHz, $CDCl_3$) :3.91 (s, 3H), 6.88 (d, 1H), 6.96-6.93(m, 1H), 7.31(ddd, 1H), 7.83-7.80 (m, 1H), 8.51(dd, 1H), 8.78(dd, 1H).
46-63		^{1}H-NMR (400MHz, $CDCl_3$) :3.91 (s, 3H), 6.87 (dd, 1H), 7.16(ddd, 1H), 7.34(dd, 1H), 7.43 (d, 1H), 7.72-7.64 (m, 2H), 8.63-8.61 (m, 1H).
46-64		mp 148.6°C; ^{1}H-NMR (500MHz, $CDCl_3$) δ (ppm): 1.63 (m; 2H), 1.99 (m; 2H), 2.27 (m; 1H), 2.60 (m; 6H), 3.52 (m; 2H), 3.71 (m; 4H), 3.78 (s; 3H), 6.36 (dd; 1H); 6.52 (d; 1H), 6.73 (d; 1H).

46-65		

47

Preparation of 4-(3-amino-4-methylbenzoyl)-piperazine-1-carboxylic acid tert-butyl ester



To a solution of 4-methyl-3-nitro-benzoic acid (300 mg, 2.76 mmol), N-butoxycarbonyl-piperazine (340 mg, 1.83 mmol) in DMF (3.0 mL), triethylamine (300 μL, 3.59 mmol), TBTU (800 mg, 2.49 mmol) and HOAt (270.5 mg,1.99 mmol) are added and stirred at room temperature for 24 hours. The mixture is poured into water and extracted twice with ethyl acetate. The organic layer is washed with water and then brine, dried over magnesium sulfate, and evaporated in vacuo. The residue is purified with silica gel column chromatography (n-hexane : ethyl acetate = 5 : 1) to afford 4-(4-methyl-3- nitrobenzoyl)-piperazine-1-carboxylic acid tert-butyl ester as a colorless solid.

^{1}H-NMR (δ, ppm) : 1.47 (s,9H), 2.64 (s, 3H), 3.88-3.28 (m, 8H), 7.42 (d, 1H), 7.56 (dd, 1H), 8.03 (d, 1H). Rf (hexane : ethyl acetate = 10:1): 0.13.

The title compound is obtained by reduction with hydrogen over 10% palladium on charcoal in methanol solution.

48

Preparation of 4-(3-amino-4-methylphenyl)-morpholine



To a suspension of 4-bromo-1-methyl-2-nitrobenzene (225 mg, 1.04 mmol), morpholine (125 μL, 1.25 mmol), and cesium carbonate (474.4 mg, 1.46 mmol) in toluene, palladium diacetate (31.2 mg, 0.139 mmol) and 2-(di-t-butylphosphino)biphenyl (125 mg, 0.403 mmol) are added and stirred at 100°C for 5 hours. After cooling, the mixture is filtered to remove insoluble material. The filtrate is poured into water and extracted with ethyl acetate twice. The organic layer is washed with water and then brine, dried over magnesium sulfate, and evaporated in

vacuo. The residue is purified with silica gel column chromatography (n-hexane : ethyl acetate = 5 : 1) to afford 4-(4-methyl-3-nitrophenyl)-morpholine as a yellow solid.

1H-NMR (δ, ppm) : 2.50 (s, 3H), 3.19-3.17 (m, 4H), 3.88-3.86 (m, 4H), 7.04 (dd, 1H), 7.21 (d, 1H), 7.47 (d, 1H). Rf (hexane : ethyl acetate = 5:1): 0.20.

The title compound is obtained by reduction with hydrogen over 10% palladium on charcoal in methanol solution.

49

Preparation of 2-[5-chloro-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-benzoic acid



To a solution of 1.0 g (3.37 mmol) of 2-(2,5-dichloro-pyrimidin-4-ylamino)-*N*-methyl-benzamide in 15 mL of acetic acid are added 2-methoxy-4-morpholinoaniline dihydrochloride (1.9 g, 6.73 mmol) and 6.0 mL of 1N ethanolic solution of hydrogen chloride (6.0 mmol). After the reaction mixture is stirred at 120°C for 16 hours and cooled to room temperature, aqueous $NaHCO_3$ solution is added to adjust the acidity between pH 5 and pH 6. The resulting precipitate is collected by a filtration and dried under reduced pressure to give 2-[5-chloro-2-(2-methoxy-4-morpholin-4-yl-phenyl-amino)-pyrimidin-4-ylamino]-benzoic acid (970 mg, 2.12 mmol, 63%) as ivory solid.

NMR (400MHz, DMSO-d6, δ): 3.10-3.20 (m, 4H), 3.78 (s, 3H), 3.70-3.80 (m, 4H), 6.52 (dd, 1H, J = 8.56, 2.52 Hz), 6.67 (d, 1H, J = 2.52 Hz), 7.08 (dd, 1H, J = 8.04, 8.04 Hz), 7.39 (d, 1H, J = 8.56 Hz), 7.35-7.45 (m, 1H), 7.99 (dd, 1H, J = 8.04, 1.52Hz), 8.14 (s, 1H), 8.28 (s, 1H) 8.70-8.80 (m, 1H).

Example 50: Sulfonamide moieties are prepared as follows:

Preparation of 2-amino-4-chloro-5-methyl-benzenesulfonyl chloride

To a solution of 2-amino-5-chloro-4-methyl-benzenesulfonic acid (3.0 g, 1.35 mmol) in dichloroethane (10 mL) is added sulfuryl chloride (4.4 mL, 3.83 mmol) and stirred at 60°C. After one hour, thionyl chloride (1.3 mL) is added and the mixture is further stirred at 100°C for 7.0 hours. The mixture is poured into iced water and extracted with ether three times. The organic layer is washed with water and then brine, dried over sodium sulfate, and evaporated in vacuo.

^{1}H-NMR (δ, ppm) : 2.35 (s, 3H), 6.68 (s, 1H), 7.75 (s, 1H).

This substituted sulfonyl chloride is reacted with a suitable amine. On reaction e.g. with methylamine, 2-amino-5-chloro-4,N-dimethylbenzenesulfonamide is formed.

Example 51

Preparation of 2-[5-bromo-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-N, N-dimethyl-benznensulfonamide



To a solution of 2-[5-Bromo-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-N-methyl-benzenesulfonamide (Ex3-19) (1.0g, 1.82mmol) in DMF (10mL), potassium carbonate (300mg, 2.17mmol) and iodomethane (116μl, 1.86mmol) are added. The resulting suspension is stirred at 50°C for 1h. To the reaction mixture, water is added and extracted with ethyl acetate three times. The organic layer is washed with water, dried over sodium sulfate, and concentrated in vacuo. The residue is purified by aluminum oxide column chromatography (AcOEt) to afford the title compound (728mg, 71% yield).

NMR (400MHz, $CDCl_3$, δ): 2.74 ((s, 6H), 3.05-3.18 (m, 4H), 3.84-3.93 (m, 4H), 3.88 (s, 3H), 6.43 (dd, 1H), 6.53 (d, 1H), 7.24 (m, 1H), 7.31 (s, 1H), 7.56 (m, 1H), 7.87 (dd, 1H), 8.05 (d, 1H), 8.21 (s, 1H), 8.49 (d, 1H), 8.49 (d, 1H), 9.27 (s, 1H). Rf: 0.23 (AcOEt:Hexane=1:1).

Example 52

Preparation of 2-[5-Bromo-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-5-fluoro-N-methyl-benzenesulfonamide



Preparation of 7-Fluoro-1,1-dioxo-1,4-dihydro-2H-1 λ^6-benzo[1,2,4]thiadiazin-3-one

To a solution of chlorosulfonylisocyanate (1.2mL, 13.5mmol) in nitroethane (10mL), 4-fluoroaniline (1.0g, 8.97mmol) is added dropwise at 0°C and the reaction mixture is stirred for 30min. To the solution, aluminum chloride (1.3g, 9.87mmol) is added at 0°C and the mixture is stirred at 100°C for 1 hour. After cooling to room temperature, water is added and the mixture is extracted with ethyl acetate twice. The organic layer is washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The resulting solids are collected by a filtration and wahed with ether to give slightly gray solids (803.9mg, 41%).

NMR (400MHz, DMSO-d6, δ): 7.22-7.28 (m, 1H), 7.45-7.57 (m, 1H), 7.60 (m, 1H), 11.15-11.30 (m, 1H). Rf: 0.43 (MeOH:AcOEt=1:5).

Preparation of 7-Fluoro-2-methyl-1,1-dioxo-1,4-dihydro-2H-1 λ^6-benzo[1,2,4]thiadiazin-3-one

To a solution of 7-Fluoro-1,1-dioxo-1,4-dihydro-2H-1- λ^6-benzo[1,2,4]thiadiazin-3-one (5.19g, 24.0mmol) in DMF (50mL), sodium hydride (1.04g, 26.0mmol) and iodomethane (1.5mL, 24.0mmol) are added successively and the mixture is stirred for 1 hour at 70°C. After cooling to room temperature, the mixture is poured into water and the precipitate is collected by a filtration and washed with water and hexane, successively, to give slightly gray solids (5.38g, 94%).

NMR (400MHz, DMSO-d6, δ): 3.32 (s, 3H), 7.44 (dd, 1H), 7.75 (ddd, 1H), 7.94 (dd, 1H).

Rf (MeOH:AcOEt = 1:5): 0.21. Rf: 0.39 (Hexane:AcOEt=1:1).

Preparation of 2-Amino-5-fluoro-N-methyl-benzenesulfonamide

6.79g of 7-Fluoro-2-methyl-1,1-dioxo-1,4-dihydro-2H-1 λ^6-benzo[1,2,4]thiadiazin-3-one (29.5mmol) is dissolved in 20% aq. sodium hydroxide and the resulting solution is stirred at 100°C for 13.5 hours. The mixture is cooled to room temperature and poured into water. 78mL of 5M HCl aq. is added and the precipitate is collected by a filtration and washed with water to afford slightly purple solids (3.96g, 65%).

NMR (400MHz, $CDCl_3$, δ): 2.60 (d, 3H), 4.55-4.82 (m, 3H), 6.74 (dd, 1H), 7.05-7.12 (m, 1H), 7.45 (dd, 1H). Rf: 0.41 (Hexane:AcOEt=1:1).

2-(5-Bromo-2-chloro-pyrimidin-4-ylamino)-5-fluoro-N-methyl-benzenesulfonamide

The reaction of pyrimidine with 2-Amino-5-fluoro-N-methyl-benzenesulfonamide is performed in the same manner described in example B.

NMR (400MHz, $CDCl_3$, δ): 2.67 (d, 3H), 4.56 (m, 1H), 7.36-7.45 (m, 1H), 7.68 (dd, 1H), 8.39 (s, 1H), 8.42 (dd, 1H), 9.26 (s, 1H). Rf 0.59 (Hexane:AcOEt = 1:1).

2-[5-Bromo-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-5-fluoro-N-methyl-benzenesulfonamide

The introduction of substituted aniline is performed according to the manner described in Example A.

NMR (400MHz, $CDCl_3$, δ): 2.65 (d, 3H), 3.09-3.16 (m, 4H), 3.87 (s, 3H), 4.50 (q, 1H), 6.41 (dd, 1H), 6.52 (d, 1H), 7.25-7.33 (m, 2H), 7.69 (dd, 1H), 7.95 (d, 1H), 8.20 (s, 1H), 8.37 (dd, 1H), 8.70 (s, 1H). Rf 0.30 (Hexane:AcOEt = 1:1)

Example 53:

Compound Number	Structure	Physical Data ^{1}H NMR 400 MHz (DMSO-d_6) and/or MS (m/z)
5		^{1}H NMR 400 MHz ($CDCl_3$) δ 12.5 (s, br, 1H), 10.3 (s, 1H), 8.39 (d, 1H, J = 8.38 Hz), 7.97 (s, 1H), 7.87 (dd, 1H, J = 1.63, 7.55 Hz), 7.49 (d, 1H, J = 8.69 Hz), 6.54 (d, 1H, J = 2.49 Hz), 6.43 (dd, 1H, J = 2.51, 8.73 Hz), 4.70 (s, 1H), 4.04 (q, 2H, J = 6.98 Hz), 3.51 (m, 2H), 3.29 (d, 1H, J = 19.2 Hz), 3.18 (m, 2H), 2.89 (d, 3H, J = 3.26 Hz), 2.77 (s, 6H), 2.39 (m, 2H), 2.22 (m, 2H), 1.40 (t, 3H, J = 6.97 Hz). MS *m/z* 561.4 (M + 1)
6		MS *m/z* 589.4 (M + 1)

7		MS *m/z* 633.4/635.4 (M + 1).
8		MS *m/z* 591.3/593.3 (M + 1).
9		MS *m/z* 547.4 (M + 1).
10		^{1}H NMR 400 MHz (acetone-d_6) δ 9.45 (br, 1H), 8.88 (br, 1H), 8.23 (m, 1H), 8.07 (s, 1H), 7.83 (m, 1H), 7.72 (dd, 1H, J = 1.25, 7.96 Hz), 7.45 (m, 1H), 7.14 (m, 2H), 6.86 (m, 1H), 6.79 (br, 1H), 6.62 (m, 1H), 6.13 (m, 1H), 3.97 (t, 2H, J = 6.98 Hz), 3.63 (m, 2H), 3.21 (m, 2H), 2.44 (m, 1H), 2.34 (s, 3H), 1.99 (m, 4H), 1.17 (t, 3H, J = 6.98 Hz). MS *m/z* 560.4 (M + 1).
11		MS *m/z* 561.4 (M + 1).
12		MS *m/z* 591.3/593.3 (M + 1).

13  MS *m/z* 547.4 (M + 1).

14  MS *m/z* 559.4 (M + 1).

15  MS *m/z* 564.5 (M + 1).

16  MS *m/z* 575.4 (M + 1).

17  MS *m/z* 605.3/607.3 (M + 1).

18		MS *m/z* 561.4 (M + 1).
19		MS *m/z* 532.4 (M + 1).
20		^{1}H NMR 400 MHz (acetone-d_6) δ 8.60 (d, 1H, J = 8.27 Hz), 8.40 (s, 1H), 8.00 (dd, J = 1.55, 7.95 Hz), 7.76 (m, 2H), 7.49 (m, 1H), 7.08 (d, J = 8.94 Hz, 1H), 6.84 (dd, J = 3.00, 8.91 Hz, 1H), 4.50 (t, J = 4.99 Hz, 2H), 4.08 (m, 2H), 4.00 (m, 2H), 3.90 (s, 3H), 3.78 (m, 4H), 3.37 (m, 4H), 1.76 (m, 2H), 0.99 (t, J = 7.44 Hz, 3H). MS *m/z* 562.4 (M + 1).

21 

MS *m/z* 560.4 (M + 1).

22 

^{1}H NMR 600 MHz (acetone-d_6) δ 11.20 (br, 1H), 9.75 (d, J = 15.25 Hz, 1H), 8.46 (m, 2H), 8.04 (dd, J = 1.12, 7.93 Hz, 1H), 7.71 (m, 1H), 7.69 (m, 1H), 7.47 (t, J = 7.63 Hz, 1H), 7.06 (m, 1H), 7.02 (m, 1H), 4.07 (m, 2H), 3.99 (s, 3H), 3.77 (m, 2H), 3.67 (m, 1H), 3.27 (m, 2H), 3.13 (t, J = 12.2 Hz, 2H), 2.85 (m, 2H), 2.46 (m, 2H), 2.26 (m, 3H), 2.08 (m, 3H), 1.95 (m, 1H), 1.75 (m, 1H), 1.66 (m, 1H), 0.89 (d, J = 6.65 Hz, 6H). MS *m/z* 672.4/674.4 (M + 1).

23 

MS *m/z* 600.4 (M + 1).

24 

MS *m/z* 586.4 (M + 1).

25 

MS *m/z* 642.5 (M + 1).

26 

MS *m/z* 640.5 (M + 1).

27 

MS *m/z* 630.3/632.3 (M + 1).

28 

MS *m/z* 633.4/635.3 (M + 1).

29 

MS *m/z* 603.4 (M + 1).

30		MS *m/z* 601.4 (M + 1).
31		MS *m/z* 603.4 (M + 1).
32		MS *m/z* 601.4 (M + 1).
33		MS *m/z* 575.4 (M + 1).
34		MS *m/z* 561.4 (M + 1).
35		^{1}H NMR 600 MHz (acetone-d_6) δ 8.47(d, J = 7.13, 1H), 8.43 (s, 1H), 8.09 (d, J = 7.85 Hz, 1H), 7.83 (m, 1H), 7.73 (t, J = 7.67 Hz, 1H), 7.50 (m, 1H), 6.87 (m, 1H), 6.71 (m, 1H), 5.46 (d, J = 31.2 Hz, 1H), 4.22 (m, 3H), 3.55 (m, 5H), 2.51 (m, 1H), 2.49 (m, 1H), 2.21 (m, 1H), 1.50 (m, 6H), 1.10 (d, J = 6.56 Hz, 6H) .MS *m/z* 575.4 (M + 1).

36		MS *m/z* 574.4 (M + 1).
37		MS *m/z* 562.4 (M + 1).
38		MS *m/z* 560.4 (M + 1).
39		MS *m/z* 546.4 (M + 1).
40		MS *m/z* 560.4 (M + 1).
41		MS *m/z* 559.4 (M + 1).
42		MS *m/z* 547.4 (M + 1).

43		MS *m/z* 559.4 (M + 1).
44		MS *m/z* 600.4 (M + 1).
45		MS *m/z* 586.4 (M + 1).
46		MS *m/z* 600.4 (M + 1).
47		MS *m/z* 599.4 (M + 1).
48		MS *m/z* 587.4 (M + 1).

49



^{1}H NMR 600 MHz (acetone-d_6) δ 10.35 (m, 1H), 8.72 (s, br, 1H), 8.42 (s, 1H), 8.00 (d, J = 7.93 Hz, 1H), 7.73 (m, 1H), 7.64 (m, 1H), 7.50 (t, J = 7.77 Hz, 1H), 6.55 (s, 1H), 6.43 (d, J = 8.51 Hz, 1H), 4.31 (m, 1H), 4.22 (q, J = 6.93 Hz, 2H), 3.97 (m, 2H), 3.80 (t, J = 8.45 Hz, 1H), 3.58 (q, J = 8.38 Hz, 1H), 3.36 (m, 1H), 3.17 (s, 1H), 2.78 (m, 1H), 2.66 (m, 1H), 2.15 (m, 2H), 1.73 (d, J = 12.9 Hz, 2H), 1.59 (d, J = 12.9 Hz, 1H), 1.55 (m, 2H), 1.43 (m, 3H), 1.35 (m, 2H), 1.25 (m, 1H). MS *m/z* 599.4 (M + 1).

50



MS *m/z* 562.4 (M + 1).

51



MS *m/z* 614.5 (M + 1).

52



MS *m/z* 640.5 (M + 1).

53



MS *m/z* 640.5 (M + 1).

54



MS *m/z* 628.5 (M + 1).

55



MS *m/z* 600.4 (M + 1).

56



MS *m/z* 644.4/646.4 (M + 1).

57



MS *m/z* 613.5 (M + 1).

58  MS *m/z* 578.5 (M + 1).

59  MS *m/z* 560.4 (M + 1).

60  MS *m/z* 586.4 (M + 1).

61  MS *m/z* 586.4 (M + 1).

62  MS *m/z* 574.4 (M + 1).

63



MS *m/z* 546.4 (M + 1).

64



MS *m/z* 590.4/592.4 (M + 1).

65



MS *m/z* 559.4 (M + 1).

66



^{1}H NMR 600 MHz (CD_3OD) δ 8.65 (br, 1H), 8.03 (br, 1H), 7.78 (d, J = 7.76 Hz, 1H), 7.49 (br, 1H), 7.30 (s, 1H), 6.38 (m, 1H), 6.33 (dd, J = 1.69, 8.64 Hz, 1H), 4.12 (q, J = 6.96 Hz, 2H), 4.06 (m, 1H), 3.71 (dd, J = 6.68, 10.74 Hz, 1H), 3.66 (m, 1H), 3.56 (dd, J = 4.71, 10.76 Hz, 1H), 3.42 (m, 3H), 3.22 (q, J = 7.28 Hz, 2H), 2.57 (m, 1H), 2.26 (m, 1H), 1.39 (t, J = 7.28 Hz, 3H), 1.34 (t, J = 6.96 Hz, 3H). MS *m/z* 524.4 (M + 1).

67		MS *m/z* 574.4 (M + 1).
68		^{1}H NMR 600 MHz (CD_3OD) δ 8.23 (s, 1H), 8.18 (d, J = 8.16 Hz, 1H), 7.98 (d, J = 8.44 Hz, 2H), 7.68 (m, 1H), 7.43 (m, 1H), 7.22 (d, J = 2.29 Hz, 1H), 6.97 (dd, J = 2.30, 8.81 Hz, 1H), 4.20 (q, J = 6.99 Hz, 2H), 3.77 (m, 2H), 3.58 (m, 2H), 2.75 (d, J = 7.03 Hz, 2H), 2.72 (m, 1H), 2.18 (m, 4H), 1.47 (t, J = 6.97 Hz, 3H), 0.75 (m, 1H), 0.30 (m, 2H), 0.00 (m, 2H). MS *m/z* 600.4 (M + 1).
69		MS *m/z* 600.4 (M + 1).
70		MS *m/z* 588.4 (M + 1).
71		MS *m/z* 560.4 (M + 1).

72 

MS *m/z* 604.3/606.3 (M + 1).

73 

MS *m/z* 573.4 (M + 1).

74 

MS *m/z* 538.4 (M + 1).

75 

MS *m/z* 573.4 (M + 1).

76 

MS *m/z* 578.5 (M + 1).

77		MS *m/z* 613.5 (M + 1).
78		MS *m/z* 511.4 (M + 1).
79		MS *m/z* 525.5 (M + 1).
80		MS *m/z* 524.5 (M + 1).
81		MS *m/z* 510.5 (M + 1).
82		MS *m/z* 525.4 (M + 1).

83 

MS *m/z* 627.5 (M + 1).

84 

^{1}H NMR 600 MHz (CD_3OD) δ 9.18 (m, 2H), 8.05 (d, J = 7.93 Hz, 1H), 7.93 (t, J = 7.64 Hz, 1H), 7.78 (m, 1H), 7.68 (m, 2H), 7.58 (t, J = 7.54 Hz, 1H), 4.72 (s, 2H), 4.07 (d, J = 12.4 Hz, 2H), 3.34 (br, 4H), 2.96 (t, J = 12.3 Hz, 2H), 2.87 (s, 6H), m, 2H), 2.28 (s, 1H), 2.00 (br, 7H), 1.81 (br, 2H). MS *m/z* 627.5 (M + 1).

85 

MS *m/z* 591.5 (M + 1).

86 

MS *m/z* 601.5 (M + 1).

87		MS *m/z* 602.4 (M + 1).
88		MS *m/z* 566.5 (M + 1).
89		MS *m/z* 656.5 (M + 1).
90		^{1}H NMR 600 MHz (CD_3OD) δ 8.16 (d, J = 8.16 Hz, 1H), 8.23 (s, 1H), 7.94 (dd, J = 1.42, 7.98 Hz, 1H), 7.79 (d, J = 9.24 Hz, 1H), 7.72 (m, 1H), 7.48 (m, 1H), 7.15 (d, J = 2.53 Hz, 1H), 7.03 (dd, J = 2.58, 8.91 Hz, 1H), 4.00 (s, 1H), 3.82 (d, J = 12.63 Hz, 2H), 3.50 (s, br, 4H), 3.29 (m, 5H), 3.19 (m, 1H), 2.96 (s, 3H), 2.73 (s, 6H), 2.25 (d, J = 12.40 Hz, 2H), 2.03 (m, 2H), 1.40 (s, 9H). MS *m/z* 657.5 (M + 1).

91



MS *m/z* 621.6 (M + 1).

92



^{1}H NMR 600 MHz (CD_3OD) δ 8.31 (d, J = 7.65 Hz, 1H), 8.19 (s, 1H), 7.94 (dd, J = 1.33, 7.96 Hz, 1H), 7.67 (t, J = 7.70 Hz, 1H), 7.49 (t, J = 7.68 Hz, 1H), 7.44 (d, J = 8.56 Hz, 1H), 6.83 (d, J = 1.37 Hz, 1H), 6.65 (d, J = 8.66 Hz, 1H), 4.69 (m, 1H), 4.11 (br, 2H), 3.91 (d, J = 12.68 Hz, 2H), 3.83 (br, 2H), 3.58 (br, 2H), 3.46 (m, 1H), 3.23 (br, 2H), 3.00 (t, J = 12.19 Hz, 2H), 2.73 (s, 6H), 2.33 (d, J = 12.14 Hz, 2H), 1.97 (m, 2H), 1.30 (d, J = 6.04 Hz, 6H).
MS *m/z* 630.5 (M + 1).

93



MS *m/z* 629.5 (M + 1).

94



MS *m/z* 594.5 (M + 1).

95		MS *m/z* 471.1 (M + 1).
96		^{1}H NMR 600 MHz (DMSO-d_6) δ 11.7 (bs, 1H), 11.14 (bs, 1H), 9.50 (b, 2H), 7.89 (d, 1H, J = 9.1 Hz), 7.72 (m, 2H), 7.55 (m, 2H), 7.18 (m, 1H), 6.62 (s, 1H), 6.46 (m, 1H), 4.06 (q, 2H, J = 6.6 Hz), 3.73 (t, 4H, J = 4 .8 Hz), 3.11 (m, 4H), 2.40 (m, 3H), 1.24 (m, 3H); MS *m/z* 485.1 (M + 1).
97		MS *m/z* 577.1 (M + 1).
98		^{1}H NMR 600 MHz (DMSO-d_6) δ 9.97 (bs, 1H), 9.34 (s, 1H), 8.48 (bs, 1H), 8.34 (bs, 1H), 8.28 (s, 1H), 7.80 (q, 1H, J = 4.8 Hz), 7.77 (d, 1H, J = 7.8 Hz), 7.48 (m, 1H), 7.39 (d, 1H, J = 8.4 Hz,), 7.25 (t, 1H, J = 7.2 Hz), 6.71 (s, 1H), 6.49 (d, 1H, J = 8.4 Hz), 3.93 (t, 2H, J = 6.0 Hz), 3.85 (d, 2H, J = 12 Hz), 3.54 (d, 2H, J = 12 Hz), 3.18 (q, 2H, J = 9.0 Hz), 2.94 (t, 2H, J = 11 Hz), 2.88 (s, 3H), 2.42 (d, 3H, J = 4.8 Hz), 1.64 (m, 2H), 0.85 (t, 3H, J = 7.2 Hz); MS *m/z* 590.1 (M + 1).
99		MS *m/z* 578.1 (M + 1).
100		MS *m/z* 593.1 (M + 1).

101		^{1}H NMR 600 MHz (DMSO-d_6) δ 10.0 (bs, 1H), 9.34 (s, 1H), 8.47 (bs, 1H), 8.33 (bs, 1H), 8.30 (s, 1H), 7.79 (s, 1H), 7.78 (d, 1H, J = 7.2 Hz), 7.50 (m, 2H), 7.27 (t, 1H, J = 7.8 Hz,), 6.75 (s, 1H), 6.53 (d, 1H, J = 7.8 Hz), 4.12 (t, 2H, J = 4.8 Hz), 3.84 (d, 2H, J = 12 Hz), 3.59 (t, 2H, J = 4.8 Hz), 3.53 (d, 2H, J = 12 Hz), 3.23 (s, 3H), 3.17 (q, 2H, J = 9.0 Hz), 2.94 (t, 2H, J = 11 Hz), 2.88 (s, 3H), 2.43 (d, 3H, J = 4.8 Hz); MS *m/z* 606.1 (M + 1).
102		MS *m/z* 594.1 (M + 1).
103		MS *m/z* 547.1 (M + 1).
104		MS *m/z* 533.1 (M + 1).
105		MS *m/z* 496.4 (M + 1).
106		^{1}H NMR 400 MHz (DMSO-d_6) δ 9.35 (s, 1H), 9.02 (s, 1H), 8.52 (s, 1H), 8.17 (bs, 1H), 7.80 (m, 2H), 7.45 (bs, 1H), 7.29 (m, 2H), 6.66 (s, 1H), 6.47 (d, 1H, J = 8.0 Hz), 4.02 (q, 2H, J = 7.2 Hz), 3.76 (t, 4H, J = 4.8 Hz), 3.14 (t, 4H, J = 4.8 Hz), 2.41 (d, 3H, J = 4.0 Hz), 1.23 (t, 3H, J = 7.2 Hz); MS *m/z* 510.4 (M + 1).
107		MS *m/z* 524.5 (M + 1).

108		^{1}H NMR 600 MHz (DMSO-d_6) δ 9.61 (s, 1H), 9.10 (bs, 1H), 8.35 (bs, 1H), 8.18 (s, 1H), 7.77 (m, 2H), 7.41 (bs, 1H), 7.26 (t, 1H, J = 7.2 Hz), 7.15 (d, 1H, J = 7.8 Hz), 6.89 (s, 1H), 6.85 (d, 1H, J = 9.6 Hz), 3.77 (t, 4H, J = 4.8 Hz), 3.15 (t, 4H, J = 4.8 Hz), 2.52 (q, 2H, J = 7.2 Hz), 2.41 (d, 3H, J = 4.8 Hz), 1.06 (t, 3H, J = 7.2 Hz); MS *m/z* 503.2 (M + 1).
109		MS *m/z* 547.2 (M + 1).
110		MS *m/z* 494.2 (M + 1).
111		MS *m/z* 557.3 (M + 1).
112		MS *m/z* 559.3 (M + 1).
113		MS *m/z* 561.2 (M + 1).
114		MS *m/z* 508.2 (M + 1).
115		MS *m/z* 529.2 (M + 1).

116		^{1}H NMR 400 MHz (DMSO-d_6) δ 9.91 (bs, 1H), 9.50 (s, 1H), 8.94 (s, 1H), 8.49 (bs, 1H), 8.17 (s, 1H), 7.74 (d, 1H, J = 7.6 Hz), 7.41 (bs, 1H), 7.23 (t, 1H, J = 7.2 Hz), 7.18 (d, 1H, J = 8.0 Hz), 6.89 (m, 2H), 3.84 (d, 2H, J = 11.4 Hz), 3.54 (d, 2H, J = 11.4 Hz), 3.18 (q, 2H, J = 8.0 Hz), 2.95 (t, 2H, J = 11.4 Hz), 2.88 (s, 3H), 2.64 (s, 6H), 2.53 (m, 2H), 1.06 (t, 3H, J = 8.0 Hz); MS *m/z* 530.2 (M + 1).
117		MS *m/z* 556.2 (M + 1).
118		MS *m/z* 556.2 (M + 1).
119		MS *m/z* 548.2 (M + 1).
120		^{1}H NMR 400 MHz (DMSO-d_6) δ 10.24 (bs, 1H), 9.54 (s, 1H), 8.50 (bs, 1H), 8.41 (d, 1H, J = 7.2 Hz), 8.21 (s, 1H), 7.80 (m, 2H), 7.50 (t, 1H, J = 7.2 Hz), 7.32 (d, 1H, J = 8.4 Hz), 7.28 (t, 1H, J = 8.0 Hz), 6.32 (d, 1H, J = 2.4 Hz), 6.17 (dd, 1H, J_1 = 2.4 Hz, J_2 = 8.4 Hz), 4.61 (m, 2H), 4.01 (m, 1H), 3.60 (m, 1H), 3.48 (m, 2H), 3.25 (q, 1H, J = 8.8 Hz), 2.88 (s, 6H), 2.42 (d, 3H, J = 4.8 Hz), 2.19 (m, 1H), 1.20 (d, 6H, J = 4.8 Hz); MS *m/z* 560.2 (M + 1).
121		MS *m/z* 600.2 (M + 1).
122		MS *m/z* 562.2 (M + 1).

123		MS *m/z* 574.2 (M + 1).
124		MS *m/z* 575.2 (M + 1).
125		MS *m/z* 600.2 (M + 1).
126		MS *m/z* 574.2 (M + 1).
127		MS *m/z* 573.2 (M + 1).
128		MS *m/z* 604.1 (M + 1).
129		MS *m/z* 576.2 (M + 1).
130		MS *m/z* 588.2 (M + 1).
131		MS *m/z* 561.2 (M + 1).
132		MS *m/z* 561.1 (M + 1).

133		MS *m/z* 589.2 (M + 1).
134		MS *m/z* 575.2 (M + 1).
135		MS *m/z* 574.2 (M + 1).
136		MS *m/z* 601.2 (M + 1).
137		MS *m/z* 560.2 (M + 1).
138		MS *m/z* 575.2 (M + 1).
139		^{1}H NMR 600 MHz (DMSO-d_6) δ 10.35 (bs, 1H), 9.45 (s, 1H), 8.47 (d, 1H, J = 7.2 Hz), 8.33 (s, 1H), 8.23 (s, 1H), 7.79 (d, 1H, J = 8.4 Hz), 7.57 (t, 1H, J = 7.2 Hz), 7.52 (d, 1H, J = 9.6 Hz), 7.23 (t, 1H, J = 7.2 Hz), 6.68 (s, 0.4H), 6.64 (s, 0.6H), 6.50 (s, 0.6H), 6.49 (s, 0.4H), 5.19 (s, 0.6H), 5.15 (s, 0.4H), 4.58 (m, 1H), 3.99 (m, 0.4H), 3.73 (m, 1.6H), 3.36 (m, 0.6H), 3.26 (m, 0.8H), 3.15 (m, 0.6H), 2.96 (s, 1.2H), 2.89 (s, 1.8H), 2.64 (s, 6H), 2.60 (m, 1H), 2.24 (m, 0.6H), 2.07 (m, 0.4H), 1.20 (d, 6H, J = 6.0 Hz); MS *m/z* 561.2 (M + 1).
140		MS *m/z* 587.2 (M + 1).

141		MS *m/z* 587.2 (M + 1).
142		MS *m/z* 560.2 (M + 1).
143		MS *m/z* 575.2 (M + 1).
144		MS *m/z* 561.2 (M + 1).
145		MS *m/z* 587.2 (M + 1).
146		MS *m/z* 587.2 (M + 1).
147		^{1}H NMR 600 MHz (DMSO-d_6) δ 9.81 (bs, 0.4H), 9.74 (bs, 0.6H), 9.59 (bs, 1H), 8.48 (bs, 1H), 8.34 (s, 0.4H), 8.33 (s, 0.6H), 8.232 (s, 0.6H); 8.228 (s, 0.4H), 7.82 (d, 1H, J = 7.8 Hz), 7.59 (m, 1H), 7.49 (d, 0.6H, J = 8.4 Hz), 7.47 (d, 0.4H, J = 8.4 Hz), 7.34 (q, 1H, J = 7.2 Hz), 6.75 (s, 1H), 6.68 (s, 1H), 6.57 (dd, 0.6H, J_1 = 2.4 Hz, J_2 8.4 Hz), 6.54 (dd, 0.4H, J_1 = 2.4 Hz, J_2 = 8.4 Hz), 4.73 (m, 0.6H), 4.58 (m, 1H), 4.52 (m, 0.4H), 3.52 (m, 1H), 3.43 (m, 1H), 3.35 (m, 0.4H), 3.33 (m, 0.6H), 3.21 (m, 1H), 3.11 (m, 1H), 2.85 (d, 1.8H, J = 4.8 Hz), 2.82 (d, 1.2H, J = 3.0 Hz), 2.25 (m, 1H), 2.07 (m, 0.4H), 2.05 (m, 0.6H), 1.98 (m, 1H), 1.76 (m, 1H), 1.20 (d, 3.6H, J = 6.0 Hz), 1.18 (d, 2.4H, J = 6.0 Hz), 1.15 (d, 6H, J = 7.2 Hz); MS *m/z* 574.2 (M + 1).

148		MS *m/z* 589.3 (M + 1).
149		MS *m/z* 575.2 (M + 1).
150		MS *m/z* 601.3 (M + 1).
151		MS *m/z* 601.3 (M + 1).
152		MS *m/z* 559.1 (M + 1).
153		^{1}H NMR 400 MHz (DMSO-d_6) δ 10.07 (bs, 1H), 9.44 (s, 1H), 8.54 (s, 1H), 8.52 (bs, 1H), 8.29 (s, 1H), 7.91 (s, 1H), 7.79 (d, 1H, J = 8.0 Hz), 7.61 (t, 1H, J = 7.6 Hz), 7.32 (t, 1H, J = 7.6 Hz), 7.22 (d, 1H, J = 8.8 Hz), 7.14 (d, 1H, J = 8.8 Hz), 4.10 (m, 2H), 3.86 (s, 3H), 3.46 (m, 2H), 3.22 (m, 2H), 3.08 (m, 2H), 2.83 (s, 3H), 2.66 (s, 6H); MS *m/z* 560.1 (M + 1).
154		MS *m/z* 586.1 (M + 1).
155		MS *m/z* 586.1 (M + 1).
156		MS *m/z* 587.2 (M + 1).

157		^{1}H NMR 400 MHz (DMSO-d_6) δ 10.05 (bs, 1H), 9.42 (s, 1H), 8.43 (d, 1H, J = 7.6 Hz), 8.35 (s, 1H), 8.31 (s, 1H), 7.91 (s, 1H), 7.79 (dd, 1H, J_1 = 1.6 Hz, J_2 = 8.0 Hz), 7.58 (t, 1H, J = 8.0 Hz), 7.32 (t, 1H, J = 8.4 Hz), 7.15 (m, 2H), 4.70 (m, 1H), 4.07 (m, 2H), 3.45 (m, 2H), 3.21 (m, 2H), 3.06 (m, 2H), 2.83 (s, 3H), 2.65 (s, 6H), 1.27 (d, 6H, J = 6.0 Hz); MS *m/z* 588.2 (M + 1).
158		MS *m/z* 614.2 (M + 1).
159		MS *m/z* 573.2 (M + 1).
160		^{1}H NMR 600 MHz (DMSO-d_6) δ 9.45 (s, 1H), 8.44 (d, 1H, J = 7.8 Hz), 8.38 (s, 1H), 8.27 (s, 1H), 7.81 (d, 1H, J = 7.8 Hz), 7.66 (d, 1H, J = 8.4 Hz), 7.64 (t, 1H, J = 7.2 Hz), 7.35 (t, 1H, J = 7.2 Hz), 6.97 (s, 1H), 6.76 (d, 1H, J = 8.4 Hz), 4.06 (q, 2H, J = 7.2 Hz), 3.59 (m, 6H), 3.29 (m, 4H), 2.92 (m, 2H), 2.86 (s, 3H), 2.64 (s, 6H), 1.31 (t, 3H, J = 6.6 Hz); MS *m/z* 574.2 (M + 1).
161		MS *m/z* 600.2 (M + 1).
162		MS *m/z* 600.2 (M + 1).
163		MS *m/z* 627.5 (M + 1).

164		MS *m/z* 628.5 (M + 1).
165		MS *m/z* 654.5 (M + 1).
166		MS *m/z* 654.5 (M + 1).
167		MS *m/z* 592.3 (M + 1).
168		MS *m/z* 588.2 (M + 1).
169		MS *m/z* 614.2 (M + 1).
170		MS *m/z* 574.2 (M + 1).
171		^{1}H NMR 600 MHz (DMSO-d_6) δ 9.66 (s, 1H), 8.48 (bs, 1H), 8.40 (d, 1H, J = 8.8 Hz), 8.30 (s, 1H), 7.66 (dd, 1H, J = 1.6 Hz, J_2 = 7.6 Hz), 7.71 (t, 1H, J = 8.4 Hz), 7.46 (s, 1H), 7.41 (t, 1H, J = 8.0 Hz), 7.17 (bs, 1H), 6.96 (s, 1H), 6.93 (bs, 1H), 4.67 (m, 1H), 4.02 (q, 1H, J = 7.2 Hz), 3.65 (m, 2H), 3.46 (m, 1H), 3.34 (m, 1H), 2.54 (m, 1H), 1.94 (m, 4H), 1.26 (d, 6H, J = 6.0 Hz), 1.15 (d, 6H, J = 6.0 Hz); MS *m/z* 587.2 (M + 1).

172 

^{1}H NMR 600 MHz (DMSO-d_6) δ 9.63 (bs, 1H), 8.50 (bs, 1H), 8.46 (bs, 1H), 8.29 (s, 1H), 7.82 (d, 1H, J = 7.2 Hz), 7.61 (t, 1H, J = 7.2 Hz), 7.43 (d, 1H, J = 8.4 Hz), 7.34 (t, 1H, J = 7.2 Hz), 6.75 (s, 1H), 6.58 (d, 1H, J = 6.6 Hz), 4.04 (q, 2H, J = 7.2 Hz), 3.82 (m, 2H), 3.76 (m, 5H), 3.44 (m, 1H), 3.22 (m, 4H), 2.85 (s, 3H), 2.82 (m, 2H), 2.09 (m, 2H), 1.71 (m, 2H), 1.25 (t, 3H, J = 7.2 Hz), 1.16 (d, 6H, J = 7.2 Hz); MS *m/z* 628.2 (M + 1).

173 

MS *m/z* 615.2 (M + 1).

174 

MS *m/z* 659.1 (M + 1).

175 

^{1}H NMR 600 MHz (DMSO-d_6) δ 9.43 (s, 1H), 8.45 (bs, 1H), 8.38 (bs, 1H), 8.24 (s, 1H), 7.91 (d, 1H, J = 8.4 Hz), 7.84 (d, 1H, J = 8.4 Hz), 7.51 (t, 1H, J = 7.2 Hz), 7.48 (d, 1H, J = 8.4 Hz), 7.26 (t, 1H, J = 7.2 Hz), 6.76 (s, 1H), 6.55 (d, 1H, J = 7.2 Hz), 4.05 (q, 2H, J = 6.6 Hz), 3.82 (m, 2H), 3.59 (m, 5H), 3.30 (m, 1H), 3.25 (m, 4H), 2.85 (s, 3H), 2.82 (m, 2H), 2.09 (m, 2H), 1.71 (m, 2H), 1.26 (t, 3H, J = 6.6 Hz), 0.92 (d, 6H, J = 7.2 Hz); MS *m/z* 643.2 (M + 1).

176 

MS *m/z* 642.2 (M + 1).

177 

MS *m/z* 643.3 (M + 1).

178 

MS *m/z* 669.3 (M + 1).

179		MS *m/z* 633.3 (M + 1).
180		MS *m/z* 629.2 (M + 1).
181		MS *m/z* 669.2 (M + 1).
182		MS *m/z* 642.2 (M + 1).
183		MS *m/z* 615.3 (M + 1).
184		^{1}H NMR 400 MHz (DMSO-d_6) δ 9.94 (bs, 1H), 9.53 (s, 1H), 8.49 (m, 2H), 8.23 (s, 1H), 7.79 (dd, 1H, J_1 = 2.0 Hz, J_2 = 8.0 Hz), 7.58 (t, 1H, J = 7.6 Hz), 7.38 (d, 1H, J = 9.2 Hz), 7.32 (t, 1H, J = 8.0 Hz), 6.68 (d, 1H, J = 2.0 Hz), 6.51 (dd, 1H, J_1 = 2.0 Hz, J_2 = 8.4 Hz), 4.21 (m, 2H), 4.04 (q, 2H, J = 6.8 Hz), 3.86 (d, 2H, J = 12 Hz), 3.68 (t, 2H, J = 12 Hz), 3.51 (d, 2H, J = 11.2 Hz), 3.38 (t, 1H, J = 12 Hz), 3.13 (m, 2H), 2.73 (t, 2H, J = 11.2 Hz); 2.64 (s, 6H), 2.16 (d, 2H, J = 11.2 Hz), 1.73 (m, 2H), 1.24 (t, 3H, J = 7.2 Hz); MS *m/z* 616.3 (M + 1).
185		MS *m/z* 642.3 (M + 1).
186		MS *m/z* 606.7 (M + 1).

187 

MS *m/z* 599.3 (M + 1).

188 

MS *m/z* 600.3 (M + 1).

189 

MS *m/z* 626.3 (M + 1).

190 

MS *m/z* 590.3 (M + 1).

191 

MS *m/z* 599.3 (M + 1).

192 

^{1}H NMR 400 MHz (DMSO-d_6) δ 9.86 (bs, 1H), 9.56 (s, 1H), 8.59 (bs, 1H), 8.47 (bs, 1H), 8.24 (s, 1H), 7.79 (dd, 1H, J_1 = 1.6 Hz, J_2 = 8.0 Hz), 7.58 (t, 1H, J = 8.0 Hz), 7.38 (d, 1H, J = 8.4 Hz), 7.33 (t, 1H, J = 7.2Hz), 6.70 (d, 1H, J = 2.4 Hz), 6.51 (dd, 1H, J_1 = 2.4 Hz, J_2 = 8.4 Hz), 4.03 (q, 2H, J = 6.8 Hz), 3.81 (d, 2H, J = 12.4 Hz), 3.58 (m, 2H), 3.28 (m, 1H), 3.11 (m, 2H), 2.74 (t, 2H, J = 12 Hz), 2.64 (s, 6H), 2.15 (d, 2H, J = 11.6 Hz), 2.03 (m, 2H), 1.86 (m, 2H), 1.73 (m, 2H), 1.24 (t, 3H, J = 6.8 Hz); MS *m/z* 600.2 (M + 1).

193 

MS *m/z* 626.2 (M + 1).

194 

^{1}H NMR 400 MHz (CD_3OD) δ 8.29 (s, br, 1H), 8.07 (s, br, 1H), 7.96 (d, 1H, J=7.8 Hz), 7.60 (m, 1H), 7.39 (t, 1H, J=7.2 Hz), 7.22(s, br, 1H), 6.31 (s, 1H), 6.22 (s, br, 1H), 4.08(q, 1H, J=6.6 Hz), 3.95 (p, 1H, J=6.0 Hz), 3.61 (m, 2H), 3.53 (dd, 1H, J=4.2, 11.4 Hz), 3.36 (m, 2H), 2.78 (s, 3H), 2.52 (m, 1H), 2.22 (m, 1H), 1.31(t, 3H, J=6.6 Hz), 0.98 (d, 6H, J=6.6Hz); MS *m/z* 560.40 (M + 1).

195 

^{1}H NMR 400 MHz (CD_3OD) δ 8.30 (s, br, 1H), 8.05 (s, br, 1H), 7.87 (d, 1H, J=7.8 Hz), 7.60 (m, 1H), 7.42 (m, 1H), 7.17 (s, br, 1H), 6.28 (s, 1H), 6.19 (s, br, 1H), 4.04 (q, 2H, J=6.6 Hz), 3.91 (p, 1H, J=5.4 Hz), 3.60 (m, 2H), 3.50(dd, 1H, J=3.6, 10.8Hz), 3.33 (m, 1H), 2.75 (s, 3H), 2.66 (s, 6H), 2.48 (m, 1H), 2.20 (m, 1H), 1.27 (t, 3H, J=6.6 Hz); MS *m/z* 546.40 (M + 1).

196 

MS *m/z* 572.40 (M + 1).

197 

MS *m/z* 545.40 (M + 1).

198 

MS *m/z* 545.40 (M + 1).

199 

^{1}H NMR 400 MHz (CD_3OD) δ 8.37 (s, br 1H), 8.11(s, br, 1H), 8.00 (d, 1H, J=7.8 Hz,), 7.65 (s, br, 1H), 7.43 (t, 1H, J=7.2 Hz), 7.25 (s, br, 1H), 6.34 (s, 1H), 6.25 (s, 1H), 4.11(q, 2H, J=7.2 Hz), 3.99 (m, 1H), 3.65 (m, 2H), 3.57 (dd, 1H, J=3.6, 10.8 Hz), 3.41 (m, 2H), 2.82 (s, 3H), 2.56 (m, 1H), 2.28 (m, 1H), 1.35 (t, 3H, J=6.6 Hz), 1.01 (d, 6H, J=6.6 Hz); MS *m/z* 560.40 (M + 1).

200 

^{1}H NMR 400 MHz (CD_3OD) δ 8.30 (s, br, 1H), 8.10 (s, br, 1H), 7.91 (d, 1H, J=7.8 Hz), 7.57 (s, br, 1H), 7.38 (t, 1H, J=7.2 Hz), 7.21 (s, 1H), 6.30 (s, 1H), 6.21 (s, 1H), 4.08 (q, 2H, J=7.2 Hz), 3.95 (m, 1H), 3.68 (m, 1H), 3.62 (m, 2H), 3.53 (dd, 1H, J=4.2, 10.8 Hz), 3.36 (m, 1H), 2.78 (s, 3H), 2.50 (m, 1H), 2.25 (m, 1H), 1.94 (m, 2H), 1.75 (m, 2H), 1.50 (m, 2H), 1.31 (t, 3H, J=7.2 Hz); MS *m/z* 572.40 (M + 1).

201 

MS *m/z* 532.40 (M + 1).

202 

MS *m/z* 546.40 (M + 1).

203 

MS *m/z* 545.40 (M + 1).

204 

MS *m/z* 532.40 (M + 1).

205 

^{1}H NMR 400 MHz (CD_3OD) δ 8.27 (s, br, 1H), 8.07 (m,1H), 7.94 (d, 1H, J=7.8 Hz), 7.61 (s, br, 1H), 7.40(t, 1H, J=7.2Hz), 7.20 (s, 1H), 6.30 (s, 1H), 6.20 (s, 1H), 4.08 (q, 2H, J=7.2 Hz), 3.95 (m, 1H), 3.60 (m, 2H), 3.53 (dd, 1H, J=4.2, 10.8 Hz), 3.35 (m, 1H), 2.78 (s, 3H), 2.73 (d, 1H, J=6.6 Hz), 2.51 (m, 1H), 2.23 (m, 1H), 1.31 (t, 3H, J=7.2 Hz), 0.742 (s, br 1H), 0.32 (s, 2H), 0.00(s,2H); MS *m/z* 572.40 (M + 1).

206 

^{1}H NMR 400 MHz (CD_3OD) δ 8.24 (s, br, 1H), 8.07 (s, br, 1H), 7.93 (d, 1H, J=8.4 Hz), 7.57 (s, 1H), 7.38 (t, 1H, J=7.2 Hz), 7.20 (s, 1H), 6.29 (s, 1H), 6.19 (s, br, 1H), 4.06 (q, 2H, J=7.2 Hz), 3.93 (m, 1H), 3.60 (m, 2H), 3.50 (dd, 1H, J=6.0, 10.8 Hz), 3.35 (m, 1H), 2.76 (s, 3H), 2.72 (d, 1H, J=6.6 Hz), 2.50 (m, 1H), 2.22 (m, 1H), 1.30 (t, 3H, J=7.2 Hz), 0.73 (m, 1H), 0.31 (m, 2H), 0.01(m, 2H); MS *m/z* 572.40 (M + 1).

207 

MS *m/z* 545.40 (M + 1).

208		MS *m/z* 549.10 (M + 1).
209		MS *m/z* 532.40 (M + 1).
210		^{1}H NMR 400 MHz (CD_3OD) δ 8.22 (d, 1H, J=7.8Hz), 8.20 (s, 1H), 7.92 (dd, 1H, J=1.2, 7.8 Hz), 7.58 (t, 1H, J=6Hz), 7.48(d, 1H, J=9.1Hz), 7.38 (t, 1H, J=7.8Hz), 6.65 (s, 1H), 6.46 (d, 1H, J=7.8Hz), 5.20 (s, 1H), 4.06 (q, 2H, J=7.2Hz), 3.86 (m, 1H), 3.38 (m, 1H),, 3.05 (m, 3H), 2.64 (m, 1H), 2.50 (s, 3H), 2.30 (m, 1H), 1.34 (t, 3H, J=7.2 Hz); MS *m/z* 577.30 (M + 1).
211		MS *m/z* 533.30 (M + 1).

212



^{1}H NMR 400 MHz (CD_3OD) δ 8.30 (d, 1H, J=7.8Hz), 8.11 (s, 1H), 7.91 (d, 1H, J=7.8Hz), 7.58)t, 1H, J=7.8 Hz), 7.55 (d, 1H, J=8.4 Hz), 7.36 (t, 1H, J=7.8 Hz), 6.65 (s, 1H), 6.47 (d, 1H, J=8.4 Hz), 5.20 (s, 1H), 4.07 (q, 2H, J=7.2 Hz), 3.87 (m, 1H), 3.38 (m, 1H), 3.23 (m, 1H), 3.00 (m, 2H), 2.64 (m, 1H), 2.50 (s, 3H), 2.38 (m, 1H), 1.35 (t, 3H, J=7.2Hz); MS *m/z* 533.30 (M + 1).

213



MS *m/z* 533.30 (M + 1).

214



MS *m/z* 519.30 (M + 1).

215



MS *m/z* 563.30 (M + 1).

216		MS *m/z* 505.10 (M + 1).
217		MS *m/z* 563.30 (M + 1).
218		MS *m/z* 563.10 (M + 1).
219		MS *m/z* 561.40 (M + 1).
220		MS *m/z* 577.30 (M + 1).

221 

MS *m/z* 524.45 (M + 1).

222 

MS *m/z* 511.20 (M + 1).

223 

MS *m/z* 573.40 (M + 1).

224 

MS *m/z* 547.40 (M + 1).

225 

MS *m/z* 547.40 (M + 1).

226 

MS *m/z* 546.40 (M + 1).

227 

MS *m/z* 546.40 (M + 1).

228 

MS *m/z* 559.40 (M + 1).

229 

MS *m/z* 559.40 (M + 1).

230 

MS *m/z* 559.40 (M + 1).

231 

MS *m/z* 519.35 (M + 1).

232 

MS *m/z* 532.35 (M + 1).

233 

^{1}H NMR 400 MHz (CD_3OD) δ 8.06 (d, 1H, J=8.0 Hz), 7.92 (s, 1H), 7.73 (dd, 1H, J=1.6, 8.0 Hz), 7.40 (t, 1H, J=7.6 Hz), 7.22 (m, 1H), 7.10 (d, 1H, J=8.8 Hz), 6.50 (d, 1H, J=2.4 Hz), 6.38 (dd, 1H, J=2.0, 8.8 Hz), 3.67 (m, 4H), 3.35 (m, 2H), 3.15 (m, 1H), 2.84 (m, 2H), 2.69(m, 2H), 2.30 (s, 3H), 2.01 (m, 2H), 1.69 (m, 7H), 1.27 (m, 1H), 0.95 (m, 1H), 0.33 (m, 2H), 0.05 (m, 2H); MS *m/z* 626.5 (M + 1).

234 

MS *m/z* 561.4 (M + 1).

235 

MS *m/z* 547.25 (M + 1).

236 

^{1}H NMR 400 MHz (CD_3OD) δ 8.23 (d, 1H, J=7.6Hz), 8.15 (s, 1H), 7.90 (dd, 1H, J=1.6, 8.0Hz), 7.56 (t, 1H, J=7.2 Hz), 7.36 (t, 1H, J=7.6 Hz), 7.31 (d, 1H, J=8.8 Hz), 6.63 (d, 1H, J=2.4 Hz), 6.51 (m, 1H), 4.10 (m, 2H), 3.83 (m, 6H), 3.34 (m, 2H), 2.82 (m, 2H), 2.48 (s, 3H), 2.23 (m, 2H), 1.78 (m, 2H), 1.14 (m, 1H), 0.51 (m, 2H), 0.23 (m, 2H); MS *m/z* 672.4 (M + 1).

237 

MS *m/z* 532.4 (M + 1).

238 

MS *m/z* 546.4 (M + 1).

239 

MS *m/z* 576.3 (M + 1).

240 

MS *m/z* 590.4 (M + 1).

241 

MS *m/z* 533.3 (M + 1).

242 

^{1}H NMR 400 MHz (CD_3OD) δ 8.26 (s, 1H), 8.10 (d, 1H, J=8.0 Hz), 7.90 (dd, 1H, J=1.2, 8.0Hz), 7.80 (d, 1H, J=8.4Hz), 7.62 (m, 1H), 7.38 (t, 1H, J=8.0Hz), 7.05 (d, 1H, J=1.6Hz), 6.83 (dd, 1H, J=1.6, 8.4Hz), 3.86 (s, 3H), 3.43 (m, 4H), 3.00(m, 4H), 2.10 (m, 2H), 1.95 (m,2H), 1.72 (m, 6H), 1.45 (m, 2H); MS *m/z* 658.4 (M + 1).

243		MS *m/z* 546.3 (M + 1).
244		MS *m/z* 591.2 (M + 1).
245		MS *m/z* 547.3 (M + 1).
246		MS *m/z*.591.2 (M + 1).
247		MS *m/z*.546.1 (M + 1).

248



MS *m/z*.560.2 (M + 1).

249



MS *m/z*.604.3 (M + 1).

250



MS *m/z*.559.4 (M + 1).

251



MS *m/z*.573.4 (M + 1).

252 

MS *m/z*.573.4 (M + 1).

253 

MS *m/z*.573.4 (M + 1).

254 

MS *m/z*.519.1 (M + 1).

255 

MS *m/z*.563.1 (M + 1).

256 

MS *m/z*.577.1 (M + 1).

257



MS *m/z*.530.4 (M + 1).

258



MS *m/z*.590.4 (M + 1).

259



MS *m/z*.588.2 (M + 1).

260



MS *m/z*.546.4 (M + 1).

261 

MS *m/z* 520.4 (M + 1).

262 

MS *m/z* 534.4 (M + 1).

263 

MS *m/z* 544.2 (M + 1).

264 

MS *m/z* 516.4 (M + 1).

265 

MS *m/z*.574.2 (M + 1).

266 

MS *m/z*.577.1 (M + 1).

267 

MS *m/z*.579.3 (M + 1)

268 

MS *m/z*.614.5 (M + 1)

269



MS *m/z*.658.4 (M + 1)

270



MS *m/z*.590.3 (M + 1)

271



MS *m/z*.546.4 (M + 1)

272



MS *m/z*.524.4 (M + 1)

273 

MS *m/z*.614.5 (M + 1)

274 

^{1}H NMR 400 MHz (CD_3OD) δ 8.17 9s, 1H0, 8.15 (d, 1H, J=8.0Hz), 7.89 9dd, 1H, J=1.2, 8.0 Hz), 7.86 (d, 1H, J=8.4hz), 7.61 (m, 1H), 7.36 (m, 1H), 7.01 (d, 1H, J=1.6Hz), 6.81(dd, 1H, J=1.6, 8.0Hz), 4.10 (q, 2H, J=7.2Hz), 3.45 (m, 3H), 2.94 9m, 4H), 2.44 (s, 3H), 2.08 (m, 2H), 1.94 (m, 2H), 1.75 (m, 6H), 1.49 (m, 1H), 1.37 (t, 3H, J=6.8Hz); MS *m/z*.628.5 (M + 1)

275 

^{1}H NMR 400 MHz (CD_3OD) δ 8.17 (d, 1H, J=8.0 Hz), 7.93 (s, 1H), 7.74 (dd, 1H, J=1.6, 8.0Hz), 7.47 (t, 1H, J=8.0 Hz), 7.25 (m, 1H), 7.13 (d, 1H, 8.8Hz), 6.48 (d, 1H, J=2.4 Hz), 6.37 (dd, 1H, J=2.4, 8.8Hz), 3.66 (m, 4H), 3.34 (m, 2H), 3.14 (m, 4H), 2.81 (m, 2H), 2.65 (m, 2H), 2.98 (d, 2H, J=12Hz), 1.68 (m, 7H), 1.30 (m, 1H), 1.02 (d, 6H, J=6.8 Hz), 0.99 (m, 1H), 0.32 (m, 2H), 0.04 (m,2H); MS *m/z*.639.5 (M + 1)

276



^{1}H NMR 400 MHz (CD_3OD) δ 8.32 (d, 1H, J=8.0 Hz), 8.11 (s, 1H), 7.92 (dd, 1H, J=1.6, 8.0Hz), 7.65 (t, 1H, J=7.6Hz), 7.43 (t, 1H, J=7.6Hz), 7.28 (d, 1H, J=8.4Hz), 6.67 (d, 1H, J=2.4Hz), 6.56 (dd, 1H, J=2.4, 8.8Hz), 4.03 (m,2H), 3.86 (m,4H), 3.73 (m, 2H), 3.36 (m, 2H), 3.35 (m, 2H), 3.23 (m, 2H), 2.85 (m, 2H), 2.23 (m, 2H), 1.83 (m, 2H), 1.19 (d, 6H), 1.13 (m, 1H), 0.48 (m, 2H), 0.21 (m, 2H); MS *m/z*.641.5 (M + 1)

277



^{1}H NMR 400 MHz (CD_3OD) δ 8.06 (d, 1H, J=7.6Hz), 7.91 (S, 1H), 7.72 (dd, 1H), J=1.6, 8.0Hz), 7.39 (t, 1H, J=7.6 Hz), 7.20 (m, 1H), 7.10 (d, 1H, J=4.8 Hz), 6.48 (d, 1H, 2.4Hz), 6.36 (dd, 1H, J=2.4, 8.8Hz), 3.85 (m, 2H), 3.66 (m,4H), 3.56 (m,2H), 3.18 (m, 2H), 3.16 (m, 1H), 2.98 (m, 2H), 2.65 (t, 2H, J=12Hz), 2.29 (s, 3H), 2.05 (m,2H), 1.64 (m, 2H), 0.95 (m, 1H), 0.32 (m, 2H), 0.03 (m, 2H); MS *m/z*.628.5 (M + 1)

278



^{1}H NMR 400 MHz (CD_3OD) δ 8.18 (d, 1H, J=8.0Hz), 8.15 (s, 1H), 7.89 (dd, 1H, J=1.6, 8.0Hz), 7.56 (t, 1H, J=7.2Hz), 7.38 (m, 1H), 7.25 (d, 1H, J=8.8 Hz), 6.65 (d, 1H, J=2.4 Hz), 6.53 (dd, 1H, J=2.4, 8.8 Hz), 3.82 (m, 4H), 3.49(m, 2H), 3.31 (m, 1H), 2.95 (m, 2H), 2.83 (m, 2H), 2.47 (s, 3H), 2.17 (m, 2H), 1.86(m, 7H), 1.52 (m, 1H), 1.15 (m, 1H), 0.49 (m, 2H), 0.21 (m, 2H); MS *m/z*.670.4 (m + 1)

279 

MS *m/z*.641.5 (M + 1)

280 

^{1}H NMR 400 MHz (CD_3OD) δ 8.13 (s, 1H), 8.10 (d, 1H, J=8.0Hz), 7.85 (t, 1H, J=1.6Hz), 7.83 (t, 1H, J=1.6Hz), 7.57 (m, 1H), 7.32 (m,1H), 7.02 (d, 1H, J=1.2Hz), 6.81 (dd, 1H, J=1.6, 8.4Hz), 4.05 (q, 2H, J=6.8Hz), 3.36 (m, 4H), 3.08 (m, 2H), 2.84 (s, 3H), 2.40 (s, 3H), 1.33 (t, 3H, J=6.8Hz); MS *m/z*.560.4 (M + 1)

281 

MS *m/z*.600.5 (M + 1)

282 

NMR 400 MHz (CD_3OD) δ 8.30 (d, 1H, J=8.0Hz), 8.21 (s, 1H), 8.00 (d, 1H, J=8.4 Hz), 7.91(dd, 1H, J=1.63, 8.0 Hz), 7.71 (m, 1H), 7.42 (m, 1H), 7.08 (d, 1H, J=2.0 Hz), 6.91 (dd, 1H, J=1.6, 8.4 Hz), 4.30 (m, 2H), 4.13(q, 2H, J=7.2 Hz), 3.60 (m, 4H), 3.16 (m, 2H),1.41 (t, 3H, J=7.2 Hz), 1.90 9d, 6H, J=6.8 Hz); MS *m/z*.573.40 (M + 1)

283 

MS *m/z*.681.5 (M + 1)

284 

MS *m/z*.559.4 (M + 1)

285 

MS *m/z*.577.3 (M + 1)

286 

NMR 400 MHz (CD_3OD) δ 8.28 (s, br, 1H), 8..11 (s, br, 1H), 7.89 (d, 1H, J=8.4 Hz), 7.53 (s, br, 1H), 7.35 (t, 1H, J=6.0 Hz), 7.29 (m, 1H), 6.30 (s, 1H), 6.20 (d, 1H, J=7.8 Hz), 4.07 (q, 2H, J=7.2 Hz), 4.02 (m, 1H), 3.68 (m, 1H), 3.60 (m, 1H), 3.54 (m, 1H), 3.34 (m, 1H), 2.95 (s, 6H), 2.57 (m, 1H), 2.51 (s, 3H), 2.25 (m, 1H), 1.30 (t, 3H, J=7.2 Hz); MS *m/z*.590.3 (M + 1)

287		MS *m/z*.533.3 (M + 1)
288		MS *m/z*.565.3 (M + 1)
289		MS *m/z*.546.4 (M + 1)
290		NMR 400 MHz (CD_3OD) δ 8.29 (d, 1H, J=8.4 Hz), 8.24 (s, 1H), 7.91 (dd, 1H, J=1.2, 7.8 Hz), 7.57 (m, 2H), 7.35 (t, 1H, J=7.2 Hz), 6.98 (d, 1H, J=9.0 Hz), 6.77 (dd, 1H, J=3.0, 9.0 Hz), 4.18 (t, 2H, J=4.8 Hz), 3.82 (s, 3H), 3.56 (m, 2H), 3.17 (t, 2H, J=4.8 Hz), 3.3 (s, 1H), 3.01 (m, 2H), 2.53 (s, 3H), 1.92 (m, 2H), 1.79 (m, 3H), 1.53 (m, 1H); MS *m/z*.591.3 (M + 1)

291		MS *m/z*.521.4 (M + 1)
292		NMR 400 MHz (CD_3OD) δ 8.28 (d, 1H, J=8.4 Hz), 8.15 (s, 1H), 7.89 (dd, 1H, J=2.4, 7.8 Hz), 7.55 (t, 1H, J=7.2 Hz), 7.44 (d, 1H, J=3.0 Hz), 7.33 (t, 1H, J=7.2 Hz), 6.99 (dd, 1H, J=3.6, 9.0 Hz), 6.80 (dd, 1H, J=3.0, 9.0 Hz), 4.18 (t, 2H, J=4.8 Hz), 3.80 (s, 3H), 3.51 (t, 2H, J=4.8 Hz), 3.29 (m, 4H), 2.50 (s, 3H), 1.30 (m, 6H); MS *m/z*.535.4 (M + 1)
293		NMR 400 MHz (CD_3OD) δ 8.31 (d, 1H, J=8.4 Hz), 8.14 (s, 1H), 7.90 (dd, 1H, J=1.2, 7.8 Hz), 7.59 (m, 1H), 7.53 (d, 1H, J=3.0 Hz), 7.33 (t, 1H, J=7.8 Hz), 6.96 (d, 1H, J=9.0 Hz), 6.76 (dd, 1H, J=3.0, 8.4 Hz), 4.18 (t, 2H, J=4.2 Hz), 3.80 (s, 3H), 3.55 (m, 2H), 3.46 (t, 2H, J=4.8 Hz), 3.00 (t, 2H, J=12.0 Hz), 2.50 (s, 3H), 1.89 (m, 2H), 1.77 (m, 3H), 1.52 (m, 1H); MS *m/z*.547.4 (M + 1)
294		MS *m/z*.605.3 (M + 1)

295 

NMR 400 MHz (CD_3OD) δ .8.33 (d, 1H, J=8.4 Hz), 8.14)s, 1H), 7.90 (dd, 1H, J=1.2, 7.8 Hz), 7.57 (m, 1H), 7.53 (d, 1H, J=3.0 Hz), 7.33 (t, 1H, J=7.2 Hz), 6.95 (d, 1H, J=9.0 Hz), 6.74 (dd, 1H, J=3.0, 9.0 Hz), 4.17 (t, 1H, J=4.8 Hz), 3.80 (s, 3H), 3.51 (m, 4H), 3.27 (m, 2H), 2.50 (s, 3H), 1.85 (m, 4H0, 1.70 (m, 4H); *m/z*.561.4 (M + 1)

296 

MS *m/z*.587.4 (M + 1)

297 

MS *m/z*.589.4 (M + 1)

298 

MS *m/z*.590.4 (M + 1)

299 

MS *m/z*.589.4 (M + 1)

300 

MS *m/z*.591.4 (M + 1)

301 

MS *m/z*.606.4 (M + 1)

302 

MS *m/z*.607.1 (M + 1)

303 

MS *m/z*.574.4 (M + 1)

304 

MS *m/z*.618.2 (M + 1)

305 

MS *m/z*.588.2 (M + 1)

306 

MS *m/z*.562.4 (M + 1)

307



MS *m/z*.530.4 (M + 1)

308



MS *m/z*.562.4 (M + 1)

309



MS *m/z*.576.2 (M + 1)

310



MS *m/z*.546.5 (M + 1)

311 

MS *m/z*.558.2 (M + 1)

312 

MS *m/z*.604.5 (M + 1)

313 

MS *m/z*.616.5 (M + 1)

314 

NMR 400 MHz (CD_3OD) δ 8.17 (d, 1H, J=8.0 Hz), 7.88 (m, 2H), 7.56 (t, 1H, J=8.0 Hz), 7.37 (m, 1H), 7.17 (d, 1H, J=8.8 Hz), 6.61 (d, 1H, J=2.4 Hz), 6.47 9dd, 1H, J=2.4, 8.4 Hz), 3.75(m, 7H), 3.12 (m, 4H), 2.42 (s, 3H); MS *m/z*.489.1 (M + 1)

315 

MS *m/z*.546.4 (M + 1)

316 

NMR 400 MHz (CD_3OD) δ 8.22 (d, 1H, J=8.4 Hz), 7.90 (d, 1H, J=4.4 Hz), 7.86 (dd, 1H, J=1.6, 8.0Hz), 7.55 (m, 1H), 7.34 (m, 1H), 7.27(d, 1H, J=8.8Hz), 6.59 (d, 1H, J=2.4 Hz), 6.45 (dd, 1H, J=1.6, 8.8 H), 4.00 (q. 2H, J=6.8 Hz), 3.75 (t, 4H, J=4.8 Hz), 3.10 (m, 4H), 2.42 (s, 3H), 1.94 (m, 6H), 1.25 (t, 3H, J=6.8Hz); MS *m/z*.503.2 (M + 1)

317 

MS *m/z*.575.4 (M + 1)

318 

NMR 400 MHz (CD_3OD) δ 8.24 9d, 1H, J=7.6 Hz), 8.17 9s, 1H), 7.94 9dd, 1H, J=1.6, 8.0 Hz), 7.60 (t, 1H, J=7.6 Hz), 7.44 (m, 1H), 7.39(t, 1H, J=7.23 Hz), 6.68 (s, 1H), 6.50 (m, 1H), 4.10 (q, 2H, J=7.2 Hz), 3.84 (m, 4H), 3.16 (m, 4H), 2.83 (t, 2H, J=7.2 Hz), 1.37 (m, 6H), 0.75(t, 3H, J=7.6 hz); MS *m/z*.591.1 (M + 1)

319 

MS *m/z*.573.4 (M + 1)

320 

MS *m/z*.586.1 (M + 1)

321 

MS *m/z*.575.4 (M + 1)

322 

MS *m/z*.572.4 (M + 1)

323 

MS *m/z*.573.4 (M + 1)

324 

MS *m/z*.572.4 (M + 1)

325 

MS *m/z*.589.4 (M + 1)

326 

MS *m/z*.589.4 (M + 1)

327 

MS *m/z*.587.4 (M + 1)

328 

MS *m/z*.587.4 (M + 1)

329 

MS *m/z*.586.4 (M + 1)

330 

MS *m/z*.587.1 (M + 1)

331 

MS *m/z*.586.4 (M + 1)

332 

MS *m/z*.600.2 (M + 1)

333 

MS *m/z*.434.2 (M + 1)

334		MS *m/z*.520.0 (M + 1)
335		MS *m/z*.478.0 (M + 1)
336		MS *m/z*.543.2 (M + 1)
337		MS *m/z*.563.2 (M + 1)
338		NMR 400 MHz (CD_3OD) δ 8.18 (d, 1H, J=7.6 Hz), 7.98 (d, 1H, J=4.4 Hz), 7.86 (dd, 1H, J=1.6, 8.0 Hz), 7.56 (m, 1H), 7.46 (s, 1H), 7.30 (m, 1H), 6.83 (m, 2H), 3.75 (s, 3H), 2.40 (s, 3H), 2.08 (s, 3H); MS *m/z*.418.1 (M + 1)

339 

NMR 400 MHz (CD_3OD) δ 8.17 (d, 1H, J=8.0 Hz), 8.00 (d, 1H, J=4.4 Hz), 7.86 (dd, 1H, J=1.6, 8.0Hz), 7.53 (m, 1H), 7.43 (s, 1H), 7.32 (m, 1H), 6.79 (s, 1H), 4.00 (q, 2H, J=6.8Hz), 3.83 9m, 4H), 3.76 (m, 2H), 2.44 (s, 3H), 1.29 (t, 3H, J=7.2 Hz), 1.24 (t, 3H, J=7.2 Hz); MS *m/z*.547.2 (M + 1)

340 

MS *m/z*.588.4 (M + 1)

341 

MS *m/z*.600.4 (M + 1)

342 

MS *m/z*.602.4 (M + 1)

343 

MS m/z 593.00/ 595.00 (M + 1)

344 

MS m/z 621.20 / 623.20 (M + 1)

345 

^{1}H NMR 400 MHz (DMSO-d_6) δ 8.95 (s, br, 1H), 8.49 (s, br, 2H), 7.80 (dd, J = 7.54, 2.13 Hz, 1H), 7.34 (t, J = 8.36, 2H), 7.14 (m, 3 H), 6.93 (m, 3 H); MS m/z 540.10 / 542.10 (M + 1)

346 

MS m/z 506.10 / 508.10 (M + 1)

347 

MS m/z 522.10 / 524.10 (M + 1)

348 

MS m/z 635.20 / 637.20 (M + 1)

349 

MS m/z 456.10 /458.10 (M + 1)

350 

MS m/z 472.10 / 474.10 (M + 1)

351 

MS m/z 585.20 / 587.20 (M + 1)

352 

MS m/z 571.20 / 573.10 (M + 1)

353 

MS m/z 448.10 / 450.10 (M + 1)

354 

MS m/z 464.10 / 466.10 (M + 1)

355 

^{1}H NMR 400 MHz (DMSO-d_6) δ 9.54 (s, br, 1H), 8.76 (s, br, 1H), 8.31 (s, 1), 8.28 (d, J = 8.14Hz, 1H), 7.95 (t, J = 5.64 Hz, 7.85 (dd, J = 7.95, 1.48 Hz, 1H), 7.51 (t, J = 7.53 Hz, 1H), 7.33 (m, 2H), 6.73 (s, 1H), 4.05 (q, J = 6.92, 2H), 3.98 (m, 4H), 3.71 (m, 2H), 3.12 (m, 4H), 2.82 (p, J = 5.77

MS m/z 563.20 / 565.20 (M + 1)

356 

357 

MS m/z 412.10 / 414.10 (M + 1)

358 

MS m/z 428.10 / 430.10 (M + 1)

359 

MS m/z 541.20 / 543.20 (M + 1)

360 

MS m/z 527.20 / 529.20 (M + 1)

361 

MS m/z 492.10 / 494.10 (M + 1)

362 

MS m/z 508.00 / 510.05 (M + 1)

363 

MS m/z 607.10 / 609.10 (M + 1)

364 

MS m/z 563.10 / 565.10 (M + 1)

365 

MS m/z 487.10 / 489.10 (M + 1)

366 

MS m/z 649.20 / 651.20 (M + 1)

367 

MS m/z 591.20 / 593.20 (M + 1)

368 

MS m/z 605.20 / 607.20 (M + 1)

369 

MS m/z 448.10 / 450.10 (M + 1)

370 

^{1}H NMR 600 MHz (DMSO-d_6) δ 9.46 (s, 1H), 8.46 (s, 1H), 8.37 (d, J = 8.12 Hz, 1H), 8.25 s, (1H), 7.75 (dd, 7.87, 1.40 Hz, 1H), 7.55 (t, J = 7.50 Hz, 1H), 7.37 (s, 1H), 7.30 (dt, J = 8.05, 0.8 Hz, 1H), 6.91 (d, J = 8.92 Hz, 1H), 6.58 (dd, J = 8.88, 3.04 Hz, 1H), 3.70 (s, 3H), 3.55 (s, 3H), 2.58 (s,

371 

MS m/z 577.20 / 579.20 (M + 1)

372 

MS m/z 563.20 / 565.20 (M + 1)

373 

MS m/z 519.20 / 521.20 (M + 1)

374 

MS m/z 533.20 / 535.20 (M + 1)

375 

MS m/z 476.20 / 478.20 (M + 1)

376 

^{1}H NMR 600 MHz (DMSO-d_6) δ 9.39 (s, 1H), 8.37 (s, 1H), 8.27 (s, 1H), 8.25 (s, 1H), 7.88 (t, J = 6.02 Hz, 1H), 7.76 (dd, J = 7.94, 1.35 Hz, 1H), 7.50 (dt, J = 8.24, 1.89 Hz, 1H), 7.40 (s, 1H), 7.25 (t, J = 7.39 Hz, 1H), 6.90 (d, J = 8.92 Hz, 1H) 5.65 (dd, J = 8.87, 3.03 Hz, 1H)., 3.70 (s, 3H), 3.54 (s,

377 

MS m/z 605.30 / 607.20 (M + 1)

378 

MS m/z 591.20 / 593.20 (M + 1)

379 

MS m/z 547.20 / 549.20 (M + 1)

380 

MS m/z 561.20 / 563.20 (M + 1)

381 

MS m/z 548.20 / 550.20 / 552.20 (M + 1)

382 

MS m/z 548.20 / 550.20 / 552.20 (M + 1)

383 

MS m/z 563.30 / 565.30 (M + 1)

384		MS m/z 577.30 / 579.30 (M + 1)
385		MS m/z 591.40 / 593.30 (M + 1)
386		MS m/z 605.40 / 607.40 (M + 1)
387		MS m/z 617.40 / 619.40 (M + 1)
388		MS m/z 619.40 / 621.40 (M + 1)
389		MS m/z 576.30 / 578.30 (M + 1)

390		MS m/z 563.30 / 565.30 (M + 1)
391		MS m/z 560.40 / 562.40 (M + 1)
392		MS m/z 574.40 / 576.50 (M + 1)
393		^{1}H NMR 400 MHz (DMSO-d_6) δ 9.47 (s, 1H), 8.45 (d, J = 7.37 Hz, 1H), 8.36 (s, 1H), 8.20 (s, 1H), 7.83 (d, J = 7.93 Hz, 1H), 7.59 (t, J = 8.07 Hz, 1H), 7.47 (d, J = 8.69 Hz, 1H), 7.32 (t, J = 7.54 Hz, 1H), 6.63 (dd, J = 12.67, 2.42 Hz, 1H), 6.49 (m, 1H), 5.16 (m, 1H), 4.01-3.68 (m, 3H), 3.48-
394		MS m/z 587.40 / 589.40 (M + 1)
395		MS m/z 573.40 / 575.40 (M + 1)

396		MS m/z 587.40 / 589.40 (M + 1)
397		MS m/z 586.40 / 588.40 (M + 1)
398		MS m/z 586.40 / 588.40 (M + 1)
399		MS m/z 560.40 / 562.40 (M + 1)
400		^{1}H NMR 400 MHz (DMSO-d_6) δ 10.30 (s, br, 1H), 9.53 (s, 1H), 8.53 (s, 1H), 8.41 (d, J = 7.90 Hz, 1H), 8.26 (s, 1H), 7.90 (dd, J = 7.91,1.25 Hz, 1H), 7.64 (t, J = 7.93 Hz, 1H), 7.46 (d, J = 8.70 Hz, 1H), 7.38 (t, J = 7.48 Hz, 1H), 6.67 (dd, J = 13.68, 2.49 Hz, 1H), 6.46 (m, 1H), 5.19 (m, 1H), 4.04 (m,
401		MS m/z 573.20 / 575.20 (M + 1)

402		MS m/z 573.20 / 575.20 (M + 1)
403		MS m/z 587.40 / 589.40 (M + 1)
404		MS m/z 573.40 / 575.40 (M + 1)
405		MS m/z 587.40 / 589.40 (M + 1)
406		MS m/z 586.40 / 588.40 (M + 1)
407		MS m/z 586.40 / 588.40 (M + 1)

408		^{1}H NMR 600 MHz (CD_3OD) δ 8.18 (d, J = 7.80 Hz, 1H), 8.03 (s, 1H), 7.87 (dd, J = 7.96, 1.21 Hz, 1H), 7.47 (m, 2H), 7.25 (t, J = 7.82 Hz, 1H), 6.59 (s, 1H), 6.40 (d, J = 8.56 Hz, 1H), 5.13 (s, 1H), 3.78 (m, 4H), 3.30 (m, 2H), 3.28 (s, 3H), 2.92 (m, 2H), 2.56 (m, 1H), 2.30 (m, 2H), 0.89 (d, J = MS m/z 547.40 / 549.40 (M + 1)
409		
410		MS m/z 547.40 / 549.40 (M + 1)
411		MS m/z 587.50 / 589.40 (M + 1)
412		MS m/z 588.50 / 590.40 (M + 1)
413		MS m/z 637.50 / 639.50 (M + 1)

414		MS m/z 638.50 / 640.50 (M + 1)
415		MS m/z 602.50 / 604.50 (M + 1)
416		MS m/z 583.40 / 585.40 (M + 1)
417		MS m/z 584.40 / 586.40 (M + 1)
418		MS m/z 548.40 / 550.40 (M + 1)
419		MS m/z 540.40 / 542.40 (M + 1)

420 

MS m/z 541.40 / 543.40 (M + 1)

421 

MS m/z 505.40 / 507.40 (M + 1)

422 

MS m/z 667.30 / 669.30 (M + 1)

423 

MS m/z 632.30 / 634.30 (M + 1)

424 

MS m/z 573.40 / 575.40 (M + 1)

425 

^{1}H NMR 400 MHz (CD_3OD) δ 8.34 (d, J = 8.4 Hz, 1H), 8.13 (s, 1H), 7.96 (dd, J = 1.2, 7.8 Hz, 1H), 7.63 (t, J = 7.8 Hz, 1H), 7.43 (m, 2H), 6.72 (d, J = 2.4 Hz, 1H), 6.57 (m, 1H), 4.07 (m, 1H), 3.40 (m, 1H), 3.02 (t, J=10.6 Hz, 1H), 2.80 (t, J=11.8, 1H), 2.65 (m, 4H), 2.54, (s, 3H), 2.26 (s, 6H), 1.56 (m, 4H), 1.36 (d, J = 7.2 Hz, 6H). MS *m/z* 574.20 (M + 1).

426 

MS *m/z* 603.20 (M + 1).

427 

MS *m/z* 504.20 (M + 1).

428



MS *m/z* 585.30 (M + 1).

429



MS *m/z* 627.20 (M + 1).

430 

MS *m/z* 616.20 (M + 1).

431 

MS *m/z* 602.20 (M + 1).

432 

MS *m/z* 562.10 (M + 1).

433 

MS *m/z* 408.1 (M + 1).

434 

MS *m/z* 421.1 (M + 1).

435 

MS *m/z* 421.1 (M + 1).

436 

MS *m/z* 480.10 (M + 1).

437		MS *m/z* 394.10 (M + 1).
438		MS *m/z* 408.10 (M + 1).
439		^{1}H NMR 400 MHz (CD_3OD) δ 8.34 (d, J = 8.4 Hz, 1H), 8.13 (s, 1H), 7.96 (dd, J = 1.3, 7.9 Hz, 1H), 7.64 (t, J = 7.9 Hz, 1H), 7.43 (m, 1H), 7.13 (d, J=2.8 Hz, 1H), 6.24 (d, J = 2.8 Hz, 1H), 4.08(m, 1H), 3.41(m, 1H), 2.58 (s, 6H), 2.54 (s, 3H). MS *m/z* 574.20 (M + 1).
440		MS *m/z* 468.20 (M + 1).

441 

MS *m/z* 552.30 (M + 1).

442 

MS *m/z* 592.30 (M + 1)

443 

MS *m/z* 504.20 (M + 1)

444



MS *m/z* 588.30 (M + 1)

445



MS *m/z* 628.30 (M + 1)

446



MS *m/z* 617.20 (M + 1)

447 

MS *m/z* 503.20 (M + 1)

448 

MS *m/z* 587.20 (M + 1)

449 

MS *m/z* 627.30 (M + 1)

450 

MS *m/z* 616.30 (M + 1)

451 

MS *m/z* 549.30 (M + 1)

452 

MS *m/z* 509.30 (M + 1)

453 

MS *m/z* 495.20 (M + 1)

454 

MS *m/z* 495.20 (M + 1)

455 

MS *m/z* 585.20 (M + 1)

456 

MS *m/z* 545.20 (M + 1)

457 

MS *m/z* 531.20 (M + 1)

458 

MS *m/z* 531.20 (M + 1)

459 

MS *m/z* 584.30 (M + 1)

460 

MS *m/z* 544.20 (M + 1)

461 

MS *m/z* 530.20 (M + 1)

462 

MS *m/z* 530.20 (M + 1)

463 

MS *m/z* 601.30 (M + 1)

464  MS *m/z* 626.30 (M + 1)

Example 54: Cell-free ZAP-70 Kinase assay

The ZAP-70 kinase assay is based on time-resolved fluorescence resonance energy transfer (FRET). 80 nM ZAP-70 are incubated with 80 nM Lck (lymphoid T-cell protein tyrosine kinase) and 4 µM ATP in ZAP-70 kinase buffer (20 mM Tris, pH 7.5, 10 µM Na_3VO_4, 1 mM DTT, 1 mM $MnCl_2$, 0.01 % BSA, 0.05 % Tween-20) for 1 hour at room temperature in a siliconized polypropylene tube. Then, the selective Lck inhibitor PP2 (1-tert-butyl-3-(4-chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine; Alexis Biochemicals) is added (final concentration 1.2 µM) and incubated for further 10 min. 10 µL of this solution is mixed with the 10 µL biotinylated peptide LAT-11 (1 µM) as substrate and 20 µL of serial dilutions of inhibitors and incubated for 4 hours at room temperature. The kinase reaction is terminated with 10 µL of a 10 mM EDTA solution in detection buffer (20 mM Tris, pH 7.5, 0.01 % BSA, 0.05 % Tween-20). 50 µL europium-labelled anti-phosphotyrosine antibody (Eu-PT66; final concentration 0.125 nM); and 50 µL streptavidin-allophycocyanine (SA-APC; final concentration 40 nM) in detection buffer are added. After 1 hour incubation at room temperature fluorescence is measured on the Victor2 Multilabel Counter (Wallac) at 665 nm. Background values (low control) are obtained in the absence of test samples and ATP and are subtracted from all values. Signals obtained in the absence of test samples are taken as 100% (high control). The inhibition obtained in the presence of test compounds is calculated as percent inhibition of the high control. The concentration of test compounds resulting in 50% inhibition (IC_{50}) is determined from the dose-response curves. In this assay, the agents of the invention have IC_{50} values in the range of 10 nM to 2 µM, preferably from 10 nM to 100 nM.

Recombinant ZAP-70 kinase is obtained as follows: A nucleic acid encoding full-length human ZAP-70 (GenBank #L05148) is amplified from a Jurkat cDNA library by RT-PCR and cloned into the pBluescript KS vector (Stratagene, California, USA). The authenticity of the ZAP-70 cDNA insert is validated by complete sequence analysis. This donor plasmid is then used to construct a recombinant baculovirus transfer vector based on the plasmid pVL1392 (Pharmingen, California, USA) featuring in addition an N-terminal hexahistidine tag. Following co-transfection with AcNPV viral DNA, 10 independent viral isolates are derived via plaque-purification, amplified on small scale and subsequently analyzed for recombinant ZAP-70 expression by Western Blot using a commercially available anti-ZAP-70 antibody (Clone 2F3.1, Upstate Biotechnology, Lake Placid, NY, USA). Upon further amplification of one positive recombinant plaque, titrated virus stocks are prepared and used for infection of Sf9 cells grown in serum-free SF900 II medium (Life Technologies, Basel, Switzerland) under defined, optimized conditions. ZAP-70 protein is isolated from the lysate of infected Sf9 cells by affinity chromatography on a Ni-NTAcolumn (Qiagen, Basel, Switzerland).
Recombinant His-tagged ZAP-70 is also available from PanVera LLC, Madison, Wisconsin, USA.

LAT-11 (linker for activation of T cell): The biotinylated peptide LAT-11 (Biotin-EEGAPDYENLQELN) used as a substrate in the ZAP-70 kinase assay is prepared in analogy to known methods of peptide synthesis. The N-α Fmoc group of Fmoc-Asn(Trt)-oxymethyl-4-phenoxymethyl-co(polystyrene-1%-divinyl-benzene), content of Asn approx. 0.5 mmol/g, is cleaved using piperidine, 20% in DMF. Four equivalents per amino-group of Fmoc-amino acid protected in their side chains [Asp(OtBu), Glu(OtBu), Asn(Trt), Gln(Trt) and Tyr(tBu)] are coupled using DIPCDI and HOBt in DMF. After complete assembly of the peptide chain the terminal Fmoc-protecting group is removed with piperidine in DMF as before. L(+)-biotinyl-aminohexanoic acid is then coupled to the terminal amino group using DIPCDI and HOBt in DMF using four equivalents of the reagents for four days at RT. The peptide is cleaved from the resin support and all side-chain protecting groups are simultaneously removed by using a reagent consisting of 5% dodecylmethylsulfide and 5% water in TFA for two hours at RT. Resin particles are filtered off, washed with TFA and the product is precipitated from the combined filtrates by the addition of 10 to 20 volumes of diethyl ether, washed with ether and dried. The product is purified by chromatography on a C-18 wide-pore silica column using a gradient of acetonitrile in 2% aqueous phosphoric acid. Fractions containing the pure compound are

collected, filtered through an anion-exchange resin (Biorad, AG4-X4 acetate form) and lyophilized to give the title compound. MS: 1958.0 $(M-H)^{-1}$

Example 56: Anchorage-independent tumor cell growth assay

Mouse mammary carcinoma 4T1 cells (5×10^3) are plated in 96-well Ultra low Attachment plates (#3474, Coming Inc.) in 100 µL of Dulbecco's modified eagle medium containing 10% FBS. Cells are cultured for 2 h and inhibitors are added at various concentrations in a final concentration of 0.1% DMSO. After 48 h, cell growth is assayed with the cell counting kit-8 (Wako Pure Chemical), which uses a water soluble tetrazolium salt WST8. Twenty µL of the reagent is added into each well and cells are further cultured for 2 h. The optical density is measured at 450 nm. The concentration of compound causing 50 % inhibition of growth is determined.

Example 59 *In vivo* activity in the nude mouse xenograft model:

female or male BALB/c nude mice (5–8 weeks old, Charles River Japan, Inc., Yokohama, Japan) are kept under sterile conditions with water and feed *ad libitum*. Tumours are induced by subcutaneous injection of tumour cells (human epithelial cell line MIA PaCa-2; European Collection of Cell Cultures (ECACC), Salisbury, Wiltshire, UK, Catalogue Number 85062806; cell line from a 65 year old Caucasian male; undifferentiated human pancreatic carcinoma cell line) into left or right flank of mice under Forene® anaesthesia (Abbott Japan Co., Ltd., Tokyo, Japan). Treatment with the test compound is started when the mean tumor volumes reached approximately 100 mm^3. Tumour growth is measured two times per week and 1 day after the last treatment by determining the length of two perpendicular axis. The tumour volumes are calculated in accordance with published methods (see Evans et al., Brit. J. Cancer 45, 466-8, 1982). The anti-tumour efficacy is determined as the mean increase in tumour volume of the treated animals divided by the mean increase in tumour volume of the untreated animals (controls) and, after multiplication by 100, is expressed as delta T/C [%]. Tumour regression is reported as the mean changes of tumor volume of the treated animals divided by the mean tumor volume at start of treatment and, after multiplication by 100, is expressed as regression [%]. The test compound is orally administered daily with or without drug holidays.

As an alternative to cell line MIA PaCa-2, another cell line may also be used in the same manner, for example:
- the 4T1 breast carcinoma cell line (ATCC Number CRL-2539; see also Cancer. 88(12 Supple), 2979-2988, 2000) with female BALB/c mice (injection into mammary fat pad).

On the basis of these studies, a compound of formula I according to the invention shows therapeutic efficacy especially against proliferative diseases responsive to an inhibition of a tyrosine kinase.

Example 60: Tablets

Tablets comprising 50 mg of active ingredient, for example one of the compounds of formula I described in Examples 1 to 131, and having the following composition are prepared in customary manner:

Composition:

active ingredient	50 mg
wheat starch	150 mg
lactose	125 mg
colloidal silicic acid	12.5 mg
talc	22.5 mg
magnesium stearate	2.5 mg
Total:	362.5 mg

Preparation: The active ingredient is mixed with a portion of the wheat starch, with the lactose and the colloidal silicic acid and the mixture is forced through a sieve. A further portion of the wheat starch is made into a paste, on a water bath, with five times the amount of water and the powder mixture is kneaded with the paste until a slightly plastic mass is obtained.

The plastic mass is pressed through a sieve of about 3 mm mesh size and dried, and the resulting dry granules are again forced through a sieve. Then the remainder of the wheat starch, the talc and the magnesium stearate are mixed in and the mixture is compressed to form tablets weighing 145 mg and having a breaking notch.

Example 61: Soft Capsules

5000 soft gelatin capsules comprising each 50 mg of active ingredient, for example one of the compounds of formula I described in Examples 1 to 131, are prepared in customary manner:

Composition:

active ingredient	250 g
Lauroglykol	2 litres

Preparation: The pulverized active ingredient is suspended in Lauroglykol® (propylene glycol laurate, Gattefossé S.A., Saint Priest, France) and ground in a wet pulverizer to a particle size of approx. 1 to 3 μm. 0.419 g portions of the mixture are then dispensed into soft gelatin capsules using a capsule-filling machine.

Biological results:

Example	FAK IC50 (nM)	Phos IC50 (μM)	Growth IC50 (μM)	Cell Migration IC50 (μM)	IGF-1R IC50 (μM)
1.00	140	0.7	>10		
2.00	13	1.2			
3.01	44	0.34	>10		
3.02	36	0.85	4		
3.03	9.1	0.14	0.8		
3.04	32	0.53	2		
3.05	21	0.17	2		>10
3.06	13	0.11	2		
3.07	16	0.45	2		
3.08	74	0.3	6		
3.09	48	0.5	0.7		
3.10	52	0.95	>10		
3.11	9	0.04	0.3		0.2
3.12	5.4	0.01	1		
3.13	58	1.7	0.6		0.74
3.14	54	0.4	5		
3.15	7	0.02	0.8		0.94
3.16	48	1.1	3		
3.17	2.8	0.03	0.2		<0.08
3.18	130	1.5	9		
3.19	6.8	0.35	0.8		0.1
3.20	16	0.22	0.3		
3.22	120	0.9	2		
3.23	38	0.39	0.5		
3.24	64	3.5	5		
3.25	22	0.3	0.3		0.81
3.26	50	0.79	2		
3.28	43	0.71	0.7		
3.29	89	0.6	>10		
3.30	69	0.6	3		
3.31	13	1.1	5		
3.32	14	0.18	0.49	0.28	0.12
3.33	2.9	0.03	0.05	0.09	0.13
3.34	7	0.1	0.24	0.13	<0.08
3.35	13	0.02	0.17	0.8	3.55
3.36	43	1.8	2.8		
3.37	39	1.1	2.6		
3.38	64	1.7	3.8		
3.39	2	0.02	0.03	1	0.09
3.40	9	>10	0.9		
3.41	22	>10	0.43		
3.42	29	0.35	0.3		
3.43	5.6	0.2	0.11		0.27
3.44	11	0.05	0.09		0.09
3.45	0.9	0.02	0.02		
3.46	4	0.1	0.18	0.3	

3.47	1	0.1	0.06			
3.48	7	0.07	0.3			0.21
3.49	39	10	0.39			
3.50	13	0.12	1			1.19
3.51	29	0.2	0.4			0.41
3.52	29	0.42	2			
3.53	6	0.07	0.21			
3.54	0.9	0.01	0.07			<0.08
3.55	34	>10	3			
3.56	28	0.53	0.15			
3.57	28	0.61	3			
3.58	21	0.08	0.3			0.14
3.59	95	1.2	>10			
3.60	90	0.93	2			
3.61	12	10	>10			
3.62	63	>10	>10			
3.63	27	>10	>10			
3.64	5	0.13	0.7	0.21		
3.65	8	0.08	0.1			0.15
3.66	1	0.08	0.07			0.25
3.67	6	0.38	0.39			
3.68	5.5	0.2	0.63	1		
3.69	4	0.2	0.11	0.58		
3.70	3.5	0.02	0.13			
3.71	11	0.05	0.08			
3.72	2.1	0.11	0.06			
3.73	11	0.03	0.29			1.63
3.74	15	0.1	0.15			
3.75	72	0.5	1.3			
3.76	15	0.29	1.3	0.7		
3.77	65	>10	3			
3.78	10	>10	0.22			
3.79	5	1.3	0.12			
3.80	12	0.22	0.45			5
3.81	21	0.52	0.98			>10
3.82	4.8	0.2	0.07			
3.83	20	0.08	0.32			0.68
3.84	10	1	0.08			
6.00	110	0.35	5			
7.00	5.3	0.21	0.47	0.04		0.19
7.01	4.7	0.6	0.54			0.19
7.02	7.5	0.1	0.36			0.77
7.03	2.9	0.3	0.39			0.27
7.04	5.2	1	0.29			
7.05	6.2	0.3	0.2			0.25
7.06	17	0.8	1.09	0.25		
7.07	4.1	0.9	0.18			
7.08	8.7	0.8	1			
7.09	8.2	1	0.85			
7.10	6.6	1	0.98			
7.11	2.5	0.6	1.2			0.77
7.12	1.9	0.9	1	0.3		0.62

				1	
7.13	5.5	0.8	1.22		
7.14	7.6	0.3	0.36		0.33
7.15	4.5	0.06	0.19		0.26
7.16	6.4	0.2	0.42		
7.17	4.3	0.7	0.69		
7.18	6.2	0.5	0.7		
7.19	13		0.33		
7.20	2.5	>10	0.11		
7.21	3.3	>10	0.46		
7.22	25		0.48		
7.23	1.4		0.25		
7.24	5.1		0.09		
7.25	13	0.2	0.73		
7.25	2	>10	0.57		
7.26	4.1		0.15		
7.27	21	0.5	0.22		
7.28	34	1	0.15		
7.29	57	2	0.48		
7.30	2.1		0.3	1	
8.01	6.6	0.6	0.33		
8.02	2.4	0.5	0.99		
8.03	13	0.22	1		>10
8.04	8	>10	1.1		
9.01	22	0.36	1	0.6	
9.02	15	0.5	0.81		
9.03	18	0.1	0.37		
9.04	13	0.2	0.73		
9.05	22	0.36	1.6		0.6
9.06	23	3	0.4	0.3	
9.07	17	>10	0.26		
10.01	39	1	0.44		
10.02	26	0.9	1.06		
10.03	23	0.9	2.4		
11.01	9	0.7	0.85		
11.02	4.1	0.8	0.69		
11.03	26	0.41	0.1		
11.04	4.3	>10	3.2		
12.01	2.5	0.09	0.4	0.2 2	
12.02	1.6		0.05		
12.03	2.3		0.25		
12.04	1.1		0.14		
12.06	2.6				
13.01	65		0.81		
14.01	19	0.2	1.47	0.2 8	
14.02	190	2	1.1	1	
14.03	30	10	1.01		
14.04	18		0.54		
14.05	37	>10	1		
14.06	63	10	1.11		
14.07	7.5	0.2	1.4		
15.01	15	10	0.47		
15.02	21	>10	0.66		
15.03	44	2	1.67		
16.01	44	>10	4		

16.02	6	>10	0.6		
16.03	21	3	>10		
16.04	9.5	>10	0.92		
16B	11	3	7		
16.C	28	0.9	>10		
18.01	19	>10	1.29		
19.01	<1	0.2	0.3	0.29	1.41
19.02	1.6	0.13	0.38		0.91
19.03	<1	0.3	0.09		0.64
19.04	1.6	0.2	0.34		0.14
19.05	1.8	0.2	0.67	0.07	0.47
19.06	5	1	0.7		
19.07	2.1	0.3	0.11		
19.08	3.2	0.03	0.4	0.29	0.13
19.09	1.3	0.17	0.39	0.3	0.48
19.10	1.3	0.06	0.56		1.02
19.11	38	>10	2		
19.12	9	>10	0.7		0.63
19.13	2.5	0.3	1.1		
19.14	2.6	0.4	1.13		0.44
19.15	3.1	0.5	0.36		
19.16	2.3	0.7	1.1		
19.17	1	>10	0.17		
19.18	7	0.13	0.87		
19.19	5.7		0.4		
19.20	1.6	0.03	0.07		0.23
19.21	84	>10	1.71		
19.22	3.4	0.12	0.51		
19.23	6.4	0.7	0.71		
19.24	1.8	0.05	0.12		
19.25	7.2	1	0.49		0.24
19.26	6.1	0.1	0.3		
19.27	1.5	0.3	0.4		
19.28	4.8	0.1	0.12	0.3	0.46
19.29	1.9				
19.30	<1	0.06	0.1		
19.31	1.8	0.4	0.38		
19.32	1.4	0.2	0.31		
20.01	10	0.3	0.18	0.25	0.7
20.02	9	0.12	0.17	0.75	0.52
20.03	42	0.4	2.5		2.78
20.04	23	0.58	1.9		
20.05	6.8	0.87	1.46		
20.06	5	0.36	0.14	49	
20.07	3	0.1	0.05		0.38
20.08	6.8	0.17	0.05	0.29	
20.09	2	0.3	0.01		
20.10	2	0.1	0.02		
20.11	26	2	0.4		
20.12	9.5				
20.13	6.3		0.04		

20.14	33		0.32		
20.15	14	0.4	0.97	0.3	
20.16	7.5		0.06		
20.17	2		0.14		
20.18	15		0.81		
20.19	28		0.21		
20.20	3.1				0.1
20.21	26	3	0.68		
20.22	8	>10	0.19		
20.23	30	0.49	3		
20.24	19	0.48	2		
20.25	6.2	0.21	0.06		
20.26	5.3	0.76	0.27		
20.27	12	0.85	0.05		0.29
20.28	9.2	0.17	0.08		0.42
20.29	6.1	0.2	0.05		0.31
20.30	7.6	0.3	0.08		0.67
20.31	39		0.5		
20.32	13		0.11		
20.33	2.5		0.38		
20.34	13	1	0.12		
20.35	8.7	0.09	0.09		0.15
21.01	1	0.07	0.19		0.47
21.02	8.5	0.33	>10		
21.03	1.7	0.3	0.3		
21.04	1.8	0.05	0.3		
22.01	43	>10	>10		
22.02	26	1	3		
22.03	6.6	0.09	0.15		0.26
23.01	3.4	0.6	0.2	0.6	0.53
23.02	1.5	0.2	0.4		0.8
23.03	1.7	1	1.12		0.82
23.04	1.2	0.9	1.07		0.6
23.05	1.9	>10	0.59		
23.06	16	1	0.57		
23.07	2.1	3	0.84		
23.08	6.7	0.3	0.49		
23.09	2.1	0.2	0.28		
24.01	3.6	0.11	0.44		0.05
24.02	2.1	0.5	0.11		0.39
24.03	1	0.3	1.08		
25.01	8.5	3	1		
25.02	3	0.4	0.13		0.64
26.01	4.4	0.05	0.35		0.29
26.02	1.9	0.03	0.12	0.0	0.39
26.03	1.4	0.1	0.13		0.23
26.04	4.9	0.05	0.43	0.2	1.16
26.05	2.1	0.09	0.23		1.5
26.06	4.4	0.1	0.35		
26.07	11	0.5	0.95		
26.08	2.9	0.01	0.18		
26.09	2.3	0.04	0.22		
26.10	2	0.01	0.14		

26.11	4.4	0.4	0.78	0.5	
26.12	3.7	0.2	0.19		
26.13	1.6	0.2	0.44		
26.14	5		0.19		
26.15	6.9	1.2	0.08		0.07
26.16	9	0.32	2		
26.17	17	0.3	0.1	0.26	
26.18	1.3	6	1.17		
26.19	9.2	0.43	0.79		
26.20	10	0.14	0.22	0.6	0.49
26.21	1.1	0.1	0.49		
26.22	<1	0.1	0.28		
26.23	1.4	0.3	0.09	0.3	0.18
26.24	1	0.5	0.48	0.9	
26.25	<1	0.6	0.73	0.3	
26.26	1.9	0.2	0.07		0.34
26.27	4.8	0.6	1.49		
26.28	2.1	0.5	1.52		
26.29	<1	0.31	0.26		
26.30	4.4	1	0.76		
26.31	2	0.3	0.16		
26.32	1.6		0.05	0.6	
26.33	4		0.06	0.23	
26.34	7		0.1	0.25	
26.35	4.5		0.05	0.3	
26.36	1.9		0.07	0.09	
26.37	<1				
26.38	<1				
26.39	3.1				
27.01	14	0.06	0.47		
27.02	5.1	0.5	1.1		
27.03	6.3	>10	0.56		
27.04	11	0.1	0.27		
27.05	8.2	0.04	0.3		
27.06	1	0.08	0.31		
27.07	5.5	2	0.57		
27.08	9.3	0.6	0.75		
27.09	4.2	0.5	0.36		
28.01	12	0.3	0.46		0.3
28.02	1.9	0.08	0.44		3.71
28.03	7.4	0.07	0.29		
28.04	7.5	0.3	0.3		
28.05	6.7	0.1	0.12		1.39
28.06	17	0.6	0.56		
28.07	47	3	>10		
28.08	4.6	0.4	0.37		
28.09	3.1	0.5	0.36		
28.10	20	3	1.85		
28.11	4.2	0.5	0.63		
28.12	3.2	0.3	0.43		0.1
28.13	7.8	0.1	0.55	0.29	
28.14	3	0.1	1.44		

28.15	10	0.5	0.69		
28.16	11	0.11	1	0.6	
28.17	15	0.16	1.9		
28.18	9.1	>10	2.03		
28.19	3.7	0.5	0.14		
28.20	4.4	2	0.4		
28.21	1.3	0.1	0.23		
28.22	1.3	0.1	0.3		
28.23	5.9	0.5	0.28		
28.24	2.9	0.2	0.09		2.57
28.25	3.9	0.04	0.13		
28.26	6.6	0.2	0.57		
28.27	2.4	0.3	0.42	0.5	
28.28	5.2	0.4	0.52	1	
28.29	11	0.4	0.36		
28.30	2.3	0.9	0.11		
28.31	7.4	0.06	1.06		
29.01	13	0.7	2.2		0.09
29.02	3.3	0.7	1.1		
29.03	5.6	0.1	0.99		
30.01	22	0.2	0.89		
30.02	12	0.2	0.47		
30.03	19	0.5	0.68		
30.04	25	0.3	0.99		
30.05	8.5	2	0.29		
30.06	15	1	1.03		
30.07	8.8	0.6	0.47		
31.01	30	>10	1.6		
31.02	31	0.28	0.29		0.42
32.01	4.1	0.1	0.29		
32.02	5.9	0.05	0.37		0.12
33.01	2.5	0.08	0.25		
33.02	5.2	0.06	0.25		0.1
34.01	8	0.1	0.37		0.28
34.02	11	0.08	1.17		
34.03	33	0.19	2.25		
34.04	13	>10	1.22		
34.05	51	0.36	5.1		
34.06	14	>10	3		
34.07	27	>10	2.7		
34.08	8.7	>10	1.9		
35.01	6.8	>10	1.43		
35.02	6.1	0.7	0.23		
51.00	8.1	0.01 3	0.19		0.2
52.00	13	0.2	0.41		<0.0 8

Claims

1. A compound of formula I



(I)

wherein

R is selected from C_{6-10}aryl, C_{5-10}heteroaryl, C_{3-12}cycloalkyl and C_{3-10}heterocycloalkyl;

each of R^0, R^1, R^2,and R^3 independently is hydrogen, C_1-C_8alkyl, C_2-C_8alkenyl, C_2-C_8alkinyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkylC_1-C_8alkyl, C_5-C_{10}arylC_1-C_8alkyl, hydroxyC_1-C_8alkyl, C_1-C_8alkoxyC_1-C_8alkyl, aminoC_1-C_8alkyl, haloC_1-C_8alkyl, unsubstituted or substituted C_5-C_{10}aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1, 2 or 3 hetero atoms selected from N, O and S, hydroxy, C_1-C_8alkoxy, hydroxyC_1-C_8alkoxy, C_1-C_8alkoxyC_1-C_8alkoxy, haloC_1-C_8alkoxy, unsubstituted or substituted C_5-C_{10}arylC_1-C_8alkoxy, unsubstituted or substituted heterocyclyloxy, or unsubstituted or substituted heterocyclylC_1-C_8alkoxy, unsubstitued or substituted amino, C_1-C_8alkylthio, C_1-C_8alkylsulfinyl, C_1-C_8alkylsulfonyl, C_5-C_{10}arylsulfonyl, halogen, carboxy, C_1-C_8alkoxycarbonyl, unsubstitued or substituted carbamoyl, unsubstitued or substituted sulfamoyl, cyano, nitro, $-S(O)_{0-2}NR_{12}R_{13}$, $-S(O)_{0-2}R_{13}$, $-NR_{12}S(O)_{0-2}R_{13}$, $-C(O)NR_{12}R_{13}$, $-C(O)R_{13}$ and $-C(O)OR_{13}$; wherein R_{12} is selected from hydrogen and C_{1-6}alkyl; and R_{13} is selected from hydrogen, C_{1-6}alkyl and C_{3-12}cycloalkyl;

or R^0 and R^1, R^1 and R^2, and/or R^2 and R^3 form, together with the carbon atoms to which they are attached, a 5 or 6 membered carbocyclic or heterocyclic ring comprising 0, 1, 2 or 3 heteroatoms selected from N, O and S;

R^4 is hydrogen or C_1-C_8alkyl;

each of R^5 and R^6 independently is hydrogen, C_1-C_8alkyl, C_1-C_8alkoxyC_1-C_8alkyl, haloC_1-C_8alkyl, C_1-C_8alkoxy, halogen, carboxy, C_1-C_8alkoxycarbonyl, unsubstitued or substituted carbamoyl, cyano, or nitro;

R is unsubstituted or substituted by R_7, R_8, R_9, R_{10}, and R'_{10};

R_7, R_8, R_9, R_{10}, or R'_{10} is a substituent independently selected from hydrogen, C_1-C_8alkyl, C_2-C_8alkenyl, C_2-C_8alkinyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkylC_1-C_8alkyl, C_5-C_{10}arylC_1-C_8alkyl, hydroxyC_1-C_8alkyl, C_1-C_8alkoxyC_1-C_8alkyl, aminoC_1-C_8alkyl, haloC_1-C_8alkyl, unsubstituted or substituted C_5-C_{10}aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1, 2 or 3 hetero atoms selected from N, O and S, hydroxy, C_1-C_8alkoxy, hydroxyC_1-C_8alkoxy, C_1-C_8alkoxyC_1-C_8alkoxy, haloC_1-C_8alkoxy, unsubstituted or substituted aminoC_1-C_8alkoxy, unsubstituted or substituted C_5-C_{10}arylC_1-C_8alkoxy, unsubstituted or substituted heterocyclyloxy, or unsubstituted or substituted heterocyclylC_1-C_8alkyl, unsubstituted or substituted heterocyclylC_1-C_8alkoxy, unsubstitued or substituted amino, C_1-C_8alkylthio, C_1-C_8alkylsulfinyl, C_1-C_8alkylsulfonyl, C_5-C_{10}arylsulfonyl, heterocyclosulfonyl, halogen, carboxy, C_1-C_8alkylcarbonyl, C_1-C_8alkoxycarbonyl, unsubstitued or substituted carbamoyl, unsubstitued or substituted sulfamoyl, cyano, nitro, $-S(O)_{0-2}NR_{12}R_{13}$, $-S(O)_{0-2}R_{12}$, $-C(O)R_{11}$, $-OXR_{11}$, $-NR_{12}XR_{11}$, $-NR_{12}XNR_{12}R_{13}$, $-OXNR_{12}R_{13}$, $-OXOR_{12}$ and $-XR_{11}$;

or two adjacent substituents on R may form together with the carbon atoms to which they are attached, a unsubstitued or substituted 5 or 6 membered carbocyclic or heterocyclic ring comprising 0, 1, 2 or 3 heteroatoms selected from N, O and S;

X is a bond or C_{1-6}alkylene; and

R_{11} is independently selected from C_{6-10}aryl, C_{5-10}heteroaryl, C_{3-12}cycloalkyl and C_{3-10}heterocycloalkyl;

and any aryl, heteroaryl, cycloalkyl or heterocycloalkyl of R_{11} is optionally substituted by 1 to 3 radicals independently selected from C_{1-6}alkyl, C_{3-10}heterocycloalkyl-C_{0-4}alkyl optionally substituted with C_{1-6}alkyl, $-C(O)R_{12}$, $-C(O)NR_{12}R_{13}$, $-XNR_{12}R_{13}$, $-NR_{12}XNR_{12}R_{13}$ and $-NR_{12}C(O)R_{13}$; wherein X is a bond or C_{1-6}alkylene; R_{12} and R_{13} are independently selected from hydrogen and C_{1-6}alkyl;

and salts thereof for the treatement of a disease associated to tyrosine kinase activity of anaplastic lymphoma kinase (ALK).

2. use of a compound of formula I according to claim 1 wherein

R^0 or R^2 independently is hydrogen, C_1-C_8alkyl, e.g. methyl, ethyl or isopropyl, hydroxyC_1-C_8alkyl, e.g. hydroxyethyl or hydroxybutyl, haloC_1-C_8alkyl, e.g. trifluoromethyl, unsubstituted or substituted C_5-C_{10}aryl, e.g. phenyl or methoxyphenyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, e.g. morpholino, piperidino, piperazino or N-methylpiperazino, C_1-C_8alkoxy, e.g. methoxy, ethoxy or isopropoxy, haloC_1-C_8alkoxy, e.g. trifluoromethoxy, C_5-C_{10}aryloxy, e.g. phenoxy,

unsubstituted or substituted heterocyclyloxy, e.g. 1-methyl-4-piperidyloxy, unsubstituted or substituted heterocyclylC_1-C_8alkoxy, e.g. 2-(1-imidazolyl)ethoxy, 3-morpholinopropoxy or 2-morpholinoethoxy, unsubstituted or substituted amino, e.g. methylamino, dimethylamino or acetylamino, C_1-C_8alkylsulfonyl, e.g. methylsulfonyl, halogen, e.g. fluoro or chloro, unsubstituted or substituted carbamoyl, e.g. cyclohexylcarbamoyl, piperidinocarbonyl, piperazinocarbonyl, N-methylpiperazinocarbonyl or morpholinocarbonyl, unsubstituted or substituted sulfamoyl, e.g. sulfamoyl, methylsulfamoyl or dimethylsulfamoyl; preferably hydrogen, piperazino, N-methylpiperazino or 1-methyl-4-piperidyloxy, -$S(O)_{0-2}NR_{12}R_{13}$, -$S(O)_{0-2}R_{13}$, -$NR_{12}S(O)_{0-2}R_{13}$, -$C(O)NR_{12}R_{13}$, and -$C(O)OR_{13}$ in particular hydrogen;

R^1 is hydrogen, C_1-C_8alkyl, e.g. methyl, ethyl or isopropyl, hydroxyC_1-C_8alkyl, e.g. hydroxyethyl or hydroxybutyl, haloC_1-C_8alkyl, e.g. trifluoromethyl, unsubstituted or substituted C_5-C_{10}aryl, e.g. phenyl or methoxyphenyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, e.g. morpholino, piperidino, piperazino or N-methylpiperazino, C_1-C_8alkoxy, e.g. methoxy, ethoxy or isopropoxy, haloC_1-C_8alkoxy, e.g. trifluoromethoxy, C_5-C_{10}aryloxy, e.g. phenoxy, unsubstituted or substituted heterocyclyloxy, e.g. 1-methyl-4-piperidyloxy, unsubstituted or substituted heterocyclylC_1-C_8alkoxy, e.g. 2-(1-imidazolyl)ethoxy, 3-morpholinopropoxy or 2-morpholinoethoxy, unsubstituted or substituted amino, e.g. methylamino, dimethylamino or acetylamino, C_1-C_8alkylsulfonyl, e.g. methylsulfonyl, halogen, e.g. fluoro or chloro, unsubstituted or substituted carbamoyl, e.g. cyclohexylcarbamoyl, piperidinocarbonyl, piperazinocarbonyl, N-methylpiperazinocarbonyl or morpholinocarbonyl, unsubstituted or substituted sulfamoyl, e.g. sulfamoyl, methylsulfamoyl or dimethylsulfamoyl; preferably hydrogen, piperazino, N-methylpiperazino, morpholino, 1-methyl-4-piperidinyloxy, 3-morpholinopropoxy or 2-morpholinoethoxy, in particular hydrogen;

R^3 is hydrogen, C_1-C_8alkyl, e.g. methyl or ethyl, hydroxyC_1-C_8alkyl, e.g. hydroxyethyl or hydroxybutyl, haloC_1-C_8alkyl, e.g. trifluoromethyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 heteroatoms selected from N, O and S, e.g. 2-pyrrolidonyl or S,S-dioxoisothiazolidinyl, C_1-C_8alkoxy, e.g. methoxy, substituted amino, e.g. acetylamino, acetyl-methyl-amino, benzoylamino, methylsulfonylamino or phenylsulfonylamino, C_1-C_8alkylsulfonyl, e.g. methylsulfonyl, propyl-sulfonyl, cyclohexyl-sulfonyl, isopropyl-sulfonyl, C_5-C_{10}arylsulfonyl, e.g. phenylsulfonyl, halogen, e.g. fluoro or chloro, carboxy, substituted or unsubstituted carbamoyl, e.g. carbamoyl, methylcarbamoyl, ethyl-amino-carbonyl or dimethylcarbamoyl, unsubstituted or substituted sulfamoyl, e.g. sulfamoyl, methylsulfamoyl,

propylsulfamoyl, isopropylsulfamoyl, isobutylsulfamoyl, cyclopropylmethyl-sulfamoyl, 2,2,2-trifluoroethylsulfamoyl, dimethylsulfamoyl or morpholinosulfonyl dimethyl-sulfamoyl, ethyl-sulfamoyl, 1-ethyl-propyl-sulfamoyl, cyclopentyl-sulfamoyl, cyclobutyl-sulfamoyl; preferably sulfamoyl, methylsulfamoyl or propylsulfamoyl;

each pair of adjacent substituents R^0 and R^1, or R^1 and R^2, or R^2 and R^3 are $-CH_2-NH-CO-$, $-CH_2-CH_2-NH-CO-$, $-CH_2-CO-NH-$, $-CH_2-CH_2-CO-NH-$, $-CH_2-NH-SO_2-$, $-CH_2-CH_2-NH-SO_2-$, $-CH_2-SO_2-NH-$, $-CH_2-CH_2-SO_2-NH-$, $-CH_2-CH_2-SO_2-$, $-CH_2-CH_2-CH_2-SO_2-$, $-O-CH_2-O-$, or $-O-CF_2-O-$, and such pairs wherein hydrogen in NH is replaced by C_1-C_8alkyl; preferably the pair of adjacent substituents R^0 and R^1, or R^1 and R^2 being $-O-CH_2-O-$, and the pair of adjacent substituents R^2 and R^3 being $-CH_2-NH-CO-$ or $-CH_2-NH-SO_2-$.

R^4 is hydrogen or C_1-C_8alkyl, e.g. methyl; preferably hydrogen;

R^5 is hydrogen; C_1-C_8alkyl, e.g. methyl or ethyl, halogen, e.g. chloro or bromo, haloC_1-C_8alkyl, e.g. trifluoromethyl, cyano or nitro; preferably hydrogen, methyl, ethyl, chloro, bromo, trifluoromethyl or nitro; in particular chloro or bromo;

R^6 is hydrogen;

each of R^7 and R^9 independently is hydrogen, C_1-C_8alkyl, e.g. methyl, ethyl or isopropyl, hydroxyC_1-C_8alkyl, e.g. hydroxyethyl or hydroxybutyl, C_1-C_8alkylcarbonyl, e.g methyl carbonyl, aminoalkoxy, e.g diethylaminoethoxy, haloC_1-C_8alkyl, e.g. trifluoromethyl, unsubstituted or substituted C_5-C_{10}aryl, e.g. phenyl or methoxyphenyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, e.g. morpholino, piperidino, piperazino or N-methylpiperazino, C_1-C_8alkoxy, e.g. methoxy, ethoxy or isopropoxy, haloC_1-C_8alkoxy, e.g. trifluoromethoxy, C_5-C_{10}aryloxy, e.g. phenoxy, unsubstituted or substituted heterocyclyloxy, e.g. 1-methyl-4-piperidyloxy, unsubstituted or substituted heterocyclylC_1-C_8alkoxy, e.g. 2-(1-imidazolyl)ethoxy, 3-morpholinopropoxy or 2-morpholinoethoxy, unsubstituted or substituted amino, e.g. methylamino, dimethylamino or acetylamino, C_1-C_8alkylsulfonyl, e.g. methylsulfonyl, heterocyclosulfonyl, e.g piperazinylsulfonyl, heterocyclocarbonyl, e.g. methylpirerazinylcarbonyl, cyano, halogen, e.g. fluoro or chloro, unsubstituted or substituted carbamoyl, e.g. cyclohexylcarbamoyl, piperidinocarbonyl, piperazinocarbonyl, N-methylpiperazinocarbonyl or morpholinocarbonyl, unsubstituted or substituted sulfamoyl, e.g. sulfamoyl, methylsulfamoyl or dimethylsulfamoyl; preferably hydrogen, methyl, isopropyl, trifluoromethyl, phenyl, methoxyphenyl, piperidino, piperazino, N-methylpiperazino, morpholino, methoxy, ethoxy, isopropoxy, phenoxy, 3-

morpholinopropoxy, 2-morpholinoethoxy, 2-(1-imidazolyl)ethoxy, dimethylamino, fluoro, morpholinocarbonyl, piperidinocarbonyl, piperazinocarbonyl or cyclohexylcarbamoyl;

R^8 is hydrogen, C_1-C_8alkyl, e.g. methyl, ethyl or isopropyl, hydroxyC_1-C_8alkyl, e.g. hydroxyethyl or hydroxybutyl, haloC_1-C_8alkyl, e.g. trifluoromethyl, C_5-C_{10}aryl, e.g. phenyl or methoxyphenyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, e.g. morpholino, piperidino, piperazino or N-methylpiperazino, heterocyclylalkyl, e.g. methylpiperazinoethyl, heterocyclylcarbonyl, e.g. piperazinocarbonyl, heterocyclyl C_1-C_8alkylamino, e.g. pyridylethyl(methyl)amino, C_1-C_8alkoxy, e.g. methoxy, ethoxy or isopropoxy, haloC_1-C_8alkoxy, e.g. trifluoromethoxy, C_5-C_{10}aryloxy, e.g. phenoxy, unsubstituted or substituted heterocyclyloxy, e.g. 1-methyl-4-piperidyloxy, unsubstituted or substituted heterocyclylC_1-C_8alkoxy, e.g. 2-(1-Imidazolyl)ethoxy, 3-morpholinopropoxy or 2-morpholinoethoxy, unsubstituted or substituted amino, e.g. methylamino or dimethylamino, C_1-C_8alkylamino-C_1-C_8alkylamino, e.g. dimethylamino-propylamino, C_1-C_8alkylsulfonyl, e.g. methylsulfonyl, halogen, e.g. fluoro or chloro, unsubstituted or substituted carbamoyl, e.g. cyclohexylcarbamoyl, piperidinocarbonyl, piperazinocarbonyl, N-methylpiperazinocarbonyl or morpholinocarbonyl, unsubstituted or substituted sulfamoyl, e.g. sulfamoyl, methylsulfamoyl or dimethylsulfamoyl, cyano, or nitro; preferably hydrogen, methyl, piperidino, piperazino, N-methylpiperazino, morpholino, methoxy, ethoxy, trifluoromethoxy, phenoxy, 1-methyl-4-piperidyloxy, 3-morpholinopropoxy, 2-morpholinoethoxy, 3-(N-methylpiperazino)-propoxy, methylamino, fluoro, chloro, sulfamoyl or nitro;

R^{10} is hydrogen, C_1-C_8alkyl, e.g. methyl, ethyl or butyl, hydroxy, cyano, hydroxyC_1-C_8alkyl, e.g. hydroxyethyl or hydroxybutyl, haloC_1-C_8alkyl, e.g. trifluoromethyl, C_1-C_8alkoxy, e.g. methoxy or ethoxy, cycloalkylalkoxy, aryloxy, haloC_1-C_8alkoxy, unsubstituted or substituted heterocyclylC_1-C_8alkoxy, e.g. 2-(1-imidazolyl)ethoxy, unsubstituted or substituted amino, e.g. methylamino or dimethylamino, halogen, e.g. fluoro or chloro; carboxy, carbamoyl, or unsubstituted or substituted sulfamoyl, e.g. sulfamoyl, methylsulfamoyl or dimethylsulfamoyl; preferably methyl, butyl, methoxy, ethoxy, 2-(1-imidazolyl)ethoxy, methylamino, dimethylamino or fluoro; and

each pair of adjacent substituents R^7 and R^8, or R^8 and R^9 or R^9 and R^{10}, are –NH-CH=CH-, -CH=CH-NH-, –NH-N=CH-, –CH=N-NH-, -CH_2-CH_2-CH_2-, -CH_2-CH_2-CH_2-CH_2-, -CH_2-CH_2-O-, -$CH_2C(CH_3)_2O$-, -CH=$C(CH_3)$O-, -OCH_2CH_2O-, -(Morpholinopropyl)N-CH=CH-, -CH=CH-O-, -O-CH_2-O-, or -O-CF_2-O-; preferably the pair of adjacent substituents R^7 and R^8 or R^8

and R^9 being -O-CH_2-O- or the pair of adjacent substituents R^9 and R^{10} being -NH-CH=CH-, -CH=N-NH-, -CH_2-CH_2-CH_2-, -CH_2-CH_2-CH_2-CH_2- or -O-CF_2-O-.

3 use of a compound of formula I according to claim 1 or 2 wherein

R^7, R^8, R^9, R^{10} and R'^{10} are ethoxy, ethyl, propyl, methyl, t-butyl, trifluoromethyl, nitrile, cyclobutyloxy, 2,2,2-trifluoroethoxy, methoxy, isobutyloxy, t-butyloxy, isopropyloxy, methyl-amino-carbonyl, cyclopropyl-methoxy, dimethylamino-propyl-amino, methoxy-ethoxy, -XR_{11}, -C(O)R_{11} and –OXR_{11}; wherein X is a bond, methylene or ethylene; R_{11} is selected from piperazinyl, piperidinyl, pyrrolidinyl, morpholino, azepanyl and 1,4-dioxa-8-aza-spiro[4.5]dec-8-yl; wherein R_{11} is optionally substituted by 1 to 3 radicals independently selected from methyl, isopropyl, acetyl, acetyl-methyl-amino, 3-dimethylamino-2,2-dimethyl-propylamino, ethyl-methyl-amino-ethoxy, diethyl-amino-ethoxy, amino-carbonyl, ethyl, 2-oxo-pyrrolidin-1-yl, pyrrolidinyl, pyrrolidinyl-methyl, piperidinyl optionally substituted with methyl or ethyl, morpholino, dimethylamino, dimethylamino-propyl-amino, methyl-amino and ethyl-amino.

4.use of a compound of formula I according to claim wherein

R^0 or R^2 independently is hydrogen, C_1-C_8alkyl, e.g. methyl, ethyl or isopropyl, haloC_1-C_8alkyl, e.g. trifluoromethyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, e.g. morpholino, piperidino, piperazino or N-methylpiperazino, C_1-C_8alkoxy, e.g. methoxy, ethoxy or isopropoxy, unsubstituted or substituted heterocyclyloxy, e.g. 1-methyl-4-piperidyloxy, unsubstituted or substituted heterocyclylC_1-C_8alkoxy, e.g. 2-(1-imidazolyl)ethoxy, 3-morpholinopropoxy or 2-morpholinoethoxy, unsubstituted or substituted amino, e.g. methylamino, dimethylamino or acetylamino, halogen, e.g. fluoro or chloro; preferably hydrogen, piperazino, N-methylpiperazino or 1-methyl-4-piperidyloxy, in particular hydrogen;

R^1 is hydrogen, C_1-C_8alkyl, e.g. methyl, ethyl or isopropyl, haloC_1-C_8alkyl, e.g. trifluoromethyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, e.g. morpholino, piperidino, piperazino or N-methylpiperazino, C_1-C_8alkoxy, e.g. methoxy, ethoxy or isopropoxy, unsubstituted or substituted heterocyclyloxy, e.g. 1-methyl-4-piperidyloxy, unsubstituted or substituted heterocyclylC_1-C_8alkoxy, e.g. 2-(1-imidazolyl)ethoxy, 3-morpholinopropoxy or 2-morpholinoethoxy, unsubstituted or substituted amino, e.g. methylamino, dimethylamino or acetylamino, halogen, e.g. fluoro or chloro; preferably hydrogen, piperazino, N-

methylpiperazino, morpholino, 1-methyl-4-piperidinyloxy, 3-morpholinopropoxy or 2-morpholinoethoxy, in particular hydrogen;

R^3 is hydrogen, C_1-C_8alkyl, e.g. methyl or ethyl, haloC_1-C_8alkyl, e.g. trifluoromethyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 heteroatoms selected from N, O and S, e.g. 2-pyrrolidonyl or S,S-dioxoisothiazolidinyl, C_1-C_8alkoxy, e.g. methoxy, substituted amino, e.g. acetylamino, acetyl-methyl-amino, benzoylamino, methylsulfonylamino or phenylsulfonylamino, C_1-C_8alkylsulfonyl, e.g. methylsulfonyl, C_5-C_{10}arylsulfonyl, e.g. phenylsulfonyl, halogen, e.g. fluoro or chloro, carboxy, substituted or unsubstituted carbamoyl, e.g. carbamoyl, methylcarbamoyl or dimethylcarbamoyl, unsubstituted or substituted sulfamoyl, e.g. sulfamoyl, methylsulfamoyl, propylsulfamoyl, isopropylsulfamoyl, isobutylsulfamoyl, cyclopropylmethyl-sulfamoyl, 2,2,2-trifluoroethylsulfamoyl, dimethylsulfamoyl or morpholinosulfonyl; preferably sulfamoyl, methylsulfamoyl or propylsulfamoyl;

each pair of adjacent substituents R^0 and R^1, or R^1 and R^2, or R^2 and R^3 are $-CH_2-NH-CO-$, $-CH_2-NH-SO_2-$, $-CH_2-CH_2-SO_2-$, $-O-CH_2-O-$, or $-O-CF_2-O-$, and such pairs wherein hydrogen in NH is replaced by C_1-C_8alkyl; preferably the pair of adjacent substituents R^0 and R^1, or R^1 and R^2 being $-O-CH_2-O-$, and the pair of adjacent substituents R^2 and R^3 being $-CH_2-NH-CO-$ or $-CH_2-NH-SO_2-$.

R^4 is hydrogen;

R^5 is hydrogen, halogen, e.g. chloro or bromo, haloC_1-C_8alkyl, e.g. trifluoromethyl, or nitro; preferably hydrogen, chloro, bromo, trifluoromethyl or nitro; in particular chloro or bromo;

R^6 is hydrogen;

each of R^7 and R^9 independently is hydrogen, C_1-C_8alkyl, e.g. methyl, ethyl or isopropyl, haloC_1-C_8alkyl, e.g. trifluoromethyl, unsubstituted or substituted C_5-C_{10}aryl, e.g. phenyl or methoxyphenyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, e.g. morpholino, piperidino, piperazino or N-methylpiperazino, C_1-C_8alkoxy, e.g. methoxy, ethoxy or isopropoxy, unsubstituted or substituted heterocyclyloxy, e.g. 1-methyl-4-piperidyloxy, unsubstituted or substituted heterocyclylC_1-C_8alkoxy, e.g. 2-(1-imidazolyl)ethoxy, 3-morpholinopropoxy or 2-morpholinoethoxy, unsubstituted or substituted amino, e.g. methylamino, dimethylamino or acetylamino, halogen, e.g. fluoro or chloro, unsubstituted or substituted carbamoyl, e.g. cyclohexylcarbamoyl, piperidinocarbonyl, piperazinocarbonyl, N-methylpiperazinocarbonyl or morpholinocarbonyl, unsubstituted or substituted sulfamoyl, e.g. sulfamoyl, methylsulfamoyl or dimethylsulfamoyl; preferably hydrogen, methyl, isopropyl,

trifluoromethyl, phenyl, o-, m- or p-methoxyphenyl, piperidino, piperazino, N-methylpiperazino, morpholino, methoxy, ethoxy, isopropoxy, phenoxy, 3-morpholinopropoxy, 2-morpholinoethoxy, 2-(1-imidazolyl)ethoxy, dimethylamino, fluoro, morpholinocarbonyl, piperidinocarbonyl, piperazinocarbonyl or cyclohexylcarbamoyl;
R^8 is hydrogen, C_1-C_8alkyl, e.g. methyl, ethyl or isopropyl, haloC_1-C_8alkyl, e.g. trifluoromethyl, C_5-C_{10}aryl, e.g. phenyl or methoxyphenyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, e.g. morpholino, piperidino, piperazino or N-methylpiperazino, C_1-C_8alkoxy, e.g. methoxy, ethoxy or isopropoxy, haloC_1-C_8alkoxy, e.g. trifluoromethoxy, C_5-C_{10}aryloxy, e.g. phenoxy, unsubstituted or substituted heterocyclyloxy, e.g. 1-methyl-4-piperidyloxy, unsubstituted or substituted heterocyclylC_1-C_8alkoxy, e.g. 2-(1-imidazolyl)ethoxy, 3-morpholinopropoxy or 2-morpholinoethoxy, unsubstituted or substituted amino, e.g. methylamino or dimethylamino, halogen, e.g. fluoro or chloro, unsubstituted or substituted sulfamoyl, e.g. sulfamoyl, methylsulfamoyl or dimethylsulfamoyl, or nitro; preferably hydrogen, methyl, piperidino, piperazino, N-methylpiperazino, morpholino, methoxy, ethoxy, trifluoromethoxy, phenoxy, 1-methyl-4-piperidyloxy, 3-morpholinopropoxy, 2-morpholinoethoxy, 3-(N-methylpiperazino)-propoxy, methylamino, fluoro, chloro, sulfamoyl or nitro;
R^{10} is C_1-C_8alkyl, e.g. methyl, ethyl or butyl, haloC_1-C_8alkyl, e.g. trifluoromethyl, C_1-C_8alkoxy, e.g. methoxy or ethoxy, unsubstituted or substituted heterocyclylC_1-C_8alkoxy, e.g. 2-(1-imidazolyl)ethoxy, unsubstituted or substituted amino, e.g. methylamino or dimethylamino, halogen, e.g. fluoro or chloro; preferably methyl, butyl, methoxy, ethoxy, 2-(1-imidazolyl)ethoxy, methylamino, dimethylamino or fluoro; and
each pair of adjacent substituents R^7 and R^8, or R^8 and R^9 or R^9 and R^{10}, are –NH-CH=CH-, -CH=CH-NH-, –NH-N=CH-, –CH=N-NH-, -CH_2-CH_2-CH_2-, -CH_2-CH_2-CH_2-CH_2-, -O-CH_2-O-, or -O-CF_2-O-; preferably the pair of adjacent substituents R^7 and R^8 or R^8 and R^9 being -O-CH_2-O- or the pair of adjacent substituents R^9 and R^{10} being -NH-CH=CH-, -CH=N-NH-, -CH_2-CH_2-CH_2-, -CH_2-CH_2-CH_2-CH_2- or -O-CF_2-O-.

5. Use of a compound of formula I wherein the compound is selected from a compound of examples 1 to 53.

6. a compound of formula I' with the proviso that this does not include any of the compounds of examples 1 to 52 inclusive.



I'

in which:

n' is selected from 1, 2 and 3;

R'_1 is selected from C_{6-10}aryl, C_{5-10}heteroaryl, C_{3-12}cycloalkyl and C_{3-10}heterocycloalkyl;

wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl of R'_1 is optionally substituted by 1 to 3 radicals independently selected from C_{1-6}alkyl, C_{1-6}alkoxy, alkoxy-substituted-C_{1-6}alkyl, halo-substituted-C_{1-6}alkyl, halo-substituted-C_{1-6}alkoxy, $-C(O)NR'_5R'_6$, $-S(O)_{0-2}NR'_5R'_6$, $-S(O)_{0-2}R'_5$, $-C(O)R'_4$, $-OXR'_4$, $-NR'_5XNR'_5R'$, $-OXNR'_5R'_6$, $-OXOR'_5$ and $-XR'_4$;

wherein X' is a bond or C_{1-6}alkylene; R'_5 is selected from hydrogen and C_{1-6}alkyl; R'_6 is selected from hydrogen, C_{1-6}alkyl and C_{3-12}cycloalkyl-C_{1-4}alkyl; and R'_4 is independently selected from C_{6-10}aryl, C_{5-10}heteroaryl, C_{3-12}cycloalkyl and C_{3-10}heterocycloalkyl;

and any aryl, heteroaryl, cycloalkyl or heterocycloalkyl of R'_4 is optionally substituted by 1 to 3 radicals independently selected from C_{1-6}alkyl, C_{3-10}heterocycloalkyl-C_{0-4}alkyl optionally substituted with C_{1-6}alkyl, $-C(O)NR'_5R'_6$, $-XNR'_5R'_6$, $-NR'_5XNR'_5R'_6$ and $-NR'_5C(O)R'_6$; wherein X is a bond or C_{1-6}alkylene; R'_5 and R'_6 are independently selected from hydrogen and C_{1-6}alkyl;

R'_2 is selected from hydrogen and halo, cyano, C_{1-6}alkyl, halo-substituted-C_{1-6}alkyl;

R'_3 is selected from halo, $-S(O)_{0-2}NR'_5R'_6$, $-S(O)_{0-2}R'_6$, $-NR'_5S(O)_{0-2}R'_6$, $-C(O)NR'_5R'_6$, $-C(O)R'_6$ and $-C(O)OR'_6$; wherein R'_5 is selected from hydrogen and C_{1-6}alkyl; and R'_6 is selected from hydrogen, C_{1-6}alkyl and C_{3-12}cycloalkyl;

and the pharmaceutically acceptable salts, hydrates, solvates, isomers and prodrugs thereof.

7. A compound of fomula I' according to claim 6 in which:

n' is selected from 1 and 2;

R'_1 is selected from C_{6-10}aryl and C_{5-10}heteroaryl; wherein any aryl or heteroaryl of R_1 is optionally substituted by 1 to 3 radicals independently selected from C_{1-6}alkyl, C_{1-6}alkoxy, -$C(O)NR'_5R'_6$, -$OX'R'_4$, -$C(O)R'_4$, -$NR'_5X'NR'_5R'_6$, -$OX'NR'_5R'_6$, -$OX'OR'_5$ and –$X'R'_4$; wherein X' is a bond or C_{1-6}alkylene; R'_5 is selected from hydrogen and C_{1-6}alkyl; R'_6 is selected from hydrogen, C_{1-6}alkyl and C_{3-12}cycloalkyl-C_{1-4}alkyl; and R'_4 is C_{3-10}heterocycloalkyl optionally substituted by 1 to 3 radicals independently selected from C_{1-6}alkyl, halo-substituted-C_{1-6}alkyl, C_{3-10}heterocycloalkyl-C_{0-4}alkyl optionally substituted with C_{1-6}alkyl, -$C(O)NR'_5R'_6$, -$X'NR'_5R'_6$, -$NR'_5X'NR'_5R'_6$ and –$NR'_5C(O)R'_6$; wherein X' is a bond or C_{1-6}alkylene; R'_5 and R'_6 are independently selected from hydrogen and C_{1-6}alkyl;

R'_2 is selected from hydrogen and halo;

R'_3 is selected from halo, -$S(O)_{0-2}NR'_5R'_6$, -$S(O)_{0-2}R'_6$, -$NR'_5S(O)_{0-2}R'_6$, -$C(O)NR'_5R'_6$ and -$C(O)OR'_6$; wherein R'_5 is selected from hydrogen and C_{1-6}alkyl; and R'_6 is selected from hydrogen, C_{1-6}alkyl and C_{3-12}cycloalkyl.

8. A compound of formula I' according to claim 6 or 7 in which R'_1 is selected from phenyl, pyridinyl, pyrazolyl and pyrimidinyl; wherein any aryl or heteroaryl of R'_1 is optionally substituted by 1 to 3 radicals independently selected from ethoxy, ethyl, propyl, methyl, t-butyl, trifluoromethyl, nitrile, cyclobutyloxy, 2,2,2-trifluoroethoxy, methoxy, isobutyloxy, t-butyloxy, isopropyloxy, methyl-amino-carbonyl; cyclopropyl-methoxy, dimethylamino-propyl-amino, methoxy-ethoxy, -$X'R'_4$, -$C(O)R'_4$ and –$OX'R'_4$; wherein X' is a bond, methylene or ethylene; R'_4 is selected from piperazinyl, piperidinyl, pyrrolidinyl, morpholino, azepanyl and 1,4-dioxa-8-aza-spiro[4.5]dec-8-yl; wherein R'_4 is optionally substituted by 1 to 3 radicals independently selected from methyl, isopropyl, acetyl, acetyl-methyl-amino, 3-dimethylamino-2,2-dimethyl-propylamino, ethyl-methyl-amino-ethoxy, diethyl-amino-ethoxy, amino-carbonyl, ethyl, 2-oxo-pyrrolidin-1-yl, pyrrolidinyl, pyrrolidinyl-methyl, piperidinyl optionally substituted with methyl or ethyl, morpholino, dimethylamino, dimethylamino-propyl-amino, methyl-amino and ethyl-amino.

9. A compound of of formula I' according to claim 6, 7 or 8 in which R'_2 is selected from hydrogen and halo; and R'_3 is selected from halo, dimethyl-sulfamoyl, isobutyl-sulfamoyl, methyl-sulfamoyl, ethyl-sulfamoyl, propyl-sulfonyl, ethyl-amino-carbonyl, 1-ethyl-propyl-

sulfamoyl, cyclopentyl-sulfamoyl, isopropyl-sulfamoyl, cyclohexyl-sulfonyl, cyclopropyl-methyl-sulfamoyl, cyclobutyl-sulfamoyl, isopropyl-sulfonyl,

10. A compound of formula I according to any one of claim 6 to 9 wherein the compound is a compound of example 53.

11. A pharmaceutical composition comprising a compound according to any one of claims 1 to 9, as active ingredient together with one or more pharmaceutically acceptable diluents or carriers.

12. The use of a compound according to any one of claims 1 to 9 for the manufacture of a medicament for the treatment or prevention of neoplastic diseases and immune system disorders.

13. A combination comprising a therapeutically effective amount a compound according to any one of claims 1 to 9 and one or more further drug substances, said further drug substance being useful in the treatment of neoplastic diseases or immune system disorders.

14. A method for the treatment of neoplastic diseases and immune system disorders in a subject in need thereof which comprises administering an effective amount of a compound according to any one of claims 1 to 9 or a pharmaceutical composition comprising same.

15. Use of a compound according to any one of claims 1 to 9 or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of a disease which responds to inhibition of FAK and/or ALK and/or ZAP-70 and/or IGF–IR.

16. The use according to claim 15, wherein the disease to be treated is selected from proliferative disease .

17. The use according to claim 16, wherein the proliferative disease to be treated is selected from a tumor of, breast, renal , prostate, colorectal, thyroid, ovarian, pancreas, neuronal, lung, uterine and gastro-intestinal tumours as well as osteosarcomas and melanomas.

18. The use according to claim 15, wherein the disease to be treated is an immune disease.

19. Use of a compound according to any one of claims 1 to 9 or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of inflammatory and/or an immune disorder.

20. Use according to claim 19 wherein the inflammatory and/or immune disorder is selected from transplant rejection, allergy and autoimmune disorders mediated by immune cells including T lymphocytes, B lymphocytes, macrophages, dendritic cells, mast cells and eosinophils.

21. The use according to any one of claims 14 to 19, wherein the compound is 2-[5-Bromo-2-(2-methoxy-5-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-N-methyl-benzenesulfonamide or5-Chloro-N*2*-{2-methoxy-4-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-phenyl}-N*4*-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine or a pharmaceutically acceptable salt thereof.

22. The use according to any one of claims 14 to 19, wherein the compound is selected from 2-[5-chloro-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-N-methyl-benzamide, N^2-(4-[1,4']Bipiperidinyl-1'-yl-2-methoxy-phenyl)-5-chloro-N^4-[2-(propane-1-sulfonyl)-phenyl]-pyrimidine-2,4-diamine and 2-{5-Chloro-2-[2-methoxy-4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-ylamino}-N-isopropyl-benzenesulfonamide, or 5-Chloro-N*2*-{2-methoxy-4-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-phenyl}-N*4*-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine a pharmaceutically acceptable salt thereof.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/009099

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D239/48 C07D405/12 C07D403/12 C07D401/12 C07D401/14
A61K31/506 A61K35/00 A61P37/00 A61P29/00 C07D401/14
C07D405/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, CHEM ABS Data, BEILSTEIN Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 03/018021 A1 (AMGEN INC., USA) 6 March 2003 (2003-03-06) page 186, line 15 - page 189, line 8; examples 66,67,70,72,74,76,79,81,83,97,105,107,109, 116	11-20
X	EP 1 054 004 A (YAMANOUCHI PHARMACEUTICAL CO., LTD., JAPAN) 22 November 2000 (2000-11-22) table 5, Ex.2,8,34,35,37,39,40. tables 7 and 9 page 12, line 45, paragraph 56; claims 1,7	11-14, 19,20

-/--

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
11 November 2004	22/11/2004

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Schuemacher, A

Form PCT/ISA/210 (second sheet) (January 2004)

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/009099

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GHOSH D: "2,4-BIS(ARYLAMINO)-6-METHYL PYRIMIDINES AS ANTIMICROBIAL AGENTS" JOURNAL OF THE INDIAN CHEMICAL SOCIETY, vol. 58, no. 5, May 1981 (1981-05), pages 512-513, XP000918018 ISSN: 0019-4522 table I; compound V	6,11
X	WO 01/60816 A1 (AMGEN INC., USA) 23 August 2001 (2001-08-23) page 18, line 22 - line 30; claims 1,19-24; examples 37,42-44,54,56-60	1-22
X	WO 00/39101 A (BREAULT GLORIA ANNE ; PEASE JANET ELIZABETH (GB); ASTRAZENECA UK LTD () 6 July 2000 (2000-07-06) page 2, line 1 - line 9; claims 1,12-14; examples 191,192,196,199-203,213,218,219	6-20
X	WO 97/19065 A (CELLTECH THERAPEUTICS LTD ; DAVIS PETER DAVID (GB); MOFFAT DAVID FESTU) 29 May 1997 (1997-05-29) page 1, line 35 - page 2, line 4; claim 1; example 125	6-20
A	WO 01/65655 A (HYDE DOUGLAS) 7 September 2001 (2001-09-07) page 2, line 1 - line 9; claim 1	6-22
X	WO 01/64656 A1 (ASTRAZENECA AB, SWED.; ASTRAZENECA UK LTD.) 7 September 2001 (2001-09-07) claims 1,14; example 29	6-20
X	WO 00/12485 A1 (ZENECA LIMITED, UK) 9 March 2000 (2000-03-09) page 1, line 30 - page 2, line 7; claims 1,10; examples 6,9-11,106	11-20
X	WO 03/030909 A1 (BAYER CORPORATION, USA) 17 April 2003 (2003-04-17) examples	11-14, 19,20
X	WO 03/063794 A2 (RIGEL PHARMACEUTICALS, INC., USA) 7 August 2003 (2003-08-07) examples 7.3; claims 1,47,52,57-62	11-14, 19,20
X	WO 99/50250 A1 (JANSSEN PHARMACEUTICA N.V., BELG.; ET AL.) 7 October 1999 (1999-10-07) claim 1; tables 5,6	11-14, 19,20

-/--

INTERNATIONAL SEARCH REPORT

Int...ational Application No
PCT/EP2004/009099

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 03/066601 A1 (SMITHKLINE BEECHAM CORPORATION, USA) 14 August 2003 (2003-08-14) claims 1,23,27,28; example 48	11-14, 19,20
X	EP 1 184 376 A (YAMANOUCHI PHARMACEUTICAL CO., LTD., JAPAN) 6 March 2002 (2002-03-06) page 9, lines 50-58; claim 1; table 10	11-14, 19,20
P,X	WO 03/078404 A1 (NOVARTIS A.-G., SWITZ.; NOVARTIS PHARMA G.M.B.H.) 25 September 2003 (2003-09-25) claims 1,4-10; examples 2,7,10-12,16,30,51,236	6-20
P,X	WO 2004/002964 A1 (YAMANOUCHI PHARMACEUTICAL CO., LTD., JAPAN) 8 January 2004 (2004-01-08) examples 79-86,167,168; tables 4,17-20	11-14, 19,20
P,X	WO 03/095448 A (CHEN JIANQING ; LIU DONGLEI (US); WOOD JILL E (US); CHEN YUANWEI (US);) 20 November 2003 (2003-11-20) claim 6; tables 1,2	11-14, 19,20
E	WO 2004/074244 A2 (SMITHKLINE BEECHAM CORPORATION, USA) 2 September 2004 (2004-09-02) the whole document	6-14,19, 22
E	WO 2004/080980 A1 (NOVARTIS A.-G., SWITZ.; NOVARTIS PHARMA G.M.B.H.) 23 September 2004 (2004-09-23) the whole document	6-22

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2004/009099

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 14 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. [ ] Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. [ ] Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest.

[ ] No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP2004/009099

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 03018021 A1	06-03-2003	US 2004063705 A1	01-04-2004
		CA 2457838 A1	06-03-2003
		EP 1427421 A1	16-06-2004
EP 1054004 A	22-11-2000	AU 1507199 A	05-07-1999
		EP 1054004 A1	22-11-2000
		US 6432963 B1	13-08-2002
		WO 9931073 A1	24-06-1999
WO 0160816 A1	23-08-2001	AU 3704101 A	27-08-2001
		CA 2400447 A1	23-08-2001
		CN 1429222 T	09-07-2003
		EP 1257546 A1	20-11-2002
		HU 0301117 A2	29-12-2003
		JP 2003532635 T	05-11-2003
		US 2003199534 A1	23-10-2003
		US 2002052386 A1	02-05-2002
		ZA 200206386 A	26-11-2003
WO 0039101 A	06-07-2000	AT 277020 T	15-10-2004
		AU 763091 B2	10-07-2003
		AU 1874300 A	31-07-2000
		BR 9916590 A	23-10-2001
		CA 2352896 A1	06-07-2000
		CN 1335838 T	13-02-2002
		DE 69920509 D1	28-10-2004
		EP 1140860 A1	10-10-2001
		WO 0039101 A1	06-07-2000
		JP 2002533446 T	08-10-2002
		NO 20013038 A	22-08-2001
		NZ 512118 A	29-08-2003
		US 6593326 B1	15-07-2003
		ZA 200104413 A	29-08-2002
WO 9719065 A	29-05-1997	AU 7631496 A	11-06-1997
		DE 69627179 D1	08-05-2003
		DE 69627179 T2	29-01-2004
		EP 0862560 A1	09-09-1998
		ES 2195020 T3	01-12-2003
		WO 9719065 A1	29-05-1997
		US 6235746 B1	22-05-2001
		US 5958935 A	28-09-1999
WO 0165655 A	07-09-2001	US 6376770 B1	23-04-2002
		AU 3354901 A	12-09-2001
		WO 0165655 A2	07-09-2001
		CA 2401436 A1	07-09-2001
		EP 1260006 A2	27-11-2002
		EP 1376800 A1	02-01-2004
		US 2003124905 A1	03-07-2003
WO 0164656 A1	07-09-2001	AU 3397901 A	12-09-2001
		BR 0108879 A	29-04-2003
		CA 2398887 A1	07-09-2001
		CN 1416423 T	07-05-2003
		EP 1278735 A1	29-01-2003
		JP 2003525279 T	26-08-2003
		MX PA02007581 A	13-12-2002

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP2004/009099

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0164656 A1		NO 20024126 A	29-08-2002
		NZ 520502 A	28-05-2004
		US 2003181474 A1	25-09-2003
		ZA 200206192 A	26-11-2003
WO 0012485 A1	09-03-2000	AU 5438299 A	21-03-2000
		EP 1107957 A1	20-06-2001
		JP 2002523497 T	30-07-2002
WO 03030909 A1	17-04-2003	NONE	
WO 03063794 A2	07-08-2003	CA 2474277 A1	07-08-2003
		EP 1471915 A2	03-11-2004
		US 2004029902 A1	12-02-2004
		EP 1468510 A2	20-10-2004
		EP 1468511 A2	20-10-2004
		EP 1467646 A1	20-10-2004
		WO 03063333 A1	31-07-2003
		WO 03061449 A1	31-07-2003
		WO 03063390 A2	31-07-2003
		WO 03063391 A2	31-07-2003
		US 2003137264 A1	24-07-2003
		US 2003137263 A1	24-07-2003
		US 2003142982 A1	31-07-2003
		US 2003170033 A1	11-09-2003
		WO 2004014382 A1	19-02-2004
WO 9950250 A1	07-10-1999	AT 232521 T	15-02-2003
		AU 751573 B2	22-08-2002
		AU 3599699 A	18-10-1999
		BG 104738 A	30-04-2001
		BR 9909191 A	05-12-2000
		CA 2324919 A1	07-10-1999
		CN 1295564 T	16-05-2001
		DE 69905306 D1	20-03-2003
		DE 69905306 T2	27-11-2003
		DK 945443 T3	02-06-2003
		EA 2973 B1	26-12-2002
		EE 200000532 A	15-02-2002
		EP 1245567 A1	02-10-2002
		EP 0945443 A1	29-09-1999
		ES 2193660 T3	01-11-2003
		HR 20000620 A1	30-06-2001
		HU 0101204 A2	28-10-2001
		ID 26291 A	14-12-2000
		JP 3507917 B2	15-03-2004
		JP 2002509920 T	02-04-2002
		NO 20004810 A	26-09-2000
		NZ 506679 A	26-11-2002
		OA 11492 A	06-05-2004
		PL 343196 A1	30-07-2001
		PT 945443 T	30-06-2003
		SI 945443 T1	31-08-2003
		SK 14062000 A3	11-06-2001
		TR 200002760 T2	21-12-2000
		TW 531534 B	11-05-2003
		US 2003083317 A1	01-05-2003
		US 6197779 B1	06-03-2001

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP2004/009099

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9950250 A1		US 2001011094 A1	02-08-2001
		EP 0945442 A1	29-09-1999
		ZA 200006044 A	26-10-2001
WO 03066601 A1	14-08-2003	CA 2476281 A1	14-08-2003
		EP 1472233 A1	03-11-2004
EP 1184376 A	06-03-2002	AU 5107900 A	28-12-2000
		EP 1184376 A1	06-03-2002
		US 6797706 B1	28-09-2004
		WO 0075113 A1	14-12-2000
		JP 2001055378 A	27-02-2001
WO 03078404 A1	25-09-2003	NONE	
WO 2004002964 A1	08-01-2004	NONE	
WO 03095448 A	20-11-2003	WO 03095448 A1	20-11-2003
		WO 2004046118 A2	03-06-2004
WO 2004074244 A2	02-09-2004	NONE	
WO 2004080980 A1	23-09-2004	NONE	